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Abstract 
 
Hump-nosed pit viper (Hypnale hypnale) is a medically important snake in Sri Lanka 
and Western Ghats of India. Envenomation by this snake still lacks effective antivenom 
clinically. The species is also often misidentified, resulting in inappropriate treatment. 
 
The median lethal dose (LD50) of H. hypnale venom varies from 0.9 µg/g intravenously 
to 13.7 µg/g intramuscularly in mice. The venom shows procoagulant, hemorrhagic, 
necrotic, and various enzymatic activities including those of proteases, phospholipases 
A2 and L-amino acid oxidases which have been partially purified. The monovalent 
Malayan pit viper antivenom and Hemato polyvalent antivenom (HPA) from Thailand 
effectively cross-neutralized the venom’s lethality in vitro (median effective dose, ED50 
= 0.89 and 1.52 mg venom/mL antivenom, respectively) and in vivo in mice, besides the 
procoagulant, hemorrhagic and necrotic effects. HPA also prevented acute kidney injury 
in mice following experimental envenomation. Therefore, HPA may be beneficial in the 
treatment of H. hypnale envenomation. 
  
H. hypnale-specific antiserum and IgG, produced from immunization in rabbits, 
effectively neutralized the venom’s lethality and various toxicities, indicating the 
feasibility to produce an effective specific antivenom with a common immunization 
regime. On indirect ELISA, the IgG cross-reacted extensively with Asiatic crotalid 
venoms, particularly that of Calloselasma rhodostoma (73.6%), suggesting that the two 
phylogenically related snakes share similar venoms antigenic properties. Double-
sandwich ELISA was specific and able to distinguish and quantify venoms of H. 
hypnale, Daboia russelii and Echis carinatus sinhaleyus (three common Sri Lankan 
viperids) in human sera; hence it may be useful in diagnostics and venom level 
monitoring especially during clinical studies. 
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In rabbits, the venom when injected intravenously showed a rapid distribution phase 
(t1/2α = 0.6 h) and a slow elimination phase (t1/2β = 20 h), consistent with prolonged 
abnormal hemostasis reported. The intramuscular bioavailability was exceptionally low 
(Fi.m = 4%), accountable for the highly varied LD50 between intravenous and 
intramuscular envenomings in animals. HPA infused post-envenomation markedly 
reduced the serum venom levels and subsequently induced venom redistribution. The 
redistributed venom was completely neutralized by a second dose of HPA. 
 
Proteomic study by shotgun-liquid chromatography-mass spectrometry/mass 
spectrometry (shotgun-LC-MS/MS) revealed 52 proteins in the venom, 70% of which 
are toxinologically related. The combined use of reverse-phase high performance liquid 
chromatography, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, peptide 
sequencing and mass fingerprinting technologies enabled the identification of the 
venom major components, i.e. zinc-dependent metalloproteases, phospholipases A2, L-
amino acid oxidases, serine proteases and C-type lectins. These toxins correlate with the 
venom’s principal effects: hematoxicity (hemorrhage, coagulopathy) and tissue 
destruction (necrosis). Understanding of the venom composition is essential for 
ascertaining the principal toxins, and for optimizing antivenom formulation. 
Furthermore, hypnobin, a 37 kDa thrombin-like enzyme was purified. It exhibits 
arginine esterese and amidase activities, besides distinct specificity towards different 
mammalian fibrinogens. In fibrinogen coagulation, hypnobin predominantly releases 
fibrinopeptide A, followed slowly by a small amount of fibrinopeptide B. The findings 
provide insights into the structures and mechanism of the thrombin-like enzyme, which 
are important for elucidation of the pathophysiology and for potential drug discovery, 
e.g. an anticoagulant for thromboembolic disorders.     
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Abstrak 
Ular Hypnale hypnale adalah penting dari segi perubatan di Sri Lanka dan Western 
Ghats, India. Envenomasi (patukan berbisa) ular ini masih tiada penawar bisa yang 
berkesan. Species ini juga kerap salah dikenalpasti dan ini mengakibatkan rawatan yang 
tidak  sewajar. 
 
Dos maut median (LD50) bisa H. hypnale berbeza dari 0.9 µg/g secara intravena ke 13.7 
µg/g scara intramuskular pada tikus. Bisa ini menunjukkan kesan-kesan prokoagulan, 
pendarahan, nekrosis dan aktiviti pelbagai enzim termasuk proteases, phospholipases A2 
serta L-amino acid oxidases yang separanya telah diekstrakkan. Monovalent Malayan 
pit viper antivenom dan Hemato polyvalent antivenom (HPA) dari Thailand 
meneutralkan kesan maut bisa ini secara in vitro (dos efektif median, ED50 = 0.89 dan 
1.52 mg bisa/mL antivenom, masing-masing) dan in vivo pada tikus, serta kesan-kesan 
prokoagulan, pendaraha dan nekrosis. HPA selepas envenomasi eksperimen turut 
mencegah kecederaan akut ginjal pada tikus. Maka, HPA mungkin bermanfaat sebagai 
rawatan bagi envenomasi H. hypnale. 
 
Antiserum dan IgG spesifik kepada H. hypnale yang dihasilkan melalui imunisasi arnab 
meneutralkan kesan-kesan maut dan toksik bisa itu. Ini menunkjukkan 
kebolehkaksanaan penghasilan suatu penawar bisa spesifik dengan rejim imunisasi yang 
am. Kajian ‘indirect ELISA’ menunjukkan IgG itu bereaksi-silang secara ekstensif 
dengan pelbagai bisa ular jenis ‘crotalid’ di Asia, khususnya Calloselasma rhodostoma 
(73.6%). Ini menunjukkan kedua-dua ular yang berhubungan filogenetik ini berkongsi 
antigen-antigen bisa yang sama. ‘Double-sandwich ELISA’ adalah spesifik dan dapat  
membezakan serta mengukur paras bisa-bisa H. hypnale, Daboia russelii dan Echis 
carinatus sinhaleyus (tiga ular jenis viperid yang biasa di Sri Lanka) dalam serum 
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manusia. Ini mununjukkan potensinya digunakkan untuk diagnostik dan pemantauan 
paras bisa khasnya semasa kajian klinikal.  
 
Bisa ini apabila disuntik secara intravena pada arnab menunjukkan fasa ‘distribution’ 
yang pantas (t1/2α = 0.6 h) dan fasa ‘elimination’ yang lambat (t1/2β = 20 h), konsisten 
dengan hemostasis abnormal berpanjangan seperti dilaporkan. ‘Intramuscular 
bioavailability’ bisa ini adalah amat rendah (Fi.m = 4%), dan menjelaskan perbezaan 
LD50 yang besar antara cara pemberian intravena dan intramuskular pada haiwan.  Infusi 
HPA selepas envenomasi eksperimental mengurangkan paras bisa dengan banyak dan 
seterusnya mendorong ‘venom redistribution’. Bisa yang diedarsemula itu dineutralkan 
oleh dos kedua HPA. 
 
Kajian proteomic dengan ‘shotgun-liquid chromatography-mass spectrometry/mass 
spectrometry (shotgun-LC-MS/MS)’ mengenalpasti 52 protein dalam bisa, di mana 
70% berkaitan dengan aktiviti toksin . Penggunaan ‘reverse-phased high performance 
liquid chromatography’, ‘sodium dodecyl sulfate-polyacrylamide gel electrophoresis’, 
‘peptide sequencing’ bersama ‘mass fingerprinting’ membolehkan komponen-
komponen utama bisa itu dikenalpastikan, iaitu zinc-dependent metalloproteases, 
phospholipases A2, L-amino acid oxidases, serine proteases dan C-type lectins. Toksin-
toksin ini berkorelasi dengan kesan-kesan utama bisa ini: hematoksik (pendarahan, 
koagulopati) dan kemusnahan tisu (nekrosis). Pemahaman komposisi bisa adalah 
penting bagi menentupasti toksin-toksin utama, dan untuk mengoptimumkan formulasi 
penawar bisa. Tambahan, hypnobin, suatu enzim jenis trombin berjisim 37 kDa telah 
diekstrakkan. Hypnobin menunjukkan aktiviti-aktiviti arginine ester hydrolase dan 
amidase, serta spesifikasi yang berbeza terhadap fibrinogen mamalia yang berlainan.  
Bagi koagulasi fibrinogen, hypnobin membebaskan fibrinopeptide A kebanyakannya, 
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diikui amaun kecil fibrinopeptide B yang dibebaskan dengan lambat. Penemuan 
sedemikian memberi pemahaman terhadap struktur dan mekanisme thrombin-like 
enzyme ini, penting bagi penerangan patofisiologi dan penemuan ubat-ubatan, 
contohnya, sebagai antikoagulan bagi rawatan penyakit tromboembolik. 
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1.1 Snakes and humans 
  
The relationship between snakes and humans has been complicated but amazing from 
prehistorical times to modern days. Evolutionary arms race begun early by constrictors 
was followed by venomous snakes throughout the mammalian evolution. The 
consequence was particularly significant in the anthropoid and primate evolution (Isbell, 
2006): a fear circuit independent of conscious cognition that lies heavily on the limbic 
structures (Öhman and Mineka, 2003), selective pressures for visual pathways 
adaptation and further brain expansion that became unique to primates that included 
primitive humans (Shibasaki and Kawai, 2009; Hayakawa et al., 2011). The influence 
of snakes continued in ancient cultures. Historical representations of snakes often 
reflected an ignorance of their true nature, demonstrating a veritable dichotomy between 
the Good and Evil: at times revered as virtuous power of knowledge, protection and 
productivity; at other times reviled as evil and cause of fall. In modern age, similar 
conflict exists: snakes’ destructive power was greatly feared for, but as civilization 
progressed snakes became animals that were hunted and farmed for purposes like show, 
food, traditional medicines, leather production, and biological control. Interestingly, the 
venomous character of certain species contributes toward their medical significance in 
human lives, also in a paradoxical context: pathologically, venom is viewed as a source 
of sickness and death; therapeutically, as a source of novel drug discovery (Chippaux, 
2006; Koh et al., 2006). 
 
1.2 Snake bites and envenomation: South Asia 
 
Venomous bites (envenomation) by snakes constitute a substantial health problem 
especially in the tropics and subtropics (Chippaux, 1998; Kasturiratne et al., 2008). The 
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complications, acute or chronic, include psychological trauma, organ dysfunctions, 
permanent disability, and death. It is hence duly indexed as a classifiable “disease” 
according to the WHO International Classification of Disease (ICD-10), appropriately 
categorized as a Neglected Tropical Disease (WHO, 2009), and aptly described as a 
disease of poverty (Harrison et al., 2009). In spite of these, envenoming issues have 
been continuously neglected systemically in many parts of the world (Gutiérrez et al., 
2006; Alirol et al., 2010), posing a great challenge to the World health Organization in 
its promotion of ‘Health for All’.  
 
At least 3 million envenomations occur worldwide (Chippaux, 2006), and the highest 
annual number (121,000) came from South Asia (Kasturiratne et al., 2008), with India 
being the most affected region recording the highest snakebite mortality rate in the 
world: 35,000-50,000 deaths occur yearly based on WHO direst estimates (Chippaux, 
1998; Kasturiratne et al., 2008). Epidemiological studies indicated that it is an 
occupational health hazard affecting particularly farmers and other agricultural workers, 
although frequent bites among housewives and students had also been reported (Alirol 
et al., 2010). In certain occasions e.g. the 2007 monsoon flood in Bangladesh, 
snakebites even became the second commonest cause of death after drowning, 
illustrating how this problem can be as serious as the other tropical health issues in the 
region (WHO, 2007). In anticipation of climatic changes due to global warming, 
snakebite “outbreak” that comes with flash flood is no longer a fictional scene, therefore 
needing precautious measures that include antivenom stock-up and adequate training of 
the medical personnel in managing snakebite emergency from time to time. A recent 
example was shown in 2011 Thailand monsoon flood, where the Thai Ministry of 
Public Health boosted the stockpile of antivenoms by a further 3,500 dosages and 
dispatched a few hundred to flood-hit areas, ensuring every public hospital outside 
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Bangkok has 10 dosages in its stock in anticipation of increased snakebite emergency. 
Such policy could only be possible when a well-supported national antivenom 
manufacturing facility is available with readily sufficient products and efficient 
distribution system within the country, as shown in the Thai scenario. The practicality 
of such recommendation in economically diverse areas in South Asia unfortunately 
remains suboptimistic. Long-term and systematic efforts that include intensive research 
and upgraded antivenom management are therefore very much needed for this region. 
 
There are at least 67 front-fanged venomous snakes in South Asia with wide varieties 
across different areas. Sri Lanka and Southwestern India share similar biogeography and 
most of the venomous species concerned. For decades, deadly venomous snakes 
prevalent in the region were thought to mainly consist of the Big Four: the Indian cobra 
(Naja naja), the krait (Bungarus caeruleus) (and B. ceylonicus in Sri Lanka), the 
Russell's viper (Daboia russelii) and the saw-scaled viper (Echis carinatus). 
Envenomation by these snakes were identified based on clinical history and syndromes; 
while the definite treatment has been conventionally the polyvalent antivenom raised 
against venoms of the Big Four, produced by Indian manufacturers (Joseph et al., 2007; 
Ariaratnam et al., 2009; Alirol et al., 2010). Nevertheless, like the countries in Africa 
and Latin America, the management of snakebite envenomation in South Asia faces 
challenges such as patient access to healthcare, dissemination of knowledge and 
education for public and medical personnel, improvement of diagnostic methods, and 
improvement of the efficacy, species coverage as well as distribution of antivenoms 
(Gutiérrez et al., 2006; Chippaux, 2008; Alirol et al., 2010). In addition, the properties 
of many snake venoms, especially related to toxin variations, awaits further exploratory 
studies for a better understanding of the pathophysiology and for finding a solution to 
the failure of antivenom therapy in some cases. The emergence or re-identification of 
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some venomous species which were previously overlooked, due to a lack of taxonomy 
knowledge or misidentification, is another pertinent issue relevant to snake 
envenomation in this region, as exemplified by the hump-nosed pit viper, Hypnale 
hypnale (Joesph et al., 2007; Ariaratnam et al., 2008).  
 
1.3 Envenomation by Hypnale hypnale 
 
In Sri Lanka and Western Ghats of India, bites from the hump-nosed pit viper (Hypnale 
hypnale) have recently been authenticated as the leading cause of snakebites with severe 
complications: local tissue destruction, hemostatic dysfunction (coagulopathy, 
fibrinolysis, thrombocytopenia, spontaneous systemic hemorrhage) as well as acute 
kidney injury, with an overall fatality rate of 1.7% (Joesph et al., 2007; Ariaratnam et 
al., 2008). The authentication that confirmed the emergence of H. hypnale as a snake of 
medical importance capable of lethal envenomation has rendered the earlier “Big Four” 
concept obsolete in terms of its completeness. Sound clinical and epidemiological 
studies are also restricted due to ambiguous venomous status and frequent 
misidentification of the snake (Simpson and Norris, 2007; Alirol et al., 2010). 
 
Despite the severity and urgency of the problem, there is no species-specific antivenom 
ever produced against H. hypnale envenoming; while the existing antivenoms available 
in the region were all proven ineffective clinically (Joseph et al., 2007; Ariaratnam et al., 
2008). Patients envenomed by H. hypnale are therefore given supportive and ancillary 
treatment including amputation for unsalvageable necrotic limb that adds to the toll of 
human suffering.  Other severe complications such as acute kidney injury and delayed 
extensive hemorrhages (Ariaratnam et al., 2008; Sunanda et al., 2010) further 
complicate the clinical management. Besides, the problem of H. hypnale envenoming is 
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further confounded by inaccurate diagnosis of the biting species, very often as Echis 
carinatus or Daboia russelii. This results in suboptimal syndrome monitoring and 
unwarranted antivenom therapy that exposes patients to fatal adverse reactions, besides 
incurring high cost of the antivenom. The root of the problem regarding H. hypnale 
envenomation hence appears to be a gap in the research knowledge of the venom 
biomedical properties (that can help elucidate the envenoming pathophysiology and 
improve diagnostics), a lack of effort in the search for an effective antidote for the 
envenomation, in addition to confusion of the snake taxonomy and systematics. 
 
1.4 Objectives of the study  
 
 
A research project on the toxinological profiles of H. hypnale venom, with a problem-
based and solution-oriented approach, is therefore relevant to holistically address the 
envenoming issue. The current study endeavored (i) to elucidate the toxinological 
properties of the venom via biochemical assays coupled with in vitro and in vivo animal 
models, (ii) to search for effective antidotes, (iii) to enhance the diagnostics of the biting 
species, and (iv) to demonstrate the feasibility of a specific antivenom production. The 
specific objectives are summarized as follows: 
 
1. To study the toxinological properties of Hypnale hypnale venom and its 
fractionated components, using biochemical assays and animal models. 
 
2. To establish the lethal and toxic parameters for H. hypnale venom and to study 
the neutralizing efficacy of selected antivenoms, using both in vitro and in vivo 
approaches. 
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3.  To examine the neutralization of nephrotoxic effect of H. hypnale venom by a 
paraspecific antivenom in a mouse model. 
 
4. To study the immunogenicity of H. hypnale venom in rabbits for the production 
of polyclonal antibody raised against the venom. 
 
5. To assess the feasibility of the production of H. hypnale-specific antivenom at 
laboratory setting. 
 
6. To develop a diagnostic assay for the identification of biting snakes (H. hypnale, 
Echis carinatus, Daboia russelii) using immunoassay. 
 
7.  To study the pharmacokinetics of H. hypnale venom and changes effected by the 
use of a paraspecific antivenom in a rabbit model. 
 
8.  To study the proteomic profile of H. hypnale venom. 
 
9. To isolate and characterize the major procoagulant enzyme from H. hypnale 
venom. 
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2.1 Snakes: evolution and taxonomy 
 
2.1.1 Evolution of the Serpentes 
The amniotes advanced their Labrynthodonts predecessors (specialized, toothed ancient 
amphibians) by developing terrestrially-adapted eggs, i.e. amniotic or shelled eggs 
which could be laid on land, as typified by basal amniotes such as Casineria (~340 mya 
in the Mississippian epoch, Lower Carboniferous Geologic Period) (Laurin and 
Reisz,1995; Monastersky, 1999; Paton et al., 1999). Traditional classification 
recognizes Reptilia as a class of the amniotes, but this it has come under critique from 
cladistics as the class is indeed paraphyletic with two other classes (Mammalia and 
Aves) being given rise by the reptiles as defined. Based on phylogenetic studies, the 
clade Amniota was instead shown to have diversed into two main classes: the Synapsida 
(mammals/ reptilian-like stem-mammals and their extinct kinds) and the Sauropsida 
(true reptiles and other amniotes more closely related to reptiles than to mammals) 
(Gauthier et al., 1988; Benton, 2004; van Tuinen and Hadley, 2004). The latter evolved 
into several clades along which included the extremely diverse Diapsida, which gave 
rise to the extinct lineages e.g. dinosaurs and pterosaurs; and the living crocodiles, 
tuatara, lizards, snakes, as well as birds (Aves) (Gauthier, 1994; Laurin and Gauthier, 
1996).  
 
One major obstacle in the studies of snake evolution is that the vast majority of snakes 
are small with typically fragile skeletons, making fossilization uncommon. Putative 
fossils, readily identified as snakes, dating as far back as 150 million years to the late 
Jurassic period have been discovered, though the traces were evanescent (Durand, 2004). 
Yet, fossils with lizard-like skeletal structures, representing some transitional forms 
have been found: there were no less than four separate genera, dating back to the 
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Cretaceous period, that were equipped with stubby, vestigial hind legs. Three of these, 
the Eupodophis, Haasiophis and Pachyrhachis, were discovered in prehistorical marine 
environment in the Middle East (Caldwell and Lee, 1997; Rieppel et al., 2003; 
Houssaye et al., 2011), consistent with the hypothesis that snakes once evolved from 
water-dwelling reptiles. However, Najash, a fossil from the Cretaceous of Argentina 
bore not only robust hind limbs but a sacrum that allowed the limbs to articulate with 
the backbone, was probably the most primitive snake yet known, and its anatomy 
suggests a terrestrial, burrowing origin for snakes (Apesteguía and Zaher, 2006). The 
prevailing view today is that snakes descended from burrowing terrestrial varanoid 
lizards, at least that the two share a common ancestor. Hence they evolved in parallel to 
the varanids and the helodrems, which are the New World venomous lizards and newts, 
to which they are still close (Chippaux, 2006). Through millions of years, and through 
several events of tectonic plates changes on Earth, snakes of different sizes and physical 
characters appeared and disappeared depending on the available environmental niches 
and how “fit” one was to cope with the force of Nature Selection. To date, the colubrids 
(of Colubridae), representing the “typical modern” snakes, with smaller body size but 
faster movement than the more primitive boids and pythons, make up over two-thirds of 
all living snake species (Greene, 1997; Vidal, 2002) .  
 
An interesting (perhaps the most important) progress seen in the reptilian evolution was 
the emergence of venom-producing species. Reptilian venoms used to be thought as 
independently developed among the venomous lizards, newts and serpents – even so 
among the various seemingly polyphyletic families of venomous snakes as a result of 
convergent evolution 60-80 mya. Surprisingly, recent discoveries of venom toxins in 
snake subfamilies previously thought to lack them (Fry et al., 2003a; Lumsden et al., 
2005; Pawlak et al., 2006), and the evidence that nearly all non-venomous snakes 
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produce venoms to a certain extent (Fry et al., 2003c, 2008; Fry, 2005), suggested a 
single, and thus far more ancient origin for venom in Serpentes than had ever been 
considered. Phylogenetic study by Vidal and Hedges (2005) dated the ancestry of 
venomous reptiles back at least to 200 mya to the Late Triassic/Early Jurassic, 
before/during the divergence among anguimorphs, iguanians and ‘advanced’ snakes, 
which formed a hypothetical venom clade named “Toxicofera”.  Fry et al. (2006) and 
Vonk et al. (2008) subsequently showed that the evolutionary origin of reptilian venom 
proteins and their delivery systems may indeed have rooted deep in the phylogeny of 
squamata, across the families Caenophidia, Anguimorpha, and Iguania (also see section 
2.2). These findings revolutionize the knowledge of evolution and systematics of 
venomous reptiles, which in turn provides a better understanding of venom distributions 
across snake families (Fry et al., 2008). This greatly widens the research platforms in 
the field of toxinology: re-evaluation of the venomous status of snakes, comparison of 
the compositions and mechanisms of venom toxins, clinical study of envenomation and 
antivenom therapy, and drug discoveries from a larger venom reservoir full of 
pharmacologically active compounds previously under-explored.  
 
2.1.2 Taxonomy of the snakes 
Taxonomy and systematics of snakes are important in toxinology: they ensure 
replicability of research results, production of appropriate antivenoms, correct clinical 
diagnosis and the subsequent management. Snakes generally follow the scientific 
classification: Animalia: Chordata: Reptilia: Squamata: Serpentes (suborder). These are 
followed by two main groups, each representing an infraorder: the Scolecophidia 
(blindsnakes and threadsnakes, ca. 340 species) and the Alethinophidia (ecologically 
diverse, ca. 2640 species). Among the Alethinophidians is the superfamily Caenophidia 
(ca. 2470 species), considerably more advanced snakes in terms of predation behavior 
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by their widely use of venom and/or constriction. In the past one to two decades, several 
large bodies of phylogentic works resulted in extensive revisions of the systematics of 
snakes, especially those with medical and toxinological concerns. The advances in this 
aspect could not be possible without the use of molecular techniques in correlating the 
mitochondrial DNA, venom gland messenger RNA and venom chemistry that greatly 
complemented the ‘gaps’ in fossil records for visualizing the evolutionary 
interrelationships among the species. Recent molecular phylogenetic studies showed a 
near consensus of the evolutionary relationship in the Caenophidia, that the 
Caenophidians evolved from a single common ancestor into several (super)families 
where each represent an independented monophyletic lineage within the Caenophidia 
(Slowinski and Lawson, 2002; Fry et al., 2003b; Lawson et al., 2005; Vidal et al., 2007). 
More interestingly, the ancestor was a venomous one with at least some parts of a 
venom delivery system; and this was later shown as homology in all venomous 
squamata (Toxicofera), dating the venom evolution to a much earlier time (Vidal and 
Hedges, 2005; Fry et al., 2006). However, the translation of these phylogenetic data into 
a stable family-level taxonomy of venomous snakes has not been reached (Lawson et al., 
2005; Vidal et al., 2007). A more restrictive approach adopted by Vidal et al. (2007) in 
the classification of venomous snakes (Caenophidia) is presented in Figure 2.1; while 
snake genera with medical or toxinological interests are shown in Table 2.1. 
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2.2 Advanced snakes: venom delivery system and toxin compositions 
 
The venom delivery systems have evolved in several living groups of reptiles, 
classically the advanced front-fanged venomous snakes and helodermatid lizards 
(Kochva, 1978; Minton and Minton, 1980; Zug, 1993). Recent findings indicated that 
venom systems exist too in many rear-fanged snakes and non-helodermatid lizards, 
collectively grouped as the toxicofera (Fry et al., 2006; Vonk et al., 2008).  
 
Among snakes, species within the Elapidae and Viperidae families, and, the sister 
genera Atractasppis and Homoroselaps within the Atractaspidine subfamily of the 
Lamprophiidae family, have elaborate, morphologically-specialized high-pressure front-
fang venom systems, with a characteristic but different pattern for each group (Fry et al., 
2008). Snake venom glands are located posterior to the eye and extend in a line along 
the upper jaw, while ventrally the supralabial mucous glands extend along the entire 
length of the upper jaw. In all front-fanged snakes, venom is delivered through muscular 
compression of the glands that helps propel it along venom duct towards the fang 
(Figure 2.2a). Differing from non-venomous primitive constrictor snakes e.g. pythons 
whose teeth lack groves (aglyphous), venomous snakes typically displayed the 
following three types of dentitions (Figure 2.3) (Gopalakrishnakone et al., 1990; 
Mackessy, 2010a): 
 
- Ophistoglyph: rearward-grooved teeth, vernacularly termed rear-fanged due to 
the teeth position in the mouth. These snakes are mainly found in the family 
Colubridae. 
- Proteroglyph: forward-grooved teeth, positioned at the anterior end of the 
maxilla, generally short, unique to the elapids. 
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- Solenoglyph: pipe-grooved teeth, anteriorly positioned and supported by a 
reduced “maxillary nub” at each side. These fangs can be as long as half the 
length of the head, foldable (against the upper palate), and rotatable in biting 
position. The dentition is unique to vipers and pit vipers, as well as Atractaspis 
(with slight difference). A typical solenoglyphous fang is shown in Figure 2.2b. 
 
Although the solenoglyphous dentition displayed by viperids appears to be the most 
mechanically sophisticated and so generally thought to be the most derived, both a 
common origin and an independent evolution of the proteroglyph and solenoglyph 
systems have been inferred (Fry et al, 2009; Kardong, 1982). The caenophidian venom 
apparatus has indeed experienced extensive evolutionary tinkering with a wide range of 
independently changing variables (from biochemical variation to the variation in 
dentition and glandular morphology), thus giving rise to myriad toxins associated with 
diverse venom systems (Vidal, 2002; Fry et al., 2008). The prominent front-fanged 
system appeared three times independently: once early with viperids, once within 
atractaspidines, and once within elapids, while the rear-fanged system, although 
evolutionarily appeared less efficient in injecting venoms, has maintained their toxin 
complexity suited for smaller and ‘simpler’ prey. Interestingly, further reduction in the 
size and complexity of venom system has been subsequently observed in species in 
which constriction evolved secondarily as the preferred method of predation, or when 
dietary preference switched from live prey to eggs or slugs/snails (Vidal & Hedges, 
2009).  
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Figure 2.1 Simplified taxonomy and evolutionary higher-level relationships in the 
Caenophidia based on molecular phylogenetic study by Vidal et al. (2007).
Superfamily Elapoidea 
Family Elapidae, Lamprophiidae 
Note: Hydrophiinae is a subfamily of 
Elapidae under this classification 
 
Superfamily Colubroidea 
Family Colubridae, Natricidae, 
Pseudoxenodontidae, Dipsadidae 
Superfamily Acrochordoidea 
Family Acrochordidae 
Superfamily Xenodermatoidea 
Family Xenodermatidae 
Superfamily Pareatoidea 
Family Pareatidae 
Superfamily Homalopsoidea 
Superfamily Viperoidea 
Family Viperidae 
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Table 2.1 Family-level classifications of snake genera (with subfamily if indicated) of documented or potential medical and toxonological 
interest. 
 
Family Viperidae Homalopsidae Colubridae Dipsadidae Natricidae Lamprophiidae Elapidae 
Subfamily:  
Genus 
 
Azemiophinae: 
Azemiops 
 
Causinae: 
   Causus 
 
Crotalinae: 
Agkistrodon 
Bothrops 
Calloselasma 
Crotalus 
Cryptelytrops 
Deinagkistrodon 
Gloydius  
Hypnale 
Ovophis 
Popeia 
Sistrurus 
Trimeresurus 
Tropidolaemus 
 
Viperinae:  
Bitis 
Cerastes  
Daboia 
Echis 
Macrovipera 
Vipera 
Cerberus 
Enhydris 
Homalopsis 
   Ahaetulla  
   Boiga   
Coelognathus 
Leptophis 
Oxybelis 
Telescopus 
Trimorphodon  
 Alsophis  
Boiruna 
Erythrolampr
us Liophis 
Tachymenis 
Xenodon 
   Amphiesma 
   Macropisthodon  
   Rhabdophis 
Atractaspidinae: 
Atractaspis 
Homoroselaps 
Macrelaps 
 
Psammophiinae: 
Malpolon 
Psammophis 
 
Pseudoxyrhophiinae
Langaha 
Madagascarophis 
Elapinae: 
Aspidelaps 
Bungarus 
Calliophis 
Dendroaspis 
   Hemibungarus 
Micrurus  
   Naja 
Ophiophagus 
Pseudohaje 
Walterinnesia 
 
Hydrophiinae: 
Acanthophis 
Drysdalia 
Enhydrina  
Furina  
Hydrophis 
Notechis 
Oxyranus 
Pseudechis 
Pseudonaja 
Toxicocalamus 
Vermicella 
Simplified from Mackessy (2010a); based on the findings of widely distributed venoms in the Caenophidia (Fry et al., 2003b; 2008), and the taxonomic revision proposed (Vidal et 
al., 2007).
1
6
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If the venom gland-fang complex has the analog of a syringe-and-needle instrument, 
venom is therefore the essential ‘dose’: following bite, it is injected and disseminated 
into the recipient’s biological system, in which it shall alter a wide range of 
physiological responses, often deleterious. Generally, venom is regarded as a complex 
secretion produced in a specialized gland, typically delivered via specialized systems 
that include the gland, specialized teeth/stings, and a suite of specific behaviors 
allowing the introduction of the venom into recipient tissues, usually by injecting (not 
ingested as in the case of poisoning) (Makessy, 2002; Vonk et al., 2008). 
 
The great diversity of snake venom toxins is due to their mode of evolution where diet 
plays the central role in the adaptive radiation of snakes (Daltry et al., 1996). Predator-
prey arms race (Heatwole and Poran, 1995) contributes to repeated gene duplication that 
creates redundancy and allows a gene copy to be selectively expressed in the venom 
gland, and subsequently undergoes neofunctionalization through positive selection and 
adaptive molecular evolution at accelerated rate (Kini and Chan, 1999; Kordis and 
Gubensek, 2000; Calvete et al., 2007b). Gene duplication followed by functional-
structural diversification as seen in such scenario is a typical example for molecular 
novelty. The occurrence of multiple isoforms within each major toxin family also 
evidences the emergence of paralogous groups of multigene families across taxonomic 
lineages where gene duplication events occurred prior to their divergence, suggesting an 
important role for balancing selection in maintaining high levels of functional variations 
in venom proteins within populations (Calvete et al., 2009). 
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Figure 2.2 Schematic representation of (a) structure of the venom gland-fang complex in a typically forward-fanged snake; (b) orifice found 
on a typical pipe-grooved fang. Venom-delivery machinery with pipe-grooved fangs anteriorly positioned in the mouth is seen in Viperidae snakes 
(true vipers and pit vipers). From the venom gland the venom is channeled into the superior orifice and injected into recipient tissue thought the 
inferior discharge orifice, which is strategically opened anteriorly and above the solid tip of the fang to avoid plugging by soft tissue in the case of a 
hollow tip opening, and to minimise expulsion of  venom if the tip penetrates the body of a small prey. 
Musculus compressor  
glandulae 
Venom gland  
Primary venom duct Accessory venom gland 
 
Secondary  
venom duct  
Venom canal  
& venom fang 
Inferior orifice: 
venom exit 
Superior orifice: 
venom entrance 
Anterior Posterior Lateral 
a b 
1
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Figure 2.3  Types of fang in advanced snakes with their relative dental positions (fangs and maxillae colored green and red, respectively) 
mapped onto their phylogeny in brief. Numbers indicate important evolutionary changes leading from an unmodified maxillary dentition to the 
different fang types in advanced snakes: (1) continuous unspecialized dental lamina; (2) developmental uncoupling of posterior from anterior teeth 
(evolution of posterior dental lamina); (3) differentiation of the posterior teeth with the venom gland began; (4) loss of anterior dental lamina and 
development of front fangs (Vonk et al., 2008). (Picture was reproduced by drawing with modification.) 
Elapidae 
Colubridae 
Viperidae 
Boidae; 
Pythonidae 
Ophistoglyph 
Proteroglyph 
Solenoglyph 
Aglyph 1 
2, 3 
4 
4 
1
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The biochemical composition of venoms among snake species (or even within a species 
itself) is known to vary greatly, although in general, the dominance of major protein 
families in venoms often follows broad taxonomic trend and is hence partially 
predictable. For instance, low molecular weight three-finger toxins predominate within 
the elapid venoms, while the viperid venoms are richer in high molecular weight 
enzymes of which many are proteases (Mackessy, 2010a). The multiplicity of toxins 
exhibits synergistic interactions that primarily function to aid predation and digestion; 
although in some instances (as in human encounter), envenoming usually reflects a self-
defense mechanism adapted by the snakes. The multiplicity of venom toxins and actions 
also give rise to complex clinical syndromes, but certain predominant pathology that 
can be anticipated based on the biting species. Table 2.2 lists some of the venomous 
snakes and their major venom toxins/enzymes that are medically or toxinologically 
important.  
 
With the understanding of snake high-level phylogeny and venom distribution among 
the advanced snakes, it is not surprising that considerable amount of taxonomic changes 
took place at not only family level but at the genus and species levels too (Wüster et al., 
1997; 2008). Recent advances in venomous snake systematics address the importance of 
correct species identity, especially relevant to toxinologists and clinicians, in 
safeguarding the validity of their research results and therapeutic approach for 
envenomed patients. In parallel to this, venom and toxin studies advanced tremendously 
in the past two decades; for example, the fractionation technology of venoms has 
become more complex and detailed, while molecular studies (genomics, transcriptomics, 
proteomics) now provide in-depth understanding of the expression of various toxins 
(Chippaux, 2006; Calvete et al.; 2009, Jiang et al., 2011). These achievements enable 
individual toxins to be studied beyond
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Table 2.2 Some medically or toxinologically important snakes with their major venom components and general characteristics. 
 
Family  
Genera 
Important component Molecular 
mass (kDa) 
Biological activity or effect References 
Viperidae 
 
Calloselasma 
Crotalus 
Daboia 
Echis 
  Trimeresurus 
L-amino acid oxidase 85-150 Cell damage, apoptosis Tan (1998) 
Hyaluronidase 73 Dissemination of venom Tu and Kudo (2001) 
Phospholipase A2 (Group II) 13-15 Cellular membrane damage, 
neurotoxicity, myonecrosis 
Gopalakrishnakone et al., 
(1984, 1997); Kini (2003) 
Thrombin-like serine proteases 31-36 Hemostatic disturbance Markland (1998a) 
C-type lectins 27-29 Anticoagulant and platelet modulator Leduc and Bon (1998a) 
Metalloproteinases 20-40 Hemorrhage, myonecrosis Fox and Serrano (2008) 
Phosphodiesterase  94-140 Hydrolysis of nucleic acids and 
nucleotides 
Mackessy (1998) 
Alkaline phosphomonoesterase  90-110 Hydrolysis of phosphomonoesterase 
bonds 
Rael (1998) 
Elapidae 
 
Naja 
Bungarus 
Ophiophagus 
Enhydrina* 
Three-finger toxins 
(cardiotoxin, α-neurotoxin, 
fasciculin etc) 
6-9 Potent neuromuscular inhibitor, cardiac 
cytotoxicity 
Kini (2002); Fry et al. (2003b); 
Nirthanan and Gwee (2004) 
Phospholipase A2 13-15 Neuromuscular toxicity, myotoxicity, 
lipid membrane damage 
Kini (1997, 2003); Geh & Toh, 
(1978); Brook et al. (1987) 
Cysteine-rich secretory proteins/ 
Helveprins 
21-29 Possibly inducing hypothermia and prey 
immobilization 
Yamazaki and Morita (2004) 
Acetylcholinesterase 55-60 Neurotransmission disturbance Anderson and Dufton (1998) 
L-amino acid oxidase 85-150 Cytotoxicity; anti-bacterial effect Tan (1998); Lee et al. (2011) 
Hyaluronidase 73 Venom dissemination Tu and Kudo (2001) 
Colubridae 
 
Boiga 
Coelognathus 
Trimorphodon 
 
Acetylcholinesterase 55-60 Neurotransmission disturbance Hill and Mackessy (2000) 
Three-finger toxins 
 
6-9 Neuromuscular inhibitor Fry et al. (2003b); Pawlak et 
al. (2006)  
Phospholipase A2 13-15 Myonecrosis, lipid membrane damage Huang and Mackessy (2004) 
*Enhydrina schistosa is a sea snake of the subfamily Hydrophiinae
2
1
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descriptive work for various diagnostic and therapeutic applications (Koh et al., 2006), 
e.g. agents like ancrod, captopril, eptifibatide, tirofiban, reptilase etc.  
 
2.3 Snake envenomation: epidemiology, management and challenges 
 
2.3.1 Global epidemiology 
Studies on the global epidemiology of snake envenoming have been fragmentary, and 
often posed a question of how representative local studies were of the wider 
epidemiological situation (Chippaux, 2008). Kasturiratne et al. (2008) estimated that at 
least 421,000 envenomings and 20,000 deaths occur worldwide from 5.5 million 
snakebites annually, although these figures may be as high as 1,841,000 envenomings 
and 94,000 deaths. 
 
The vast majority of the estimated burden of snakebite is in South and Southeast Asia, 
sub-Saharan Africa, and Central and South America. Despite its high incidence of 
snakebite, mortality due to snake envenoming is relatively lower in Central and South 
America when compared to other high incidence regions, possibly due to better 
snakebite management systems, including the development of locally effective 
antivenoms in many Latin American countries. India, with its population of over a 
billion people, accounted for the highest estimated number of bites and deaths for a 
single country. Under-reporting is a known issue affecting the reliability of snakebite 
incidence estimation, and this is likely reflected in the lower estimates in sub-Saharan 
Africa (Kasturiratne et al., 2008). One undisputable fact about snake envenoming is that 
it affects predominantly developing countries in the tropics/subtropics – endemic areas 
where snakebite victims often have poor access to healthcare centers, many of which are 
already suboptimal to start with. The problem has been aptly described as a “disease of 
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poverty”, and is known for its neglected status, where the solutions to such problem are 
possible only in the presence of a global partnership (Gutiérrez et al., 2006; Harrison et 
al., 2009).  
 
2.3.2 Management 
The management of snake envenomation entails first aid, diagnostics, ancillary 
treatment and most importantly, the definite antivenom therapy – the usefulness and 
safety of which depend greatly on correct diagnosis (WHO, 2005). Particularly 
challenging are issues related to the diagnosis of biting species and the efficacy as well 
as availability of antivenom. Snake diagnosis can be reliable if the species is directly 
identified by a herpetologist, but not all cases are presented with a captured or killed 
specimen at the hospital – in fact, it might be dangerous trying to capture the biting 
snake.  Diagnosis therefore depends much on patients’ descriptions, or by monitoring 
the clinical syndrome to deduce the likely cause of offending snake (WHO, 2005). For 
instance, the development of neuromuscular paralysis is suggestive of elapid 
envenoming, while incoagulable blood and hemorrhagic syndrome is likely due to 
viperid bites in certain localities. However, a delay in diagnosis would inevitably result 
in late administration of appropriate antivenom when indicated. To date, there is no 
diagnostic kit available for rapid identification of the biting venomous snakes apart from 
the CSL
TM
 snake venom detection kit used in Australia (White, 2001). 
 
2.3.3 Antivenom for snake envenoming 
In the late 19
th
 century, Albert Calmette developed the ‘antivenomous serum’ (Calmette, 
1896) which therapeutic principle remains valid to date. In current medical context, 
such therapeutic, termed antivenom, is the only etiological treatment for snake 
envenoming (Chippaux and Goyffon, 1998; WHO, 2010). Antivenoms are usually made 
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of polyclonal antibodies (immunoglobulin G, IgG) of heterologous origin, mainly 
horses and sheep which were immunized with the snake venom(s) (Theakston and 
Warrell, 1991; Gutiérrez et al., 2003). Based on the molecular mass of the neutralizing 
molecules, generally three main types of antivenom products are available (Gutiérrez et 
al., 2003): (i) whole IgG antivenom (~150 kDa); (ii) F(ab’)2 antivenom (~100 kDa); (iii) 
Fab antivenoms (~50 kDa). Antivenom exerts its in vivo pharmacological action by 
forming immunocomplexes with the venom toxins, which will be subsequently 
eliminated (by phagocytosis or renal route), hence neutralizing the deleterious effects of 
the toxins (Gutiérrez et al., 2003; 2007). Due to its heterologous origin, patients given 
antivenom are at risk of developing hypersensitive response, which may manifest as 
early (anaphylaxis) or late (serum sickness) reactions (Malasit, 1986). Various 
laboratory efforts have been advocated to improve the product purity and safety, as well 
as to minimize the allergenic properties of antivenoms, besides reducing infection risks. 
These include methods such as pasteurization, nanofiltration, affinity 
immunopurification and ion-exchange chromatography (Smith et al., 1992; 
Grandgeorge et al., 1996; Raweerith and Ratanabanangkoon, 2003; Burnouf et al., 2004; 
Khomvilai, 2008).  
 
2.3.4 Challenges in the management of snake envenoming 
Gutiérrez et al. (2006) highlighted various scientific, technological and political tasks 
needed in the form of global collaboration to improve snake envenoming prevention and 
treatment. The efficacy, quality and distribution of antivenoms are particularly of 
concern. The coverage and effectiveness of antivenoms depend greatly on the 
knowledge of venom properties and toxin variations, and this aspect has been frequently 
addressed and looked into by fundamental research. However, at the level of 
commercial production and distribution of antivenoms, there is still a serious lack of 
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antivenoms in many remote areas due to market failure (Chippaux, 1998, 2008; 
Theakston and Warrell, 2000). Suggestions that have been made to address this 
deficiency include technology transfer to facilitate local antivenom production, public-
private partnership to make antivenom accessible at reasonable price, and better 
information on the global burden of snakebite so the antivenom manufacturers would be 
able to better regulate their production, while medical authorities could effectively 
allocate antivenoms to where they are most useful and needed (Gutiérrez et al., 2006; 
Chippaux, 2008). In 2008, the Global Snakebite Initiative (GSI) was founded in 
collaboration with the International Toxinology Society and works toward the 
development of an integrated approach to overcome the long-standing antivenom crisis 
(Williams et al., 2010). Mechanisms proposed include international collaboration on 
evaluating existing antivenoms, and the application of venom proteomics in the 
production of polyvalent antivenoms with improved potency and quality (Williams et 
al., 2011). 
 
 
2.4 Toxinology of snake venom: some laboratory aspects 
 
2.4.1 Characterizing the toxic effects 
In envenoming, the clinical presentation of a victim represents a complex syndrome 
resulted from the body responses to the pharmacological actions of different 
components in the snake venom. Venom toxic effects have often been conveniently 
classified as neurotoxic, hemotoxic, cardiotoxic, nephrotoxic, myotoxic and so on based 
on the predominant clinical effect of a particular venom. Such targeted organ system-
based descriptions at times receive critique that the classification seemingly over-
simplifies the complexity of venom effects and does not represent the interaction of 
various toxins on tissues from different organs and the resultant complex systemic 
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response. Nevertheless, the descriptions have been commonly used especially at clinical 
setting, as they generally denote the prominent clinical syndrome observed and 
anticipated. This simplified classification of the venom effects probably has more of a 
practical value in planning for monitoring and management; for example, the 
preparation of intubation facility, blood products for transfusion, dialysis facility and so 
on, in anticipation of the likely pathological outcome. 
 
On the other hand, laboratory characterizations of venom toxicities cannot be over-
simplified and it necessitates multiple disciplinary approaches, involving both in vitro 
and in vivo methods. Venom toxinological studies investigate the fundamental toxic 
effects of a venom for better insight into its pathophysiology, and aim to establish 
parameters that can be useful for future references, especially in neutralization study. 
Table 2.3 summarizes some essential aspects in toxinological profiling of snake venoms, 
highlighting some commonly used experimental methods and outcomes. 
 
2.4.2. Separation of snake venom components 
Separation (and identification) of venom components is achieved by two commonly 
used methods: electrophoresis and liquid chromatography (Chippaux et al., 1991). In 
the past one to two decades, optimization and modification with sophisticated 
technologies, such as the combinational use of isoelectric focusing, 1- or 2-dimentional 
electrophoresis, high performance liquid chromatograph, and mass spectrophotometry 
enable most venom toxins to be fractionated to the purest and identified even at 
nanogram level (Li et al., 2004; Calvete et al., 2009). Detailed characterizations of a 
purified individual component are necessary for elucidating its mechanism of action, 
developing antidote for inhibition and neutralization, as well as therapeutic application 
in drug discovery.  
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Table 2.3 Important aspects for characterizations in toxinological profiling of snake venoms. 
 
Biological and toxic 
activities  
Example Method and observation References 
Enzymatic activities 
 
 
Phospholipases A2 
Thrombin-like enzyme 
Proteolytic enzyme 
In vitro; phospholipid degradation 
In vitro; fibrinogen clotting 
In vitro: caseinolysis 
 
Tan and Arunmozhiarasi, 
(1989) 
Collins and Jones (1972) 
Tan et al. (1986) 
Hemorrhagic activity Hemorrhagin In vivo: intradermal bleeding Tan and Saifuddin (1990)  
Necrotic activity Viperid venom In vivo: dermal necrosis Theakston and Reid (1983) 
Lethality A compound effect, may be 
predominated by one or more 
principal toxins  
In vivo: median lethal dose (LD50) is expressed from a dose-
response curve 
 
Theakston and Reid (1983) 
Cytotoxicity Cytotoxic components in snake 
venom 
In vitro; cell death and apoptosis on cell culture 
In vivo; reduced tumor size in mice 
Damico et al. (2007) 
Gebrim et al. (2009) 
Neurotoxicity Neurotoxic components especially in 
elapids; neurotoxins 
In vitro; isolated chick biventer cervicis or phrenic nerve-
diaphragm preparation showing neuromuscular blockade  
In vivo; whole animal study under anesthesia showing respiratory 
muscle paralysis 
Harvey et al. (1994) 
 
Geh (1993)  
Myotoxicity Myotoxins, many are phospholipases 
A2 and cytotoxins 
In vitro: direct damage on chick biventer cervicis; skeletal muscle 
cell death on cell culture 
In vivo: myonecrosis in mice 
Harvey et al. (1994) 
Geh and Toh (1978) 
Núñez et al. (2001) 
Cardiotoxicity / 
vascular effect 
Cardiotoxic components, many are 
cytotoxins from elapid venoms 
In vitro: isolated rat atria or endothelium-intact aorta showing 
decreased contractility 
In vivo: whole animal study showing decreased cardiac output and 
blood pressure; might be accompanied with electrocardiogram 
changes 
Lee et al. (1967); Bell et 
al. (1998) 
Geh (1993); Chanhome et 
al. (2010) 
Nephrotoxicity Secondary to hemodynamic changes 
(indirect effect), or caused by direct 
cytotoxic effects of the venom 
In vitro: isolated perfused kidney showed reduced glomerular 
filtration rate and cell injury 
In vivo: whole animal showed altered renal hemodynamics and 
blood/urine biochemistry abnormality 
de Castro et al. (2004) 
 
Chanhome et al. (2010) 
Hematoxicity 
(hemostatic 
disturbance) 
Procoagulant enzymes (purpurase) 
Fibrinolytic enzymes (ussurenase) 
Platelet aggregation inhibitor 
(rhodocetin) 
In vitro: formation of friable fibrin clots, fibrinogenolytic assay 
In vitro: hydrolysis of fibrin clot 
In vitro: inhibition of platelet aggregation  
 
Tan (2011) 
Sun et al. (2006) 
Wang et al. (1999a, b) 
2
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It is noteworthy that most of the separation techniques employ successive use of various 
liquid chromatographies, e.g. gel filtration, ion exchange and/or affinity columns, to 
ensure a pure entity is recovered with minimal loss of activity (Ponnudurai et al., 1994; 
Peichoto et al., 2009; Tan et al., 2012). Reverse-phase chromatography is a useful 
separating tool for venom proteins, but like electrophoretic separation, it is mostly 
reserved for physicochemical studies as the experimental condition may be harsh 
enough to render loss of biological activity of the components.  
 
More recently, with the advancement of venom gland genetic database and peptide 
mapping technology, studies of the identities of various proteins expressed in different 
snake venoms become feasible and reliable (Li et al., 2004; Serrano et al., 2005). This 
strategy has been termed venomics, based on proteomic approach in which the global 
expression of proteins in a mixture is studied (Calvete et al., 2009). This method is 
possible for identifying proteins from venoms of different species, due to the presence 
of high consensus regions within the peptides, consistent with gene duplication over 
evolutionary time that resulted in a structurally conserved protein family. Using 
sophisticated instruments like mass spectrometry coupled with bioinformatic technology, 
it is now possible to unravel snake venom composition at the molecular level (see 
Section 2.7.1-2.7.2). Following the development, antivenomics – a proteomic approach 
in studying antivenom neutralization of particular important toxins in venom was 
reported, with implication in the design and production of toxin-specific antivenom, 
believed to have improved effectiveness and lesser allergenic properties (Calvete et al, 
2009; Gutiérrez et al., 2009). 
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2.4.3   Neutralization of venom effects by antivenom 
 
Studies of neutralization of snake venoms are important preclinical assessment for 
validating the potential clinical use of an antivenom. Neutralization studies require prior 
understanding of the venom’s toxic effects that should be abolished or attenuated by the 
treatment of antivenom. All clinically relevant toxic effects (neuromuscular depressant, 
hemorrhagic, necrotic, procoagulant, or nephrotoxic activities) are important aspects to 
be assessed in neutralization, although lethality is the single most vital activity that must 
be effectively neutralized (Bogarín et al., 2000). Both in vitro and in vivo neutralization 
methods are commonly adopted: in vitro neutralization is achieved by preincubation of 
venom and antivenom followed by testing the incubate on animals, substrates, or 
isolated tissue preparation; while in vivo neutralization involves administering venom 
and antivenom independently into an animal (Lomonte et al., 2009). It is of upmost 
importance to ensure that the experiment protocols are strictly controlled and 
standardized, as the results are indicative of therapeutic potentials for clinical 
application. Methodology details such as challenge doses, routes of administration, 
animal strains, experiment end points, and definitions of ‘effective doses’ should all be 
explicitly stated. Some clinically relevant snake venom toxic effects along with the 
methods to study their neutralization by antivenom are shown in Table 2.4. 
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Table 2.4 Some medically important venom effects and neutralization by antivenom studies. 
 
Toxic effect Challenge dose  Methodology used Effectiveness measurement  Venom  Reference 
Lethality  3-5 LD50 Preincubation with antivenom for 30 
min followed by i.v. or i.p. injection 
ED50 Bothrops sp.; Naja 
sp., Echis 
oceallatus 
Bogarín et al. 
(2000); Ramos-
Cerrillo et al. 
(2008) 
Lethality Predetermined 
lethal doses  
i.p. or i.v. injection of venom 
followed by i.v. or i.m. injection of 
antivenom independently 
Survival ratio Bothrops asper; 
Micrurus 
nigrocinctus 
Léon et al., 
(1999, 2001); 
Chaves et al. 
(2003) 
Procoagulant  2 MCD Preincubatio with antivenom for 30 
min followed by plasma clotting test 
ED  Bothrops sp. Bogarín et al. 
(2000) 
Hemorrhagic 3.5 MHD Preincubation with antivenom for 30 
min followed by i.d. injection 
ED50 Echis ocellatus Ramos-Cerrillo 
et al. (2008) 
Necrotic 2.5  MND Preincubatio with antivenom for 30 
min followed by i.d. injection 
ED50 Echis ocellatus Ramos-Cerrillo 
et al. (2008) 
In vivo 
defribrinogenation 
3.2. MDD Preincubation with antivenom for 30 
min followed by i.p. injection 
Neutralizing dose Echis ocellatus Ramos-Cerrillo 
et al. (2008) 
Neurotoxicity  1 µg/ml  Antivenom added at time when 
venom produced 90% inhibition on 
indirect twitches in an isolated chick 
biventer cervicis neuromuscular 
preparation 
Magnitude (%) of reversal of 
muscle twitch blockade 
Enhydrina 
schistosa, Lapemis 
curtus, Laticauda 
colubrina, 
Aipysurus sp.   
Chetty et al. 
(2004) 
Myotoxicity Predetermined 
myonecrotic dose 
Venom injected i.m. in mice, 
followed by i.v. antivenom at various 
time points 
Plasma creatinine kinase level 
as a quantitative index of 
myonecrosis 
Micrurus 
nigrocinctus 
Léon et al. 
(1999) 
Nephrotoxicity 250 µg/ml Antivenom added at various time 
points following venom onto isolated 
renal proximal tubule preparation  
Level of lactate 
dehydrogenase (LDH) release 
indicated extent of cellular 
injury and reversal.  
Bothrops jararaca de Castro et al. 
(2004) 
 
LD50: median lethal dose; MCD: minimum coagulant dose; MHD: minimum hemorrhagic dose; MND: minimum necrotic dose; ED: effective dose; ED50: median effective dose. 
3
0
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The efficacy of an antivenom can be quantified and expressed, usually as median 
effective dose (ED50), determined from its dose-response curve or by statistical means. 
Variations of efficacy determination however are not uncommon, notably due to 
differences in venom challenge dose and routes of administration (apart from inevitable 
batch variations of venom and antivenom). It is known that neutralization studies with 
venom and antivenom do not strictly follow the “law of multiple proportions”, and the 
absorption rate of lethal toxins into blood determines the onset of systemic effects, 
which are usually the fatal ones (Bogarín et al., 2000). Generally, the efficacy of an 
antivenom to neutralize the lethal effect of a venom is lower when a higher challenge 
dose of the venom is given intravenously. In order to standardize the comparison of 
neutralizing efficacy on lethality and to avoid ambiguity using ED50 alone, the 
parameter ‘potency’, P, has been adopted by some researchers as it is independent of the 
number of LD50 used in challenge (Araujo et al.; 2008; Morais et al., 2010). 
 
Binding of antivenom (paratopes) to venom toxin (epitopes), which strength is 
described by affinity, is the most fundamental action of the antivenom in neutralization 
of venom toxic effects. Generally, the molecular regions of the toxins involved in the 
interaction with their targets are blocked, precluding their toxic action. Such blockade 
may be achieved by direct or indirect mechanisms: (a) binding of the antivenom to 
epitopes which are the ‘active site’ of the toxin, (b) antivenom binds to epitopes in the 
vicinity of the toxin’s ‘active site’, providing steric hindrance over it, and (c) antivenom 
recognizes an epitope distant from the toxic site, subsequently induces conformational 
changes in the toxin molecule (Gutiérrez et al., 2003). The recognition and binding of 
antivenom-toxin are species-specific, although in many instances an antivenom can 
cross-react with heterologous venom toxins (not included in immunization scheme for 
antivenom production), presumably due to the presence of common antigenic properties 
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between the different venoms. This may result in cross-neutralization, a well-known 
phenomenon in antivenom studies: where the antibody raised against a specific venom 
is capable of neutralizing the toxic effects of a heterologous one (Otero et al., 1996; 
Seddik et al., 2002; Rodríguez et al., 2012). Typically, these species are 
phylogenetically closely related with similar ecological niche, implying well conserved 
structure-function properties of their toxins. Cross-neutralization has important 
implications as existing antivenoms can be of therapeutic use for envenoming cases by 
heterologous snakes even in another country. This is beneficial in terms of antivenom 
utilization, as the manufacturing of antivenom costs highly and is associated with many 
marketing obstacles (Krifi et al, 1999; Chippaux, 2008), hence it is practically quite 
impossible for many under-developed countries to embark on such industry all on their 
own.  
 
2.5 Immunological approaches in studying snake venoms 
   
2.5.1 Snake venom antibody production for therapeutic purpose 
During the late 19
th
 century serum therapy was pioneered in treating microbial 
infections (diphtheria, tetanus) as well as “snakebite poisoning”. Over a period of more 
than a century, tremendous progress in the science of immunology has enabled the 
treatment of many microbial infections to “evolve” into a stage of preventive medicine, 
i.e. vaccination, which principle, in brief, is the generation of protective immunity 
iatrogenically achieved by repeatedly challenging the host with detoxified/inactivated 
toxin(s) or toxin derivatives. Snake venoms, comprised of various substances, have 
however not lent themselves to human vaccination to date even though interesting 
attempts existed, either by self-experimentation (Kagen & Muthiah, 2004) or clinical 
trial (Sawai et al., 1969). A recent case of naturally passive acquisition of immunity was 
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reported in an elderly snake handler previously bitten by an Australian death adder 
(Acanthopis sp.), evidenced by high circulating IgG titer that rendered his blood venom 
level low in subsequent Acanthopis bite; however, the condition did not prevent local 
envenoming effect (myonecrosis) (Isbister et al., 2010). Although theoretically feasible, 
human vaccination against snake envenomation, with its questionable efficacy, safety 
and ethics concerns, has never been validated for any realistic clinical application. Anti-
snake “serum therapy” thus remains amongst the few centennial medications still in use 
today. While the mode of sourcing antibody (from animals) has not changed much, the 
methods of purification and utilization of the antibody have improved profoundly 
thereon, leading to the abandonment of the term “serum therapy” in favor of a more 
concise terminology: “immunotherapy”, or “antivenom therapy” (Chippaux, 2006). 
 
Generally, the immunization protocol depends on the toxicity and the immunogenicity 
of venom, the species of animal to be immunized and the quality of immunological 
response of the hyperimmunized animal. Most commonly used animals are mammals of 
large body size such as horses (Theakston and Warrell, 1991; Gutiérrez et al., 2003). 
Adjuvants, e.g. Freunds adjuvant, are added to amplify the immunogenicity of the 
venom, and repeated injections (10 to 15) spread over a period of three to fifteen months 
may be needed for a satisfactory antibody production in the animals (Chippaux, 2006). 
The antibody titers are monitored, usually by indirect ELISA, to determine if the 
antibody production has reached an optimal level for harvest. The choice of immunogen 
as one venom (monovalent) or several in the form of a mixture (polyvalent) depends on 
many considerations: types of venomous snakes and frequency of bites in the region, 
efficacy of neutralization, adverse effects and so on. Two questions concerning the 
benefits of monovalent over polyvalent antivenoms are whether it is more efficacious 
and whether it is less allergenic – based on the belief that less amount of antivenom 
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protein is administered than with the use of a polyvalent one. However, in reality there 
is often an observable higher neutralizing potency of polyvalent antivenom than that of 
monovalent antivenom. This could be explained by enhanced immunogenicity exerted 
by different venoms in a mixture for immunization, or due to cross-neutralization 
conferred by synergistic antibodies in the polyvalent form (Chippaux, 2006). This may 
in turn imply that less amount of polyvalent antivenom is required in treatment. 
Consequently, patients will have less exposure to heterologous antivenom proteins, and 
also a lower treatment cost incurred. 
 
In many envenoming cases, identification of the biting snake based on patient’s 
description may not be reliable; hence the choice of antivenom is usually empirically 
made according to patient’s initial clinical signs and symptoms. In cases where 
diagnosis is ambiguous, a polyvalent antivenom, relevant to the local condition, seems 
to be the most appropriate choice of therapy. Besides, the manufacturing of polyvalent 
antivenom may effectively reduce the cost of high animal maintenance by minimizing 
the number of animals used and veterinarian care and hence relieving the burden of high 
production cost. 
 
2.5.2 Immunodiagnostic assay for species identification 
Diagnosis of biting snake species is clinically crucial as it guides towards the 
appropriate mode of monitoring or investigation and thw choice of antivenom (WHO, 
2005). Accurate identification of the species also has an important implication in 
epidemiology study, which will lend itself meaningless if the species documented are 
subjected to queries. In addition, species identification plays a vital role in forensic 
study (unexplained deaths and suicides suspicious of envenoming) (Selvanayagam et al., 
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1999), as well as in legal cases concerning illegal trafficking of wildlife and venoms 
(Singh et al., 2012). 
 
The most reliable species identification would probably be seen in an ideal scenario 
where the victim brings along the biting snake, live or dead, to be identified by a 
herpetologist well versed in the taxonomy of local snakes, at the hospital – this however 
is not usually possible. In fact, misidentification is not uncommon even with the real 
snake being brought to the hospital (Joseph et al., 2007; Ariaratnam et al., 2008). From 
time to time, various techniques for venom detection and identification of snake species 
have been reported, including immunological assays and DNA-based molecular 
approaches (Theakson, 1983; Ho et al., 1986a; Selvanayagam and Gopalakrishnakone, 
1999; Dong et al., 2003; Pook & McEwing, 2005). Enzyme-linked immunosorbent 
assay (ELISA), typically the double-sandwich or antibody-capture type, is likely the 
most widely studied diagnostic approach compared to polymerase chain reaction (PCR)-
related technology which is much more technically demanding and cost-inhibitive.  
 
Double-sandwich ELISA employs the principle of ex vivo antibody-antigen binding on 
a specially treated polystyrene surface, which interaction can be detected by a signaling 
enzyme-substrate reaction, e.g. horse-radish peroxidase activity (Figure 2.4). The 
antibody derived from the blood of an animal immunized with the venom or toxin of a 
particular species, has to be optimally purified to reduce non-specific binding that could 
lead to erroneous result interpretation. The purification can be achieved by affinity 
chromatography using Protein A or Protein G columns, depending on the source of 
animal plasma. Due to its sensitivity, the double-sandwich ELISA is also a commonly 
used method in determining blood venom levels in subjects following envenomation, 
both in clinical and laboratory studies (Ho et al., 1990; Ariaratnam et al., 1999; 
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Selvanayagam and Gopalakrishnakone, 1999). A limitation associated with double-
sandwich ELISA diagnostic method is cross-reactivity that could possibly reduce its 
specificity. This usually affects venoms of closely-related snakes especially of the same 
family and locality, due to the presence of appreciable amount of common antigens in 
their venoms. Le et al. (2003) demonstrated the reduction of such cross-reactivities by 
developing a species-specific ELISA kit using purified toxins specific to venoms of 
different species, and the tool has now been applied in a national clinical trial. However, 
in many countries, research for snakebite immunodiagnostic kit remains an academic 
exercise, considering the various socioeconomical constraint faced by an under-
developed country, with limited market demand and poor buying power that are 
unlikely to attract commercial investors. Currently, snake venom detection kit 
(immunodiagnostic method) is routinely used in Australia for its endemic venomous 
species (death adder, tiger snake, brown snake, black snake, and taipan) (White, 2001). 
Nonetheless, research effort in improving snakebite diagnostics should continue along 
with the call for global collaboration in addressing various challenges faced by the 
developing countries.  
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Figure 2.4 Fundamental principles of a double-sandwich ELISA (with horseradish 
peroxidase enzyme) in the detection of venom antigens. The coated IgG binds 
specifically to the venom proteins, while the other non-binders (serum components) will 
be eliminated through washing. With multiple epitopes, the venom protein antigens will 
be then bound by the secondary IgG which is HRP-conjugated. Addition of substrate 
(OPD) leads to HRP enzymatic reaction signaled as light absorbance.   
 
IgG: polyclonal immunoglobulin G produced from immunization with a specific venom 
Solid phase: polystyrene ELISA microtiter plate 
HRP: horseradish peroxidase 
OPD: o-phenylenediamine (substrate for horseradish peroxidase) 
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2.6 Pharmacokinetics of snake venoms 
 
2.6.1 General approach in studying venom pharmacokinetics 
Pharmacokinetics in classical sense refers to the study of a series of events a substance 
(usually a drug) undergoes when it is applied externally into a living organism. The 
processes involved are absorption, distribution, metabolism and excretion, with the 
latter two often collectively referred as elimination. The concept of pharmacokinetic 
model has been applied in the study of snake venoms, although literature on snake 
venom pharmacokinetics is apparently scarce compared with that on general 
biochemical characterizations of venoms. Venom pharmacokinetic studies were usually 
conducted on small laboratory animals like mice, rats and rabbits, making interspecies 
comparison and correlation of the data to human somewhat complicated, as 
pharmacokinetics depends greatly on various physiologic properties, which in essence 
are related to the organ mass size and body surface area of the animal. Added to this 
complex picture is the venom’s nature as a mixture of various proteins, for which the 
‘pharmacokinetics’ in strict sense needs to be interpreted carefully. In spite of these 
limitations, venom pharmacokinetic studies are essential in view of the scarcity of its 
database and the useful information that can be derived for improved understanding of 
the evolution of clinical syndrome and treatment protocols.  
 
Venom pharmacokinetic experiments focus on the changes of venom concentrations in 
blood over a time course. Data from such studies provide information on the absorption, 
distribution and elimination of venom in a biological system, although, these data must 
be noted to be representative of various components in the venom as a whole. A purist 
approach in studying venom pharmacokinetics may involve studies on various toxins 
individually isolated from the whole venom, e.g. alpha-neurotoxins and thrombin-like 
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enzyme (Ismail et al., 1996; Zhao et al., 2001). However, the effects (and presumably 
the kinetic behaviors) of the venom are likely influenced by the interactions of various 
components in its mixture state, and hence may not optimally represent the profile of 
actual envenoming. Some independent variables that are important when designing 
venom pharmacokinetic experiments include the route of administration, and the time 
points, and duration of blood sampling. Intramuscular or subcutaneous injection of 
venom is certainly more representative of a natural bite, but may generate a more 
complex picture where certain parameters differ greatly from that of intravenous route. 
Sampling times are important especially in the beginning phase where distribution takes 
place as it provides crucial information for compartmental analysis.  
 
Some of the aspects commonly discussed in the study of venom pharmacokinetics are 
listed below with their implications in the study of envenoming: 
 
(a) Compartmental model:  This is a mathematical model without truly defining any 
anatomical space. Usually a 2-compartment model is described, with one 
compartment representing the peripheral tissues into which the venoms deposit, and 
the other compartment representing the blood and highly perfused organs where 
venoms circulate freely. A 3-compartment analysis is possible with certain toxins 
penetrating much further into deep tissues which form the third compartment. 
Equilibrium always exists among these compartments where the venom toxins 
transfer accordingly.  
(b) Distribution: In a 2-compartment model, this refers to the reversible movement of 
venom toxins to penetrate and bind onto peripheral tissues after they are introduced 
into the blood (through intravenous injection, or absorption from bite site). A larger 
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volume of distribution (Vd) signifies a higher affinity of the substance towards 
peripheral tissues than the circulating blood. 
(c) Elimination: This is the irreversible removal process of venom toxins following 
metabolism and/or excretion. The slower the elimination process, the longer the 
venom toxins remain in the system, and the likelihood of more profound toxic 
effects induced. 
(d)  Clearance: It measures how fast venom toxins are removed from the system, usually 
expressed as unit volume of blood (being cleared of the toxins) per unit time. Total 
body clearance or systemic clearance is a summation of all clearance processes, 
whether by metabolism or excretion.  
(e)  Half-life:  Generally it refers to the time required for the venom concentration (in 
blood) to reduce to 50% of its initial level.  It often differs between the phases of 
distribution and elimination, where the former is shorter (rapid distribution) than 
the latter (slow elimination). Conventionally, the plasma half-life refers to the 
elimination half-life. 
(f) Bioavailability: This is a measurement of the extent of venom toxins entering the 
systemic circulation through any route of administration. Bioavailability of a drug 
by i.v. route is 100%. However, intramuscular or subcutaneous injection would be 
more common in actual envenoming, and the venom bioavailablity by these non-
vascular routes may be lower than that of intravenous injection.  
 (g) Area under the curve: This parameter can be used to estimate the amount of venom 
toxins in the blood over a time course. It is useful in the determination of venom 
bioavailability by non-vascular routes, and in comparing the extent of 
immunocomplexation in the presence of a neutralizing antivenom. 
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On the technical aspect, the venom dose chosen has to be within a quantifiable range of 
a sensitive assay; and the levels depicted should be meaningful to reflect an actual 
situation of envenoming. Preclinical assessment of venom pharmacokinetics on animal 
models usually employs the use of a radioisotope (e.g. iodine-131) coupled to the 
venom, or an enzyme (e.g. horse-radish peroxidase or alkaline phosphatase) conjugated 
to an antibody as in ELISA (Gutiérrez et al., 2003).  There are pros and cons in both 
experimental operations and the interpretation of data. Table 2.5 summarizes the major 
differences between these two methods of venom quantitation in pharmacokinetic study. 
 
 
2.6.2 Changes of venom pharmacokinetics effected by antivenom and 
implications 
 
The pharmacological action of antivenom is by principle the formation of 
immunocomplexes with venom components, rendering them inactive prior to 
elimination by phagocytosis. The therapeutic efficacy in actual bites, however, is greatly 
influenced by the time and route of administration as well as the posology/dosing 
regimen (Chippaux, 2006). Intravenous route of antivenom administration is 
recommended for fast action, in view of the fact that most venom components (with 
molecular weights lower than that of antivenom) distribute rapidly into tissues 
following absorption. The intravenous route is also preferred over intramuscular route 
as the latter has a much lower bioavailability. An effective antivenom injected 
intravenously can reduce the blood venom level drastically and the neutralizing effect 
persists as long as the amount of free antivenom is sufficient to bind to venom toxins 
that are slowly absorbed from injection site or re-emerge into the blood from peripheral 
tissues. However, a rebound venom level is often seen following the initial 
neutralization, presumably due to an enhanced venom transfer from tissues back into the 
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blood following a shift in the intercompartmental equilibrium following the law of mass 
diffusion (Chippaux, 2006). Other possible factors contribute to a resurgence in venom 
level following antivenom administration include slow absorption of venom from bite 
site while the venom is being eliminated slower than the antivenom. The phenomenon, 
often referred to as “venom redistriubution” following immunotherapy, should be 
carefully addressed when designing the protocol for antivenom treatment (Gutiérrez et 
al., 2003). 
 
In addition, antivenom of different molecular types [whole IgG, Fab, F(ab’)2] have 
different pharmacokinetics especially related to elimination. Due to their larger 
molecular sizes (100-150 kDa), IgG and F(ab’)2 have a relatively longer elimination 
half-life as they are not readily removed by kidneys, and the affinity towards vascular 
compartment is high, i.e. less tissue-penetrating ability. Fab with a smaller molecular 
size (50 kDa) on the other hand, can be renally eliminated and hence has a shorter half-
life. It however penetrates deeper tissues and is particularly useful in binding or 
displacing smaller toxins bound to receptors of the deep tissues. The diverse 
pharmackinetics of antivenom and the complex absorption and distribution of venom 
components can potentially result in a mismatch of pharmacokinetic-pharmacodynamic 
relationship of the envenoming immunotherapy, affecting its clinical effectiveness 
(Seifert & Boyer, 2001). In vivo pharmacokinetic experiments are therefore important to 
complement neutralization tests by demonstrating an appropriate administration and 
dosing regimen for the optimization of the antivenom protocol.  
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Table 2.5 Major differences between the radioisotope and enzyme methods for measuring venom levels in pharmacokinetic studies. 
 Radioisotope method Enzyme immunoassay method 
Technical preparation Coupling of radioisotope onto the venom components is 
needed prior to injection. 
 
Stability and half-life of radioisotope need to be closely 
monitored for validity of results. 
 
Special precautionary measures are needed against 
radiation exposure (e.g. I-131 decay gives off beta and 
gamma rays) 
Antibodies (IgG) against the venom components need to be raised and purified prior to 
study.  
 
Enzyme conjugation to IgG is needed.  
 
Pure and enzyme-conjugated IgG generally can be stored (at -20 °C) without 
jeopardizing the stability and function for at least several months.  
 
Conjugated IgG serves as capturing antibody, while unconjugated IgG serves as coating 
antibody.  
 
Nature of inoculate  Venom components coupled to radioisotopes Innate venom components without chemical conjugates 
 
Measuring method Radioactivity reading, ex vivo Enzymatic activity detected as light absorbance, ex vivo 
 
Influence on duration of 
study  
Possible, radioisotope has a half-life to be taken into 
consideration (e.g. 8 days for I-131) when measuring the 
activity 
 
Unlikely, as the venom exists in vivo in its innate form 
 
Measuring target All components which are coupled to the radioisotope 
including the degraded venom components 
All antigenic components that are specific for the IgG binding 
 
Detection of 
immunocomplexation 
during antivenom 
therapy 
Unable, as the reading implies the totality of venom 
components (including both free venom components and 
immunocomplexes) before they were eliminated/excreted 
 
Reliable, as the capturing IgG binds specifically to only the unoccupied antigenic sites of 
venom components not neutralized by the antivenom 
Relevance to toxins and 
envenomation 
Useful for measuring total venom level in the system 
regardless of the nature (toxicity and antigenicity) and 
conditions (free or antivenom-bound) of venom 
components 
Generally more specific for measuring level of venom components that are antigenic 
(usually, the toxic proteins); and is able to indicate the extent of venom neutralization in 
the presence of antivenom 
 
Practical clinical use Not applicable  Applicable in measuring the blood venom antigen level from human patients. Readings 
are representative of free un-neutralized venom components.  
 
Can be used to determine the presence and amount of venom distributed to various 
organs and tissues. 
 
4
3
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Overall, an ideal antivenom should possess the following characteristics (Gutiérrez et 
al., 2003): 
 
(a)  High affinity towards the principal venom toxins 
(b)  Similar rate and volume of distribution to that of the venom toxins 
(c)  Slow elimination to ensure adequate neutralization of venom reaching the 
bloodstream later in the course of envenoming; and to accelerate venom 
redistribution (for removal) from tissue compartments.  
 
 
2.7 Proteomic studies of snake venoms 
 
2.7.1 Revealing the identities of venom proteins and the implications 
Within the Class of Reptilia, toxicofera evolved and radiated for at least 200 million 
years and a distinct development accompanying these biological events is the 
production of venom of great diversity across various taxa (Fry et al., 2006). The 
existence in the same venom of a diverse set of proteins (even of the same family) 
which differ from each other in their pharmacological effects well reflect an adaptive 
molecular evolution giving rise to molecular novelties (Calvete et al., 2009). 
Characterizations of diverse bioactive components from venom (the majority are 
proteins and peptides) have a number of potential benefits for fundamental research, 
clinical studies, development of research and diagnostic tools, drug discovery, 
antivenom production strategies (Gutiérrez et al., 2009); and even for correlation with 
taxonomy and evolutionary study of the species (Fry, 2005). 
 
Traditionally, venom biodiversity study depends greatly on bioassay-guided 
fractionation, where fractions displaying the desired activity in a particular assay are 
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further characterized. The approach, however, does not address the many other 
potentially useful components as they do not possess the particular niche of activity 
being researched. An in-depth knowledge of the identity of proteins and peptides 
expressed in venom is therefore essential; not only for basic research purpose but also to 
better elucidate envenoming mechanisms as venom toxicity is often determined by the 
combination of toxins. Venom proteomic study, termed ‘venomics’ by some authors, 
aims to identify the various venom components (essentially proteins) of both high and 
low abundances. With a robust knowledge of the proteomics of a particular venom, the 
immunoreactivity of antivenoms against individual venom components can be then 
assessed by studying the extent of immunodepletion of particular toxins when the 
venom is incubated with an antivenom prior to proteomic analysis. This in vitro 
approach, termed ‘antivenomics’, is considered complementary to preclinical antivenom 
assessment on animal models, and it provides information for an optimization of 
antivenom formulation (Gutiérrez et al., 2009). 
 
2.7.2 Molecular approach in venom proteomic studies 
The identity of a venomous protein is conventionally identified, following their 
separations, by antibody recognition or peptide N-terminal sequencing. Unfortunately, 
both these methods are inadequate for global analysis of proteins in venom. Recent 
advancement in proteomic field, with the availability of genomic sequences, powerful 
protein separating tools (various high performance liquid chromatographies, multi-
dimensional electrophoresis), modern mass spectrometers with high sensitivity and 
high-throughput coupled with sophisticated computational methods, has made global 
analysis of venom proteins/peptides possible. This however depends greatly on the 
completeness of gene sequences of a particular protein, or at least those proteins closely 
homologous. As expected, snake venoms underwent molecular adaptations under 
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accelerated evolution, where gene duplications have greatly conserved many gene 
sequences of a protein family across various taxa, hence making the homology-
orientated protein identification possible for closely related snake species. However, 
accelerated evolution also led to rapid amino acid divergence in which the peptide 
homology of some inter-species protein may appear low and deemed insignificant by 
automated search engine, although they indeed belong to a same protein family.  
 
Proteomic study involves sophisticated analytical science that greatly depends on the 
use of mass spectrometry (MS). MS is a fundamental approach that can accurately 
determine the masses of intact protein or peptides for further deduction of the amino 
acid sequence (Liebler, 2002). Tandem mass spectrometry (MS/MS) analysis involves a 
series of events where precursor ions are selected in the initial stage of analysis, and 
subjected to fragmentation to produce product ions in the second stage of analysis. This 
is followed by the analysis of the product ions to obtain the amino acid sequence of a 
peptide: each experimental peptide mass is compared with the mass of the theoretical 
peptide produced by the digestion of the protein from a selected database (de Hoffmann, 
1996; Marcotte, 2007). Where the sample is potentially a mixture of more than one 
protein, reverse-phase liquid chromatography coupled with tandem mass spectrometry 
(LC-MS/MS) will be useful, as used in several studies on venom proteins (Fry et al., 
2003c; Li et al., 2004;  Soogarun et al., 2008). 
 
The peptide sequences (internal or terminal) derived from MS/MS spectra were then 
matched to available protein databases for protein identification. Search engines that are 
commonly available include MASCOT, SEQUEST and BLAST, and search is done 
against protein database resources such as those available from the National Center for 
Biotechnology Information (NCBI), SwissProt and European Bioinformatics Institute 
(EBI). In the case where particular protein information is absent from the databases, 
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protein identification may be unsuccessful. It should be noted that venom proteins 
exhibit a wide spectrum of rapid amino acid sequence divergence, as expected under 
accelerated evolution (Ogawa et al., 1995; Kordis and Gubensek, 1996; Ohno et al., 
1998), and hence the possibility of peptide ion spectra being unmatched to an existing 
database particularly for species which genes lack sequencing studies. Specifically, 
venom gland transcriptomics plays an important role in detailing the possible protein 
sequences in becoming “venom”. Unfortunately, transcriptomic data of such may not be 
always readily available in view of the cost, technology sophistication and concern on 
wildlife conservation. To overcome the limitation of matching venom ion spectra, a 
novel proteomic-bioinformatic approach has been described by Bringans et al. (2008) 
where purified peptides were analyzed by tandem mass spectrometry, de novo-
sequenced and the homology of short sequences were matched against known peptides 
in a public protein database, using search engine such as BLAST (Basic Local 
Alignment Search Tool) that identifies regions of local similarity between sequences. 
The  In the proteomic work by Bringans et al. (2008), some extents of statistical 
stringency were modified to enable the de novo-sequenced peptides matched to the 
existing database for protein identification, and subsequently the protein family is 
determined based on the putative function assigned.  
 
Commonly employed modern methods of protein fractionation, digestion and 
sequencing in the studies of venom proteomes are shown in Table 2.6.  
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Table 2.6 Protein fractionation, enzymatic digestion and peptide sequencing 
methods in venom proteomic studies. 
 
Fractionation of 
whole venom 
 
Digestion of protein** Sequencing of 
peptides 
Reference  
1-dimensional 
SDS-PAGE 
 
In-gel tryptic digestion 
on excised gel bands 
LC-MS/MS Li et al. (2004) 
2-dimensional 
electrophoresis* 
In-gel tryptic digestion 
on excised gel spots 
MS/MS for 
peptide 
fingerprinting 
 
N-terminal 
sequencing 
 
Öhler et al.(2010) 
(Not applicable) Tryptic digestion of 
whole venom (shotgun 
analysis) 
 
LC-MS/MS Li et al. (2004) 
Reverse-phase 
HPLC and 1-
dimensional SDS-
PAGE 
In-gel tryptic digestion 
on excised gel bands 
MS/MS for 
peptide 
fingerprinting; 
N-terminal 
sequencing 
Calvete et al. 
(2007a) 
Angulo et al., (2008) 
Lomonte et al. 
(2008) 
Sanz et al., (2008) 
Fernández et al., 
(2010) 
 
Gel filtration 
HPLC and 1- or 2-
dimensional 
electrophoresis 
 
In-gel tryptic digestion 
of excised gel 
bands/spots 
LC-MS/MS; or 
MS/MS for 
peptide 
fingerprinting 
Li et al. (2004) 
Soogarun et al. 
(2008) 
 
*2-dimensional electrophoresis is typically achieved by isoelectric focusing followed by SDS-PAGE 
based on molecular mass. 
**digestion of protein is done enzymatically, usually with trypsin. Occasionally chymotrypsin can be 
used. 
MS/MS: tandem mass spectrometry 
LC-MS/MS: reverse-phase liquid chromatography coupled with tandem mass spectrometry 
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2.8 Snakebite in South Asia: with special reference to Sri Lanka 
 
2.8.1 Biodiversity and medically important snakes 
South to the Himalaya Range is one of the world’s most bio-diverse regions, with India as 
one of the eighteen “megadiverse countries”, hosting two important biodiversity hotspots: 
the Himalayas and the Western Ghats. Sri Lanka, a large island country located south to 
India subcontinent, is closely associated with the latter for their striking similarities in 
geology, climate and evolutionary history, forming “a community of species” that validates 
both areas as one biogeographic unit (Myers et al., 2000). The apparent biotic affinities 
within the Western Ghats–Sri Lanka biodiversity hotspot are the results of frequent 
migration during several extended periods of ocean-level lowstands, although the large 
number of endemics is likely credited to locally extensive radiation (Bossuyt et al., 2004). 
Where venomous snakes are concerned, both areas are infested by a number of similar 
species. The “Big Four” (Daboia russelii, Naja naja, Echis carinatus, Bungarus sp.) used 
to represent the most highly venomous snakes in this region that cause most bites. Hump-
nosed pit vipers, Hypnale hypnale, was recently added onto the list (Figure 1.3), as their 
bites were validated to be frequent, capable of causing severe complications and even death 
(Joseph et al., 2007; Ariaratnam et al., 2008). It presents two new challenges to the medical 
community: (1) there is no specific antivenom for treating H. hypnale envenoming; (2) 
revised clinical studies indeed showed that misidentification of hump-nosed pit viper was 
common, and the bite by this snake was estimated to be as frequent as that of D. russelii 
and N. naja. Other venomous snakes in the region include coral snakes, green tree pit vipers 
and sea snakes, which bites however appeared less frequently reported (Alirol et al., 2010).  
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The similarity of biodiversity between the Western Ghats and Sri Lanka was indirectly 
reflected in some common features of snake envenomation affecting both areas. This 
implies that experience of snakebite management from one area may serve as a lesson to 
the other. Collaborative work especially pertaining to the improvement of antivenom 
coverage and efficacy would be of great mutual benefit to both sides. Currently, 
antivenoms used clinically in Sri Lanka are products of India against the Big Four, which 
have been proven clinically not effective against H. hypnale envenomation (Sellahewa et 
al., 1995; Joseph et al., 2007; Ariaratnam et al., 2008). 
 
Venomous snakes of medical importance in South India have been illustrated on 
educational poster (Figure 2.5a) and circulated by the WHO Southeast Asia Office, 
highlighting the status of “The Big 5 venomous snakes” that included the hump-nosed pit 
viper. In Sri Lanka, a guide jointly published by the Environamental Foundation and 
Wildlife Conservation Society classified the hump-nosed pit viper as a moderately 
venomous snake based on the venom toxic profile; however it emphasizes and agrees with 
the opinion of the Expert Committee on Snake Bite of the Sri Lanka Medical Association 
which re-classified the hump-nosed pit viper as a “highly venomous snake” status, due to 
its high prevalence and capability in causing severe  dysfunction and death if not correctly 
treated (Figure 2.5b).   
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Figure 2.5 Educational publications regarding local venomous snakes in (a) South India; (b) Sri Lanka (inset is the enlarged portion for a 
statement found within the pamphlet).   
Source: (a) retrieved from http://www.flickr.com/groups/672105@N20/discuss/72157612167869325/; (b) courtesy of Mr Dinal Selvator from the serpentarium at 
Faculty of Medicine, University of Colombo, Sri Lanka.
 
a b 
5
1
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2.8.2 Hump-nosed pit viper (Hypnale species) 
 
2.8.2.1 Zoology, distribution and systematics 
Hypnale hypnale (hump-nosed pit viper) is by now considered as a highly venomous 
snake in Sri Lanka and southwestern coast of India (Joseph et al., 2007; Ariaratnam et 
al., 2008). It has been now listed as a snake of category I of medical importance by the 
World Health Organization (WHO, 2010), owing to its wide distribution and high 
prevalence of bites which cause significant morbidity and mortality in the region. 
Maduwage et al. (2009) reported a taxonomic revision of the hump-nosed pit viper 
(Hypnale sp.) considered to comprise three species: H. hypnale, common to Sri Lanka 
and the Western Ghats of peninsular India; and H. nepa and H. walli, both of which are 
endemic to Sri Lanka. H. walli is a junior synonym of H. nepa, and is restricted to the 
higher elevations of Sri Lanka’s central mountains, while H. zara is distributed in the 
island’s south-western ‘wet-zone’ lowlands. Envenoming by the latter two species is 
relatively infrequent, while H. hypnale, the widest distributed species in both Sri Lanka 
and the Western Ghats is responsible for most of the envenoming cases reported 
clinically (Ariaratnam et al., 2008, 2009; Alirol et al., 2010).  
 
H. hypnale has a stout body build typical of viperids, but it is relatively slender 
compared to most other crotalids, and is small in size (body length rarely exceeds 0.5 
m). It has a wide, triangle-shaped head with large frontal and parietal shields, while 
those on the snout are small and irregular. The snout is pointed and turned upwards,
 
ending in a hump (Gloyd & Connant, 1990; Maduwage et al., 2009). The color pattern 
is grayish with heavy brown mottling, overlaid with a double row of large dark spots. 
The ventral surface is brownish or yellowish with dark mottling, while the tip of the tail 
is yellow or reddish (Figure 2.6). The snake is mainly nocturnal and terrestrial. Its 
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existence is broad: it inhabits both wet and dry deciduous zones; can be found from 
secondary forests, hilly areas, various plantations to low land gardens and even latrines 
within home compounds. Though a slow mover, it easily turns aggressive if agitated, 
and is capable of making fast strikes. When confronted, it typically coils its body into 
C- or Z-shape, head raised along with hisses, and is capable of thrusting upward (where 
body left the ground momentarily) to attack. Being well camouflaged and tiny in size, it 
is also easily missed and trodden upon even in the day time, resulting in its defensive 
bite (Ariaratnam et al., 2008).  
 
H. hypnale, used to be in the Agkistrodon complex from the old systematics, was 
elevated to its current genus taxon based on morphological details and mitochondrial 
DNA analysis, which also confirmed its close phylogenetic relatedness to the Malayan 
pit viper, Calloselasma rhodostoma (Parkinson et al., 1997; Vidal and Lecointre, 1998) 
as two basal Asiatic crotalids. The close phylogenetic relationship between H. hypnale, 
found in India subcontinent and C. rhodostoma, found in Southeast Asia, is a 
fascinating example of the existence of the ‘Malayan’ element in the fauna of 
Peninsular India. This phenomenon has been known since a long time, and the cause of 
these similarities have been explained by the Satpura Hypothesis (Hora, 1949), 
according to which fauna migration followed the Satpura trends of mountain through 
Peninsular India during the Pleistocene. The validity of Satpura Hypothesis, however, 
has been disputed later by Karanth (2003), who proposed the likelihood of a convergent 
evolution as the basis to the similarities observed. The phylogenetic information 
nevertheless suggests the possibility of similar venom properties of the two species, and 
the research potential in immunological profiling of the venoms.  
Chapter 2: Literature Review  
    
 
54 
 
  
 
 
 
Figure 2.6 An adult Hypnale hypnale The snake was a live male specimen kept at the 
serpentarium of the Faculty of Medicine, University of Colombo. approximately 0.25 m 
in length, with a stout body, wide head and a pointed snout that turns upwards, ending 
in a hump, and hence the common name hump-nosed pit viper. (Snake was 
photographed with permission from the serpentarium in-charge person, Prof. Christeine 
A. G.) 
 
Inset showed a picture taken from a dissection on a dead adult specimen of approx. 0.2 
m in length. Note the relatively smaller size of the head, comparable to the proximal 
phalanx of the thumb. Exposed was the prominent venom gland (right) situated in the 
temporal region behind the eye. 
 
 
3 cm 
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2.8.2.2 Venomous bites and effects on human 
Hypnale hypnale bites have long been noted for causing local tissue destructions, as 
reflected in its local name “kunakatuwa” which means “rotten bone” (another local 
name in Sinhalese is “polonthelissa” meaning viper with upturned lip). Local 
envenoming effects include hemorrhagic blistering, necrosis, pain and swelling as part 
of inflammation, and tender regional lymphadenopathy (commonly affected the inguinal 
lymph nodes). These local effects were well documented, however for more than a 
century it had been controversial as to whether H. hypnale bites could be fatal (Davy, 
1821; Tennent, 1861; Wall, 1921; Deraniyagala, 1955; Sellahawa and Kumararatne, 
1994). However, in a few of proven or suspected early cases of H. hypnale bites, 
systemic effects e.g. coagulopathy, microangiopathic hemolysis and renal failure have 
been observed (Varagunam and Panabokke, 1970; de Silva et al., 1994; Premawardena 
et al., 1996, 1998; Kularatne and Ratnatunga, 1999; Karunatilaka et al., 2001). Recent 
clinical studies by Joseph et at. (2007) and Ariaratnam et al. (2008) authenticated the 
high prevalence and the severe complications of H. hypnale bites with an overall fatality 
rate of 1.7%.  
 
Ariaratnam et al. (2008) reported that one-half of H. hypnale bites in a series of 302 
cases occurred between 1800 h and midnight, while people were returning home from 
work and recreational activities. Approximately 50% of cases occurred within patient’s 
compound (while walking, building, gardening, picking firewood, visiting wells or 
latrines), others occurred on roads or footpaths and at agricultural sites. Male patients 
outnumbered female in frequency of bites, and most bites (81%) were inflicted at the 
lower limbs (feet or ankles). Local effects with tissue destruction were common among 
the patients, with some severe cases needing amputation and skin grafting. Systemic 
envenoming was seen in approximately 40% of cases, characterized by hemostatic 
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dysfunction (coagulopathy, fibrinolysis, thrombocytopenia, spontaneous systemic 
hemorrhage), and acute kidney injury developed in about 30% of those showing 
hemostatic disturbances. Sunanda et al. (2010) reported a case where massive 
retroperitoneal hemotoma was only detected five weeks after H. hypnale bite, with 
lower limb deep vein thrombosis developed concurrently possibly secondary to the 
pressure effect of the hematoma. It appears that envenoming by H. hypnale typically 
results in local tissue destructions as described in most viperid bites, while the systemic 
complications are associated with varied degree of hemostatic disturbances that could 
culminate in a lethal hemorrhagic disorder and possibly complicate acute kidney injury 
in the victims (Sitprija, 2008).  
 
2.8.2.3 Diagnosis, management and problems associated 
In the Western Ghats of India and Sri Lanka, diagnosis of biting snake is often made 
either by identification of the snake brought to the hospital or based on description 
given by the victims. These are not always possible especially if the bite occurs in the 
dark or in bushes.  In fact, frequent misidentification of H. hypnale as Echis carinatus or 
occasionally D. russelii had been reported (Joseph et al., 2007; Ariaratnam et al., 2008), 
even when the biting snakes were brought to the hospitals. This resulted in the 
administration of unwarranted, inappropriate antivenom, which was totally ineffective 
and costly, besides risking fatal complications, e.g. anaphylaxis. As such, Ariaratnam et 
al. (2009) proposed a syndromic approach to ascertain the cause of snake envenomation 
based on a step-wise clinical assessment on a series of envenoming features. The 
syndromic approach however may have certain limitations of use when a patient’s 
clinical progress does not follow strictly the typical syndrome outlined. For instance, the 
development of acute kidney injury is a key feature to discern between H. hypnale and 
E. carinatus envenomings for a patient with hemostatic derangement (while 
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neurologically intact – ruling out D. russelii envenoming). However, acute kidney 
injury does not complicate all H. hypnale systemic envenomations; hence the absence of 
this anticipated complication may not totally rule in E. carinatus bite and does not 
warrant its antivenom. Nevertheless, coupled with patient’s account, the syndromic 
approach mentioned currently represents the most useful clinical guide map for 
diagnosis in the absence of a reliable laboratory test for validating the biting species.  
 
To date, despite the recent authentication of H. hypnale in causing severe envenoming, 
there is still no antivenom clinically available as effective treatment. Antivenoms 
available in the region are manufactured by Indian companies, raised against the 
historical Big Four, which have been proven ineffective in H. hypnale envenoming 
(Sellahewa et al., 1995; Joseph et al., 2007; Ariaratnam et al., 2008). H. hypnale-
envenomed patients are therefore managed with supportive and ancillary treatments 
such as blood product transfusion, renal replacement therapy (usually peritoneal dialysis) 
and surgical intervention for necrotizing wounds, without the definite antidote, i.e. 
antivenom. In view of some of the envenoming effects that may develop slowly, e.g. 
prolonged coagulopathy and extensive tissue necrosis, antivenom should be given as 
early as possible to neutralize the venom in the body before its pathophysiological 
effects set far. Unfortunately, despite the lack of effective antivenom  recognized 
(Ariaratnam et al., 2008), research and production of an antidote against H. hypnale 
envenoming seemingly have not received much attention from most manufacturers, 
possibly due to market consideration and investment hindrance. The search for effective 
antivenom thus becomes an urgent effort to overcome the endemic medical crisis related 
to envenomation by H. hypnale.   
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Therefore, research works on the toxinological profiles of the venom of H. hypnale 
should address the following aspects: 
 
(1) The toxic effects of the venom, especially on the hematoxicity. Several toxins 
may be responsible for this; particularly noteworthy is the procoagulant or 
thrombin-like enzymes commonly present substantially in the venoms of vipers 
and pit vipers.  
(2) The composition of venom toxins and their correlations with the envenoming 
syndrome. Ascertaining the principal toxins is essential for clinical management 
and antivenom design. 
(3)  Antivenom assessment for paraspecific protection in view of the lack of 
effective antivenoms in the region. 
(4) The immunological property of the venom and specific antibody production. 
This will have implications in the development of a diagnostic immunoassay as 
well as antivenom production in the future. 
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3.1 MATERIALS 
3.1.1 Animals  
Male Sprague Dawley rats (~150-300 g), albino mice of ICR-strain (~15-25 g) were 
supplied by the Laboratory Animal Center, University of Malaya. New Zealand White 
rabbits (~2 kg) were purchased from Chenur Supplies, Seri Kemabangan, Malaysia. The 
use of animals was approved by the institute [ethics clearance number: 
PM/03/03/2010/FSY(R)] and the animals were handled according to the guidelines 
given by the Council for Internatiuonal Organization of Medical Sciences (CIOMS) on 
animal experimentation (Howard-Jones, 1995). As the studies involved the use of 
venom that could induce great pain and distress in animals, the number of animals had 
been minimized (n = 3-4). Nevertheless, the experimental conditions and animal 
preparation were optimized to reduce variations, and the results were analyzed with 
appropriate statistical tests for significance (see Section 3.3.3 and Methods section in 
respective chapters). 
 
3.1.2 Anesthesia 
Xylazine and ketamine were supplied by Troy Laboratories, Australia. Diethyl ether 
was supplied by R & M Marketing, Essex, UK. 
 
3.1.3 Snake venoms  
Hypnale hypnale venom was a pooled sample obtained from the milking of >10 adult 
snakes captured in Sri Lanka (Gamapha, Kelaniya, Avissawela, Colombo regions). The 
snakes were kept at the serpentarium at the University of Colombo, Sri Lanka and were 
identified by Anslem de Silva, an expert herpetologist. Daboia russelii and Echis 
carinatus sinhaleyus venoms were obtained from the same source and the snakes were 
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captured in Sri Lanka (Anuradhapura, Ratnapura, Galle, Colombo regions for D. 
russelii; and Mannar for E. carinatus sinhaleyus).  
 
The following venoms were obtained from the respective suppliers: Protobothrops 
flavoviridis, Protobothrops tokarensis, Cryptelytrops purpureomaculatus, Cryptelytrops 
albolabris, Tropidolaemus wagleri, Daboia siamensis (Thai and Myanmar origins), 
Naja nigricollis, Bungarus flaviceps, Bungarus candidus, Ophiophagus hannah, Naja 
naja (Sri Lanka), Naja sputatrix (Java) from Latoxan (France); Agkistrodon piscivorus 
leukostoma, Crotalus atrox from Sigma (USA); Crotalus viridis from Miami 
Serpentarium (USA); Popeia popeiorum, Viridovipera stejnegeri, Bothrops asper from 
Ventoxin (USA); Dendroaspis angusticeps, Pseudonaja textilis, Oxyuranus 
microlepidotus from Venom Supplies (South Australia); Calliophis bivirgatus from a 
local snake handler (Malaysia), Enhydrina schistosa from Penang Snake Venom 
Institute (Malaysia). 
 
3.1.4 Antivenoms 
Monovalent Malayan pit viper antivenom (MPVA) (Batch no. CR00909, exp.date 
2/11/2014) and Hemato polyvalent antivenom (HPA) (Batch no. HP00108, exp.date 
6/11/2013) were free gifts from Queen Saobhva Memorial Institute, Thai Red Cross 
Society (TRCS). The Bharat Polyvalent ASVS (anti-snake venom serum) (Batch 
no.A5309049, exp.date 03/2013) was supplied by Bharat Serums and Vaccines, 
Mumbai, India.  
 
3.1.5 Chemicals and consumables 
Chromatography columns and media: Resource
® 
Q ion-exchange column (6.4 mm x 30 
mm, 1 ml gel volume, 15 µm particle size), HiTrap
TM
 Protein A-Sepharose gel affinity 
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column (1.6 x 2.5 cm, 5 ml gel column, 34 µm particle size), Sephadex
®
 G-25 gel 
filtration medium and Superdex
TM
 200 HR 10/30 gel filtration column (10 × 300 mm, 
13 µm particle size) were from GE Healthcare, Uppsala, Sweeden. LiChrospher
®
  WP 
300 C18  column (250 x 4 mm, approx. 5 ml gel volumn, 5 µm particle size) was from 
Merck KGaA, Darmstadt, Germany. 
Nylon syringe filter with polypropylene housing (13 mm, 0.2 µm) and filter papers 
grade 1 (retention size: 11 µm; diameter: 180 mm) (both from Whatman Inc., USA), 
nitrocellulose filter (0.22 µm, 47 mm) (Millipore, USA), mini iBlot
® 
Transfer Stacks 
with PVDF membranes (Invitrogen
TM
, USA), 96-well flat bottom microtiter plates 
(Nunc, Denmark), Vivaspin™ centrifugal concentrators (Sartorius Stedim Biotech, 
Germany), urine test strips (Combur
TM
 10, Roche Diagnostics, Germany), disposable 
syringes (Terumo, Philippine), needles and U-100 insulin needles (Terumo, Japan) were 
purchased from the respective manufacturers. 
 
Goat anti-rabbit IgG-horseradish peroxidase (HRP) conjugate and goat anti-equine IgG-
HRP conjugate were supplied by Bio-Rad Laboratories, USA. Protein markers. i.e. 
Spectra™ Multicolor Broad Range Protein Ladder (Thermo Scientific, USA), BIO-
RAD SDS-PAGE Molecular Weight Standards Broad Range and BIO-RAD Gel 
filtration Standards (Bio-Rad Laboratories, USA) were supplied by the respective 
manufacturers. Acetonitrile (HPLC grade), ethanol, methanol and formaldehyde were 
from Friendemann Schimdt Chemicals, Germany. Glycerol, hydrogen peroxide, acetic 
acid, phosphoric acid and sulfuric acid were from J. T. Baker, USA. Glycine 
(electrophoresis grade) and Tris were from MP Biomedicals, France. Thrombin of 
bovine origin prepared as 1000 unit/mL was from Parke-Davis, USA. All other 
chemicals and reagents utilized were of analytical grade supplied by Sigma, USA. 
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3.1.6 Common buffers 
Filtered and deionized ‘ultrapure’ (Type 1) water was obtained from the ELGA 
PURELAB Option-Q water purification system (Veolia Water Solutions and 
Technologies, UK). 
 
Phosphate-buffered saline (PBS; 1X) 
PBS was prepared by dissolving 8.00 g of NaCl, 0.20 g of KCl, 2.68 g of 
Na2HPO4.7H2O and 0.24 g of KH2PO4 in 1 L ultrapure water and the solution was 
adjusted to pH 7.4. 
 
Normal saline  
Normal saline was prepared by dissolving 8.00 g of NaCl in 1 L ultrapure water and the 
solution was adjusted to pH 7.4. 
 
3.2 GENERAL METHODS 
 
3.2.1 Determination of protein concentration 
Protein concentration was determined by the protein dye binding method according to 
Bradford (1976). In brief, the Bradford reagent (5X stock) containing 0.05% (w/v) 
Coomassie Brilliant Blue G-250, 25% (v/v) ethanol and 42.5% (v/v) phosphoric acid 
was prepared with ultrapure water and stored in an amber bottle staored at room 
temperature. One millilitre of the reagent (diluted 1:4 in ultrapure water) was added 
with 20 µL standards/protein samples and incubated at room temperature for 5 minutes 
prior to absorbance reading at 595 nm. A calibration curve was constructed from a 
series of diluted bovine serum albumin, prepared from a standard 1 mg/mL bovine 
serum albumin stock. 
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3.2.2 Electrophoresis 
3.2.2.1 Sodium Dodecyl Sulfate (SDS) Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
 
SDS-PAGE was conducted in an electrophoresis (slab) system (Enduro PAGE System; 
Labnet International, USA) according to the principle of Laemmli (1970) and method as 
modified by Studier (1973). The following reagents or buffers were prepared: 
 
Solution A: 29.2% (w/v) acrylamide, 0.8% (w/v) N-N’-methylene bisacrylamide, in 
ultrapure water. 
Solution B: 1.5 M Tris-HCl buffer, pH 8.8, containing 0.4% sodium dodecyl sulfate 
(w/v). 
Solution C: 10% (w/v) ammonium persulfate, freshly prepared. 
Solution D: 0.5 M Tris-HCl containing 0.4% sodium dodecyl sulfate (w/v), pH 6.8. 
Electrophoresis buffer: 0.025 M Tris, 0.192 M glycine, 0.1% sodium dodecyl sulfate, 
pH 8.3. 
Reducing sample incubation buffer*: 62 mM Tris-HCl, pH 6.8, 2.3% sodium dodecyl 
sulfate (w/v), 10% (v/v) glycerol, 5% (v/v) beta-mercaptoethanol and 0.005% 
bromophenol blue. 
Fixing solution: 40% (v/v) methanol, 10% (v/v) acetic acid in ultrapure water. 
Staining solution: 0.2% (w/v) Coomassie Blue R-250 in the fixing solution, filtered. 
Destaining solution: 5% (v/v) methanol, 7% (v/v) acetic acid in ultrapure water. 
*For non-reducing sample incubation buffer, beta-mercaptoethanol was omitted. 
 
3.2.2.2 Preparation of separating and stacking gels 
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The gel contents were prepared according to Table 3.1 (amount sufficient for 2 gels). 
Table 3.1 Preparation of separating and stacking gels for SDS-PAGE. 
Composition 12.5% separating gel 15% separating gel 4% stacking gel 
Solution A (mL) 3.75 4.5 1.4 
Solution B (mL) 3 3 - 
Solution C (µL) 50 50 200 
Solution D (mL) - - 2.5 
Ultrapure water (mL) 2.25 1.5 6.1 
TEMED* (µL) 25 20 10 
*TEMED: tetramethylethylenediamine 
 
For separating gel preparation, upon adding TEMED, the solution mixture was swiftly 
poured between the glass plates, up to approx. 2 cm below the notch. The slab gel size 
was 10 cm x 10 cm x 0.1 cm. Ultrapure water was layered on the gel to achieve an even 
surface. Polymerization occurred within 15 min and the water was poured off. For 
stacking gel preparation, upon adding TEMED, the solution mixture was layered on top 
of the polymerized separating gel. A comb was quickly inserted to create sample 
loading wells, and was left in situ for 20 min to ensure complete polymerization. Both 
the separating and stacking gels were prepared carefully to avoid formation of air 
bubbles within the gels. 
 
3.2.2.3 Preparation and loading of protein samples 
All protein samples were mixed with the sample incubation buffer in 1:1 volume ratio. 
Heating of the mixture in a boiling water bath for 15 min was needed for reducing SDS-
PAGE. The mixture of protein sample with sample incubation buffer typically made up 
~20-25 µL. Heated samples (for reducing SDS-PAGE) were left to cool at room 
temperature. All sample mixtures were briefly centrifuged to spin down any residues on 
the wall of the preparation tubes. The sample mixtures (and appropriate protein marker) 
were then separately pipetted and loaded onto the wells created in the stacking gel.  
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3.2.2.4 Running condition 
The glass plates with gels formed within were assembled onto the electrophoresis 
chamber. The chamber were filled with the electrophoresis buffer and connected to a 
power supply. Electrophoresis was carried out with at a constant voltage of 80 volts for 
sample stacking (~14 min), followed by a constant voltage of 100 volts for sample 
separation (~2 h). The advancement of the front dye of sample was monitored. The 
electrophoresis was completed when the front dye of sample was approx. 1 cm from the 
bottom edge of the gel. 
 
3.2.2.5 Fixing, staining and destaining 
Upon completion of the electrophoresis, the plates were carefully opened to expose the 
sandwiched gel, which was then immersed in the fixing solution for 5 min prior to 
Coomassie Blue R-250 staining (for 15 min). The gel was destained in the destaining 
solution until clear.  
 
3.2.2.6 Protein molecular mass calibration by SDS-PAGE 
The log10 molecular mass of the standard proteins was plotted against their respective Rf 
(relative mobility) to obtain a calibration curve. Rf was defined as the ratio of distance 
migrated by protein to the distance migrated by front gel. The following two sets of 
protein markers, available commercially, were used:  
 
(1) Spectra™ Multicolor Broad Range Protein Ladder (Thermo Scientific, USA): 10 
proteins with molecular masses (kDa) of 10, 15, 25, 35, 40, 50, 70, 100, 140, 260; 
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(2) SDS-PAGE Molecular Weight Standrads, Broad Range (Bio-Rad, USA): 8 proteins 
with molecular masses (Da) of 7 100, 20 461, 29 054, 37 659, 51 783, 96 190, 115 
281, 200 768. 
 
3.3.3 Statistical analysis 
Median lethal dose (LD50) and median effective dose (ED50) were expressed along with 
95% confidence intervals (C.I.) according to probit analysis method of Finney (1952) 
using BioStat 2009 software (AnalystSoft Inc.). Statistical significance (p < 0.05) 
between mean values were analysed by unpaired Student’s t-test or one-way ANOVA 
(with Tukey's post hoc test), using SPSS software.  
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4.1 INTRODUCTION 
 
Snake venoms are mixtures of biologically active compounds (mainly proteins and 
peptides), with important roles in predation and digestion. The complex nature is 
unveiled by the fact that each component may target at one or more tissue receptors or 
biochemical pathways, causing profound alteration in the normal physiology of the 
envenomed. Defensive venomous bites on human result in envenoming syndromes that 
constitute a substantial health problem in many parts of the world. The problem 
becomes even more clinically challenging when knowledge of the venom’s properties is 
limited and when specific treatment i.e. effective antivenom is not available. H. hypnale 
envenoming, which is prevalent and critical in Sri Lanka, shares the characteristics of 
such a clinical issue. In this chapter, the venom was studied from the point of milking, 
followed by a series of enzymatic as well as toxic profiling. The most important 
toxinological parameter, median lethal dose (LD50), of the venom was established in 
laboratory mice for different routes of administration. The venom’s SDS-PAGE 
profiling, its fractionation by anion exchange high performance liquid chromatography 
and biological testing of each fraction were also performed. The knowledge gained from 
studying fundamental biological properties of this venom is essential for a deeper 
understanding of its clinical syndrome, for venom neutralization study, and for the 
indication for further research of relevant toxins.  
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4.2 METHODS 
 
4.2.1 Collection of the venom of Hypnale hypnale and the quantitation of average 
venom mass 
 
Each individual snake (prior to weekly oral feeding) was removed carefully from its 
terrarium with a snake hook and placed on a flat surface. The snake head was pinned 
down with the hook that was quickly replaced by the index finger, while both sides of 
the head were grasped by the thumb and the middle finger just behind its eyes. Gentle 
massage was applied to the venom glands at the post-orbital regions while the snake 
was induced to bite once through a thin film stretched to cover a polystyrene collecting 
vial. Venom expelled through the fangs was collected in the vial for each snake and 
freeze-dried individually, following which its dry mass was determined (n = 6). 
 
4.2.2 Separation of Hypnale hypnale venom by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Venoms of H. hypnale, Calloselasma rhodostoma, Cryptelytrops purpureomaculatus, 
Tropidolaemus wagleri, Daboia russelii, Echis carinatus sinhaleyus, Calliophis 
bivirgatus, Bungarus multicinctus, Naja sputatrix (10 µg each) dissolved in distilled 
water and incubated with reducing incubation buffer at 1:1 ratio (total volume = 20 µL). 
The mixtures were then boiled at 100
 o
C for 10 minutes, cooled down and centrifuged 
briefly to gather the condensed liquid. The samples were loaded onto a 15% SDS 
polyacrylamide gel, and subjected to running condition as following: constant voltage 
of 80 volts in stacking phase, followed by constant voltage of 100 volts in separating 
phase. Upon completion, the gel was stained with Coomassie Blue R-250. 
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4.2.3 Fractionation of Hypnale hypnale venom by Resource
®
 Q ion exchange high 
performance liquid chromatography 
 
Five milligrams of the venom dissolved in 200 µL of starting buffer (20 mM Tris-HCl, 
pH 8.5) was filtered with a 0.2 µm pore size syringe filter. It was then injected into 
Resource
®
 Q ion exchange column (6.4 mm x 30 mm, 1 mL gel volume, 15 µm particle 
size, 200-10,000 Å, from GE Healthcare, Switzerland) pre-equilibrated with starting 
buffer, and subsequently eluted by a linear, 0.0 to 0.5 M sodium chloride gradient (0-
30% from 5 to 30 min, followed by 30-100% from 30 to 55 min), at the flow rate of 1 
mL/min. The solvent delivery and gradient formation over 60 min was achieved using 
the Shimadzu LC-20AD high performance liquid chromatography (HPLC) system.  
Protein peaks were monitored by measuring the absorbance at 280 nm. The protein 
content of each fraction was determined by Bradford method.  
 
4.2.4 Determination of enzymatic activities 
 
(This part of work was done on the venoms of H. hypnale and Calloselasma 
rhodostoma for comparison, as well as on the HPLC-isolated protein fractions of H. 
hypnale venom. Two independent experiments were carried out on each test for each 
sample (whole venom for the two snakes; and each HPLC fraction of H. hypnale 
venom.) The average results were reported.) 
 
4.2.4.1 Protease assay 
Protease activity was measured by modification of the method described by Kunitz 
(1947). One mililiter of 1% casein in 0.25 M sodium phosphate buffer, pH 7.75, and 50 
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μL of sample solution were incubated for 30 min at 37 oC. The reaction was terminated 
by adding 1 mL of 5% trichloroacetic acid. After centrifugation at 10,000 g for 10 min, 
the absorbance of the supernatant was measured at 280 nm. One unit of protease activity 
was defined as an increase of one absorbance unit per hour at 280 nm.  
 
4.2.4.2 Phospholipase A2 assay 
Phospholipase A2 activity was determined by the acidimetric method (Tan and Tan, 
1988). The egg yolk substrate suspension was prepared by mixing one part of chicken 
egg yolk, one part of 18 mM calcium (II) chloride, and one part of 8.1 mM sodium 
deoxycholate. The pH of the substrate suspension was adjusted to 8.0 with 1 M sodium 
hydroxide. The suspension was stirred to ensure good mixing. A hundred microliters of 
sample was added to 15 mL of the substrate suspension and the rate of decrease in pH 
was recorded using a pH meter (Sartorius, Germany). A decrease of 1 pH unit of the egg 
yolk suspension corresponded to 133 μmoles of fatty acids released. 
 
4.2.4.3 Arginine ester hydrolase assay 
Arginine ester hydrolase was assayed using α-benzoyl arginine ethyl ester as substrate 
(Collins and Jones, 1972). The assay mixture contained 0.95 mL of 0.8 mM substrate in 
0.05 M Tris-HCl buffer, pH 7.8, and 50 μl of sample solution. The reaction was 
followed by measuring the rate of increase in absorbance at 255 nm. The difference in 
the extinction coefficient at 255 nm is 815 cm
-1∙M-1. 
 
4.2.4.4 Phosphodiesterase assay 
Phosphodiesterase activity was determined by a method modified from Lo et al. (1969). 
A hundred microliters of sample was added to an assay mixture containing 0.5 mL of 
2.5 mM calcium bis-p-nitrophenylphosphate, 0.3 mL of 0.01 M magnesium sulfate and 
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0.5 mL of 0.17 M veronal buffer, pH 9.0. The hydrolysis of the substrate was followed 
by measuring the rate of increase of absorbance at 400 nm. The extinction coefficient is 
8100 cm
-1∙M-1. 
 
4.2.4.5 Alkaline phosphomonoesterase assay 
Alkaline phosphomonoesterase activity was determined by a method modified from Lo 
et al. (1969). A hundred microliters of sample was added to an assay mixture containing 
0.5 mL of 0.5 M glycine buffer (pH 8.5), 0.5 mL of 10 mM p-nitrophenylphosphate and 
0.3 mL of 0.01 M magnesium sulfate. The mixture was incubated at 37 °C for 30 min. 
At the end of the incubation period, 2 mL of 0.2 M sodium hydroxide was added and 
allowed to stand for 20 min at room temperature. The absorbance at 400 nm was then 
measured. The extinction coefficient is 18500 cm
-1∙M-1. 
 
4.2.4.6 5’-Nucleotidase assay 
5’-Nucleotidase activity was determined using 5’-AMP as substrate (Heppel and 
Hilmore, 1955). A hundred microliters of sample was added to an assay mixture 
containing 0.5 mL of 0.02 M 5’-AMP (pre-adjusted to pH 8.5), 0.5 mL of 0.2 M glycine 
buffer, pH 8.5, and 0.1 mL of 0.1 M magnesium sulfate. The mixture was incubated for 
10 min at 37 °C, and the reaction was terminated by the addition of 1.5 mL of 10% 
trichloroacetic acid. The ascorbic acid method (Chen et al., 1956) was used to determine 
the inorganic phosphate content. To the above mixture, 1 mL of ascorbic acid reagent, 
containing equal parts of 3 M sulfuric acid, 2.5% ammonium molybdate, 10% ascorbic 
acid and water was added. The mixture was left at room temperature for 30 min, and the 
absorbance at 820 nm was then measured. A standard curve was constructed using 
known concentrations of inorganic phosphate. 
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4.2.4.7 Hyaluronidase assay 
Hyaluronidase activity was determined turbidimetrically (Xu et al., 1982). The assay 
mixture contained 0.45 mL of 0.2 M acetate buffer, pH 5.0, containing 0.15 M sodium 
chloride and 0.2 mg of human umbilical cord hyaluronic acid and 50 μl of sample 
solution. The mixture was incubated for 1 h at 37 °C. Reaction was terminated by the 
addition of 1 mL of 2.5% cethyltrimethyl-ammonium bromide in 2% sodium hydroxide 
solution. After 30 min the absorbance at 400 nm was measured, and the enzymatic 
activity was expressed as NFU/mg (NFU = National Formulary Units). Appropriate 
dilutions of sample were made to ensure that the difference in absorbance between the 
blank and sample was less than 0.4. Hyaluronidase (EC 3.2.1.35) of bovine testes 
origin, purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.) was used as 
standard, its activity is 270 National Formulary Unit (NFU) per mg. Various dilutions of 
hyaluronidase representing a series of NFUs were tested on solution containing 0.2 mg 
hyaluronic acid. The absorbance values were plotted against the NFUs as calibration.  
 
4.2.4.8 L-amino acid oxidase 
L-amino acid oxidase activity was determined as described in Tan et al. (1986). Fifty 
microliters of horseradish peroxidase (100 purpurogalin unit/mg) was added to 0.9 mL 
of 0.2 M triethanolamine buffer, pH 7.6, containing 0.1% L-leucine and 0.0075% o-
dianidisine and incubated for 3 min at room temperature. Sample solution (50 μl) was 
then added and the increase in absorbance at 436 nm was measured. The molar 
absorption coefficient is 8.31 x 10
3
 cm
-1∙M-1. 
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4.2.5 Determination of lethality, hemorrhagic, procoagulant and necrotic Activities  
 
4.2.5.1 Median lethal dose (LD50) 
The LD50 values of H. hypnale venom were determined for three different routes of 
injection (intravenous, intraperitoneal, intramuscular) of the venom into mice (n = 4 per 
dose) whose survival ratio was recorded after 48 hours. The sites of i.v., i.p. and i.m. 
injections were, respectively, caudal vein, left lower abdominal quadrant, left or right 
quadriceps muscles. The LD50 (and the 95% confidence intervals, CI) of the venom was 
calculated using the Probit analysis method of Finney (1952).  
 
4.2.5.2 Procoagulant activity 
Procoagulant activity was determined by the method described by Bogarin et al. (2000). 
The venom (50 µg in 0.1 mL) or venom fraction (0.1 mL) was added to 0.2 mL of 
bovine fibrinogen solution (2 g/L) at 37°C. The coagulation time (time required for 
fibrin strands to form) was recorded. A shorter coagulation time suggests higher 
procoagulant activity. 
 
4.2.5.3 Hemorrhagic activity  
Hemorrhagic activity was determined according to Theakston and Reid (1983) with 
modification. The venom dissolved in phosphate-buffered saline (50 μg in 50 μL) or the 
venom fraction (50 μL) was injected intradermally into the shaved dorsal skin of lightly 
anesthetized (by diethyl diether) mice. After 90 minutes, the animals were euthanized 
with an overdose of diethyl ether. The dorsal skin was removed carefully, and the mean 
diameter of the hemorrhagic lesion on the inner surface of the skin was measured.  
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4.2.5.4 Necrotic activity 
Necrotic activity was determined by a modified version of the method of Theakston and 
Reid (1983). The venom (50 μg in 50 μL) or venom fraction (50 µL) was injected 
intradermally into the shaved dorsal skin of lightly anesthetized (with diethyl diether) 
mice. After 72 hours, the animals were euthanized with an overdose of diethyl ether, the 
dorsal skin was removed, and the mean diameter of the necrotic lesion was measured.  
 
4.2.6 Fibrinogen clotting activity 
 
The fibrinogen clotting activity (procoagulant effect) of H. hypnale venom was tested 
further on fibrinogens from several mammalian sources. Venoms from two other 
Asiatic pit vipers, C. rhodostoma and C. purpureomaculatus, well known for their 
procoagulant effects (Tan and Ponnudurai, 1996; Tan, 2010) were studied 
simultaneously for comparison. 
 
The venom (50 µg in 0.1 mL) was added to 0.2 mL of fibrinogen solution from various 
animal sources (2 g/l) at 37 °C. The coagulation time (time taken for fibrin strands to 
form) was recorded.  To study the time course of venoms procoagulant activities, each 
venom (50 µg in 0.1 mL) was added to 0.2 mL of fibrinogen solution (2 g/l) 
preincubated at 37 °C. The absorbance of the mixture at 450 nm was read up to 10 
minutes to monitor the formation and degradation of fibrin clots. 
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4.3 RESULTS  
 
4.3.1 Collection and quantitation of Hypnale hypnale venom  
 
Lyophilization left the venom milked from H. hypnale in yellowish crystalline powder 
form. In the investigation of venom yield, the milking of six adult H. hypnale snakes 
yielded 10.0 mg, 8.7 mg, 11.4 mg, 20.0 mg, 12.2 mg and 15.6 mg, individually, of 
lyophilized venom. The average amount of venom obtained per milking is therefore 13 
mg (± 4.2 mg).  
 
4.3.2 SDS-PAGE profiling of Hypnale hypnale and several Asiatic snake venoms 
 
The SDS-PAGE showed that the venoms of H. hypnale and several Asiatic vipers and 
pit vipers (except Tropidolaemus wagleri) contain predominantly moderate-to-high 
molecular mass proteins. In contrast, proteins of low molecular masses are abundant in 
the elapid venoms with relatively lesser high molecular mass proteins (except 
Ophiophagus hannah)  (Figure 4.1).  
 
4.3.3 Lethality of Hypnale hypnale venom  
 
The lethality of the venom was expressed in term of median lethal dose (LD50), with 
comparison made among the different routes of administration. The intravenous, 
intraperitoneal and intramuscular median lethal doses of H. hypnale venom were, 
respectively, 0.90 µg/g (95% CI: 0.42-1.84 µg/g), 6.0 µg/g (95% CI: 4.20-8.10 µg/g) 
and 13.7 µg/g (95% CI: 8.44-19.50 µg/g) of mouse body weight.  
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Figure 4.1 SDS-PAGE of the venoms of Hypnale hypnale and several Asiatic 
snakes. The venoms (10 µg each) were loaded on a 15% SDS polyacrylamide gel and 
electrophorosed under reducing condition. Left panel shows the typical possible protein 
families found in the venom; right panel shows the molecular weights; lower panel 
shows the species of the snakes with the subfamilies they belong to. 
 
Hh: Hypnale hypnale; Cr: Calloselasma rhodostoma; Cp: Cryptelytrops 
purpureomaculatus; Tw: Tropidolaemus wagleri. (Crotalinae) 
Dr: Daboia russelii; Ec: Echis carinatus. (Viperinae) 
Bm: Bungarus multicinctus; Cb: Calliophis bivirgatus; Ns: Naja sputatrix;  
Oh: Ophiophagus hannah. (Elapinae) 
 
PDE: phosphodiesterase, LAAO: L-amino acid oxidase, SVMP: snake venom 
metalloproteases, SVSP: snake venom serine proteases; CRiSP: cysteine-rich secretory 
proteins, PLA2: phospholipase A2, CTL: C-type lectin, 3-FTX: three-finger toxin, MM: 
molecular mass. 
 
 
Elapinae Viperinae Crotalinae 
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4.3.4 Biological properties of Hypnale hypnale and Calloselasma rhodostoma 
Venoms  
 
H. hypnale venom exhibited enzymatic properties similar to C. rhodostoma venom 
(Table 4.1), which are quite typical of pit viper venoms, notably the presence of 
arginine ester hydrolase and potent protease activities. 
 
H. hypnale venom also showed potent procoagulant or thrombin-like enzyme activities 
(lower than that of C. rhodostoma), as well as hemorrhagic and necrotic properties 
(higher than or similar to that of C. rhodostoma).  
 
 
4.3.5 Fractionation of Hypnale hypnale venom by Resource

 Q anion exchange 
chromatography  
 
With Resource

 Q column, an anion exchange HPLC column, H. hypnale venom was 
resolved with various NaCl concentrations at pH 8.5 to yield twelve major fractions 
(Figure 4.2). Protein determination by the Bradford method showed that fraction 12 has 
very little protein content. Fractions 1 and 2 were unbound fractions and contained basic 
proteins, while the remaining fractions generally contained proteins of an increasingly 
acidic nature.  
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Table 4.1 Enzymatic, hemorrhagic and necrotic activities of Hypnale hypnale and Calloselasma rhodostoma venoms. 
         Activity 
 
Species 
PRO PLA2 LAO AEH PME PDE 5’-Nuc HYA TLE HEM NEC 
H. hypnale
# 15.8 191.5 191.7 10.05 4.8 4.1 1.8 115.5 20 23 7.5 
C. rhodostoma
# 18.5 79.8 165.4 8.96 4.6 18.5 1.9 76.6 10 16 8.0 
H. hypnale
@ 7.8 126 110 15.2 12 6 2.7 85 22 1.6* ND 
 
PRO: protease, unit/mg; PLA2: phosphopholipase A2, µmole/min/mg; LAO: L-amino acid oxidase, nmole/min/mg; AEH: arginine ester hydrolase, 
µmole/min/mg; PME: alkaline phosphomonoesterase, nmole/min/mg; PDE: phosphodiesterase, nmole/min/mg; 5’-Nuc: 5’-nucleotidase, 
µmole/min/mg; HYA: hyaluronidase, NFU/mg; TLE: thrombin-like enzyme (procoagulant enzyme), s/50 µg venom; Hem: hemorrhagin, mm/50 µg 
venom; NEC: necrosis, mm/50 µg venom; ND: not determined. Values were the average results from two independent experiments.  
 
#
 Present study; 
@
 reference to Tan and Ponnudurai (1996); * the unit was expressed as the product of two perpendicular diameters of the lesion, which 
is different from the unit defined in the present study. 
8
0
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Figure 4.2 Fractionation of Hypnale hypnale venom with Resource
 
Q anion 
exchange chromatography. The venom (5 mg) was injected into the column 
equilibrated with 20 mM Tris-HCl, pH 8.5, and eluted by a linear, 0.0 to 0.5 M NaCl 
gradient (0-30% from 5 to 30 minutes, followed by 30-100% from 30 to 55 minutes. 
Flow rate was 1 mL/min. (-----): NaCl concentration gradient (%). 
 
 
4.3.6 Biochemical properties of the protein fractions of Hypnale hypnale venom  
 
Table 4.2 shows the biological properties of the 12 fractions obtained from Resource

 Q 
chromatography of H. hypnale venom. Fraction 1, containing the basic proteins, was 
certainly heterogeneous, as it possessed multiple enzyme activities including proteases, 
phospholipase A2, alkaline phosphomonoesterase, phosphodiesterase and 5’-
nucleotidase activities. It was also the fraction that exhibited remarkable hemorrhagic 
and necrotic activities. Other enzymatic properties were detected in the following acidic 
fractions, with generally 1-3 enzymes co-eluted in a fraction. Hyaluronidase and L-
amino acid oxidase appeared to be highly acidic proteins present in the venoms. 
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Table 4.2 Enzymatic, hemorrhagic and necrotic activities of major protein fractions of Hypnale hypnale venom obtained from Resource
®
 Q 
ion exchange chromatography. 
     Activity 
 
Fraction 
AMT PRO PLA2 LAO AEH PME PDE 5’-Nuc HYA TLE HEM NEC 
1 240 8.3 79.8 – – 0.5 9.8 0.18 – – 9 6 
2 59 – – – – – – – – 470 – – 
3 77 – 159.6 – – – – – – 212 – – 
4 32 – – – – – – 0.15 – 115 – – 
5 47 – – – 9.8 – – 0.30 – 84 – – 
6 58 – – – 2.5 – – 0.66 – 77 – – 
7 28 – – – – – – – – 146 – – 
8 18 – – – – 1.7 – – – 610 – – 
9 12 – – 13.8 – 0.9 – – 6.9 – – – 
10 41 – – 11.3 – 0.1 – – 46.9 – – – 
11 10 – – – – – – – 6.6 – – – 
12 4 – – – – – – – – – – – 
 
AMT: Total protein amount recovered in each respective fraction, µg; PRO: protease, unit/mL; PLA2: phosphopholipase A2, µmole/min/mL; LAO: L-amino acid 
oxidase, nmole/min/mL; AEH: arginine ester hydrolase, µmole/min/mL; PME: alkaline phosphomonoesterase, nmole/min/mL; PDE: phosphodiesterase, 
nmole/min/mL; 5’-Nuc: 5’-nucleotidase, µmole/min/mL; HYA: hyaluronidase, NFU/mL; TLE: thrombin-like enzyme (procoagulant enzyme), s/100 µL; HEM: 
hemorrhagic activity, mm/50 µL; NEC: necrotic activity, mm/50 µL, –: absent activity. Values were the average results from two independent experiments. 
8
2
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4.3.7 Fibrinogen clotting activity 
 
The clotting activity of H. hypnale venom showed distinct species differences. Table 4.3 
shows the procoagulant effect of the three different pit viper venoms measured in 
clotting time, while Figure 4.3 illustrated the time course of the procoagulant acticity. 
Venoms of C. rhodostoma and C. purpureomaculatus were included in the assays for 
comparison purpose. 
 
Table 4.3 Procoagulant effects of venoms from three pit vipers on mammalian 
fibrinogens. 
Venom H. hypnale C. rhodostoma C. purpureomaculatus 
Source of 
fibrinogen 
Clotting time* (s) 
(mean ± SEM) 
Clotting time (s) 
(mean ± SEM) 
Clotting time (s) 
(mean ± SEM) 
Rabbit 18.3 ± 0.9 30.7 ± 1.2 Turbidity > 120 s 
Horse 42.2 ± 1.0 40.1 ± 0.6 Turbidity > 60 s 
Dog Turbidity** > 180 s Turbidity > 180 s Turbidity > 80 s 
Goat 30.3 ± 0.9 33.0 ± 0.6 71.0 ± 0.6 
Bovine 14.3 ± 0.3 11.3 ± 0.9 56.7 ± 0.7 
Human 32.7 ± 0.7 28.4 ± 0.8 75.0 ± 0.6 
 
* Clotting time is defined as the time (s) for apparent fibrin strands to appear in the 
mixture of venom and fibrinogen.  
** Turbidity refers to cloudiness appearing in the mixture of venom and fibrinogen, 
which may be interpreted as the formation of fibrin clots.  
Results are expressed as the mean ± SEM from three experiments. 
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Figure 4.3 Time course of thrombin-like enzyme (procoagulant) activity of three different crotalid venoms on fibrinogens from several 
mammals (indicated on graph). The slope (gradient) for each curve is calculated from the steepest upward portion of the graph representing the 
maximal clotting rate expressed as absorbance/minute. Absorbance at 450 nm reflects the change in mixture clarity, which is responsible for the 
formation of fibrin strands as well as their dissolution/degradation. “Clot” used in this discussion represents the formation of fibrins.  
 
8
4
 
 
 Chapter 4: Enzymatic & Toxinological Activities 
 
  85 
4.4 DISCUSSION 
 
4.4.1 Collection and estimation of Hypnale hypnale venom average amount 
 
The maximum amount of venom injected per bite by H. hypnale is estimated to be 
around 10-20 mg, much lower than the approximately 50 mg per venom milking 
reported for its sister taxon, C. rhodostoma (Tan and Ponnudurai, 1996). This is to be 
expected as the body size of H. hypnale is small and rarely grows beyond 0.5 m (Figure 
2.3). This information has a practical implication in pharmacokinetic study of the 
venom, and in neutralization study where the usefulness of an antivenom (if available) 
is evaluated according to the venom amount injected. 
 
The prominent yellowish color of the venom, as observed in the venoms of C. 
rhodostoma and Ophiophagus hannah, suggests high content of L-amino acid oxidases 
(LAAOs) due to the presence of flavin coenzymes in LAAOs (Tan and Fung, 2010). 
Indeed, the venom exhibited high LAAO activity (Section 4.3.4), and a proteomic study 
revealed the composition of LAAOs as high as 20% of dried venom mass (Section 
10.3.2.1). 
 
4.4.2 Comparison of SDS-PAGE profiles of venoms 
 
The venoms of vipers and pit vipers generally contain toxin proteins of higher 
molecular mass, which include metalloproteases (20-60 kDa depending on the class), 
cysteine-rich secretory proteins (20-25 kDa), serine proteases (25-40 kDa), L-amino 
acid oxidase (50-60 kDa), hyaluronidase (70-80 kDa), nucleases (80-90 kDa) and so on, 
in addition to medium molecular mass proteins such as phospholipase A2 and C-type 
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lectins (13-15 kDa), as well as less abundant disintegrins of low molecular mass (6-7 
kDa) (Mackessy, 2010a). The predominance of the high molecular mass toxins, 
typically the proteolytic and hydrolytic enzymes such as metalloproteases and serine 
proteases in these venoms, correlates well with the predominant pathology and clinical 
syndrome in envenomation by these Viperinae and Crotalinae snakes: hemorrhagic 
syndrome with deranged hemostasis and consumptive coagulopathy, extensive local 
tissue destruction and necrosis; while in some advanced cases, complications involving 
target organs such as pituitary infarct (Daboia russelii) and acute kidney injury occur 
(Daboia russelii, H. hypnale) (Than-Than et al., 1989; Warrell, 1989; de Silva et al., 
1994; Ariaratnam et al., 2008). The venom of Tropidolaemus wagleri, however, is 
atypical among the other pit vipers as its principal toxins being vasoactive or neurotoxic 
polypeptides of very low molecular mass (~3 kDa), and there is very low abundance of 
high molecular mass hemotoxic proteases (Tan and Tan, 1989; Weinstein et al., 1991). 
On the other hand, the Elapinae venoms generally contain abundant low molecular mass 
toxins that belong to three-finger toxin family (~7 kDa), with potent neurotoxic and 
cytotoxic properties (Kini, 2002; Fry et al., 2003b). The venom of Ophiophagus hannah 
(king cobra), however, also contains large amount of high molecular mass proteins, 
majority of which are known to be L-amino acid oxidases (Tan and Fung, 2010).  
 
4.4.3 Lethality of the venom 
 
The variations in the median lethal doses (LD50) among the three routes of 
administration (i.m., i.p., i.v.) suggest that the potency of toxins causing lethality differs 
depending on the routes of administration. A much lower intravenous LD50 indicates 
that the venom is likely to be principally hematoxic in view of its instant procoagulant 
action causing thromboembolic events, while the intraperitoneal LD50 is higher than the 
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intravenous value possibly due to delayed and/or incomplete absorption (as in first-pass 
phenomenon) of venom toxins before reaching the systemic circulation (Ghosh, 1984; 
Turner, 1965). A relatively lower intraperitoneal LD50 value compared to the 
intramuscular value suggests a higher bioavailability of the venom readily absorbed 
from the peritoneum with its larger surface area and richer blood supplies. Furthermore, 
intraperitoneal route would avoid the potential of venom components binding and 
interacting with muscles and dermal tissues, which might disrupt the toxin absorption as 
tissue and vasculature damages ensue.  The i.v. LD50 reported herein (0.9 µg/g) is lower 
than an earlier report of 65.4 μg per mouse by Ariaratnam et al., (2008), which was 
approximately equivalent to 3 μg/g (assuming mouse body weight to be 20 g). The 
difference could be due to either geographical or individual variation of the snake 
samples, which are known sources of variations in venom composition (Mackessy, 
2010a). 
 
It is also interesting to note that median lethal doses may be slightly varied from one 
laboratory to another. Based on unpublished observation, the different sizes of needle 
used for i.v. injection could technically cause variation in the determination of LD50, as 
a ‘larger bore’ (relative to the diameter of mouse vein) hypodermic needle (< 27 gauge) 
potentially caused extravasation or wastage of content when injection was done via the 
caudal vein of mouse. Such technical variations should however be minimized using a 
more standardized protocol, to be established especially between laboratories working 
on a similar project.  
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4.4.4 Biological properties of the venoms 
 
The Hypnale hypnale venom used in this study showed higher activities of proteases, 
phospholipase A2, L-amino acid oxidase and hyaluronidase than those found previously 
by Tan and Ponnudurai (1992) who used commercially available venom source from an 
American serpentarium. This may be due to ontogenic differences as the venom used in 
this study was a recently pooled sample from snakes in their native country. The 
procoagulant activity, however, did not differ markedly between the two reports.  
 
Venoms of H. hypnale and C. rhodostoma exhibited prominent and comparable 
procoagulant, hemorrhagic and necrotic activities, which are hallmarks of the 
pathophysiology induced by viperid venoms. The general similarities in the biological 
activities of H. hypnale venom and C. rhodostoma venom are also anticipated as they 
are closely related phylogenetically, and hence the possibility of sharing similar venom 
antigens (Parkinson et al., 1997; Vidal and Lecointre, 1998). Particularly noteworthy is 
the substantially higher phospholipase A2 activity in H. hypnale venom in comparison 
to C. rhodostoma venom which usually exhibits rather low phospholipase A2 activity. 
Phospholipases A2 are known to exhibit multiple pharmacological activities, including 
lipid membrane damage, myotoxicity and myonecrosis (Kini, 1997, 2003). Substantial 
amounts of phospholipase A2, proteases and L-amino acid oxidase, known for their 
cytotoxic and tissue-damaging properties, are likely responsible for the local 
envenoming features, e.g. edema, necrosis and hemorrhagic blistering, commonly seen 
after H. hypnale bites (Kini, 2003; Fox and Serrano, 2005; Joseph et al., 2007; 
Ariaratnam et al., 2008; Tan and Fung, 2010). In addition, hyaluronidase that presents 
substantially in the venom can synergistically potentiate the venom propagation and its 
local effects, contributing to severe local tissue destruction (Girish et al., 2004). 
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4.4.5 Biochemical properties of the HPLC protein fractions of Hypmale hypnale 
venom 
 
Ion exchange chromatography separates proteins based on their ionic charges. It has 
been useful in snake venom fractionation as it does not affect the biological activity of 
eluted proteins, hence allowing their characterizations (Tan et al., 1986; Tan, 2010). The 
hemorrhagic and necrotic activities of fraction 1 were likely associated with its high 
proteolytic activity, as reported for viperid metalloproteinases (Fox and Serrano, 2005). 
Both fractions 1 and 3 exhibited phospholipase A2 activity, suggesting that the venom 
contains at least two forms of phospholipase A2. This finding is in accord with a 
previous report (Wang et al., 1999b), where only two out of four PLA2 isoforms isolated 
from H. hypnale venom, using combined gel filtration and reverse-phased 
chromatography, exhibited enzymatic activities. We suggest that these two reported 
enzymes belong to a basic form (fraction 1) and an acidic form (fraction 3), 
respectively. The other two isoforms, suggested relating to myonecrotic pathology by 
Wang et al. (1999b), were not detected by the current enzymatic micellar assay but 
revealed in the proteomic study described in Chapter 10. 
 
Hydrolytic enzymes – such as phosphodiesterase (a nuclease), 5’nucleotidase and 
alkaline phosphomonoesterase – are high molecular weight proteins known to be widely 
distributed across many snake taxa, but their toxic effects have been less extensively 
characterized partly due to the fact that these enzymes share similar substrates and 
biochemical properties (Dhananjaya et al., 2009). In general, the present results showed 
that all three enzymes were found in H. hypnale venom in appreciable amounts, 
particularly phosphodiesterase, which is usually abundant in crotalid venoms. Increase 
in phosphodiesterase activity had been associated with a drop in mean arterial pressure 
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and with locomotor depression, presumably due to reduced cAMP levels (Russell et al., 
1963). This feature, however, has not been reported in systemic envenomation by H. 
hypnale, implying that its function might be more digestive than purely toxinological. 
The chromatography result also showed that 5’-nucleotidase and phosphomonoesterase 
from H. hypnale venom exist in both basic and acidic isoforms. It is intriguing to note 
the existence of acidic phosphomonoesterase in this venom, as this enzyme, contrary to 
the basic/alkaline phosphomonoesterase, and so far only been purified from sea snake 
venoms and has rarely been reported in other snake venoms (Uwatoko-Setoguchi, 
1970). 
  
Thrombin-like activity was found to be widespread from fraction 2 to fraction 8, 
indicating that the enzyme likely existed in multiple isoforms. The two fractions 
(fraction 5, 6) with the strongest thrombin-like activity were also the two fractions that 
hydrolyzed arginine esters, suggesting that the thrombin-like enzymes exhibited 
arginine ester hydrolase activity, a property similar to that of ICR-50 arvin, a coagulant 
enzyme derived from C. rhodostoma venom (Collins and Jones, 1972). The enzyme 
esterolytic activity towards N-α-benzoyl-l-arginine ethyl ester indicated its specific 
binding to the arginine residues in its substrate.  
 
The venom also contained one or more forms of L-amino acid oxidase that appeared to 
be more acidic than many other enzymes, and its activity was noted to be lost on 
freezing. Such freeze-labile activity had been reported and the mechanism is 
presumably due to a limited conformational change of the enzyme structure (Curti et al., 
1968; Iwanaga and Suzuki, 1979). Fraction 12, which contained few proteins, was 
found to be devoid of enzymatic activities. As demonstrated, venom fractionation helps 
elucidate the different components in venoms allowing their toxic characterizations for 
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pathophysiological correlations. Nonetheless, it also opens the door to manipulating 
specific toxins in search of potential therapeutic compounds, as already observed in 
drug discoveries of ancrod, captopril etc. (Koh et al., 2006).  
 
4.4.6 Fibrinogen clotting activity 
 
The species-specificity of H. hypnale venom action on different mammalian fibrinogens 
was indicated by the differences in the clotting times (in increasing order as follows: 
bovine < rabbit < goat < human < horse < < dog). The clotting activity of C. 
rhodostoma venom exhibited a similar pattern (most and least active towards the bovine 
and dog, respectively) indicating that the thrombin-like activity of the venoms of these 
two phylogenetically related crotalids exhibited similar specificity to some extents 
towards fibrinogens. On the other hand, the specificity of the clotting activity of C. 
purpureomaculatus venom (bovine < goat < human < horse < < rabbit, dog) was 
somewhat different, and generally showed a lower clotting potency for bovine, goat and 
human fibrinogens.   
 
The clotting activities of the three venoms were also monitored spectrophotometrically 
where the turbidity of the reaction mixture was continuously monitored for absorbance 
at 450 nm. The investigation of the time course of clot assembly had also been 
described by Pirkle et al. (1986). Generally, the appearance of fibrin or clots would 
result in turbidity, while degradation of the clots would reduce this property. Figure 4.3 
shows that both H. hypnale and C. rhodostoma venoms caused rapid clotting with 
fibrinogens from bovine, goat, horse and rabbit specimens. Dissolution of clots was 
rapid in the case of horse and goat fibrinogens (turbidity reduced from 30 seconds). 
Both venoms were active in the clotting of human fibrinogen, showing a slow but 
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prolonged clotting effect. C. purpureomaculatus venom generally demonstrated 
moderate to low clotting activities, except for the case of dog fibrinogen where it 
appeared more active than the venoms of H. hypnale and C. rhodostoma. It is therefore 
suggested that a rapid clotting profile implies the possibility that the venom may 
precipitate acute thrombotic syndrome that can be instantly fatal, as observed in an 
experiment where a rabbit was injected with H. hypnale venom intravenously 
(unpublished data). In cases where clot formation is less rapid, or is accompanied by a 
concurrent degradation, the most likely cause of death would be a consumptive 
coagulopathy that gradually affects hemostasis, causing prolonged bleeding and a 
“slower” death. This is consistent with clinical features reported in cases of 
envenomation by C. rhodostoma (Reid et al., 1963; Ho et al., 1986a) and H. hypnale 
(Joseph et al., 2007; Ariaratnam et al. 2008). Deranged hemostasis leading to systemic 
bleeding has been a major feature in systemic envenomation by these crotalids. This 
severe, potentially fatal complication might only manifest itself following the bite as the 
preexisting coagulant factors get depleted or rendered inactive by the venom more 
rapidly than their production, hence tilting the hemostatic balance towards a tendency to 
bleed. A recent example was that of an extensive retroperitoneal hemorrhage only 
detected five weeks after a bite by H. hypnale in an adult patient (Sunanda et al., 2010). 
The findings indicated that frequent and extended monitoring of patient’s clotting 
profile may be necessary clinically; while at laboratory setting, the procoagulant 
enzyme from H. hypnale venom should be further isolated and characterized.  
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5.1 INTRODUCTION 
A pertinent issue surrounding the medical urgency of Hypnale hypnale envenomation in 
Sri Lanka and southwestern coast of India (Kerala) is the lack of a clinically effective 
antivnenom. Locally available polyvalent antivenoms failed to cross-neutralize the 
venom (Sellahewa et al., 1995; Premawardena et al., 1996, 1998; Joseph et al., 2007; 
Ariaratnam et al., 2008), and to date there is still no update about specific antivenom 
production to be undertaken by any pharmaceutical company. Initiating antivenom 
production is known to require intensive research and long-term monetary investment 
on various aspects:  animal (horse) farming and veterinarian care, expertise solicitation, 
laboratory facility for blood product processing and immunobiological testing, product 
quality control, antivenom packaging, storage, distribution, marketing and so on; hence, 
the expensive charges of antivenom products incurred worldwide. Unfortunately, the 
target markets - mostly developing and under-developed third world countries, are 
unlikely to promise a profitable return. The most practical solution therefore would be 
one that depends on existing heterologous effective antivenom so that the cost of 
production could be shared and minimized. In this study, we surveyed existing 
antivenoms outside the endemic area for cross-neutralization potential based on the 
likelihood of venom similarity of the snakes. Two recent products of the Thai Red Cross 
Society, monovalent Malayan pit viper antivenom and Hemato polyvalent 
antivenom,were chosen as the Malayan pit viper and H. hypnale are closely related 
phylogenically. They were tested for neutralizing potential on the lethal and various 
toxic effect of H. hypnale venom, both in vitro and in vivo in a mouse model. 
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5.2 METHODS 
 
5.2.1 Determination of lethal and toxic doses of Hypnale hypnale venom 
 
5.2.1.1 Determination of median lethal dose (LD50) and minimal lethal dose (MLD) 
The i.v. and i.m. LD50 values of H. hypnale venom were determined as described in 
Chapter 4 (see 4.2.5.1). The i.m. MLD (minimum lethal dose) of the venom is defined 
as the minimal venom dose that killed all the mice tested (n = 4) over 48 h when 
injected intramuscularly at the hind limb. 
 
5.2.1.2 Determination of minimum hemorrhagic dose (MHD) 
Hemorrhagic activity was determined in mice, by a method modified from Theakston 
and Reid (1983) (in the Bulletin of the World Health Organization) where rats were 
used. The minimum hemorrhagic dose (MHD) was determined by injecting 40 μL of 
varying amounts of venom (dissolved in normal saline) intradermally into the shaved 
dorsal skin of lightly sedated mice (with diethyl ether). After 90 min, the animals (n = 3 
per dose) were killed by an overdose of diethyl ether and the dorsal skin was removed. 
The mean diameter of the hemorrhagic lesion on the inner surface of the skin was 
measured immediately upon skin removal (Figure 5.1a). Dose response curve between 
the mean diameter of the hemorrhagic lesion and venom dose was plotted. The MHD 
was the dose that caused a hemorrhagic lesion diameter of 10 mm.  
 
5.2.1.3 Determination of minimum necrotic dose (MND) 
As modified from Theakston and Reid (1983) (in the Bulletin of the World Health 
Organization), necrotic activity was determined by injection of the venom at varying 
amounts intradermally into the shaved dorsal skin of lightly sedated mice (with diethyl 
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ether), and the animals were given free access to water and feed ad libitum. After 72 h, 
the animals (n = 3 per dose) were killed by an overdose of diethyl ether and the dorsal 
skin was removed. The mean diameter of the necrotic lesion was then measured 
immediately upon skin removal (Figure 5.1b). The minimum necrotic dose (MND) is 
defined as the amount of venom that induces a necrotic lesion with a diameter of 5 mm.  
 
 
Figure 5.1 Measurement of the mean diameter for (a) a hemorrhagic spot, and (b) 
a necrotic spot. Mean diameter (mm) was determined from the average of the two 
widest diameters perpendicular to one another.   
 
 
5.2.1.4 Determination of minimum coagulant dose (MCD) 
Procoagulant activity was determined by the method adapted from Bogarín et al. 
(2000). Various amounts of venom, dissolved in 0.1 mL of normal saline, were added 
separately into 0.2 mL of bovine fibrinogen solution (2 g/L) or 0.2 mL of human 
citrated plasma at 37
 
°C. Coagulation times were recorded. The experiment was 
performed in triplicate. The minimum coagulant dose (MCD) is defined as the minimal 
amount of venom (μg/mL) that clots a standard solution of bovine fibrinogen or human 
citrated plasma in 60 s.  
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Using the methods described above, the lethal, hemorrhagic, necrotic and procoagulant 
doses of Malaysian Calloselasma rhodostoma venom were also established. Intravenous 
LD50 of Daboia russellii (Sri Lanka) venom and Echis carinatus sochureki (Pakistan) 
venom were also determined in mice. These parameters from non-H. hypnale species 
were established for the purpose of comparing the neutralizing efficacy of selected 
antivneoms. 
 
5.2.2 In vitro neutralization of the venom lethality, hemorrhagic, procoagulant and 
necrotic activities by antivenoms 
 
These were carried out as modified from Ramos-Cerrillo et al. (2008). The antivenoms 
used were monovalent Malayan pit viper antivenom (MPVA) (Batch no. CR00909, 
exp.date 2/11/2014), Hemato polyvalent antivenom (HPA) (Batch no. HP00108, 
exp.date 6/11/2013) and Bharat Polyvalent ASVS (anti-snake venom serum) (Batch 
no.A5309049, exp.date 03/2013). The Thai antivenoms (Figure 5.2) were freeze-dried 
F(ab’)2 (90%) immunoglobulin fragments, obtained from hyperimmunized horses, 
refined by caprylic acid precipitation and pepsin digestion. The antivenoms were 
derived from equine plasma. For HPA, the horses were hyperimmunized with mixture 
of venoms from Malayan pit viper (Calloselasma rhodostoma), white-lipped green tree 
pit viper (Cryptelytrops albolabris) and Russell’s viper (Daboia simensis), all of Thai 
origin. The Indian antivenom is a refined and concentrated preparation of F(ab’)2  
obtained by fractionating antisera  from hyperimmunized horses, and is capable of 
neutralizing cobra, common krait, Russell’s viper and saw-scaled viper venoms 
according to the manufacturer (snake species not specified). The antivenoms were 
reconstituted with sterile water according to instructions and stored at -20 °C. All 
antivenoms were used before their expiry dates.  
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Figure 5.2 The monovalent Malayan pit viper antivenom (left) and Hemato 
polyvalent antivenom (right) produced by Thai Red Cross Society, Queen 
Saovabha Memorial Institute, Bangkok.  The Hematopolyvalent antivenom is raised 
against venoms from Malayan pit viper (Calloselasma rhodostoma), white-lipped green 
tree pit viper (Cryptelytrops albolabris) and Russell’s viper (Daboia siamensis), all of 
Thai origin. Both the antivenoms were gifts from the Queen Saovabha Memorial 
Insitute and used before the expiry dates. Each product contained ~1g freeze-dried 
F(ab’)2 immunoglobulin fragments, obtained from equine plasma, refined by caprylic 
acid precipitation and pepsin digestion.  
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5.2.2.1. Neutralization of lethality 
Five times the intravenous median lethal dose of LD50 of H.  hypnale venom was mixed 
thoroughly with various dilutions of the antivenom in phosphate-buffered saline (PBS), 
to give a total volume of 200 μL. The mixture was incubated at 37 °C for 30 min with 
gentle shaking. The mixture was subsequently centrifuged at 10,000 g and then injected 
intravenously into the caudal vein of mice (n = 4 per dose), and the number of animals 
that survived 48 h post-injection was recorded. Neutralization potency of the antivenom 
was measured by ED50 (μL antivenom/5 LD50 venom), which is defined as the amount 
of antivenom (μL) at which the survival ratio of the animals (challenged with the 
specified amount of venom) is 50%. The estimated amount of venom neutralized per 
mL of antivenom was then calculated based on the antivenom ED50 value, the venom 
LD50 value and body mass of animals used.  
 
5.2.2.2 Neutralization of the hemorrhagic activity 
Twice the minimum hemorrhagic dose (MHD) of H. hypnale venom was mixed 
thoroughly with various dilutions of the antivenom in PBS, to give a total volume of 40 
μL. The mixtures wre incubated at 37 °C for 30 min with gentle shaking, before injected 
intradermally into the dorsal areas of lightly sedated mice (with diethyl ether) (n = 3 per 
dose). After 90 min, the animals were killed by an overdose of diethyl ether. The dorsal 
skin was removed immediately and the mean diameter of the hemorrhagic spot was 
measured. Neutralization potency of the antivenom was measured by ED50 which is 
defined as the volume of antivenom (μL) which reduced the activity of the challenge 
dose (2 MHDs) of the venom by 50%. For comparison purpose, it is also expressed in 
terms of the ratio of μL antivenom per milligram venom.  
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5.2.2.3 Neutralization of necrotic activity 
Two and a half times of minimal necrotic dose (MND) of H. hypnale venom (100 µg) 
was mixed well with various dilutions of the antivenoms in PBS to give a total volume 
of 50-80 μL. The mixtures were incubated at 37 °C for 30 min under gentle agitation, 
and subsequently injected intradermally into the dorsal areas of lightly sedated mice 
(with diethyl ether) (n = 3 per dose). The animals were given access to feed and water 
ad libitum. After 72 h, the animals were killed by an overdose of diethyl ether and 
following which, the skins were removed immediately to examine the mean diameter of 
the dermal necrotic lesion. Neutralization potency of the antivenom was measured by 
ED50 which is defined as the volume of antivenom (μL) which reduced the necrotic 
activity of the challenge dose (2.5 MNDs) of the venom by 50%. For comparison 
purpose, it is also expressed in term of the ratio of μL antivenom per milligram venom. 
 
5.2.2.4 Neutralization of procoagulant activity 
Twice the minimum coagulant dose of H. hypnale venom were mixed thoroughly with 
various dilution of the antivenom in PBS, to give a total volume of 100 μL. The mixture 
was incubated at 37
o
C for 30 min with gentle shaking. To these, 200 μL of bovine 
fibrinogen (2 g/L) or human citrated plasma, pre-incubated at 37 °C, were added and the 
coagulation times were recorded. The experiment was repeated in triplicate. 
Neutralization potency of the antivenom was measured by effective dose (ED), which is 
defined as the volume of the antivenom (μL) at which coagulation time was increased 
three times when compared to the coagulation time of the fibrinogen solution or citrated 
human plasma incubated with venom alone.  For comparison purpose, it is also 
expressed in terms of the ratio of μL antivenom per milligram venom. 
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The above neutralization assays were repeated for the lethal, hemorrhagic, necrotic and 
procoagulant effects of C. rhodostoma venom, using the Thai monovalent and 
polyvalent antivenoms. Neutralization of the lethal effect of D. russelii and E. carinatus 
sochureki venoms were tested using only the Thai polyvalent antivenom. 
 
5.2.3 In vivo neutralization of the lethality of Hypnale hypnale venom by Hemato 
polyvalent antivenom using a rodent model 
 
This was carried out by intramuscular injection of the minimum lethal dose (20 μg/g as 
predetermined) of H. hypnale venom into mice (n = 4) followed by intravenous 
injection of 200 μL of the Hemato polyvalent antivenom, 5 min after the venom 
inoculation. The number of animals survived 48 h post-injection was recorded. The 
local effects of the venom were also examined. The control group consisted of mice (n 
= 4) challenged with the same intramuscular minimum lethal dose of the venom, but 
followed by intravenous injection of 200 μL of normal saline. 
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5.3 RESULTS 
 
5.3.1 Toxinological parameters of the venoms 
 
The LD50 of H. hypnale venom was determined as 0.90 μg/g (i.v.) and 13.7 μg/g (i.m.), 
as described in Chapter 4 (see 4.3.2). The i.v. LD50 values of the venoms of C. 
rhodostoma, D. russelii and E. carinatus sochureki were, respectively, 1.48 μg/g (95% 
CI: 0.78-2.06 μg/g), 0.24 μg/g (95% CI: 0.19-0.62 μg/g) and 2.08 μg/g (95% CI: 1.02-
4.42 μg/g).  
 
H. hypnale venom exhibited strong procoagulant, hemorrhagic and necrotic activities. 
The minimum coagulation dose (MCD) is 56.2 μg/mL for bovine fibrinogen, and 55.1 
μg/mL for human citrated plasma. The minimum hemorrhagic dose (MHD) and 
minimum necrotic dose (MND) are 10.5 μg and 39.3 μg, respectively. These values are 
comparable to those of the C. rhodostoma venom, with MCDs of 27.3 μg/mL for bovine 
fibrinogen and 24.9 μg/mL for human citrated plasma; MHD of 24.0 μg and MND of 
28.7 μg, respectively.  
 
These toxinological parameters were established for use in neutralization study, and are 
presented in Table 5.1. 
 
5.3.2 In vitro neutralization of Hypnale hypnale and Calloselasma rhodostoma 
venoms 
 
The abilities of three commercial antivenoms to neutralize the toxic activities of H. 
hypnale venom in vitro were examined. The neutralization was evaluated in assays 
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involving incubation of venom and antivenom for 30 min prior to testing on the various 
toxinological assays. 
 
Bharat polyvalent antivenom (ASVS), the antivenom produced by immunizing horses 
with venoms from the ‘Big 4’ (Naja naja, Bungarus caeruleus, Daboia russelii and 
Echis carinatus) failed to protect against H. hypnale venom: all mice (n = 4) injected 
with 5 LD50 (i.v.) of the venom died despite receiving 200 μL/mouse of the antivenom.  
 
Table 5.1 and Table 5.2 showed the in vitro results of the monovalent Malayan pit viper 
(MPV) and tivenom and Hemato polyvalent antivenom (HPA) in neutralizing the lethal, 
hemorrhagic, necrotic and procoagulant effects of H. hypnale venom. The neutralizing 
efficacies of the two antivenoms were studied simultaneously on the toxic effects of the 
venom of C. rhodostoma for comparison purpose. C. rhodostoma is regarded as the 
homologous species to which the antivenoms were produced.   
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Table 5.1 Neutralization of lethality of Hypnale hypnale, Calloselasma rhodostoma 
and other venoms by the monovalent Malayan pit viper antivenom (MPVA) and 
Hemato polyvalent antivenom (HPA). 
 
Antivenom 
 
Venom LD50 (i.v.) 
μg/g 
ED50 
(μL antivenom / 
5 i.v.LD50) 
mg venom 
neutralized per 
mL antivenom 
 
Monovalent 
Malayan pit 
viper 
antivenom 
 
 
 
C. rhodostoma 
 
 
H. hypnale 
 
1.48 μg/g 
(0.78-2.06) 
 
0.90 μg/g 
(0.42-1.84) 
 
41.53 μL 
(20.4-88.4) 
 
70.71 μL 
(33.7-148.4) 
 
3.23 
 
 
0.89 
 
Hemato 
polyvalent 
antivenom 
 
 
C. rhodostoma 
 
 
H. hypnale 
 
 
D. russelii 
 
 
E. carinatus  
sochureki 
 
 
1.48 μg/g 
(0.78-2.06) 
 
0.90 μg/g 
(0.42-1.84) 
 
0.24 μg/g 
(0.19-0.62) 
 
2.08 μg/g 
(1.02-4.42) 
 
22.47 μL 
(14.8-34.1) 
 
41.53 μL 
(20.4-88.4) 
 
7.52 μL 
(3.53-15.3) 
 
> 200 μL 
 
7.14 
 
 
1.52 
 
 
2.50 
 
 
Not 
effective 
 
Values in range for LD50 and ED50 indicated 95% confidence intervals. For 
neutralization experiments, mice (n = 4) were challenged with 5 i.v. LD50 of the various 
venoms. 
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Table 5.2 Neutralization of the procoagulant, hemorrhagic and necrotic activities 
of Hypnale hypnale and Calloselasma rhodostoma venoms by the monovalent 
Malayan pit viper antivenom (MPVA) and Hemato polyvalent antivenom (HPA). 
 
Toxic activity Minimum dose Neutralization by 
MPVA  
( ED or ED50) 
Neutralization by 
HPA  
(ED or ED50) 
 
Procoagulant  
 
 H. hypnale 
 
     
 
 
 
 
C. rhodostoma 
 
 MCD  
       
56.2 ± 1.3 μg/mL* 
  
 
55.1 ± 1.4 μg/mL# 
     
 
 
27.3 ± 0.3 μg/mL* 
 
 
24.9 ± 0.4 μg/mL# 
 
 
ED  =  4.8 ± 0.1 μL* 
(432.1 ± 10.9 μL/mg) 
 
ED  =  4.2 ± 0.1 μL# 
(384.4 ± 11.2 μL/mg) 
 
 
ED =   1.1 ± 0.0 μL* 
(209.2 ± 0.2 μL/mg) 
  
ED =   0.8 ± 0.0 μL# 
(152.7 ± 3.7 μL/mg) 
 
 
 
ED = 1.3 ± 0.0 μL* 
(114.2 ± 2.7 μL/mg) 
  
ED = 1.3 ± 0.0 μL# 
(121.3 ± 0.7 μL/mg) 
 
 
ED = 0.7 ± 0.0 μL* 
(133.9 ± 0.3 μL/mg) 
 
ED = 0.5 ± 0.0 μL# 
(104.0 ±1.2 μL/mg) 
 
Hemorrhagic  
       
H. hypnale 
 
 
C. rhodostoma 
 
MHD  
 
10.5 ± 0.6 μg 
 
 
24.0 ± 0.9 μg 
 
 
ED50 = 9.9 ± 0.3 μL 
(472.3 ± 13.9 μL/mg)  
 
ED50 = 7.3 ± 1.4 μL 
(151.7 ± 29.3 μL/mg) 
  
 
    
ED50 = 1.4 ± 0.1 μL 
( 67.4 ± 5.1 μL/mg) 
 
ED50 = 5.9 ± 0.2 μL  
(122.8 ± 3.9 μL/mg) 
Necrotic  
 
 H. hypnale 
 
 
C. rhodostoma  
   
MND 
 
39.3 ± 1.6 μg 
 
 
28.7 ± 2.6 μg 
 
 
ED50 = 61.2 ± 1.7 μL 
(612.6 ± 17.5 μL/mg) 
 
ED50 = 2.7 ± 0.1 μL            
(38.1±1.9 μL/mg) 
 
 
 
ED50 = 5.3 ± 0.1 μL 
(53.8 ± 0.59 μL/mg) 
 
ED50 = 2.1 ± 0.0 μL  
(29.7 ± 0.4 μL/mg) 
Neutralization of hemorrhagic and procoagulant activities were determined by challenge 
with 2 MHDs and incubation with 2 MCDs, respectively, of the venom. For 
neutralization of necrotic activity, mice were challenged with 2.5 MNDs of venom 
intradermally.  Values are expressed as mean ± S.E.M. (n= 3 for procoagualnt, 
hemorrhagic and necrotic activities). The standard volume of antivenom was expressed 
in μL and the amount of venom neutralized was in mg. 
*
 Procoagulant activity tested on bovine fibrinogen 
#
 Procoagulant activity tested on human citrated plasma 
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5.3.3 In vitro neutralization of the lethalities of Daboia russelii and Echis carinatus 
sochureki venom by Hemato polyvalent antivenom 
 
The ability of Hemato polyvalent antivenom to neutralize the lethal effects of two 
common vipers (D. russelii and E. carinatus) found in Sri Lanka and India subcontinent 
was also investigated. The in vitro results of the neutralization assay in mice were 
included in Table 5.1.  
 
5.3.4 In vivo neutralization of Hypnale hypnale venom in a rodent model of 
envenomation 
 
To further evaluate the potential of the application of Hemato polyvalent antivenom in 
the treatment of H. hypnale bites, an in vivo neutralization experiment, using a rodent 
model was carried out. In this experiment, four mice received intravenous injection of 
200 μL of Hemato polyvalent antivenom 5 min after i.m. injection of minimum lethal 
dose (400 μg per mouse) of H. hypnale venom. All four mice survived, and 
observations of the treated animals indicated that in addition to in vivo neutralization of 
the venom lethality, the antivenom also prevented or largely reduced the occurrence of 
venom-induced local tissue damage (myonecrosis and bleeding from the injection site) 
of H. hypnale venom.  
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5.4 DISCUSSION 
 
5.4.1 In vitro neutralization of the toxinological activities of snake venoms 
 
5.4.1.1 Against Hypnale hypnale and Calloselasma rhodostoma venoms 
Envenomation by H. hypnale receives much attention in recent years owing to re-
identification of the biting snake and subsequent authentication of its high prevalence 
with severe clinical outcomes. To date, H. hypnale envenoming remains an endemic 
medical crisis in the absence of an effective antivenom available in the region. Bharat 
polyvalent antivenom used in the region for treating the Big Four envenomation (Joseph 
et al., 2007) is totally not effective against Sri Lankan H. hypnale venom in the current 
cross-neutralization study using a rodent model. This is consistent with the clinical 
observations reported by Joseph et al. (2007) that administration of Bharat polyvalent 
antivenom did not bring any benefits to patients envenomated by H. hypnale in the 
Southwestern coast of India. Other authors also reported that the Haffkine polyvalent 
antivenom (also produced against the ‘Big Four’) was totally ineffective in the 
treatment of victims bitten by H. hypnale (Sellahewa et al., 1995; Ariaratnam et al., 
2008), highlighting the distinct uniqueness of H. hypnale venom antigenic profiles from 
the Big Four’s, hence needing a more specific or paraspecific antivenom for effective 
treatment. 
 
The capability of the monovalent Malayan pit viper antivenom (MPVA)  to neutralize 
H. hypnale venom was then examined, as Malayan pit viper (C. rhodostoma) is 
considered a sister taxon to H. hypnale by mitochondrial DNA analysis (Parkinson et 
al., 1997). Ariaratnam et al. (2008) reported that (expired) MPVA failed to neutralize 5 
i.v.LD50 of H. hypnale venom in vitro, even with 200 μL of the antivenom. A 
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preliminary study, however, showed that when lesser amount of H. hypnale venom were 
used (2 LD50, intraperitoneal injection), the newly manufactured MPVA could 
neutralize the lethality of the venom in mice, though moderately. The present study 
showed that the newly manufactured MPVA indeed could effectively protect mice 
injected with 5 i.v. LD50 of H. hypnale venom, and the ED50 was determined to be 70.71 
μL/5 i.v. LD50, or equivalent of 0.89 mg venom neutralized per mL of antivenom. The 
discrepancies with the previous report by Ariaratnam et al. (2008) could be due to batch 
differences in the antivenom, as the current batch of the antivenom used in this study 
was manufactured using a new process (caprylic acid precipitation) and appears to be 
more potent (Khomvilai, 2008). The MPVA was also effective in the neutralization of 
the procoagulant effect on both bovine fibrinogen and human citrated plasma, with EDs 
of 432.1 μL/mg venom and 384.4 μL/mg venom; respectively. It also neutralized the 
hemorrhagic and necrotic activities of H. hypnale venom, with ED50s of 472.3 μL/mg 
venom and 612.6 μL/mg venom, respectively. As expected, the MPVA was much more 
potent in the neutralization of the lethality and toxicities (p < 0.05) of the homologous 
C. rhodostoma venom, in particular the necrotic and hemorrhagic activities. The ED50 
against C. rhodostoma venom lethal effect was 41.53 μL/5 i.v. LD50, or equivalent of 
3.23 mg venom neutralized per mL of antivenom. The neutralization ED/ED50s are 
209.2 μL/mg and 152.7 μL/mg for procoagulant activities against bovine fibrinogen and 
human citrated plasma, respectively; 151.7 μL/mg for hemorrhagic activity and 38.1 
μL/mg for necrotic activity of the venom. Nevertheless, these results suggest that at 
least some of the venom toxins from the two crotalids, H. hypnale and C. rhodostoma, 
are antigenically similar. It is known that the procoagulant enzymes (thrombin-like 
enzymes) and hemorrhagins from different venomous snakes can have very different 
antigenic properties. For example, thrombin-like enzyme from Cryptelytrops 
purpureomaculatus exhibited very little ELISA cross reactions with the thrombin-like 
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enzymes from C. rhodostoma venom (Tan, 2010). Also, Fung (2002) reported that the 
major hemorrhagin of C. purpureomaculatus venom did not cross-react with C. 
rhodostoma venom at all when examined on double-sandwich ELISA. The distinct 
antigenic differences may be associated with variation in niche and diet, as it is noted 
that both C. rhodostoma and H. hypnale are mainly terrestrial while C. 
purpureomaculatus is an arboreal species. The ability of the MPVA to neutralize the 
lethality, procoagulant, hemorrhagic and necrotic activities of H. hypnale venom 
therefore also supports the conclusion by Parkinson et al (1997) that C. rhodostoma is a 
sister taxon to H. hypnale. This is an interesting example of similarities in the 
immunological properties of the venom proteins support phylogenetic relationship 
derived from mitochondrial DNA analysis. The close phylogenetic relationship between 
H. hypnale, found in India subcontinent and C. rhodostoma, found in Southeast Asia, is 
a fascinating example of the existence of the ‘Malayan’ element in the fauna of 
Peninsular India. This phenomenon has been known since a long time, and the cause of 
these similarities have been explained by the Satpura Hypothesis (Hora, 1949), 
according to which fauna migration followed the Satpura trends of mountain through 
Peninsular India during the Pleistocene. Karanth (2003) provided an alternative 
hypothesis that the phenomenon was instead a result of convergent evolution. 
 
Recently, a new polyvalent antivenom against hematoxic snake venoms in Thailand has 
become available. This polyvalent antivenom, termed Hemato polyvalent antivenom, 
was produced from plasma of horses hyperimmunized by venoms from the three 
common viper and pit vipers in Thailand: Green pit viper (Cryptelytrops albolabris), 
Russell’s viper (Daboia siamensis) and Malayan pit viper (C. rhodostoma). The Hemato 
polyvalent antivenom was found to be much more effective than the MPVA in 
neutralizing the lethality, procoagulant, hemorrhagic and necrotic activities of C. 
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rhodostoma venom: the ED50 for neutralization of the lethality was determined to be 
22.47 μL/5 i.v. LD50, or 7.14 mg venom neutralized per mL of antivenom. The EDs for 
the neutralization of procoagulant activities against bovine fibrinogen and human 
citrated plasma are 133.9 μL/mg and 104.0 μL/mg venom, correspondingly; whereas the 
ED50s for the neutralization of hemorrhagic and necrotic activities are 122.8 μL/mg 
venom and 29.7 μL/mg venom respectively.  It is therefore not surprising to find that 
the Hemato polyvalent antivenom is also very effective in the neutralization of the 
lethality, procoagulant, hemorrhagic and necrotic activities of H. hypnale venom. 
Against 5 LD50 (i.v.), the ED50 of the polyvalent antivenom was determined to be 41.53 
μL, which is equivalent to neutralization of 1.52 mg of H. hypnale venom per mL of the 
reconstituted Hemato polyvalent antivenom. In comparison, 1 mL of MPVA neutralized 
only 0.89 mg of the venom. Comparison of the ED/ED50s of neutralization of 
procoagulant, hemorrhagic and necrotic activities of the venom also showed that the 
Hemato polyvalent antivenom is far more effective (p < 0.05) than the MPVA in 
neutralizing the toxic activities of the H. hypnale venom. In fact, the ED50s of the 
neutralization of the procoagulant, hemorrhagic and necrotic activities of H. hypnale 
venom by the Hemato polyvalent antivenom is comparable to the ED/ED50s against C. 
rhodostoma venom although the antivenom is more effective against C. rhdostoma than 
H. hypnale in term of neutralization of lethality (7.14 mg venom/mL antivenom, versus 
1.52 mg venom/mL antivenom, p < 0.05). 
 
The greater efficacy of the Hemato polyvalent antivenom than the MPVA in the 
neutralization of H. hypnale (as well as C. rhodostoma) venom suggested that the 
inclusion of other two venoms (of D. siamensis and C. albolabris) used in the 
immunization scheme of preparation of the polyvalent antivenom could have 
synergistically enhanced the immunogenicity and the antivenom production.  The 
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venoms may also contain venom toxins that are immunologically similar to some H. 
hypnale venom toxins, resulting in the production of some cross reacting antibody. The 
current preclinical studies therefore suggest that both the monovalent Malayan pit viper 
and Hemato polyvalent antivenom may be useful in the antivenom treatment of 
systemic H. hypnale envenoming. The polyvalent antivenom might be the preferred one 
because of its greater efficacy, though the drawback is its higher cost (USD 60 per vial 
compared to USD 40 per vial for the monovalent antivenom). In view of the relatively 
low yield of venom from H. hypnale (average of 13 mg per milking, Section 4.3.1) 
because of its relatively small size, and the strong neutralization capacity of the Hemato 
polyvalent antivenom, 1-2 vials (10-20 mL reconstituted antivenom) of the polyvalent 
antivenom would probably be sufficient in the treatment of most systemic H. hypnale 
envenomation. Nevertheless, while the results of the preclinical studies are promising, 
these studies must be followed by a randomized controlled clinical trial in the relevant 
regions, which is the final criterion for assessing the clinical efficacy and safety of the 
antivenom. 
 
5.4.1.2 Against Daboia russelii and Echis carinatus venoms 
 
Daboia russelii and Echis carinatus are two vipers that contribute significantly to 
snakebite envenomation in the region. Unfortunately, it is not always possible to 
identify the biting species among these vipers and H. hypnale. The cross-neutralization 
study however showed that the Hemato polyvalent antivenom could neutralize the Sri 
Lankan D. russelii venom effectively, with an ED50 of 7.52 µL/5 LD50 (i.v.), or 
equivalent to 2.50 mg venom per mL antivenom. The Hemato polyvalent antivenom 
indeed was raised against a mixture of 3 venoms, including the Thai D. siamensis 
venom, which presumably contains some common antigens with the Sri Lanka D. 
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russelii venom to which cross-neutralization occurs. The polyvalent antivenom, 
however, was not effective in the neutralization of E. carinatus sochureki venom: all 4 
mice that were injected with 5 LD50 (i.v.) died despite receiving a maximum of 200 µL 
of the antivenom. When the cross-neutralization assay was performed, the E. carinatus 
venom used was sourced from a subspecies sochureki found in Pakistan and Northern 
India, and not exactly the subspecies sinhaleyus endemic to Sri Lanka, due to the 
unavailability of Sri Lankan specimen and its venom at that time of study. Despite the 
difference in subspecies status, we believed that in general the toxin antigenic profile of 
E. carinatus venom is far different from the three venoms (of C. rhodostoma, D. 
siamensis and C. albolabris) used in the production of Hemato polyvalent antivenom, as 
indicated by the total ineffectiveness of the polyvalent antivenom against it.  
Nevertheless, the ability of the Hemato polyvalent antivenom to neutralize D. russelii 
venom increases the potential benefit of the use of Hemato polyvalent antivenom in 
management of viper/pit viper bites in Sri Lanka and Southern India, as D. russelii is 
the second commonest cause of snake bite in the region, next to H. hypnale (Ariaratnam 
et al., 2009). Since clinically it is not always possible to distinguish between 
envenomation by H. hypnale, D. russelii and E. carinatus, double-sandwich ELISA 
should be developed to assist in biting species identification in future clinical trials of 
the antivenoms. 
 
5.4.2 In vivo neutralization of the lethality of Hypnale hypnale venom 
 
The Hemato polyvalent antivenom has been specifically used in the in vivo 
neutralization assay in view of its greater in vitro efficacy and potentially better cost-
effectiveness compared to that of the monovalent antivenom. It was noted in this study 
that mice challenged by the venom died much faster than what was reported in human 
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cases (Ariaratnam et al., 2008), hence “5 minutes post-envenomation” has been 
standardized as the point to begin antivenom injection. This was done essentially to 
validate the in vivo effectiveness of the antivenom, although the time of intervention 
might not be reflective of actual clinical situation and hence may require extended time 
points in future study. Nevertheless, the prevention of death and attenuation of local 
tissue damages conferred by Hemato polyvalent antivenom in vivo is indeed consistent 
with the result of in vitro neutralization of the lethal, necrotic and hemorrhagic activities 
of H. hypnale venom. Immunotherapy to abrogate venom-induced local tissue 
destruction represents a difficult challenge, and neutralization was shown to achieve 
only to a partial extent in several studies (Léon et al., 1997; Léon et al., 2000; Gutiérrez 
et al., 2003). The neutralization of local effects, however, though may not appears very 
promising, is nonetheless possible and potentially useful in viper and pit viper bites 
where local microvasculature changes (i.e. increase in vascular permeability and 
hemorrhage) favor the extravasation of antivenom, leading to local neutralization (Léon 
et al., 2001). The in vivo result in this study is qualitatively consistent with this concept 
and the observations reported previously.   
 
The cross-neutralization results (in vitro and in vivo) indicated that there are substantial 
immunological cross-reactivities between toxic components present in H. hypnale 
venom and the viperid (most notably C. rhodostoma) venoms used in the production of 
the Thai antivenoms, despite differences in the species. Extensive cross-neutralization 
between several Bothrops venoms and antivenoms has been described (Bogarín et al., 
2000; Rojas et al., 2005). The results therefore support the hypothesis that some 
antivenoms can be effective against heterologous venoms in other countries and may be 
helpful in situations where locally produced antivenoms are not available, as 
demonstrated by Otero et al. (1996).  
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Nephrotoxicity of Hypnale hypnale Venom and Neutralization 
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6.1 INTRODUCTION 
 
Kidney, as a highly vascularized excretory organ, is certainly vulnerable to toxic effects 
of venoms, especially from vipers and pit vipers, venoms of which have been 
conveniently categorized as ‘hematoxic’ and/or ‘myotoxic’ type. In envenomation, 
toxin enzymes like phospholipases A2 and various proteases can initiate inflammatory 
response that generates proinflammatory cytokines and vasoactive mediators, resulting 
in systemic and renal hemodynamic alterations with decreased renal blood flow. Toxin 
enzymes also exert direct effects on erythrocytes, myocytes, blood coagulation factors 
(including fibrinogen), and vascular endothelial cells, leading to intravascular 
hemolysis, rhabdomyolysis, consumptive coagulopathy, bleeding diathesis, etc. that 
further compromise renal perfusion. In some instances, direct tubular nephrotoxicity is 
exhibited by venoms with strong cytolytic enzymes that target the renal tubular 
epithelial cells. Kidneys respond to venom effects at various degrees, and the 
manifestation is often acute kidney injury (AKI), attributed to the combined effects of 
reduced renal blood flow and consumptive coagulopathy or direct tubular toxicity 
(Kanjanabuch and Sitprija, 2008; Sitprija, 2008). In a series of over 300 hump-nosed pit 
viper bites, Ariaratnam et al. (2008) reported that 117 (39%) were systemically 
envenomed, characterized by hemostatic abnormalities. Thirty patients out of these 117 
cases developed acute renal failure, suggesting some associations between the two 
pathologies. The renal complication resulted in death or chronic morbidity (chronic 
kidney disease); hence it is a relevant toxic feature to be studied and, more importantly, 
tested for neutralization by potential antivenoms.  
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6.2 METHODS 
 
6.2.1 Determination of venom median lethal dose (LD50) for nephrotoxicity study 
 
The intramuscular and intraperitoneal LD50 values of H. hypnale venom were 
respectively standardized at 13.7 µg/g and 6.0 µg/g as determined in a mouse model, 
described in Chapter 4 (see 4.3.2).  
 
The intramuscular LD50 value of Daboia siamensis (Myanmar origin) venom was 
determined by injecting 100 µL venom in PBS into the quadriceps muscles of mice (n = 
4 per dose), whose survival ratio was recorded after 48 hours. The LD50 (and the 95% 
confidence intervals, CI) of the venom was calculated using the Probit analysis method 
of Finney (1952). The venom of Daboia siamensis was used as a positive control for 
inducing acute kidney injury (see 6.4.1.1) 
 
6.2.2 Preliminary study of in vivo nephrotoxic effect of Hypnale hypnale venom at a 
sublethal dose in rats 
 
The intramuscular LD50 for Sprague Dawley rats were adapted from the values 
determined in mice as described. Sprague Dawley rats were divided into three groups of 
three animals each: normal saline (NS) group, H. hypnale venom (HV) group and 
Daboia siamensis (Myanmar) venom (DV) group. The NS group and DV groups 
represented, respectively, the negative and positive controls. Rats from each group 
received intramuscular injections of treatment as follows: 200 µL of normal saline or 
200 µL of venom solution corresponding to one third of the venom’s intramuscular 
LD50 (predetermined to be sublethal). The rats were individually housed in metabolic 
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cage with access to food and water ad libitum for 24 hours. Urine was collected 
throughout 24 hours, while blood was collected via cardiac puncture under anesthesia 
with a mixture of xylazine and ketamine (1 and 10 mg, respectively, per 200 g rat) at the 
end of experiment. The urine and blood samples were sent for biochemical analysis, to 
an outsourced service at a pathology analytical laboratory (Pathology & Clinical 
Laboratory, Malaysia). Subsequently, the rats were euthanized by cervical dislocation, 
and the major organs harvested from rats were sent for histopathological studies. The 
organ specimens were fixed in 10% formalin in PBS, followed by paraffin wax-
embedding, sectioning of tissue, dewaxing, rehydration and staining with hematoxylin 
and eosin. Wax-embedding, sectioning and staining of tissues were conducted at the 
Pathology’s Unit for Research and Education (Department of Pathology, University of 
Malaya). The sections were cover-slipped and images were captured using a Nikon 
Research Trinocular Teaching Microscope Eclipse 80i equipped with a camera 
(Japan).  
 
6.2.3 Nephrotoxicity study of Hypnale hypnale venom at lethal doses in mice 
 
Further study on the venom nephrotoxicity involved the use of albino mice of ICR-
strain (instead of rats) and intraperitoneal route of envenomation (instead of 
intramuscular route) to minimize the amount of venom used in view of the explorative 
nature of the study. Albino mice of ICR-strain in this study were divided into one 
control group and two challenge groups (Group A and Group B). Mice in the control 
group (n = 4) each received 200 μL normal saline; while mice in Group A (n = 9) each 
received H. hypnale venom at 1 intraperitoneal LD50 (6 µg/g), and those in Group B (n 
= 4) each received the same venom at 1.5 intraperitoneal LD50 (9 µg/g). The venom was 
dissolved in normal saline and the volume of injection was adjusted to 200 μL. Venom 
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and vehicle (normal saline) were all injected intraperitoneally. Upon receiving the 
injections, mice were housed individually in standard metabolic cages with access to 
food and water ad libitum. Hourly observations on the mice’s behaviors and evidence of 
toxic signs were charted over 48 hours. Mice that showed features suggestive of 
impending death (labored breathing with pauses, feeble heartbeat, loss of righting 
reflex, inability to walk, and lack of response to manipulation) were more closely 
monitored until spontaneous death, upon which blood was collected immediately from 
the heart, and this was followed by dissection to harvest major organs for gross and 
microscopic examinations.  
 
At 48 h, all surviving mice were sedated with a mixture of xylazine and ketamine (0.1 
and 1.0 mg, respectively, per 20 g mouse) and blood was collected via cardiac puncture. 
Subsequently, the mice were euthanized by cervical dislocation, and the major 
tissues/organs were harvested. Blood collected in plain tubes were observed for clotting 
time before processing for blood urea and creatinine analysis. Urine collected 
throughout the study period was tested on urine test strips for specific gravity, 
hematuria and proteinuria.  The major organs harvested upon death were fixed in 10% 
formalin in PBS, followed by paraffin wax-embedding, sectioning of tissue, dewaxing, 
rehydration, and staining with hematoxylin and eosin. Kidney tissues were specifically 
sectioned at 1.5 μm thin layer.  
 
6.2.4 Neutralization of nephrotoxicity of Hypnale hypnale venom by antivenom 
 
The experimental envenoming with 1 LD50 and 1.5 LD50 doses was repeated in Group C 
(n = 9) and Group D (n = 4), respectively. Intervention was carried out 5 minutes 
following the venom challenge, where each mouse from both groups received an 
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injection of 200 μL of Hemato polyvalent antivenom (reconstituted as 1 vial of HPA: 10 
ml normal saline) via the caudal vein. Animal housing, monitoring of signs, collection 
of blood and urine samples, processing of tissues/organs of the mice and further 
analyses were performed essentially as described in the nephrotoxic model described in 
Section 6.2.3. The significance of the differences of the means of the results was 
determined by one-way ANOVA and Tukey’s post hoc test.  
 
6.2.5 A preliminary study on time-dependent effect of Hypnale hypnale venom on 
mouse renal function and histology 
 
Twenty albino ICR mice were intraperitoneally injected with 1 LD50 of H. hypnale 
venom, and individually housed in metabolic cage with free access to food and water, 
similar to that described in nephrotoxic modelling (see 6.2.3).  Mice that survived 
envenomation (beyond day 2, n = 12) were sacrificed at specific day interval (day 5, 10, 
15 and 21; n = 3 at each interval).  Sedation, euthanasia, collection of urine (last 24 
hours) and blood, processing of tissues/organs of the mice and further analyses were 
performed essentially as described in 6.2.3. The significance of the differences of the 
means of the results was determined by one-way ANOVA and Tukey’s post hoc test.  
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6.3 RESULTS 
 
6.3.1 Intramuscular median lethal dose (LD50) of Daboia siamensis  
 
The LD50 value of D. siamensis (Myanmar origin) was determined to be 0.70 µg/g (95% 
CI: 0.45-0.90 µg/g) in mice. 
 
6.3.2 Preliminary nephrotoxicity study of Hypnale hypnale venom at sublethal dose 
in rats 
 
Rats from both HV and DV groups treated with sublethal dose (1/3 LD50) of venoms of 
H. hypnale and D. siamensis respectively, exhibited envenoming signs e.g. local 
hemorrhage, malaise, drowsiness and limping in the first few hours. All animals 
survived through 24 hours observation. Gross inspection on urine samples showed 
marked hematuria for the DV group, with no difference in the urine volumes among the 
groups. Urine biochemical and microscopic analysis revealed significant proteinuria and 
hematuria in the DV group compared to the HV and NS groups (p < 0.05) (Table 6.1). 
The blood urea and creatinine levels, used as indicators for acute kidney injury, were 
observably higher in the DV group although not significantly different from the other 
two groups (Table 6.1). Histological examination of the organs revealed no major 
differences between rats from the HV group and NS control group (Figure 6.1). 
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Table 6.1 Effects of sublethal dose (1/3 intramuscular LD50) of Hypnale hypnale 
and Daboia siamensisvenoms on blood and urine parameters (n = 3). 
 
                Group of rat 
Parameter 
(mean ± SEM) 
Normal 
saline 
Hypnale hypnale 
venom 
Daboia 
siamensis venom 
Urine  
Color Straw Straw Reddish 
Appearance Clear Clear Hazy 
Volume (ml) 4.2 ± 0.7 4.0 ± 0.8 3.9 ± 0.7 
Protein (+) 0.0 ± 0.0 0.0 ± 0.0 2.3 ± 0.5* 
Blood (Hematuria) (+) 0.0 ± 0.0 0.0 ± 0.0 1.4 ± 0.8* 
Microscopic red blood cell 0.0 ± 0.0 0.0 ± 0.0 3.3 ± 0.9* 
Nitrite (+) 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
Bacteria (+) 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
Blood  
Urea (mmol/l) 6.0 ± 0.8 6.9 ± 0.6 14.5 ± 7.0 
Creatinine (μmol/l) 18.7 ± 3.2 18.0 ± 3.6 32 ± 13.0 
 
* Significantly different from the other two groups, p < 0.05, one-way ANOVA 
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(Figure 6.1) 
a) Kidney 
      a(i)                                                               a(ii) 
      
 
b) Lung 
                                b(i)                                                               b(ii) 
    
 
c) Heart 
                                c(i)                                                               c(ii) 
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(Figure 6.1, continued.) 
d) Diaphragm 
                            d(i)                                                               d(ii) 
     
 
e) Liver 
                                e(i)                                                               e(ii) 
     
 
f) Spleen 
                                f(i)                                                               f(ii) 
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Figure 6.1 Histological findings of the effect of Hypnale hypnale venom on major 
organ-tissues of rat. Representative formalin-fixed, paraffin-embedded tissue sections 
of a(i) kidney of HV group, a(ii) kidney of NS group, x100; b(i) lung of HV group, b(ii) 
lung of NS group, x40; c(i) heart of HV group, c(ii) heart of NS group, x100; d(i) 
diaphragm of HV group, d(ii) diaphragm of NS group, x100; e(i) liver of HV group, 
d(ii) liver of NS group, portal track, x100; f(i) spleen of HV group, f(ii) spleen of NS 
group, x40.  
 
HV group: Challenge group (rats injected intramuscularly with H. hypnale venom at 1/3 
LD50) 
NS group: Control group (rats received normal saline intramuscularly as control) 
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6.3.3 Nephrotoxicity study of Hypnale hypnale venom at lethal doses in mice 
 
Hypnale hypnale venom at median lethal dose (LD50) killed 5 out of 9 mice (Group A) 
(fatality rate: 56%) within the observatory period. The blood urea and creatinine levels 
were noticeably increased (Figure 6.2a), and the clotting time was prolonged (Table 
6.2). Hematuria and proteinuria were also present in all mice experimentally envenomed 
with the venom (Table 6.2). 
 
In mice challenged with 1.5 LD50 (Group B), severe azotemia (with blood creatinine 
level increased much higher than urea level) was observed in all mice (Figure 6.2b). The 
blood clotting time was prolonged, with significant proteinuria in the absence of 
hematuria detected (Table 6.2). On autopsy, patches of pallor were noted on the renal 
cortices of the challenged mice (Figure 6.3a). However, histopatholgical examination 
did not reveal remarkable findings under light microscopy within the study period (48 h 
maximum) for most of the challenged mice (> 80%). In minority (one each from Group 
A and B), there was mild degree of tubular dilation, vascular congestion and epithelial 
denudation of the kidneys (Figure 6.4a(i) & b(i)-(ii)), and hemorrhage in the lungs 
(Figure 6.3b; Figure 6.4c(i)). Table 6.2 also showed that the clotting time was 
prolonged, and the urine specific gravity was marginally raised in the challenged mice 
(p = 0.04). 
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Table 6.2 Effects of Hypnale hypnale venom on urine and blood parameters of mice experimentally envenomed with 1 LD50 (Group A) and 1.5 
LD50 (Group B) venom. 
         Test 
 
 
Group 
Time to 
death
 
(h) 
Urine Blood 
Specific 
gravity 
Hematuria
 
(+) 
Proteinuria 
(+) 
Clotting time 
(s) 
Urea 
(mmol/L) 
Creatinine 
(μmol/L) 
Control 
(n = 4) 
Not 
observed 
1.023 ± 0.002 0.0 ± 0.0
 
1.0 ± 0.0 12.5 ± 2.9 7.8 ± 0.6 19.3 ± 3.1 
A 
(n = 9) 
18.4 ± 2.1
 
1.026 ± 0.001 1.8 ± 0.6
a 
1.9 ± 0.3 28.9 ± 6.5
b 
19.0 ± 4.5 28.6 ± 7.6 
B 
(n = 4) 
7.4 ± 1.3 1.029 ± 0.001
a
 0.0 ± 0.0
a 
1.8 ± 0.3 45.0 ± 2.9
b 
14.4 ± 1.0 76.3 ± 3.3
c 
 
Venom was dissolved in normal saline and volume was adjusted to 200 uL for intraperitoneal injection. Data were expressed as means ± SEM. Fatality 
in Group A = 56%; Group B = 100%. 
Means (for Groups A and B) indicated with letters showed significant difference from the corresponding means of control for the test, as determined by 
one-way ANOVA and Tukey’s post hoc test: a p ≤ 0.05; b p ≤ 0.01; c p ≤ 0.001. 
1
2
6
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6.3.4 Neutralization of nephrotoxicity of Hypnale hypnale venom with antivenom 
 
Death and nephrotoxicity (AKI as a likely cause of death) were effectively prevented by 
Hemato polyvalent antivenom (HPA) in this in vivo rodent model, evidenced by the 
normalization of blood and urine biochemistry of the envenomed animals (Figure 6.2a: 
significant amelioration of hematuria (p ≤ 0.001), proteinuria (p ≤ 0.001) and ureamia (p 
≤ 0.05); Figure 6.2b: significant amelioration of proteinuria (p ≤ 0.05), ureamia (p ≤ 
0.001) and azotemia (p ≤ 0.001)). Moreover, in the intervened groups, urine specific 
gravity improved significantly (p ≤ 0.05), along with normal anatomy of the kidneys 
and lungs (Figure 6.3a-b and 6.4a-b) as well as 100% survival.  
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Figure 6.2 Effect of Hemato polyvalent antivenom on the urine and blood 
biochemical parameters of mice envenomed with Hypnale hypnale venom at (a) 1 
LD50, and (b) 1.5 LD50. Group A was challenged with 1 i.p. LD50 (n = 9, 55% death); 
(b) Group B was challenged with 1.5 i.p. LD50 (n = 4, 100% death). Group C and Group 
D were the intervened groups which received i.v. 200 μL of antivenom (HPA) 5 
minutes after envenomation for each mouse. Control was treated with normal saline 
instead of venom and antivenom. Data were expressed as means ± SEM. Significant 
differences of meand between the challenged group and the intervened and/or control 
groups were indicated as * (p ≤ 0.05) or ** (p ≤ 0.001) over the bars, determined by 
one-way ANOVA and Tukey’s post hoc test. No significant difference of means was 
noted between the intervened groups and the corresponding controls. 
(a) 1 LD50 venom 
(b) 1.5 LD50 venom 
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Figure 6.3 Effect of Hemato polyvalent antivenom treatment on the venom-
induced gross pathologies in (a) kidneys, and (b) lungs of mice envenomed with 
Hypnale hypnale venom at 1.5 LD50. In (a), arrows indicate patches of pallor on renal 
cortices from mice challenged with H. hypnale venom. Note the absence of pallor in the 
treated and control specimens. In (b), arrow indicates hemorrhagic spots in the lung of a 
mouse challenged with the venom. Note the absence of this feature in the treated 
specimen.   
 
b 
a 
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a) Kidney  
          a(i)         a(ii)         a(iii) 
   
  
b) Kidney 
                 b(i)         b(ii)         b(iii) 
    
 
c) Lung 
           c(i)         c(ii)         c(iii) 
   
 
Figure 6.4 Effect of Hemato polyvalent antivenom on the histology of kidneys and 
lungs of mice envenomed with Hypnale hypnale venom. Representative formalin-
fixed, paraffin-embedded tissue sections of a(i) kidney from Group A, a(ii) kidney from 
Group C , a(iii) kidney from control group, all x100; b(i) kidney from group B, x100, 
b(ii) kidney from group B, x200, b(iii) kidney from Group D, x100; c(i) lung from 
Group C, c(ii) lung from Group D, c(iii) lung from control group, all x100.  
 
→ 
→ 
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In a(i), mild degree of tubular dilation and vascular congestion were noted. Image b(i) 
shows that some epithelial cells were denuded from a tubule (arrow) (enlarged in b(ii)).  
In c(i), pulmonary hemorrhage was observed with red blood cells filling the bronchiolar 
and alveolar spaces. These abnormalities were markedly prevented with the treatment of 
Hemato polyvalent antivenom.  
 
Group A and Group B: Challenge groups (mice injected intraperitoneally with H. 
hypnale venom at 1 LD50 and 1.5 LD50, respectively) 
 
Group C and Group D: Treatment groups (mice received i.v. 200 µL Hemato polyvalent 
antivenom post-envenoming of 1 LD50 and 1.5 LD50, respectively). 
 
Control group: mice received normal saline intraperitoneally 
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6.3.5  Preliminary study on time-dependent effect of Hypnale hypnale venom on 
mouse renal function and histology 
 
Hypnale hypnale venom at 1 LD50 (6 µg/g) injected intraperitoneally killed 8 out of 20 
mice in less than 24 hours. Uremia (increased blood urea), hematuria and proteinuria 
were noted as early as day 2 post-challenge in mice surviving H. hypnale experimental 
envenoming. While the blood urea level seemed to decrease on the following days, the 
blood creatinine level increased most significantly from day 2 to day 5 (p < 0.05), 
accompanied by worsening hematuria and proteinuria (p < 0.01) in the surviving mice. 
Observation on the animals revealed typical signs of inactivity, slow and shallow 
breathing, and lack of response to manipulation in the beginning course of envenoming, 
lasted up to 3-5 days. The signs generally improved from day 5 onwards, accompanied 
by an improvement in the blood and urine biochemistry of the surviving mice. 
Histological examination revealed no remarkable changes on the kidneys of the mice 
that survived the envenomation from day 2 to day 21.  
 
The results from the 12 surviving mice which represented time-dependent effect of the 
venom at day 5, 10, 15 and 21 post-envenoming are shown in Figure 6.5 (urine and 
blood biochemistry) and Figure 6.6 (histology of kidneys). The results from mice 
surviving at day 2 (n = 4) and from the control group (n = 4), adapted from Section 
6.3.2, were included in Figure 6.5 for comparison. 
Chapter 6: Nephrotoxicity & Neutralization 
133 
 
  
 
Figure 6.5 Time-dependent effect of Hypnale hypnale venom (1 LD50) on urine and 
blood biochemical parameters of mice that survived the venom challenge. Control 
was treated with normal saline instead of venom and antivenom. Data were expressed as 
means ± SEM. Significant differences of mean between the challenged group and the 
control group were indicated as * (p ≤ 0.05) or ** (p ≤ 0.001) over the bars, determined 
by Student t-test.  
 
Day 2 Day 21 Day 15 Day 10 Day 5 Control 
* 
** ** 
* 
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      2 days                    5 days                  10 days 
    
 
        15 days          21 days     Control  
   
 
Figure 6.6 Time-dependent effect of Hypnale hypnale venom (1 LD50) on mouse 
kidney histology. Representative formalin-fixed, paraffin-embedded tissue sections of 
kidneys (x100) from mice survived H. hypnale venom injection at1 LD50. Kidneys were 
harvested at different time points (days) following envenomation. There were no 
remarkable changes on the renal histology under light microscopy over the time course 
in these surviving mice. 
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6.4 DISCUSSION 
 
6.4.1 Nephrotoxic effect of Hypnale hypnale venom 
 
6.4.1.1 A preliminary study in rats with sublethal dose 
In this study, D. siamensis venom from Myanmar was used in the positive control group 
(DV group) to produce acute kidney injury (AKI) as the venom was known to be highly 
nephrotoxic (Ratcliffe et al., 1989; Soe et al., 1993; Willinger et al., 1995; Chaiyabutr 
and Sitprija, 1999). The blood urea and creatinine, used as biochemical indicators for 
renal failure (as in acute kidney injury), however, showed no remarkable findings 
probably due to the fact that the observation period was not sufficiently long. 
Nevertheless, the significant proteinuria and hematuria are sufficient indication that the 
D. siamensis venom injected did cause acute nephrotoxicity in the animals.  The 
absence of these features in rats injected with similar sublethal dose of H. hypnale 
venom suggested that H. hypnale venom may not cause direct nephrotoxicity at the 
given dose of the venom. This is further demonstrated by light microscopic examination 
of the histology of kidney and other vital organs (heart, lung, liver, spleen and 
diaphragm) of rats injected with the sublethal dose of H. hypnale venom, where all 
tissues appeared histologically intact. Thus, a tentative explanation of nephropathy 
observed in a number of victims (da Silva et al., 1979; Ariaratnam et al. 2008) is that 
the kidney damage is likely the result of complications from the venom hematoxic 
effects mediated through its procoagulant and fibrinolytic actions, causing renal 
insufficiency. This suggestion is in line with the view that the clinical nephropathy was 
likely associated with disseminated intravascular coagulopathy (Sitprija, 2008).  
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Gunatilake et al. (2003) observed epithelial cellular necrosis in the proximal convoluted 
tubules of rabbit kidney slices that were incubated at 10 mg/ml venom concentration for 
3-4 hours, and suggested that hump-nosed pit viper venom had direct nephrotoxic effect 
on kidney cells. The conclusion is, however, questionable as the necrotic effect was 
only induced by venom at extremely high concentration (10 mg/mL). In fact, using the 
same methodology, the report also showed that the local cobra venom caused the most 
severe degree of direct nephrotoxic effect (even more so than that caused by Russell’s 
viper and hump-nosed pit viper venoms) – a feature not clinically reflected in actual 
cobra-bite cases. Their findings, nevertheless, indicated that there are substantial 
components, likely cytolytic enzymes, present in the venom that may be able to cause 
direct cell death under specific conditions. In view of the venom’s prominent 
proteolytic, necrotic and cytotoxic activities (Maduwage et al., 2011; Chapter 4: Section 
4.3.4-4.3.5), a direct tissue-damaging effect on the kidney, or indirect immunological 
responses induced by the venom at higher doses cannot be completely ruled out at this 
stage. 
 
6.4.1.2 Extended tests in mice with lethal doses 
This study was a continuation of the preliminary nephrotoxicity study in rats. The 
methodology was modified for the choice of animal (mice instead of rats) and route of 
venom administration (intraperitoneal instead of intramuscular route) to minimize the 
amount of venom used in view of the explorative nature of the study. The challenge 
dose was increased from 1/3 LD50 to 1 LD50 and 1.5 LD50; while the observation period 
was also lengthened from 24 h to 48 h to allow for the development of a more 
prominent nephrotoxic feature. 
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H. hypnale venom at median lethal dose (LD50) (Group A) caused blood biochemical 
derangement suggestive of acute renal failure, most prominently uremia (and 
observably increased serum creatinine level). Elevated blood urea level (directly 
proportionate to blood urea nitrogen) generally indicates a moderate-to-severe degree of 
renal failure; and this is supported by the development of hematuria and proteinuria that 
correlated with the deteriorating renal function and signs observed in mice dead by 24 h.  
 
In mice challenged with 1.5 LD50 (Group B), severe azotemia (with blood creatinine 
increased much higher than urea) observed in all mice indicated that the renal function 
was further compromised. While significant proteinuria and prolonged clotting time 
were observed, there was however no hematuria detected, probably because glomerular 
involvement was not extensive in view of the shorter period of time to death. Pallor 
noted on the renal cortices was suggestive of renal insufficiency and probable renal 
ischemia, supported by early histological changes of acute tubular necrosis although the 
abnormal histology was not extensive and did not involve all animals. This suggests that 
electronic microscopic examinations may be necessary for a more thorough 
investigation of subcellular ultrastructural changes in the mouse model. On the other 
hand, it appears that the nephrotoxic effect of the venom was associated with bleeding 
disorders shown by prolonged clotting time and lung hemorrhage. The increased urine 
specific gravity of the mice constituted a supportive finding indicative of pre-renal 
azotemia, which is likely a complication of reduced renal perfusion secondary to altered 
hemodynamics. 
 
The result in general suggests that death in mice experimentally envenomed with H. 
hypnale venom was associated with AKI in a background of deranged hemostasis, 
consistent with several clinical reports (Joseph et al., 2007; Ariaratnam et al., 2008). 
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6.4.2 Neutralization of nephrotoxicity of Hypnale hypnale venom with antivenom 
 
Although antivenom remains as the definite treatment for snakebite envenoming 
(Chippaux and Goyffon, 1998), there is currently no effective antivenom clinically 
available to treat H. hypnale envenoming. However, in laboratory mice, the Hemato 
polyvalent antivenom (HPA) was proven to be effective in neutralizing the lethal, 
hemorrhagic and necrotic effects of this venom, in addition to neutralization of 
procoagulant activity on bovine fibrinogen and human citrated plasma (Chapter 5). 
HPA thus may be a potential therapeutic solution for the endemic medical urgency 
caused by H. hypnale envenoming, although a controlled clinical trial will be needed 
eventually to validate its effectiveness in human victims. Nevertheless, acute kidney 
injury (AKI), observed in approximately 10% of cases (Ariaratnam et al., 2008), is a 
severe complication known to be the most likely fatal cause in H. hypnale 
envenomation. Clinically, although AKI complicating H. hypnale bite were often 
reversible with timely acute care (demanding dialysis), some surviving patients 
eventually progressed into chronic kidney disease with ensuing death within a year, 
simply because of the lack of affordable renal replacement therapy in a developing 
country that is socioeconomically constrained (Ariaratnam et al., 2008). Therefore, any 
antivenom therapy proposed for the treatment of H. hypnale bite needs to address the 
issue of venom nephrotoxicity, in addition to its neutralizing efficacy on other major 
hematoxic effects, and above all, lethality.  In this context, Hemato polyvalent 
antivenom (HPA) was shown to effectively prevent death and AKI in the in vivo rodent 
model, evidenced by the normalization of blood and urine biochemistry as well as 
kidney and lung anatomy of the envenomed animal. The mechanism of nephrotoxicity 
neutralization likely involved the HPA cross-neutralizing the procoagulant and 
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hemorrhagic effects of H. hypnale venom (as shown in Chapter 5), hence preempting 
AKI, a complication associated with consumptive coagulopathy (Sitprija, 2008). The 
cross-neutralization observed was in fact also supported by immunological cross-
reactivity study (Chapter 8), which reflects similarity of antigenic properties between 
the venoms of H. hypnale and Calloselasma rhodostoma venoms. However, venom-
induced defibrinogenation complicating AKI is not a known feature in C. rhodostoma 
envenoming (Ho et al., 1986a), hence implying subtle differences in the biochemical 
aspects of the procoagulant enzymes from these two crotalid venoms, possibly at the 
fibrinogenolytic mechanism. Essentially, the current data based on in vivo animal 
experiment complements the cross-neutralization study reported previously on the 
venom’s hematoxic and lethal effects, hence supporting the ability of HPA to confer 
paraspecific protection, and justifying the suggestion for its clinical trial in the future. 
 
6.4.3 Time-dependent nephrotoxic effect of Hypnale hypnale venom 
 
In the group of mice challenged with H. hypnale venom at 1 LD50 (Group A), death 
with AKI occurred as early as 11 h post-envenoming, while the nephropathic features 
(proteinuria, hematuria, uremia) persisted in the surviving mice. Following the time 
course profiles of the biochemical indicators, it might be concluded that acute kidney 
injury (AKI) developed as early as few hours post-envenomation, progressed to 
azotemic state from day 2 to day 5 where hematuria still persisted in the surviving mice. 
The abnormalities however appeared to be reversible in mice, as the increase in blood 
creatinine, hematuria and proteinuria were subsequently normalized by day 10 to day 
15, consistent with the improvement in the signs of the animals. The histology of the 
kidneys of the surviving mice was unremarkable throughout the observation period up 
to 21 days. Usually, histological changes of tubular epithelium are more subtle in the 
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ischemic type than that in the toxic injury; and altered epithelial structure is often 
accompanied by a repair as expected in view of the reversible renal dysfunction, thus 
causing a less conspicuous necrotic feature of the cells when examined under light 
microscopy.  
 
The findings implies that serum and urine biochemical abnormalities may present in the 
initial course of envenoming of H. hypnale and warrant close monitoring for early 
detection of nephrotoxicity, in addition to urine output monitoring (for oliguric or anuric 
types of AKI). Although spontaneous recovery was observed in surviving mice in the 
current rodent model, clinically appropriate and early supportive intervention 
(hydration, renal dialysis) are likely the most essential measures at this stage to ensure 
full recovery before the tissue injury is profound enough to progress into chronic kidney 
disease. The prognosis, nevertheless, is hoped to improve in the future with the 
introduction of effective antivenom as the definite treatment that pre-empts the onset of 
AKI altogether. 
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CHAPTER 7 
 
Immunological Properties of Hypnale hypnale venom: 
Immunogenecity and Antibody Production towards  
Potential Therapeutic Application 
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7.1 INTRODUCTION 
 
 
Extensive immunological studies on snake venoms over a century clearly showed that 
snake venoms are complex mixtures of immunogenic components that are able to 
induce antibody production in animals. Most “anti-venom” immunoglobulins 
(antibodies) are produced by hyperimmunization of mammals (most commonly, horses 
and rabbits for therapeutic and diagnostic purposes, respectively), and the products are 
often polyclonal immunoglobulin G (IgG). The anti-venom antibodies ideally can bind 
in a specific manner to venom antigens, forming immunocomplexes and thus 
neutralizing the lethal and other toxic effects of venoms. They serve as the most 
fundamental biological compounds from which therapeutic antivenoms are derived. The 
production of antibody in vivo and the antibody potency in neutralizing venom toxic 
effects, however, vary according to the source of venom used, the inherent 
immunogenic potential of particular toxins and, to a certain degree, the type of host 
animals employed.  When used against heterologous venom, the ‘variation’ in terms of 
antivenom efficacy is usually even bigger due to the paraspecific nature of a 
heterologous antivenom, presumably, with suboptimal binding of various toxins 
originated from a different species. Although certain paraspecific antivenoms may be 
effective against some heterologous venoms, conceptually, a species-specific antivenom 
would be able to recognize and bind more toxin antigens than a paraspecific one, as the 
antivenom is optimally raised against the homologous venom to ensure a wider 
spectrum of toxins to be neutralized. This chapter discusses the work on the 
immunogenic response induced by Hypnale hypnale venom in rabbits, and the 
neutralizing potency of the resultant antibody against the lethal and toxic effects of the 
venom.  
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7.2 METHODS 
 
7.2.1 Immunization 
 
Rabbits (n = 3) of 2 kg each were initially immunized intramuscularly over the back 
muscles with H. hypnale venom (50 µg in 0.5 mL PBS, pH 7.4) emulsified in 0.5 mL 
complete Freund’s adjuvant, followed by three subsequent intramuscular doses of 100 
µg venom in 0.5 mL PBS emulsified in 0.5 mL incomplete Freund’s adjuvant at 
fortnightly intervals.  
 
Blood (~2 mL) was collected via the rabbits’ marginal ear veins, just before each 
immunization, including the first dose. The blood sample was left to clot in plain tubes 
at room temperature, and subsequently centrifuged at 3,000 g to separate the serum. 
From the serum (antiserum), the antibody titer levels (at two weeks following each 
injection) were monitored by indirect ELISA (Section 7.2.2). 
 
7.2.2 Indirect ELISA for determination of antibody production 
 
Microtiter wells were each coated with 100 µL venom of H. hypnale (100 ng/mL in 
carbonate-bicarbonate buffer, pH 9.6) overnight at 4 °C. After washing with 100 µL 
PBS-Tween 20 for four times, each well was incubated with 100 µL serum samples 
diluted 1:400 in PBS-Tween 20, pH 7.4, for 1 h at room temperature. Following another 
cycle of washing, goat anti-rabbit IgG-HRP in PBS-Tween 20 (1:3000 dilution made up 
to 100 µL) was added and left for 1 h at room temperature. The HRP activity was 
commenced after washing by incubation with substrate o-phenylenediamine (OPD, 0.4 
mg/mL and 0.006% H2O2 in 0.1 M citrate-phosphate, pH 5) for 30 min at room 
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temperature in the dark. The reaction was terminated by addition of 50 µL of 12.5% 
H2SO4 and the absorbance was read at 492 nm with a microplate reader (SUNRISE-
TECAN Type Touch Screen F039300). All experiments were performed in triplicates. 
 
7.2.3 Purification of immunoglobulins G (IgG) 
 
Antisera showing highest antibody titer (as monitored by ELISA) were collected from 
rabbits by cardiac puncture under anesthesia (intramuscularly injected cocktail of 
xylazine and ketamine, at 5 mg/kg and 50 mg/kg body weight of rabbit, respectively).  
 
The purification of anti-H. hypnale (anti-Hh) IgG was then carried out with protein 
precipitation technique using caprylic acid. The procedure was carried out according to 
Rojas et al. (1994). Caprylic acid was mixed with 10 mL anti-Hh serum to a final 
concentration of 5% at pH 6. Following vigorous stirring for 1 h at room temperature, 
the mixture was centrifuged at 10,000 g for 10 min, and the supernatant was collected 
and diafiltered with distilled water several times using Vivaspin
TM
 concentrator (with 
molecular weight cut-off point of 30,000 kDa). The IgG in distilled water was then 
lyophilized, and the product was kept at -20 °C for later use in venom neutralization 
studies. 
 
7.2.4 Determination of lethality, hemorrhagic, procoagulant and necrotic activities 
 
The value of intravenous median lethal dose (LD50) of H. hypnale venom in mice was 
based on that described in Chapter 4 (Section 4.3.2). Minimum hemorrhagic dose 
(MHD, the dose that caused a hemorrhagic lesion diameter of 10 mm), minimum 
coagulant dose (MCD, the minimal dose that clots a standard solution of bovine 
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fibrinogen in 60 s), and the minimum necrotic dose (MND, the minimal dose that 
induces a necrotic lesion with a diameter of 5 mm) were based on previous 
determinations from Chapter 5 (Section 5.1.2-5.1.4).  
 
7.2.5 In vitro neutralization of the venom lethality, hemorrhagic, procoagulant and 
necrotic activities by anti-Hh serum and IgG 
 
These were carried out as modified from Ramos-Cerrillo et al. (2008) and made 
comparable to the work described in Chapter 5 (see 5.3.2).  
 
Challenge doses for lethality, procoagulant, hemorrhagic and necrotic effects were 
respectively 2.5 LD50 (for antiserum) or 5 LD50 (for IgG), 2 MCD, 2 MHD and 2.5 
MND.  In brief, the venom was mixed thoroughly with various dilutions of antiserum or 
IgG solution (made up to 50 µL for intradermal injections; and 200 µL for intravenous 
injections). The IgG dilution was carried out according to MPVA/HPA instruction 
manual where 1 vial of ~1g antivenom is to be rconstituted in 10 mL solution. The 
mixtures of venom and antiserum or IgG were then incubated at 37 °C for 30 min with 
gentle shaking, following which tests for the corresponding toxic activities were carried 
out. The effective doses (ED or ED50) were calculated as described in Chapter 5 
(Section 5.2.2.1-5.2.2.4). In addition, potency of the antivenom, P, defined as the 
amount of venom (expressed in number of median lethal doses) that is completely 
neutralized per unit volume of antivenom (specifically for lethality test), was calculated 
according to the European Directorate for the Quality of Medicines (1997) and Araujo 
et al. (2008) as follows:  
P = (n-1) LD50/ ED50 
  Chapter 7: Immunogenicity and Therapeutic Antibody 
 
 
 146 
where LD50 is the median lethal dose and n is the number of LD50 used in the challenge 
assay. The expression (n-1) is used instead of the total number of n, because at the 
endpoint of the neutralization assay, 1 LD50 remains unneutralized and causes the death 
of 50% of mice.  
 
 
  Chapter 7: Immunogenicity and Therapeutic Antibody 
 
 
 147 
7.3 RESULTS 
 
7.3.1 Immunization and antiserum production 
 
The antigenicity of H. hypnale venom was expressed with a rapid rise of titer level in 2 
weeks following the primary immunization (Fig. 7.1). The antibody titer level 
subsequently rose steadily towards the third immunization, following which it plateaued 
on subsequent booster. The final level upon completion of the immunization was noted 
to be slightly lower than the previous one but the difference was not statistically 
significant.  
 
7.3.2 Neutralization of the lethal and toxin effects of Hypnale hypnale venom with 
anti-Hypnale hypnale (anti-Hh) serum and IgG 
 
Preliminary tests with 5 LD50 of H. hypnale venom incubated with 200 μl antiserum 
unfortunately killed most mice. When tested against 2.5 LD50 in mice, the antiserum 
nevertheless appeared effective in neutralizing the lethality of the venom with an ED50 
of 97.6 µL (95% C: 46.6-187.2 µL). The IgG isolated using caprylic acid precipitation 
method showed a more superior neutralizing efficacy than that of the antiserum, with an 
ED50 of 83.1 µL (95% CI: 40.9-176.8 µL) when tested against the lethal effect of 5 
LD50. Its neutralizing efficacy was comparable to that of the monovalent Malayan pit 
viper antivenom (MPAV), but less potent than that of Hemato polyvalent antivenom 
(HPA). Table 7.1 summarizes the data on neutralizing efficacy against lethality for the 
different types of immunological derivatives tested thus far for comparison. 
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The anti-Hh sera were effective to neutralize the procoagulant, hemorrhagic and 
necrotic activities of the venom in vitro. The efficacies of neutralization were however 
significantly increased with use of the anti-Hh IgG (p < 0.05). Nevertheless, the 
effective doses of anti-Hh IgG against the three common toxic effects of viperid venoms 
were significantly higher (lower potencies) compared to those of HPA (p < 0.05), a 
finding in line with the result from lethality neutralization test. The IgG was also 
slightly less potent than MPVA in neutralizing the procoagulant and hemorrhagic 
effects, but not the necrotic effect where both were equally effective.  
 
Table 7.2 shows the in vitro neutralizing effective doses of the different types of 
immunological derivatives on procoagulant, hemorrhagic and necrotic activities of H. 
hypnale venom. 
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Figure 7.1 Immune response elicited in three rabbits monitored by indirect ELISA 
following a fortnightly immunization schedule. Arrows show the days of 
immunization with contents of injection: Hhv – H. hypnale venom; CFA: Complete 
Freund’s adjuvant; IFA: Incomplete Freund’s adjuvant. Values were mean absorbance ± 
SEM. 
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Table 7.1 Neutralization of the lethal effect of Hypnale hypnale venom by the 
monovalent Malayan pit viper antivenom, Hemato polyvalent antivenom, anti-
Hypnale hypnale sera and anti-Hypnale hypnale IgG. 
 
 
Antivenom 
 
ED50 (95% CI.) 
 
Potency, P 
(μL antivenom/challenge dose) (LD50 per mL) 
Monovalent Malayan Pit Viper 
antivenom (MPVA) 
70.7 μL* (33.7-148.4)   57 
Hemato Polyvalent antivenom 
(HPA) 
41.5 μL*(20.4-88.4) 96 
Anti-Hypnale hypnale sera 97.6 μL** (46.6-187.2) 15 
Anti-Hypnale hypnale IgG 83.1 μL* (40.9-176.8) 48 
 
* Venom challenge dose = 5 LD50, ** Venom challenge dose = 2.5 LD50. The i.v. LD50 
of H. hypnale venom (0.9 μg/g), ED50 of MPVA and HPA were based on previous 
findings in Chapter 5. 
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Table 7.2 Neutralization of the procoagulant, hemorrhagic and necrotic activities 
of Hypnale hypnale venom by the monovalent Malayan pit viper antivenom 
(MPVA), Hemato polyvalent antivenom (HPA), anti-Hypnale hypnale sera (anti-
Hh sera) and anti-Hypnale hypnale IgG (anti-Hh IgG). 
 
 
Toxic activity ED or ED50 
(MPVA)    
µL/mg 
ED or ED50 
(HPA) 
µL/mg 
ED or ED50 
(anti-Hh sera) 
µL/mg 
ED or ED50 
(anti-Hh IgG) 
µL/mg 
Procoagulant
a 
432.1 ± 10.9 114.2 ± 2.7 644.1 ± 8.1 556.36 ± 12 
Hemorrhagic
b 
472.3 ± 13.9 67.4 ± 5.1 781.00 ± 11.4 618.50 ± 12 
Necrotic
c 
612.6 ± 17.5 53.8 ± 0.5 646.0 ± 20.5 615.59 ± 11 
 
a
Minimal procoagulant dose: 56.2 ± 1.3 µg/mL 
b
Median hemorrhagic dose: 10.5 ± 0.2 µg 
c
Median necrotic dose: 39.3 ± 1.6 µg 
The minimal doses of procoagulant, hemorrhagic and necrotic activities, as well as the 
effective doses of MPVA and HPA were based on the previous findings stated in 
Chapter 5. Values were expressed as mean ± SEM.  
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7.4 DISCUSSION 
 
7.4.1 Immunogenicity and antibody production for H. hypnale venom 
 
In the current study, immunization of animals with H. hypnale venom was carried out 
for the first time, and the satisfactory antibody titer rising indicated that the venom was 
sufficiently antigenic to generate a good immune response in the animals. Some 
important factors associated with immunogenicity of antigens have been considered for 
the immunization: rabbits (host animal) certainly have a very distant phylogenic 
relationship with the snake (source of antigen), while the venom is generally made up of 
proteins and peptides with high complexity. Viperid venoms are known to be 
qualitatively and quantitatively different from many elapid venoms, with the 
predominant presence of high molecular weight components especially hydrolytic 
enzymes, e.g. serine proteases and metalloproteases (Serrano et al., 2005; Mackessy, 
2010a). H. hypnale venom has been shown to exhibit various enzymatic activities, 
notably the thrombin-like enzyme, proteolytic enzyme, hyaluronidase, L-amino acid 
oxidase and phospholipase A2 (Chapter 4). These toxic protein components are medium 
to large molecules (molecular weights of 14-28 kDa and above) which generally elicit 
greater antibody production, as immunogenicity is known to increase with the size of 
the antigen (Harlow and Lane, 1988). The use of adjuvant in the immunization scheme 
also served to augment the antigen complexity, hence enhancing the immune response 
and antibody production (Herbert, 1928), demonstrated by the rapid rise in antibody 
titers in the first three immunizations. Plateauing of the antibody titer level thereafter 
implied that the immune response was mature and the antibodies produced were 
essentially immunoglobulins G from the secondary response. The results suggest that in 
production of antivenom against H. hypnale venom, a short duration (3 immunizations 
  Chapter 7: Immunogenicity and Therapeutic Antibody 
 
 
 153 
in total) may be adequate based on the described protocol, hence reducing the amount of 
venom required for antivenom production. This is an important consideration as supply 
of H. hypnale venom is always limited due to the tiny body size of the snake (Joseph et 
al, 2007; also see 4.4.1 of Chapter 4,).  
 
7.4.2 Neutralizing efficacy of anti-Hh serum and IgG as species-specific antivenom 
 
Currently, the Hemato polyvalent antivenom (HPA) has been suggested for therapeutic 
use in endemic Sri Lanka where antidotes are urgently needed to abate the envenoming 
crisis (Christeine A. Gnanathasan, personal communication, 26 June 2011) in view of 
its capability of cross-neutralizing H. hypnale venom (Chapter 5). However, the 
antivenom is yet to be assessed for its clinical efficacy in human patients. It is presumed 
that in paraspecific protection, though effective, not all toxins of the H. hypnale venom 
will be neutralized at optimum by a heterologous antivenom. Conceptually, the 
production of specific antivenom using the homologous H. hypnale venom is therefore 
essential and warranted; and long-term efforts should be undertaken for this industry. 
To apply such therapeutic principle, two pertinent issues need to be addressed: (a) the 
antigenicity of the venom for antibody production, and the resultant antibody potency in 
neutralizing the venom; (b) the identification of biting species for an accurate 
immunotherapy. It is known that H. hypnale has been misidentified especially as Echis 
carinatus (saw-scaled viper), or occasionally as Daboia russelii (Russell’s viper) – two 
common biting snakes in those areas, hence complicating the clinical management 
(Joseph et al., 2007, Ariaratnam et al., 2009). The latter issue is addressed in Chapter 8. 
 
In the current study, the crude anti-Hh serum failed to neutralize the lethal effect of high 
dose H. hypnale venom (5 LD50 as recommended by the European Pharmacopoeia 
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(1997) and adopted by most authors), but appeared moderately effective when the 
challenge dose was reduced to 2.5 LD50. Such discrepancy could be explained by the 
fact that venom-antivenom dose-response relationship does not necessarily follow 
linearity at higher doses of venom, as was also observed by Bogarín et al. (2010). In 
another word, venom-antivenom neutralization study does not necessarily follow the 
‘law of multiple proportions’, since different venom toxins may exert a ‘relevant’ 
(medically significant) role at different challenge doses (Christensen, 1966), hence the 
complexity of in vivo effects induced at different doses. The expression of the efficacy 
of antivenom should be therefore standardized for consistency: by avoiding ambiguity 
from using ED50 alone when comparing neutralization efficacy of various products 
against different ‘n’ (numbers) of venom LD50. The parameter ‘potency’, P, that 
represents the property of a product in conferring 100% protection against lethality, was 
adopted for this reason (Morais et al., 2010).  
 
The neutralizing efficacy of anti-venom product certainly relies on the density of the 
paratopes (or fragment of antigen binding) of immunoglobulins to which toxin antigens 
bind. Caprylic acid precipitation, a common and effective way of yielding IgG from 
crude serum in large-scale antivenom production (Rojas et al., 1994; Raweerith and 
Ratanabanangkoon, 2003; Khomvilai, 2008) by precipitating the non-IgG proteins from 
the antiserum could have improved the purity and amount of IgG in the current study, 
hence explaining the higher potency than the antiserum one. Caprylic acid precipitation 
method was used in this study as to mimic the production of the monovalent Malayan 
pit viper antivenom (MPVA) and Hemato polyvalent antivenom (HPA) by the Thai Red 
Cross Society from hyperimmunized equine sera. The efficacy of paraspecific 
neutralization by the mentioned antivenoms has been proven and discussed (Chapter 5). 
However when comparing these two commercial paraspecific antivenoms to the 
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homologous IgG, the IgG, although being species-specific, was generally less potent 
especially than the HPA. The observation indicates that HPA at a given volume 
contained higher fractions of IgG paratopes which could recognize and bind to the H. 
hypnale venom toxin antigens. This is either due to the additional treatment during HPA 
manufacturing, i.e. pepsin digestion of the antibodies from hyperimmunized horses 
yielding concentrated (90%) F(ab')2 fragments  (Khomvilai, 2008), or due to the shared 
antigenic properties of components from D. siamensis and/or C. albolabris venoms used 
together with C. rhodostoma venom as immunogens in the production of HPA. This is 
supported by the observation that anti-Hh IgG cross-reacted substantially with C. 
albolabris venom in both indirect and double-sandwich ELISA (see Chapter 8). The 
efficacy of anti-Hh IgG in neutralizing the procoagulant and hemorrhagic activities was 
also slightly lower than that of the monovalent MPVA, which also had undergone 
pepsin digestion of its antibody. At this stage we were unable to test the various 
parameters to optimize caprylic acid precipitation and pepsin digestion as the amount of 
antisera/IgG collected were limited due to the use of small animals (rabbits) for 
antibody production. However, the results imply that the anti-Hh sera neutralizing 
capacity for venom toxicity could be improved by caprylic acid precipitation to yield 
the IgG. Pepsin digestion, initially used to remove allergenic Fc of heterologous 
antibody (Pope, 1933), should also be considered in future anti-Hh antivenom 
production for enhancing its therapeutic potency.  
 
The potential application of anti-Hh IgG can also be further explored for the venoms of 
Hypnale nepa and Hypnale walli, although envenoming by these two species is far less 
frequent than that by H. hypnale, which is responsible for most reported severe clinical 
problems (Christeine A. Gnanathasan, personal communication, 26 June 2011). While 
the Hemato polyvalent antivenom (HPA) has been proposed for use in H. hypnale 
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envenoming in view of the medical urgency, the production and refinement of an H. 
hypnale-specific antivenom is nonetheless the therapeutic of choice in the long term.  In 
view of the suboptimal socioeconomic and healthcare system in developing countries, 
instead of producing a new monovalent antivenom, it is suggested that H. hypnale 
venom to be incorporated into the immunizing regimen for existing polyvalent 
antivenoms used in the country – for therapeutic coverage of a more complete list of 
medically important venomous snakes in the region. This however requires further 
efforts in fine-tuning the optimization for antivenom efficacy especially on a large-scale 
production, hence representing a research area beyond academic exercise that awaits 
global partnership with supports in order to overcome various challenges ahead 
(Gutiérrez et al., 2006).  
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CHAPTER 8 
 
ELISA Cross-reactivity Study and Application in Diagnostics 
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8.1 INTRODUCTION 
 
 
Enzyme-linked immunosorbent assay (ELISA) is an analytical biochemical tool that 
uses one subtype of heterogeneous, solid-phase enzyme immunoassay (EIA) to detect 
the presence of a substance (usually an antigen) and where possible, to quantitate it. Its 
use in the study of snake venoms has been made popular since the 1980’s for detection 
and quantitation of snake venoms from biological samples of snakebite victims. ELISA 
has played an important role clinically in confirmatory diagnosis of the biting snake, 
and for studying venom concentration-time profile during clinical trials. This would be 
relevant to the current study of Hypnale hypnale venom, as misidentification of the 
snake is not uncommon in the affected region. A proper diagnosis as well as venom 
quantitation would be essentially necessary in anticipation of future clinical studies. The 
assay, known for its high sensitivity, is however bound for limitation on specificity. In 
this chapter, works on purification of antibody and development of an optimized 
indirect as well as double-sandwich ELISA for H. hypnale venom were discussed. The 
assays were also applied in cross-reactivity study against various venoms, and for 
studying the immunological titer of H. hypnale venom with the monovalent Malayan pit 
viper antivenom and Hemato polyvalent antivenom. The double-sandwich ELISA was 
also modified for potential diagnostic as well as venom quantitation use in the future.  
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8.2 METHODS 
 
8.2.1 Raising antisera of venoms in rabbits  
 
The production and collection of anti-Hypnale hypnale sera from rabbits were described 
in Chapter 7 (Section 7.2.1). Using the same immunization protocols, Daboia russelii 
and Echis carinatus sinhaleyus venoms, both of Sri Lankan origin, were used to raise 
antibodies from rabbits (n = 2 and n = 1 respectively) for double-sandwich ELISA. The 
antibody titer levels were monitored using indirect ELISA, every two weeks following 
each injection. 
 
 8.2.2 Purification of Immunoglobulins G (IgG) 
 
Antisera showing highest antibody titer (as monitored by ELISA) were collected from 
rabbits by cardiac puncture under anesthesia (i.m. injection of xylazine (1 mg/kg) and 
ketamine (10 mg/kg). The purification of the IgG of the three venoms (Hypnale 
hypnale, Daboia russelii and Echis carinatus sinhaleyus) was then performed separately 
by affinity chromatography using Protein A column.  
 
The antisera were first desalted by Sephadex G-25 gel filtration column to yield the 
serum protein fractions which were subsequently pooled and freeze-dried. In this 
desalting method the Sephadex G-25 gel filtration column was packed to a 100 mL 
volume in a glass column with length 50 cm and inner diameter 2.5 cm connected to 
Micro Tube Pump MP-3 (Tokyo Rikakidai Co). For every run, 10-15 mL of antiserum 
was loaded onto the gel column and the serum proteins were eluted using 0.05% acetic 
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acid at a flow rate of 5 mL/min. The protein fractions were determined at 280 nm 
absorbance before pooling for lyophilization.  
 
The IgG purification was carried out as described by Hudson and Hay (1980) with 
slight modifications. One hundred milligrams freeze-dried serum proteins was dissolved 
in 1 mL 20 mM sodium phosphate (pH 8.0), and applied to the HiTrap
TM
 Protein A-
Sepharose gel affinity column (5 mL gel volume) connected to Micro Tube Pump MP-3 
(Tokyo Rikakidai Co). Washing of unbound components began with 20 mM sodium 
phosphate, followed by elution with 0.1 M citric acid pH 3.0 in 1 M Tris-HCl buffer, 
pH 9.0), at a flow rate of 5 mL/ min. The eluted fractions were monitored at 280 nm 
absorbance, and the peaks were screened for antibody activity by indirect ELISA 
(method as outlined in Section 8.4); while the protein purity was monitored by 15% 
SDS-PAGE under reducing (with 2-mercaptoethanol) and non-reducing conditions. The 
determined IgG fractions were then pooled, desalted with Vivaspin
TM
 concentrator and 
lyophilized. The freeze-dried IgG was kept at -20 
o
C for use in double-sandwich ELISA 
and for horseradish peroxidase conjugation.  
 
8.2.3 Conjugation of IgG with horseradish peroxidase 
 
The assay was performed according to the method of Tijssen (1985). Four milligrams 
horseradish peroxidase (HRP) was dissolved in 1.0 mL of distilled water and 0.2 mL of 
freshly prepared 0.1 M sodium periodate was added to it and stirred. The resulting 
HRP-aldehyde was diafiltered with 1 mM sodium acetate buffer (pH 4.4) at 4 °C for 
several changes of buffer to reduce auto-conjugation. The pH was then raised to 
approximately 9.0-9.5 by adding 20 µL of 0.2 M sodium carbonate buffer (pH 9.5). 
Eight miligrams IgG, dissolved in 1 mL of 0.01 M sodium carbonate buffer (pH 9.5), 
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was added immediately. The mixture was stirred for 2 h at room temperature, followed 
by the addition of 100 µL freshly made sodium borohydride solution (4 mg/mL in 
distilled water) to reduce the Schiff’s base. After 2 h incubation at 4 °C, the IgG-HRP 
conjugate was diafiltered for buffer exchange with PBS (pH 7.2) at 4 °C, aliquoted and 
stored at -20 °C. 
 
8.2.4 Indirect ELISA for determination of antibodies 
 
Microtiter wells were each coated with 100 µL venom of H. hypnale, Daboia russelii or 
Echis carinatus sinhaleyus respectively (100 ng/mL in carbonate-bicarbonate buffer, pH 
9.6) overnight at 4 °C. After washing four times with 100 µL PBS-Tween 20, each well 
was incubated with 100 µL serum samples diluted 1:400 in PBS-Tween 20, pH 7.4, for 
1 h at room temperature. Following another cycle of washing, goat anti-rabbit IgG-HRP 
in PBS-Tween 20 (1:3000 dilution made up to 100 µL) was added and left for 1 h at 
room temperature. The HRP activity was commenced after washing by incubation with 
substrate o-phenylenediamine (OPD, 0.4 mg/mL and 0.006% H2O2 in 0.1 M citrate-
phosphate, pH 5) for 30 min at room temperature in dark. The reaction was terminated 
by the addition of 50 µL of 12.5% H2SO4 and the absorbance was read at 492 nm with a 
microplate reader (SUNRISE-TECAN Type Touch Screen F039300). All experiments 
were performed in triplicates. 
 
8.2.5 Double-sandwich ELISA for detection of venom antigen 
 
Microtiter wells were each coated with 100 µL affinity-purified rabbit anti-venom IgG 
(4 µg/mL for anti-H. hypnale; 5 µg/mL for anti-Daboia russelii and anti-Echis 
carinatus sinhaleyus, respectively, as determined by chequerboard titration) dissolved in 
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carbonate-bicarbonate buffer, pH 9.6, by incubating overnight at 4 °C. After washing 
four times with 100 µL PBS-Tween 20, each well was incubated for 2 h at room 
temperature with 100 µL venom solution (100 ng/mL) dissolved in PBS-Tween 20, or  
in human sera diluted with PBS-Tween 20 (1:10 dilution made up to 100 µL). 
Following another cycle of washing, rabbit anti-venom IgG-HRP conjugate, freshly 
diluted to 100 µL (1:200 for anti-H. hypnale; 1:600 for anti-E. carinatus sinhaleyus; 
1:800 for anti-D. russelii, determined by chequerboard titration) was dispensed into 
each well and left for another 2 h at room temperature. The HRP activity was initiated 
after washing by incubation with 100 µL substrate OPD (0.4 mg/mL and 0.006% H2O2 
in 0.1 M citrate-phosphate, pH 5) for 30 min at room temperature in the dark. The 
reaction was terminated by the addition of 50 µL of 12.5% H2SO4, and the absorbance 
was read at 492 nm with a microplate reader (SUNRISE-TECAN Type Touch Screen 
F039300). All experiments were performed in triplicates. 
 
8.2.6 ELISA cross-reactivity of anti-Hypnale hypnale (anti-Hh) serum and anti-Hh 
IgG with various venoms 
 
Venoms of various species (100 µL of 100 ng/mL solution) were coated on microtiter 
walls by overnight incubation. Anti-Hh serum (1:400) from the final (4
th
) immunization 
and purified IgG (1:500; stock concentration: 1 mg/mL), diluted in PBS-Tween 20 (for 
both, made up to 100 µL), were each incubated with the pre-coated venoms then for 1 h 
and the cross-reactivities were determined using indirect ELISA as described in Section 
8.2.4. 
 
For double sandwich ELISA, anti-Hh IgG (100 µL of 4 µg/mL solution) was coated on 
microtiter wells by overnight incubation. A hundre microliters venoms of various 
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species (100 ng/mL solutions) were used as samples to incubate with the precoated IgG 
for 2 h, and the cross-reactivities were then determined based on the protocol as 
described in Section 8.2.5. ELISA cross-reactivities were expressed in mean percentage 
± SEM of the absorbance with reference to reaction between anti-Hh serum or IgG with 
H. hypnale venom. 
 
8.2.7 ELISA cross-reactivity of Hypnale hypnale venom with Calloselasma 
rhodostoma monovalent and polyvalent antivenoms (MPVA and HPA) 
 
For indirect ELISA, 100 µL H. hypnale venom (100 ng/mL) was used to coat the 
microtiter wells overnight. Washing was then done with PBS-Tween 20, and the venom 
was incubated with 100 µL antivenoms (MPVA or HPA, with 1:5000 dilution in PBS-
Tween 20 made up to 100 µL) for 1 h. Following another cycle of washing, goat anti-
equine IgG-HRP conjugate (1:8000 dilution in PBS-Tween 20 made up to 100 µL) was 
used as secondary antibody (1 h incubation) to which the HRP activity on OPD was 
subsequently measured. A hundred microliters C. rhodostoma venom (100 ng/mL) 
coated on microtiter well was used as the positive control, where homologous venom 
neutralization has been established in murine model (Chapter 5); while 100 µL N. naja 
venom (100 ng/mL) coated on microtiter well served as the negative control, where no 
in vitro cross-neutralization has been observed with either MPAV or HPA. 
 
The study was repeated with double-sandwich ELISA, where both coating and primary 
antibodies were replaced by antivenoms (MPVA or HPA) in 100 µL coating buffer or 
PBS-Tween 20 (1:5000 dilution made up to 100 µL) accordingly. Goat anti-equine IgG-
HRP conjugates (1:8000 dilution in PBS-Tween 20 made up to 100 µL) served as 
secondary antibodies to which HRP activity on OPD was measured then. The samples 
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consisted of 100 µL venoms (100ng/mL) of H. hypnale, C. rhodostoma (positive 
control) and N. naja (negative control). The protocol was essentially following that 
described in Section 8.2.5. The cross-reactivities were expressed in mean percentage ± 
SEM of the absorbance with reference to the controls. 
 
8.2.8 Detection and quantitation of venoms in human sera 
 
H. hypnale, E. carinatus sinhaleyus and D. russelii venoms were respectively dissolved 
in a 1:10 mixture of human serum and PBS-Tween 20, subsequently diluted with the 
mixture to a series of known concentrations (0-100 ng/mL). These then served as the 
standard samples for the double-sandwich ELISA as described in Section 8.2.5, under 
each optimal working condition as predetermined. The absorbance values were then 
plotted against the standard venom concentrations. Limit of detection (LoD) and limit of 
quantitation (LoQ) for venom detected in human sera were calculated with the LoD 
defined as three times (3x) the standard deviation of the blank, and the LoQ defined as 
ten times (10x) the standard deviation of the blank, with the blank being human serum 
(1:10 dilution) without venom antigens. 
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8.3 Results  
 
8.3.1 Production of antisera against the venoms of Hypnale hypnale, Daboia russelii 
and Echis carinatus sinhaleyus 
 
The production of antisera for D. russelii and E. carinatus sinhaleyus venoms generally 
followed the pattern similar to that for H. hypnale venom (Figure 7.1), where the 
antibody titers increased steadily towards the third immunization, following which a 
plateau was observed (Figure 8.1a and b). 
 
8.3.2 Purification of immunoglobulins G 
 
By a successive utilization of gel filtration and affinity chromatography, polyclonal 
immunoglobulins G (IgG) were purified from the crude antisera raised against different 
venoms (H. hypnale, D. russelii, E. carinatus sinhaleyus). Figure 8.2a shows the 
isolation of serum proteins (commonly known as desalting of antiserum) which were 
subsequently purified further to immunoglobulins G (Figure 8.2b). The fractions 
containing IgG (theoretically the eluted fraction from Protein A column) were screened 
positive for antibody activity by indirect ELISA (with net absorbance > 0.3). The IgG 
purity monitored by 15% SDS-PAGE under reducing (with 2-mercaptoethanol) and 
non-reducing conditions was shown as inset in Figure 8.2b. The non-reduced sample 
presented predominantly as IgG with high molecular mass of ~130-160 kDa. These high 
molecular weight proteins were however reduced to two main products suggestive of 
IgG derivatives: the heavy chain with ~50 kDa and the light chain with ~25 kDa. There 
were no remarkable protein aggregates and albumin detected.  
  Chapter 8: ELISA & Diagnostics 
 
166 
 
 
 
Figure 8.1 Immune responses elicited in rabbits monitored by indirect ELISA following a fortnightly immunization schedule with (a) Sri 
Lankan Daboia russelii venom, n = 2; (b) Echis carinatus sinhaleyus venom, n = 1. Arrows show the days of immunization with contents of 
injection. Drv: D. russelii venom; Ecv: E. carinatus sinhaleyus venom; CFA: Complete Freund’s adjuvant; IFA: Incomplete Freund’s adjuvant.  
1
6
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Figure 8.2 A representative diagram of step-wise isolation of immunoglobulins G (IgG) from rabbit sera: (a) Desalting of antisera using 
Sephadex G-25 gel filtration column, yielding serum proteins represented by one major peak; (b) Purification of IgG from serum proteins 
using Protein A affinity column. Arrow in (b) shows the eluted IgG fraction. Inset shows the 12.5% SDS-PAGE of isolated IgG under non-reducing 
(NR) and reducing (R) conditions. 
a b 
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8.3.3 ELISA cross-reactivity of anti-Hh sera and IgG with various venoms 
 
Cross-reactivities of the anti-Hh antisera with various venoms on indirect ELISA were 
extensive: most prominent with venoms of Asiatic Crotalinae (~80-90%), moderate 
with viperinae (~60-80%), and least with Elapidae and Hydrophiidae (below 50%). 
ELISA non-specific binding by antiserum was effectively reduced by replacing the 
coating antisera with affinity-purified anti-Hh IgG (Table 8.1), especially on the venoms 
from non-Viperidae snakes. Using double-sandwich ELISA, the level of cross-
reactivities of indirect ELISA was even further reduced to an extent of > 60% (Table 
8.1). On both indirect and double-sandwich ELISA using affinity-purified IgG, the 
cross-reactivity with C. rhodostoma venom was consistently observed to be strongest.  
 
8.3.4 ELISA cross-reactivities of monovalent Malayan pit viper (C. rhodostoma) 
antivenom (MPVA) and Hemato polyvalent antivenom (HPA) with Hypnale 
hypnale venom 
 
Indirect ELISA showed that both antivenoms cross-reacted strongly with H. hypnale 
venom (> 90%) and partially with N. naja venom (< 50%).  Using double-sandwich 
ELISA that has higher degree of specificity, the cross-reactivities of MPVA and HPA 
with H. hypnale venom were shown as 90.2% and 91.5% respectively, while that of N. 
naja venom was nil (Table 8.2).  
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Table  8.1  ELISA cross-reactivities of the anti-Hypnale hypnale sera and anti-Hypnale hypnale IgG with various venoms, using indirect or 
double-sandwich ELISA. 
 
 
                                                   Test 
Venom 
Indirect ELISA with antisera Indirect ELISA with IgG    Double-sandwich ELISA with IgG 
Cross reactivity % ± SEM % 
 
Cross reactivity % 
 
± SEM % 
 
Cross reactivity % 
 
± SEM % 
    
Basal crotalids:    
Hypnale hypnale  100.0 0.0 100.0 0.0 100.0 0.0 
   Calloselasma  rhodostoma 90.0 1.0 73.6 0.1 11.8 1.1 
    
Old World, Asiatic crotalids:    
    Protobothrops flavoviridis 91.4 1.7 42.1 1.4 10.4 0.8 
Protobothrops tokarensis 87.1 0.2 50.9 4.3 6.5 1.0 
Viridovipera stejnegeri 82.6 0.9 61.4 0.1 9.9 2.0 
Popeia popeiorum 82.6 0.4 27.5 1.6 6.4 1.7 
     Cryptelytrops. purpureomaculatus 58.0 1.4 35.0 0.5 7.6 3.8 
Cryptelytrops albolabris 76.5 0.6 40.2 1.2 2.1 2.1 
Tropidolaemus wagleri 71.0 3.8 0.5 0.5 0.4 0.1 
    
New World, invasion from Asia, 
Beringian dispersal crotalids: 
   
Agkistrodon piscivorus leukostoma 90.1 0.3 
 
13.0 
 
0.8 
 
5.4 
 
1.3 
Crotalus viridis 83.9 2.0 38.4 0.8 7.4 1.5 
Crotalus atrox 60.7 1.5 24.2 0.8 6.6 2.9 
Bothrops asper 79.8 1.4 14.8 2.3 3.1 1.2 
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Table 8.1, continued. 
 
Viperinae (Africa to Asia dispersal 
vipers)    
Echis carinatus sinhaleyus 63.8 2.3 
 
1.2 
 
0.3 1.1 
 
0.2 
       
Viperinae (Eurasian dispersal)    
Daboia russelli (Sri Lanka) 80.4 2.7 
 
2.5 
 
0.4 
 
2.0 
 
0.4 
Daboia siamensis 52.8 2.9 2.4 0.2 0.5 0.1 
    
Elapids: 
   Elapidae (Asian dispersal) 
Bungarus flaviceps 21.4 0.2 0.0 0.0 0.0 0.0 
Bungarus candidus 47.1 0.5 0.0 0.0 0.0 0.0 
Ophiophagus hannah 13.4 2.4 0.0 0.0 0.0 0.0 
Naja naja (Sri Lanka) 13.3 2.4 0.0 0.0 0.0 0.0 
Naja sputarix (Java) 14.9 1.1 0.0 0.0 0.0 0.0 
 
Elapidae (African dispersal)    
Naja nigricollis 17.3 0.5 0.0 0.0 0.0 0.0 
Dendroaspis angusticeps 8.5 0.7 0.0 0.0 0.0 0.0 
Elapidae (Papuo-Australian) 
 
 
 
 
 
 
 
 
 
Pseudonaja textilis 7.9 0.7 0.0 0.0 0.0 0.0 
 
Elapidae, Subfamily Hydrophiinae 
(Papuo-Australasian dispersal)    
Oxyuranus microlepidotus 7.7 0.9 0.0 0.0 0.0 0.0 
 
   Family Hydrophiidae 
Enhydrina schistosa 16.6 0.3 0.0 0.0 0.0 0.0 
       
 
Values were expressed as mean absorbance ± SEM. Grouping of majority of the species were done according to Wüster et al. (2007). 
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Table 8.2  ELISA cross-reactivities between monovalent MPV antivenom and Hemato polyvalent antivenom with venoms of Calloselasma rhodostoma, 
Hypnale hypnale and Naja naja, using indirect and double-sandwich ELISA. 
 
Venoms   
Indirect ELISA  Double-sandwich ELISA 
 
Cross 
reactivity % 
(MPVA) 
 
 
± SEM % 
 
Cross 
reactivity % 
(HPA) 
 
 
± SEM % 
 
 
 
 
 
Cross  
reactivity % 
(MPVA) 
 
 
± SEM % 
 
Cross 
reactivity % 
(HPA) 
 
 
± SEM % 
 
Calloselasma 
rhodostoma 
  
 
 
 
 
 
 
 
 
 
100.0 
 
0.0 
 
100.0 
 
0.0 
 
 
 
100.0 
 
0.0 
 
100.0 
 
0.0 
 
Hypnale hypnale 
 
 
 
 
 
 
 
 
91.7 
 
1.2 
 
93.6 
 
1.9 
 
 
 
90.2 
 
1.7 
 
91.5 
 
1.1 
Naja naja 
 
 
 
 
 
 
40.3 
 
0.7 
 
45.9 
 
0.4 
 
 
 
0.0 
 
0.0 
 
0.0 
 
0.0 
 
MPVA: Malayan pit viper antivenom (monovalent); HPA: Hemato polyvalent antivenom. Both antivenoms were noted effective in cross-neutralization 
of H. hypnale venom, but totally ineffective against Naja naja venom. C. rhodostoma is the homologous species from which the antivenoms were 
produced; H. hypnale is phylogenetically closest to it, while N. naja is phylogenetically most distant among the three.  
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8.3.5 Detection and quantitation of venoms in human sera 
 
When double-sandwich ELISA was applied, the titration of H. hypnale venom 
concentrations in human serum yields a parabolic curve with a regression factor of 
0.9955, within the concentration range of 0-75 ng/mL (Figure 8.3a). The assay was 
sensitive with the limit of detection (LoD) of 2.78 ng/mL and the limit of quantitation 
(LoQ) of 10.88 ng/mL venom with 1:10 dilution in human serum.  
 
Besides, the double-sandwich ELISA demonstrated practically no cross-reactivity with 
the venoms of E. carinatus sinhaleyus and D. russelii, both of Sri Lankan origin. We 
broadened the venom identification study by including two separate assays for D. 
russelii and E. carinatus sinhaleyus venoms, using double sandwich ELISA as 
described (Figure 8.3b–8.3c). Both the assays were sensitive towards their respective 
homologous venoms, with the LoD and LoQ being 1.64 ng/mL and 5.75 ng/mL for E. 
carinatus sinhaleyus; while for D. russelii, 2.43 ng/mL and 9.83 ng/mL. Cross-
reactivities of the different IgG with heterologous venoms were practically minimal and 
unoikely to interfere with the identification of the snake species. 
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Figure 8.3 Titration curves for the concentrations of venoms from three common biting snakes in Sri Lanka dissolved in human serum, with 
1:10 dilution in PBS-Tween 20, on double-sandwich ELISA using IgG for (a) Hypnale hynale venom, (b) Echis carinatus sinhaleyus and (c) Sri 
Lankan Daboia russelii. Values were mean absorbance ± SEM.  
a b 
c 
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8.4 DISCUSSION 
 
8.4.1 Immunization of rabbits with Sri Lankan vipers’ venoms and IgG    
purification 
 
The immune responses elicited in rabbits by the Daboia russelii and Echis carinatus 
sinhaleyus venoms, separately, were satisfactory following a fortnightly immunization 
schedule, and maintained with subsequent boosters. The antisera were raised against the 
venoms of the selected two species in order to determine the cross-reactivities of the 
antibodies among the three main Viperidae snakes in the region: Hypnale hypnale, 
Daboia russelii and Echis carinatus sinhaleyus, which are not uncommon in causing 
misidentification (Joseph et al., 2007; Ariaratnam et al., 2008). The study was geared 
towards the potential development of an immunoassay-based diagnostic tool for 
discerning the biting species in future clinical studies. 
 
In pharmaceutical industry, most therapeutic antivenoms are produced by protein 
precipitation method, where antibody can be recovered in a relatively simple and fast 
way suitable for down-stream processing at large-scale basis, such as that for the 
MPVA and HPA. For research applications where the degree of purity and the quantity 
of IgG antibody are not crucial, such as in indirect ELISA and indirect flow cytometry 
assays, unpurified forms of antibody (as in antiserum) can be utilized. Nevertheless, 
purified antibodies must be used when accurate concentration or titrations are required, 
when chemical modifications are needed, and when non-specific binding is to be 
eliminated (Andrew and Titus, 2001). Several choices of antibody purification assays 
are available; in the current study, Protein A affinity chromatography has been 
employed in view of its high specificity and affinity for the IgG class from rabbit 
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antibodies: Protein A with its bacterial origin (from Staphylococcus aureus), it binds 
notably to mammalian IgG, disrupting opsonization and phagocytosis as an aid to the 
bacterium survival and, thus, virulence (Hjelm et al., 1972; Bjorck and Kronvall, 1984; 
Goodyear and Silverman, 2003). The application in immunology research as a tool to 
isolate IgG antibodies has been well established (Hudson and Hay, 1980), and modified 
accordingly for antivenom IgG separation by various authors (Coulter et al., 1980; 
Kukongviriyapan et al., 1982; Carroll et al., 1992; Selvanayagam et al., 1999; Dong et 
al., 2003; Tan, 2010; Tan et al., 2012). This method produces purified IgG that is 
suitable for chemical modification (enzyme- or radioisotope conjugation), and to ensure 
minimal non-specific interaction by other serum proteins which is an important aspect 
in double-sandwich ELISA.  
 
8.4.2 ELISA cross-reactivity of anti-Hh serum and IgG with various venoms 
 
The discrepancies in the cross-reactivity readings between anti-Hh serum and anti-Hh 
IgG with various venoms reflected the highly non-specific nature of indirect ELISA 
using crude antisera, which contained various serum proteins that could have 
contributed to non-specific binding. Using IgG purified by affinity chromatography, 
false positive ELISA signals attributable to various components in the crude antisera 
were effectively reduced. The highest cross-reactivity of the IgG was observed with C. 
rhodostoma venom (73.6%), followed by the venoms of several Old World crotalids, 
with exceptionally low value for Tropidolaemus wagleri venom – this is not surprising 
as the venom is known to be quite atypical among the crotalids, whereby it does not 
exhibit hemorrhagic activity, is feebly procoagulant, contains unique phospholipases 
A2, and is rich in atypical low molecular weight proteins (Tan and Tan, 1989; Weinstein 
et al., 1991; Wang et al., 1999b). Based on the extent of the cross-reactivities, H. 
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hypnale venom and C. rhodostoma venom appear to be the most similar antigenically, 
and this is likely due to their very close phylogenetic relatedness despite distant 
geographical distribution (Parkinson et al., 1997). Observations where immunological 
properties of venom proteins supported snake taxonomy and systematics derived from 
mitochondrial DNA analysis had been reported in the case of Trimeresurus Complex 
(Tan, 2010; Tan et al., 2012). In this study, the cross-reactivities generally became less 
with the increased distance of the snakes phylogenetic relationships, and were 
practically absent for venoms from Elapidae snakes. Generally, the cross-reactivities 
between the anti-Hh IgG with Crotalinae venoms appeared much stronger than that with 
the Viperinae and Elapidae venoms, suggesting that there are antigenically similar toxin 
structures conserved among the Crotalinae snakes venoms.  
 
Double-sandwich ELISA has been known for its high specificity (Tan et al., 1993) in 
the detection of venom antigens. It requires an antigen to be stably bound twice by a 
specific type of IgG: first by coating IgG, followed by secondary IgG (in this work, 
HRP-labeled IgG), hence it is more stringent than direct and indirect ELISA. We 
demonstrated that high level of cross-reactivities of indirect ELISA was reduced 
markedly (> 60%) using the double-sandwich ELISA, hence improving the assay 
specificity for H. hypnale venom (Table 8.1). In the case of anti-Hh IgG cross-reacting 
with C. rhodostoma venom, the different magnitudes of cross-reactivities between the 
indirect ELISA (73.6%) and double-sandwich ELISA (11.8%) suggest that the anti-Hh 
IgG, although having affinity for C. rhodostoma venom antigens, may have an overall 
lesser avidity towards them. The IgG cross-reactivities on double-sandwich ELISA 
were also low with the venoms of E. carinatus sinhaleyus and D. russelii (two 
medically important vipers in Sri Lanka), hence prompting further investigation into the 
potential application of double-sandwich ELISA for biting species diagnosis in H. 
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hypnale envenomation. Proper identification of that biting snake species in Sri Lanka 
and Southwestern India is essential as it would ensure the appropriate therapy is 
instituted and woultd this avoid the use of unnecessary antivenom that risks 
hypersensitivity adverse effects, especially since the biting species had been frequently 
misidentified in this region (Joseph et al., 2007). 
 
8.4.3 ELISA cross-reactivities of monovalent Malayan pit viper (Calloselasma 
rhodostoma) antivenom (MPVA) and Hemato polyvalent antivenom (HPA) with 
Hypnale hypnale venom 
  
Previous studies had shown that MPVA and, to a greater extent, HPA, conferred 
paraspecific neutralization of H. hypnale venom (Chapter 5 and Chapter 6). The strong 
ELISA cross-reactivities of these antivenoms with H. hypnale venom supported the 
cross-neutralization reported in animal studies. In fact, the ELISA (both indirect and 
double-sandwich types) results have been consistent and comparable for both venoms of 
H. hypnale and, C. rhodostoma, the homologous species, but remarkably distinct from 
N. naja venom where no binding occurred. The findings, however, differed from the 
low cross-reactivity (11.8%) between anti-Hh IgG and C. rhodostoma venom examined 
on double-sandwich ELISA under the same condition (Table 8.1). This is probably due 
to both higher affinity and avidity of anti-C. rhodostoma antibodies towards the H. 
hypnale venom, as compared to that of anti-Hh IgG towards the C. rhodostoma venom. 
It is hypothesized that the anti-C. rhodostoma antibodies exhibit greater number of 
multivalencies (paratopes) that were are to recognize epitopes of H. hypnale venom, in 
contrast to anti-Hh IgG which multivalent sites are likely endowed with fewer binding 
sites for the antigenic epitopes of C. rhodostoma venom. 
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8.4.4 Detection and quantitation of venoms in human sera 
 
Several factors have been known to affect the sensitivity and specificity of 
immunoassays (ELISA particularly) in detecting and quantitating venom antigens in 
biological samples - mainly, the non-specific reactivity, cross-reactivity and the quality 
of immuno-reagents (Ho et al., 1986b). Various contributions have been made to 
improve the sensitivity, specificity, rapidity and simplicity of ELISA methods 
(Selvanayagam and Gopalakrishnakone, 1999). In the current study, the antibodies used 
were derived from very high titre antisera of animals after repeated immunization doses. 
Generally, the repeated immunization protocol hyperimmunized the animals to produce 
specific antibodies with high affinity as well as avidity to the immunizing antigens 
(Harlow and Lane, 1988) – crucial determinants for the sensitivity of immune-detection 
assays. Subsequent use of affinity chromatography to yield specific IgG has largely 
eliminated non-specific binding observed with antisera in indirect ELISA, and the 
specificity was further improved with double-sandwich ELISA. ELISA is known to be 
inherently sensitive, and since Theakston et al. (1977) described its use for the detection 
of snake venom and venom antibodies in sera, many ELISAs have been reported for 
snake venom detections in different types of biological samples from envenomed 
animals or snakebite victims (Table 8.3). Typically, the range of detection is within 
several nanograms of mL (ng/mL) of biological samples; and the lower the limit of 
detection (LoD), the higher the sensitivity of the assay.   As H. hypnale is small in size 
(≤ 50 cm), the average dry mass of venom yield per milking is small too (averagely 13 
mg). Given a situation where 13 mg of venoms is injected into a 60-kg Asian man with 
a plasma volume of 2.5 L (through bite on muscle and subcutaneous tissue), and the 
systemic absorption has been estimated to be 5% (unpublished data on bioavailability; 
see Chapter 9), the theoretical serum concentration of venom would be close to 260 
ng/mL, of which 1:10 dilution would be equivalent to 26 ng/mL and is detectable and 
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quantifiable by the assay (LoD = 2.78 ng/mL, LoQ = 10.88 ng/mL). The sensitivity of 
the assay for H. hypnale venom nevertheless may be further improved in the future in 
view of the possibility of a low amount of venom injected into the victim. One 
suggestion of such possible optimization is the use of biotinylated antibody as shown by 
Selvanayagam et al. (1999) and Dong et al. (2002, 2003). 
 
In situation where misidentification of biting species is concerned, the anti-H. hypnale 
IgG in double-sandwich ELISA demonstrated practically no cross-reactivities with the 
venoms of E. carinatus and D. russelii, two endemic biting snakes in the same regions 
which often cause misidentification for H. hypnale. Interestingly, anti-E. carinatus 
sinhaleyus IgG and anti-D. russelii IgG, apart from showing satisfactory sensitivity for 
its own venom antigens, demonstrated no cross-reactivities with the heterologous 
viperid venoms. The lack of IgG cross-reactivities among the three species venoms 
correlated well with the lack of cross-neutralization of the venoms (Chapter 5): H. 
hypnale venom was not cross-neutralized by Bharat polyvalent antivenom that 
contained anti-D. russelii and anti-E. carinatus propeprties; while Hemato polyvalent 
antivenom, which although neutralized H. hypnale veom and Sri Lankan D. russelii 
venom, was not effective against E. carinatus sinhaleyus venom. The result hence 
suggests that the double-sandwich ELISA developed from affinity-purified anti-venom 
IgG has the potential to be developed into a specific diagnostic kit for viperid 
envenomation in the region, and this is important in clinical studies where the biting 
species needs to be accurately diagnosed, and the blood venom levels to be monitored. 
It also has the potential to improve routine clinical diagnosis and to ensure that 
appropriate serotherapy is instituted. Although in practice, many dubious snakebite 
cases were empirically treated with polyvalent antivenoms, this approach can be 
dangerous and is not appropriate in H. hypnale envomonation as the polyvalent 
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antivenom available in Sri Lanka is only effective against D. russelii and E. carinatus, 
but not against H. hypnale. In addition, the documentation of accurate biting species 
identity is vital for epidemiology study, an important aspect for global health 
sustainability; and this also provides accurate information for future research at both 
clinical and laboratory settings.  
 
In highlighting the benefits of a potential ‘Sri Lankan hematoxic viperids’ diagnostic 
kit, cost is always an obstacle that should be addressed. Among the various proposed 
and experimental venom-screening tools, ELISA-based methods are likely the most 
economical, least technically demanding and most stable way as compared to 
radioisotopic assay, polymerase chain reaction or immunoblotting. A portable pocket-
sized plate or strip can be designed to have three parallel panels, each consisting two 
control wells (negative and positive) and two to three sample wells for venom detection 
based on chromogenicity. ELISA is a rather generic facility that should be available in 
major medical centers in the developing countries for common serology use, and in 
places where such facility has been equipped, costing would mainly concern 
consumables like buffers, IgG, enzyme and substrate, which are generally required in 
very small, diluted amounts. In situations where cost and technology are permissible, 
the detection kit can be even further upgraded to a simplified, rapid detection version 
using optical immunoassay (OIA) as demonstrated by Van Dong et al. (2004) in 
Vietnam. Hence, it is hoped that with international collaborative supports, such 
diagnostic application can be made possible at low-resource setting in the future
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Table 8.3 Enzyme-linked immunoassays (ELISA) for snake venom detection. 
 
Snake species Types of samples Sensitivity (ng/mL) Reference 
Bitis arientans, Causus maculatus, Echis carinatus, 
Naja haje, Naja nigricollis 
Human and rat sera 1.0 Theakston et al. (1977) 
Australian and other snakes Human serum, wound swab 6.0 Coulter et al. (1980) 
Bungarus candidus, B. fasciatus, Naja kaouthia Human serum 10.0-50.0 Viravan et al. (1986) 
Calloselasma rhodostoma, Trimeresurus albolabris, 
Daboia russelii, Naja kaouthia 
Human serum 10.0-20.0 Silamut et al. (1987) 
Vipera aspis Human bood and urine 1.0 Audebert et al. (1992) 
Calloselasma rhodostoma PBS 5.0 Tan et al. (1992) 
Bothrops sp., Crotalus durissus Mouse plasma 5.0 Chávez-Olórtegui et al. 
(1997) 
Echis carinatus Tissue homogenate 2.5 Selvanayagam et al., 1999 
Bungarus caeruleus, Naja naja, Echis carinatus, 
Daboia russelii 
Tissue homogenate 0.1* Selvanayagam et al. (1999) 
Naja atra Human sera 0.5 Huang et al. (2002) 
Trimeresurus popeorum, Calloselasma rhodostoma, 
Naja naja, Ophiophagus hannah 
Various biological samples 0.2-1.6* Dong et al. (2003) 
Pseudonaja sp. Human serum 3.0 O’Leary et al. (2006) 
Oxyuranus sp. Human and rat sera 0.15* Kulawickrama et al. (2010) 
 
  *with the use of biotinylated antibodies 
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CHAPTER 9 
Pharmacokinetics of Hypnale hypnale Venom  
and Changes Effected by Hemato Polyvalent Antivenom 
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9.1 INTRODUCTION 
 
Database of snake venom pharmacokinetics remains small. Studies on the 
pharmacokinetics of various snake venoms have not been extensively conducted, 
despite the usefulness of the information for a better understanding of the envenoming 
syndrome and for a treatment optimization. To date, there is no reported study on the 
time course of H. hypnale venom concentrations, in humans or animals. One of the 
reasons for this could be the lack of a specific venom quantitation assay. ELISA, an 
immunological assay, has the advantage in measuring blood venom concentrations as it 
works fundamentally on the immunological properties of the venom, the toxin proteins 
of which are usually the antigenic targets for antivenom to form immunocomplexes 
during neutralization. The measurement by ELISA hence reflects the extent of antibody-
toxin binding and indicates the level of toxins in the body that correlates with the 
clinical syndrome. 
 
The previous chapter (Chapter 8) describes the development of a double-sandwich 
ELISA using IgG specific to H. hypnale venom, and demonstrates the sensitivity as well 
as reliability of this assay in quantitating H. hypnale venom level in human serum. The 
double-sandwich ELISA was employed in this current study to monitor H. hypnale 
venom concentrations in the sera of experimentally envenomed rabbits. Changes of the 
venom levels in blood over time following Hemato polyvalent antivenom 
administration were also studied to understand the in vivo antivenom-venom interaction. 
This paraspecific antivenom was studied in this pharmacokinetic study in view of its 
greater neutralization efficacy and its potential use for the endemic urgency caused by 
H. hypnale envenomation (Joseph et al., 2007; Ariaratname et al., 2008), while there is 
still a long way to go before a specific antivenom can be developed. 
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9.2 METHODS 
 
9.2.1 Immunization, production of anti-Hypnale hypnale IgG and horseradish 
peroxidase (HRP) conjugate 
 
These were carried out as described in Chapter 8 to develop a double-sandwich ELISA 
for venom detection and quantitation (Sections 8.2.5 & 8.2.8). The IgG purification was 
carried out with protein A affinity column as described by Hudson and Hay (1980) with 
slight modification (Section 8.2.2). Conjugation of IgG with HRP was carried out 
according to Tijssen (1985) (Section 8.2.3).  
 
9.2.2 Double-sandwich ELISA for venom detection and quantitation 
 
Microtiter wells were each coated with 100 µL of anti-H. hypnale (anti-Hh IgG (4 
µg/mL) overnight at 4 
º
C. After washing with 100 µL PBS-Tween 20 for four times, the 
wells were incubated for 2 h at room temperature with 100 µL of rabbit sera (1:10 
dilution in PBS-Tween 20) obtained from pharmacokinetic experiments at various time 
intervals (Section 9.2.4). Following another cycle of washing (4 times), rabbit anti-Hh 
IgG-HRP conjugate, freshly diluted to 100 μL (1:200 dilution in PBS-Tween 20) were 
dispersed into each well and incubated for another 2 h. The wells then underwent 
another cycle of washing (4 times), before 100 μL of substrate (OPD) was added to 
initiate the enzymatic reaction. After 30 minutes the reaction was terminated by adding 
50 µL of 12.5% H2SO4, and the absorbance was read at 492 nm. The optimal working 
conditions were determined by chequerboard titration, and all assays were performed in 
triplicates. 
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9.2.3 Pharmacokinetic experiments 
 
9.2.3.1 Envenoming model for Hypnale hypnale venom in rabbits 
Six adult rabbits were divided into two groups: intravenous (i.v., n = 3) and 
intramuscular (i.m., n = 3) groups. Each rabbit from the i.v. group (1.95 ± 0.05 kg) was 
injected with 0.02 mg of H. hypnale venom in 200 μL PBS (approximated to 0.01 
mg/kg) via its marginal ear vein, whereas the rabbit from the i.m. group (2.03 ± 0.06 kg) 
was injected in the dorsal aspect of hind leg intramuscularly with 2 mg of the venom in 
500 μL PBS (approximated to 1 mg/kg). The venom dose for each route of 
administration was determined from preliminary studies based on the ELISA limit of 
measurement and the animal’s tolerance to the venom toxic effect. Blood samples (1 
mL) were collected serially (including pre-envenoming sample) in plain tube from the 
central artery of the ears. Sera were obtained by centrifuging the blood samples at 3,000 
g for 10 minutes, and the venom concentrations at various time points were determined 
using double-sandwich ELISA as described above.  A standard curve for venom 
concentrations was constructed using venom appropriately diluted in the pre-
envenoming sera. 
 
9.2.3.2 Effects of immunotherapy on the pharmacokinetics of H. hypnale venom 
Immunotherapy for envenoming was performed with Hemato polyvalent antivenom 
(HPA), where 1 vial (approx. 1 g of freeze-dried F(ab’)2) was dissolved in 10 mL of 
normal saline. The envenoming model was the same as that described in Section 9.3.1 
for the intramuscular route of venom administration: 2 mg of the venom dissolved in 
500 µL PBS was injected in the hind leg muscle. Pre-envenomed serum samples were 
collected from all animals prior to tests. 
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9.2.3.2.1 Preliminary study with a single dose of HPA 
Preliminary dosing tests with 2 mL and 4 mL HPA, each given 1 h post-envenoming, 
were conducted. One rabbit each for the dose received the antivenom (2 mL and 4 mL, 
respectively) over 10 minutes via manual infusion into its marginal ear vein. Blood 
samples at timed intervals were collected from the central artery of the contralateral ear, 
and processed as described for venom concentration determination by double-sandwich 
ELISA (Section 8.2.5). The animals were kept in standard individual cage with access 
to food and water ad libitum throughout the experiments. 
 
9.2.3.2.2 Repeated dosing of HPA in rabbits injected with Hypnale hypnale venom 
A regime with two doses of 4 mL HPA, each given at 1 h and 7 h following 
envenoming, was adopted for 3 rabbits envenomed intramuscularly with 2 mg of the 
venom. The antivenom was intravenously infused over 10 minutes via the marginal ear 
vein. Blood samples at timed intervals were collected and processed for venom 
concentration determination by double-sandwich ELISA as described above (Section 
9.2.3.2.1). All animals were kept in standard individual cage with access to food and 
water ad libitum throughout the experiments. 
 
9.2.3.3 Pharmacokinetic parameters determination 
Data of the serum concentration-time profiles were submitted to compartmental analysis 
through dissociation in exponential equations. Pharmacokinetic parameters were 
derived from equations described by Gibaldi and Perrier (1982) and Shargel and Yu 
(1999). A curvilinear relationship between the venom antigens concentrations on 
semilogarithmic plots and the time represents a multi-exponential equation, where the 
fitted curves correspond to a linear combination of two exponential terms, derived by 
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the method of residuals. Distribution half-life (t1/2α) and elimination half-life (t1/2β) were 
obtained by means of the equation 
 

2ln
2/1 t
       
2ln
  
 
where α and β are hybrid first-order rate constants for the distribution phase and 
elimination phase, respectively, obtained from the slopes of the biphasic curve on 
semilogarithmic plots. The individual intercompartmental rate constants k12, k21 and the 
elimination rate constant k were calculated from the values obtained for α and β. The 
volumes of distribution (VD), time to steady state of distribution (tss) and systemic 
clearance by body weight (CL) were all calculated according to Shargel and Yu (1999). 
 
The area under the curve (AUC) was calculated using the trapezoidal rule. The 
concentration for 0 h was obtained by extrapolation of the concentration-time curves, 
and the AUCs from last determined time point (ω h) to ∞ hours was calculated as:  
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The intramuscular bioavailability (Fi.m.) of the venom was calculated according to the 
equation: 
..
..
..
..
.
mi
vi
vi
mi
mi
Dose
Dose
AUC
AUC
F 
 
 
Comparison between the AUC of untreated and antivenom-treated groups was also done 
to assess the efficacy of the antivenom in neutralizing the venom. 
   or  
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9.3 RESULTS 
  
9.3.1 Pharmacokinetics of Hypnale hypnale venom 
 
Following i.v. administration of the venom (0.02 mg), a typical curvilinear relationship 
was obtained (Figure 9.1). By the method of residuals (Gibaldi and Perrier, 1982; 
Shargel and Yu, 1999), a biexponential equation was determined: Cp = Ae
-αt
 + Be
-βt
, 
where Cp is the venom level in serum at any given time, A and B are the respective y-
intercepts of the distribution and elimination phases, while the α and β coefficients were 
derived graphically from the gradients of the biphasic curves on semilogarithmic plots. 
A two-compartment open model was hence adopted in this study, with descriptions 
made on the transfer of venom antigens between the central and tissue compartments. 
The time to steady state (tss) of 2.9 ± 0.9 h indicated a time point following which the 
venom transfer from tissue into circulation is greater than that in the distribution phase. 
All calculated pharmacokinetic parameters of the venom are shown in Table 9.1.  
 
When H. hypnale venom (2 mg) was injected intramuscularly, the initial absorption 
phase demonstrated multiple peak concentrations especially in the first 30 minutes 
(Figure 9.2). Therefore, the absorption phase of the venom by i.m. route could only be 
explained with description for its patterns: Generally, 2 to 3 major peaks (measurable 
between 281-457 ng/mL) were observed within the first 30 min post-envenoming, and 
followed by a smaller rise (~40% height of the major peaks) by 2 h before the levels 
began to drop steadily. As the curve established its linear declining fashion consistent 
with an elimination phase, selected pharmacokinetic parameters were calculated as 
shown in Table 9.2. The i.m. bioavailability of the venom was extremely low, where 
only about 4% of venom injected i.m. was detected in the blood.  
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Forty eight h following venom injections, the serum venom levels were practically 
undetectable (< 10 ng/mL) for the intravenous profile, and were decreasing below 30 
ng/mL for the intramuscular profile. The slopes of the terminal portion of the 
semilogarithmic graphs for each administration route appeared parallel. Figures 9.1 and 
9.2 depict the venom concentration profiles on semilogarithmic plots within a time 
period where the best fitted linearity for terminal phase was determined.  
 
9.3.2 Effects of antivenom on the serum pharmacokinetics of Hypnale hypnale 
venom 
 
9.3.2.1 Preliminary study with a single dose of HPA 
In a preliminary study with the i.v. infusion of 2 mL HPA at 1 h post-envenoming (by 
i.m. injection of 2 mg venom), the serum venom level was reduced from a peak 
concentration of ~200 ng/mL to ~50 ng/mL. The neutralization was largely incomplete 
as the venom persisted at 50-60 ng/mL in the circulation throughout the following 6 
hours. This was followed by a resurged venom level to ~200 ng/mL at 7 h post-HPA 
infusion (Figure 9.3a). Infusion of i.v. 4 mL HPA at 1 h under the same envenoming 
condition appeared to effectively depleted the free venom antigens for the first 7 hours, 
but this too was subsequently followed by a rise in the venom level (to a level of ~150 
ng/mL) (Figure 9.3b).  
 
9.3.2.2 Effects of repeated HPA doses in envenomed rabbits 
The intervention experiment was repeated with an initial dose of 4 mL HPA at 1 h post-
envenoming, followed by an additional dose of 4 mL HPA 7 h. Immediately following 
the first dose, HPA effectively reduced the blood venom antigen level to < 50 ng/mL in 
one rabbit (80% reduction) and < 10 ng/mL in two rabbits (95% reduction) (Figure 9.4). 
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In one of the rabbits the blood venom level was completely depleted within an hour 
following the first dose of HPA, while a small increment of venom antigen level to ~50 
ng/mL was noted in the other two rabbits following the initial drop. Nevertheless, the 
venom levels continued to drop markedly and were soon depleted in one of the two 
rabbits; while in the last rabbit, the venom level decreased further to ~10 ng/mL towards 
7 h before the second dose of HPA was administered. The resurgence of venom 
antigens anticipated in the later course of envenoming (Figure 9.3a-b) was prevented by 
the second dose of HPA (Figure 9.4). Overall, the mean concentrations of venom 
antigens at various time points following HPA administrations at 1 h and 7 h were 
significantly lower than those in the untreated group (p < 0.05, Student’s t-test) (Figure 
9.5a-b). In addition, the total areas under the curve (AUC) representing the total 
concentrations of venom in blood (Figure 9.5b) for the treated group (494.6 ± 174.4 
ng∙h/mL) was significantly lower when compared to that of the untreated group (5511.7 
± 1291.5 ng∙h/mL) (p < 0.05, Student’s t-test). For visual and comparative purpose, 
Figure 9.4 depicts the time course profiles of individual treated rabbits, while Figure 
9.5a and Figure 9.5b show the concentration-time profiles (based on mean values) on 
normal and semilogarithmic plots, respectively. 
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Figure 9.1 Pharmacokinetic profiles of Hypnale hypnale venom (0.02 mg) injected 
intravenously on semilogarithmic plots. Concentrations of free venoms in the sera 
were measured with double-sandwich ELISA. Values are the means ± S.E.M. of three 
independent experiments using a rabbit model. 
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Figure 9.2 Pharmacokinetic profiles of Hypnale hypnale venom (2 mg) injected 
intramuscularly on semilogarithmic plots. Concentrations of free venoms in the sera 
were measured with double-sandwich ELISA. Values are the means ± S.E.M. of three 
independent experiments in a rabbit model. 
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Table 9.1   Pharmacokinetic parameters of Hypnale hypnale venom when injected 
intravenously in rabbits (Injection dose = 0.02 mg venom in 200 μL PBS).  
 
Parameter Description Unit Mean S.E.M. 
C0 Concentration at t0 ng/mL
 
346.85 68.94 
α Rate constant for distribution phase h-1 1.39 0.27 
β Rate constant for elimination phase h-1 0.04 0.00 
t1/2α Half-life at distribution phase h 0.54 0.10 
t1/2β Half-life at elimination phase h 20.10 2.45 
Vc Volume of central compartment mL 62.49 12.39 
(VD)ss 
Apparent volume of distribution at steady 
state mL 329.62 30.51 
(VD)area Volume of distribution by area mL 390.73 75.21 
CL Systemic clearance by body weight mL/h/kg
 
7.45 1.51 
tss Time at steady state h 2.83 0.50 
AUC 0-∞h 
Area under curve from time zero to 
infinity ng∙h/mL 1441.9 244.67 
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Table 9.2   Pharmacokinetic parameters of Hypnale hypnale venom when injected 
intramuscularly in rabbits (Injection dose = 2 mg venom in 500 μL PBS). 
 
Parameter Description Unit Mean S.E.M. 
β Rate constant of elimination phase h-1 0.04 0.00 
t1/2β Half-life at elimination phase h 19.31 0.73 
(VD)area Volume of distribution by area mL 405.03 65.69 
CL Systemic clearance by body weight mL/h/kg 7.38 1.50 
AUC 0-∞h 
Area under curve from time zero to 
infinity ng∙h/mL 5511.71 1291.49 
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Figure 9.3 Modifications of pharmacokinetics of 2 mg intramuscularly injected 
Hypnale hypnale venom in rabbits induced by (a) 2 mL, and (b) 4 mL of Hemato 
polyvalent antivenom (HPA) administered 1 h post-envenomation. Values are the 
venom concentration in blood at various time points in each rabbit. The venom 
concentrations were labeled on a normal axis to demonstrate the resurgence in blood 
venom concentrations.  
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Figure 9.4 Effect of Hemato polyvalent antivenom (HPA, constituting a “4+4 
regimen”) on the serum pharmacokinetics of i.m. Hypnale hypnale venom in 3 
rabbits which time course profiles were illustrated individually. Included on the 
plots was the mean concentrations ± S.E.M. for am envenomed group of rabbits without 
antivenom treatment. All venom concentrations were labeled on a normal axis to 
demonstrate the resurgence in blood venom concentrations.  
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(Figure 9.5) 
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Figure 9.5 Effect of Hemato polyvalent antivenom (HPA, constituting a “4+4 
regimen”) on the serum pharmacokinetics of i.m. Hypnale hypnale venom. Rabbits 
(2 kg) were envenomed intramuscularly with 2 mg venom with and without 
subsequent antivenom treatment. Blood venom antigen levels were shown on (a) 
normal plots and (b) semilogarithmic plots. In (b), dashed line (from 12 h to 24 h) 
shows an imaginary line representing the decline in blood venom concentrations by 24 h 
(which could have possibly completed earlier by then, between 12-24 h). Arrows show 
the time points at which 4 mL of antivenom was infused. Values are the means ± S.E.M. 
of three independent experiments for each antivenom-treated and untreated group. 
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9.4 DISCUSSION  
 
9.4.1 Pharmacokinetics of Hypnale hypnale venom 
 
Depending on the routes of administration (i.v. or i.m.), different doses of venom were 
given to the animals. The venom dose for intramuscular injection was higher than that 
injected intravenously to compensate for the venom’s low bioavailability in order to 
yield blood venom concentrations that were within a meaningful quantifiable range. The 
low i.v. dose when given intramuscularly resulted in very low sera concentrations way 
below the range of ng/mL that does not reflect the actual situation of most snakebite 
envenomations. The i.m. dose was therefore increased accordingly by trials to 2 mg and 
it was with this amount that the venom concentrations were measured reliably and 
comparable to the intravenous group (within a concentration range of 10-1000 ng/mL). 
An attempt to standardize the i.v. dose based on the relatively higher i.m. dose 
unfortunately appeared lethal, almost instantly, to the animal. The phenomenon was 
likely due to the procoagulant nature of the venom that precipitated an acute 
thromboembolic event by direct intravenous route. Hence, this explains the difference in 
venom dosages administered by different route in this study. During data analysis, 
pharmacokinetic parameters dependent on the initial dosage were normalized by the 
ratio between intravenous and intramuscular doses.  
 
Following intravenous injection, the pharmacokinetics of H. hypnale venom followed a 
two compartmental open model as depicted below: 
 
k12 
Central compartment                Tissue compartment 
k21 
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Symbols k12 and k21 represent the intercompartmental transfer rate constants, 
respectively, from the central compartment to the tissue compartment and vice versa. 
The venom exhibited a fast distribution from the central (typified by the vascular 
compartment and highly perfused organs) to the peripheral (tissue) compartment, 
evidenced by a relatively short distribution half-life (t1/2α), and a greater transfer into the 
tissues with a k12/k21 ratio of 3.2. This finding of fast distribution is comparable to that 
of Vipera aspis (a European viper) venom by intravenous route (~0.7 h); while its 
elimination half-life (t1/2β) was considerably longer than that of V. aspis venom (~12 h), 
studied in rabbits (Audebert et al., 1994). Similar patterns of a fast distribution (t1/2α < 
0.5 h) followed by a slow elimination (t1/2β < 10 h) has been reported for the viperid 
venoms of Bothrops erythromelas (t1/2α ~0.2 h, t1/2β ~6.6 h; Rocha et al., 2008) and 
Vipera russelli (Daboia russelii)  (t1/2α ~0.3 h, t1/2β ~8.9 h; Maung-Maung-Twin et al., 
1988), both studied in mice. Although venoms of the Viperidae family is known to 
generally contain similar high molecular mass enzymatic proteins and hence may 
exhibit similar distribution and elimination patterns, it is noteworthy to mention that 
experiments in mice might generate smaller parameter values for VD and t1/2 due to the 
low body weights and large body surface area to mass ratios in these animals. The H. 
hypnale venom appeared readily distributed into the tissue compartment based on its 
large volume of distribution by area, (VD)area, which is approximately three times of a 2-
kg rabbit’s total blood volume (120-150 mL). The high affinity towards tissues and low 
systemic clearance by body weight (CL) of this venom are likely accountable for its 
long t1/2β observed in this study. Clinically, this indicates that the venom systemic 
effects could be sustained well over many days, consistent with the prolonged or late 
onset clinical features typically related to consumptive coagulopathy (Ariaratnam et al., 
2008; Sunanda et al., 2010). In view of the venom slow elimination and prolonged or 
late complications, antivenom treatment seems to have a favorable therapeutic outcome 
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as it may still benefit patients who present late to the healthcare before the 
complications set far.   
 
On the intramuscular serum kinetic profiles, each concentration peak during the short 
absorption phase possibly represented the Cmax (maximal concentration) of one or 
collectively several toxin components from the venom, due to their varied initial rates of 
absorption from the perivascular injection site (Tan et al., 2009). Nevertheless, the t1/2β, 
(VD)area and CL of H. hypnale venom intramuscularly injected were all comparable to 
that of the intravenous profile, reflecting the consistency of the venom systemic 
pharmacokinetic behavior. The similarity between the i.v. and i.m. t1/2β for H. hypnale 
venom indicated that the slow elimination process is likely the rate-limiting step for its 
terminal phase, although a “sustained release” of venom from the i.m. injection site 
could be a concurrent contributing cause of prolonged terminal half-life, as reported by 
Auderbert et al. (1994). 
 
The very low intramuscular bioavailability of H. hypnale venom, on the other hand, 
implies poor systemic absorption of the venom from the injection site. From the 
literature search, it was found only one article where i.m. bioavailability of whole snake 
venom was reported (67% for Vipera aspis venom, Auderbert et al., 1994). General 
pharmacokinetic concept would predict a nearly 100% bioavailability for most 
therapeutic agents given intramuscularly, although exception has been reported for 
F(ab’)2 antivenom which i.m. bioavailability was as low as 36% (Pépin-Covatta et al., 
1996), possibly due to the large molecular size of the protein. Contrary to the 
pharmacokinetic concept, existing data showed that at least two viperid venoms were 
not completely absorbed via the intramuscular route. Possible explanations for this 
anomaly include:  
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(1)  Impeded absorption due to major local tissue destruction and compromised 
vasculatures (see Chapter 4), especially for the abundantly high molecular mass 
venom proteins;  
(2)    Persistent binding of some venom components at the injection site, followed by in 
situ degradation as local inflammation and necrosis set in, triggering phagocytosis 
and destruction of the toxins before they were circulated;  
(3)  Altered structures of the venom antigen epitopes following interaction with local 
tissues, which in turn affects the ELISA detectability.  
 
The phenomenon illustrates a ‘pre-systemic loss’ for i.m. venom absorption that is 
likely a result from the local toxicity of the venom itself. For the first time, we try to 
explain the variation between i.v. and i.m. LD50 of venom by correlating lethality to 
bioavailability: a huge difference of fifteen times between the i.v. and i.m. LD50 of H. 
hypnale venom (0.90 and 13.7 μg/g, respectively, Chapter 4) could be accounted for by 
the venom i.m. bioavailability of less than 10%. In the case of Vipera aspis venom, the 
i.v. LD50 was reported as 1.0 mg/kg by Brown (1973) and 0.55 μg/g by Komori et al. 
(1998); while Tu et al. (1969) reported 4.7 mg/kg for its i.m. LD50. The LD50 varied by 
five to ten times between the two routes of administration, although the i.m. 
bioavailability reported by Auderbert et al. (1994) appeared higher (67%) by 
proportion. Further interpretation of this phenomenon is however limited as the LD50 
values were derived from rodent models, which were different from rabbits in most 
pharmacokinetics studies.  On the other hand, the very low systemic absorption of H. 
hypnale venom by i.m. route is in accord with clinical case reports where local 
envenoming represented the commonest presentation of H. hypnale bites (91%), in 
contrast to systemic envenoming (39%) characterized by hemostatic disturbances 
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(Ariaratnam et al., 2008). The venom however appears highly toxic and potentially fatal 
should it enter the circulation, with its systemic effect being predominantly “hematoxic” 
(causing deranged hemostasis and coagulopathy). Acute kidney injury – a severe though 
infrequent fatal consequence has been suggested as a complication of disseminated 
intravascular coagulopathy, mediated through the procoagulant and fibrinolytic actions 
of H. hypnale venom (Kanjanabuch and Sitprija, 2008; Sitprija, 2008). Therefore, in 
view of the venom’s long elimination half-life and its prolonged hematoxic nature in 
general, the coagulation profile as well as renal function of patients should be monitored 
closely on an extended basis over days and even weeks, as some disastrous bleeding 
complications might present as late as 5 weeks post-bite (Sunanda et al., 2010). 
 
9.4.2 Effects of antivenom on the serum pharmacokinetics of Hypnale hypnale 
venom 
 
9.4.2.1 Preliminary dosing 
Preliminary dosing with 2 mL HPA given 1 h post-envenoming was insufficient for 
complete neutralization of the venom. The subsequent rise in the venom level several 
hours later presumably was caused by an enhanced transfer of venom antigens from 
tissues into the vascular space. These redistributed venom antigens, as expected, were 
beyond the neutralizing capacity of the 2 mL HPA administered several hours ago.  
 
The intervention repeated with 4 mL HPA at hour 1 effectively reduced the free venom 
antigens for the following 7 hours. This reflects that a higher first dose of antivenom is 
needed to neutralize the circulating venom toxins following envenomation. A drastic 
drop in plasma free venom level induced by i.v. antivenom infusion has been reported, 
and the phenomenon is vital since the plasma venom level correlates well with the 
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severity of envenomation (Ismail et al., 1996; Otero et al., 1996). This implies that the 
amount of first dose antivenom sufficient to optimally reduce the initial venom level 
should be determined during clinical study in order to preempt the onset of severe 
envenoming. In fact, the initial dosages of most antivenoms recommended for use in 
snakebites in South Asia/Southeast Asia are within 5 to 10 vials, considerably high 
doses to ensure early and adequate elimination of the venom (WHO, 2010). Following 
that, antivenom can be repeated empirically as when indicated clinically (by incomplete 
resolution of systemic effects). However, recovery may be delayed on blood 
coagulability even when a large dose of antivenom is given to adequately neutralize the 
circulating venom procoagulant enzymes. This is due to the fact that generally 3-9 hours 
are needed for the liver to restore coagulable levels of fibrinogens and other clotting 
factors (WHO, 2010). Nevertheless, an early and adequate antivenom treatment is 
principally the aim of antivenom therapy to ensure an early elimination of venom from 
the system for a faster recovery before complications set far. 
 
The single dose of 4 mL HPA given at 1 h, unfortunately, did not prevent the venom 
resurgence in blood that occurred ~7 h after its administration. The venom resurgence 
however appeared slightly smaller than that observed in the case of 2 mL HPA, 
although in essence, it reflects the inadequacy of the antivenom to sequester the 
subsequently resurged venom antigens. This could be due to either an insufficient 
amount of functional paratopes, or a lack of affinity towards certain toxin antigens that 
reappeared into the blood.  
 
9.4.2.2 Venom redistribution and repeated dosing of HPA 
A rebound increase of drug concentration in blood following immunotherapy has been 
described for drugs like digitoxin (Smith et al., 1976) and colchicine (Sabouraud et al., 
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1992) in overdose poisoning. The term ‘drug redistribution’ has been coined to denote 
the enhanced transfer of a drug from tissue into vascular compartment following 
immunotherapy for the drug. Similar phenomenon on venom ‘redistribution’ induced by 
antivenom had also been reported, both in snakebites (Rivière et al., 1997; Rocha et al., 
2008) and scorpion stings (Revelo et al., 1996; Krifi et al., 2005). The recurrent venom 
antigenemia occurs mainly by following the law of mass distribution (Chippaux, 2006), 
where the shifted intercompartmental equilibrium (due to clearing of circulating venom 
antigens within a brief period) favors the transfer of tissue-deposited antigens into the 
blood. Such modification of venom pharmacokinetics depends not only on the affinity 
of antibodies for toxins but also on the dose of antivenom and the timing in antivenom 
administration (Rivière et al., 1997; Gutiérrez et al., 2003). The redistribution 
phenomenon however provides a mechanism essential for detoxification as it extracts 
venom toxins deposited in the peripheral tissues into the blood, where the redistributed 
toxins can be further bound by circulating antivenom for elimination (Gutiérrez et al., 
2003, 2007). It is also known that for viperid venoms that cause local tissue destruction 
(due to hemorrhagic and necrotizing toxins e.g. metalloproteases), antibody-induced 
redistribution can halt further tissue damages, although it is unlikely to restore the 
already affected areas with irreversible damages (Gutiérrez et al., 1998).   
 
In anticipation of a venom redistribution phenomenon induced by the first dose of 
antivenom, an additional dose of HPA was administered at 7 h post-envenoming. The 
efficacy of the first dose of HPA in producing a drastic reduction (80-90%) of the 
venom levels in all rabbits indicated that the antivenom is effective against the major 
toxins in the heterologous venom, although minor variations in the decline of venom 
level were initially observed in two rabbits. Nevertheless, the reduction was still 
statistically highly significant compared to the untreated group. The subsequent dose of 
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HPA enhanced the clearing of residual venom antigens in one rabbit, evidenced by the 
steeper gradient on its terminal phase. More importantly, however, this additional dose 
of HPA successfully prevented the anticipated venom redistribution in all rabbits. The 
extent of immunocomplexation (the principal therapeutic mechanism of antivenom) 
between the HPA doses and the major toxins was excellent, as indicated by the 
significantly smaller AUC in the treated group.  
 
The minor variations noted in the declining pattern of venom level following the first 
dose of HPA, based on an in vivo experiment as such, appear to imply the following: 
 
(a) Variations in pharmacogenetics of the animals could have affected the antivenom 
metabolism and consequently its interactions with the venom antigens; 
(b) The time for administering the first dose of antivenom (1 h post-envenoming) was 
when the venom’s complex absorption and distribution largely took place (from the 
time of envenoming up to 3-5 h), and thus complicating the neutralizing effect; 
(b) Certain antigens were not optimally bound by HPA at the dose of 4 mL. The HPA 
is, after all, a paraspecific antivenom; whereas the ELISA was developed using 
anti-H. hypnale venom IgG that could have detected specific antigens ‘missed’ by 
HPA in the circulation. A much higher dose of HPA (> 4 mL), nonetheless, may be 
possible to overcome such shortcoming in view of the paraspecific origin of the 
antivenom, and hence representing a potential future work for dosing optimization.  
 
Essentially, the significant pharmacokinetic changes indicate a remarkable therapeutic 
potential with the use of HPA for H. hypnale envenoming. In fact, the neutralization of 
venom antigens, characterized as a graded response, does not necessarily work on an 
‘all-or-none’ (none being zero antigen level) basis: an antivenom with good affinity can 
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significantly reduce the venom concentration to a subtoxic level, thereby preventing or 
reversing the envenoming syndrome. In the current pharmacokinetic study, the 
reduction and subsequent complete depletion of H. hypnale venom antigens by HPA is 
consistent with previous pharmacodynamic outcomes where HPA has been proven to 
neutralize the lethal, hemorrhagic, necrotic, procoagulant, as well as nephrotoxic effects 
of the venom (Chapter 5 and chapter 6). The findings hence imply that the “4+4 
regimen” of HPA appears to be timely and adequate to assure satisfactory 
immunocomplexation with the circulating venom toxins, as well as promoting venom 
redistribution from tissues into vascular space where further neutralization takes place.  
 
Interestingly, although the in vitro neutralization test showed that 1 mL of HPA could 
neutralize 1.5 mg of H. hypnale venom (based on ED50 calculation, Chapter 5, see Table 
5.1), a total of 8 mL HPA was required in current in vivo pharmacokinetic experiment 
(where 2 mg of venom was injected intramuscularly in rabbit) for the venom antigens to 
be effectively neutralized over the study period. Such observation based on an in vivo 
animal model suggests that an initial antivenom dose higher than that established in 
vitro, coupled with repeated dosing, may be necessary for adequate in vivo venom 
neutralization over the prolonged time course. It also emphasizes the fact that in vitro 
neutralization tests should always be supported by in vivo pharmacokinetic experiments 
for a more realistic and practical understanding of the pharmacology of an antivenom, 
as the venom (and the corresponding antivenom) introduced/administered into a 
biological system is bound to undergo pharmacokinetic processes, specifically, 
distribution and elimination. These deductions based on experimental basis are 
potentially useful as complementary information for treatment design. Clinical trials are 
therefore required in the future to establish an optimized protocol of the antivenom 
treatment. 
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10.1 INTRODUCTION 
 
Pit vipers (Crotalinae) are the most widely distributed subfamily of the Viperidae 
family, with major radiations over 190 species (~75% of viperid species allocated in 29 
genera) (http://reptile-database.org) in both the Old and New Worlds. Over millions of 
years the diverse ecological niche has triggered off accelerated evolution, characterized 
by rapid amino acid sequence divergence of venom proteins that led to a tremendously 
diverse number of proteins and peptides in snake venom with equally diverse biological 
functions. Knowledge of the diversity of venom proteins entails identification of various 
proteins/peptides in the venom of a particular species. Although with current molecular 
technology, transcriptomics of venom gland virtually unmasks the identity of all 
proteins/peptides at transcript level, it does not provide quantitative data on their 
relative amount according to various post-translational proteins i.e. the composition of 
toxins. Venom proteomic studies nevertheless address the concern by providing 
information on the types and composition of major toxins in a venom; hence, a better 
understanding of the pathophysiology of the venom. This is especially relevant for 
medically important species which still lacks characterizations of the venom properties, 
e.g. Hypnale hypnale. Unfortunately, there can be no single unique method utilized for 
all proteomic analyses to date. In the study of H. hypnale venom proteome, two 
approaches were adopted: (1) trypsin-digested venom subjected to shotgun-LC-MS/MS; 
(2) venom separated by reversed-phase HPLC and SDS-PAGE, followed by N-terminal 
amino acid sequencing and protein digestion for peptide mass fingerprinting using 
tandem mass spectrometry. An additional effort of de novo peptide sequencing was 
undertaken for sequences not matched to current database, likely due to a lack of 
species-specific transcriptomic database. 
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10.2 Methods 
. 
10.2.1 Shotgun-LC-MS/MS and de novo sequencing of Hypnale hypnale venom 
proteins 
 
The venom protein sample (1 mg) was reduced, alkylated and trypsin digested 
according to the iTRAQ
TM
 Reagents protocol (Applied Biosystems Sciex). Peptides 
were analysed by LC-MALDI analysis using the UltiMate
TM
 3000 nano-HPLC system 
(Dionex, C18 PepMap100, 3 µm) equipped with a ProBot robotic spotter (LC Packings) 
coupled to AB SCIEX TOF/TOF
TM
 5800 System Proteomics Analyzer (Applied 
Biosystem Sciex). In brief, peptides were loaded onto the reverse-phase HPLC and 
separated with a gradient of 10-45% acetonitrile (containing 0.1% trifluoroacetic acid) 
over 165 minutes. Spectra were analysed to identify protein of interest using Mascot 
sequence matching software (Matrix Science) with Uniprot database and taxonomy set 
to Serpentes (Downloaded September 2011; 15,468 sequences). 
 
For de novo sequencing analysis, the venom sample was resuspended in 100 µL of 2% 
CH3CN/H2O (containing 0.1% TFA). From this solution 2 µL was added to 18 µL of 
2% CH3CN/H2O (containing 0.1% TFA). Ten µL was injected onto the UltiMate
TM
 
3000 nano-HPLC system (Dionex, C18 PepMap100, 3 µm) and separated with a 
gradient of 10-40% acetonitrile (containing 0.1% TFA) with spotting using a ProBot 
robotic spotter (LC Packings) over 180 min. Peptides were analysed by MALDI-TOF-
TOF mass spectrometer using AB SCIEX TOF/TOF
TM
 5800 System Proteomics 
Analyzer (Applied Biosystem Sciex). MS/MS spectra were analysed using PEAKS 
Studio Version 4.5 SP2 (Bioinformatics Solutions). All de novo-derived sequences from 
MS/MS spectra were submitted for BLAST (Basic Local Alignment Search Tool) 
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search in the blastp suite at www.ncbi.nlm.nih.gov/BLAST, using the following settings 
for the non-redundant protein sequences (nr) database:  
 
Taxonomy = Serpentes (taxid: 8570) for Sequence 1-10, except Sequence 4 with 
Viperidae (taxid: 8689). 
Expect threshold = 10 
Word size = 3 
Matrix: BLOSUM 80 
Gap costs: Existence: 10 Extension: 1 
Compositional adjustment: No adjustment 
Filter: not selected 
 
Following BLAST searching, the de novo-derived sequences were putatively assigned a 
protein family and a function using a scoring system modified from Bringans et al. 
(2008). In brief, for each peptide, the functions of the homologous BLAST hits with the 
three highest hit scores (generally correlated with the lowest three Expectation values/E-
values) were evaluated from the database entry. A score of one point was given to a 
functional category each time the function is matched to a protein within the top three 
hits. For matches with equivalent hit scores and E-values, proteins of the same family 
(note the different accession numbers though) but originated from different species were 
treated as different entities considering the extreme diversity of venom proteins; hence, 
one point would be scored for each match. However, a maximum of one point only was 
given to matches with equivalent hit score or E-value if the particular protein originated 
from a same species; or if the matches reflected sequence repetition within a protein 
molecule. The de novo-derived sequence is then putatively assigned the functional 
protein category with the highest overall score. Where two or more functions had 
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equivalent scores, the function would be labelled as undetermined. Sequences assigned 
to a same protein family were checked for the accession numbers and organism sources 
of the scoring proteins to determine if they possibly belong to the same protein 
molecule. 
 
Shotgun-LC-MS/MS and de novo sequencing were conducted at Proteomics 
International, Perth, Australia which provided the service on mass spectrometry 
proteomic facility. Data analysis and BLAST search of the de novo-sequences were 
completed back in the University of Malaya, Kuala Lumpur, Malaysia.  
 
10.2.2 Reverse-phase HPLC separation of H. hypnale venom proteins and further 
characterizations    
 
Two milligrams of H. hypnale venom dissolved in 0.1% TFA was fractionated on a 
LiChrospher
®
 RP100 C18 reverse phase column (Merck, 250 x 4 mm, 5 µm particle 
size). The sample was eluted at 1 mL/min with a linear gradient of 0-66% acetonitrile 
(ACN) containing 0.1% TFA over 60 min. The solvent delivery and gradient formation 
over 60 min was achieved using the Shimadzu LC-20AD HPLC system. Eluted 
fractions were collected manually according to 215 nm absorbance, and dried in a 
Speed-Vac system. The relative abundances (percentage of the total venom proteins) of 
the different protein families in the venom were estimated from the relation of the sum 
of the areas of the reverse-phase chromatographic peaks containing proteins from the 
same family to the total area of venom protein peaks. 
 
Isolated protein fractions were further assayed by SDS-PAGE on 15% polyacrylamide 
gels under reducing condition with beta-mercaptoethanol as the reducing agent. The 
Chapter 10: Proteomic Study 
 
213 
separated proteins were transferred onto polyvinylidene fluoride (PVDF) membranes by 
using Invitrogen iBlot
TM
 System (Program P2, 8-10 minutes), and the protein bands 
were made visible by Coomassie Blue R-250 stain. The protein samples were subjected 
to peptide N-terminal sequencing by Edman degradation method using the Procise 
Sequencer (Applied Biosystem Sciex) available at the Mission Biotech of Taipei, 
Taiwan ROC. The N-terminal amino acid sequences determined were subsequently 
subjected to similarity searches against the available databases using the BLAST search 
program (www.ncbi.nlm.nih.gov/BLAST), with settings as described for the de novo 
sequencing work (Section 10.2.1).  
 
A separate set of gels from the SDS-PAGE of the reverse-phase HPLC fractions were 
stained with Coomassie Blue R-250 to determine the molecular masses of purified 
proteins, and for further in-gel enzymatic digestion for peptide mass fingerprinting as 
described by Bringans et al. (2008). Excised protein bands were destained by 3 cycles 
of 45-min washes with 25 mM ammonium bicarbonate in 50:50 acetonitrile:water, and 
the gel plugs/pieces were vacuum-dried and stored at -20 °C. For in-gel protein 
digestion, 10 µL of digestion buffer (12.5% µg/ml sequencing-grade bovine pancreatic 
trypsin in 25 mM ammonium bicarbonate) was added to each gel piece and incubated 
overnight at 37 °C. The tryptic peptides were subsequently extracted by two 20-min 
incubations with 10-20 µL ACN containing 1% TFA. The extracts were dried by rotary 
evaporation and stored at -20 °C pending further peptide mass analysis. 
 
Peptide mass analysis was performed by MALDI-TOF/TOF MS/MS on the AB SCIEX 
TOF/TOF
TM
 5800 System Proteomics Analyzer (Applied Biosystem Sciex).  The 
peptide samples were reconstituted in 2 µL diluent (30:70 ACN:water). The solution 
was diluted 1:10 with matrix solution (alpha-cyano-4-hydroxycinnamic acid (Sigma), 
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10 mg/ml) and spotted on a 384-well Opti-TOF stainless steel plate. The spotted 
samples were analysed using a first run of standard TOF MS. The system was set to 
perform a second run of MS/MS focused on the 15 most intensive peaks of the first MS 
excluding peaks known to be trypsin. The laser was set to fire 400 times per spot in MS 
mode and 2000 times per spot in MS/MS mode. Laser intensity was 2800 J (MS) and 
3900 J (MS/MS). A mass range of 400-4000 u (unified atomic mass unit) with a focus 
of 2100 u was used.  Spectra were analysed to identify protein of interest using Mascot 
sequence matching software (Matrix Science) with Ludwig NR Database and taxonomy 
of Serpentes (June 2012, 16,183 sequences). In-gel digestion, tryptic peptides extraction 
and subsequent peptide mass printings were carried out at Proteomics International, 
Perth, Australia which provided the mass spectrometry proteomic facility. 
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10.3 Results  
 
10.3.1 Shotgun-LC-MS/MS and de novo sequencing 
 
Figure 10.1 shows that the loaded tryptic peptides were completely eluted at an 
acetonitrile concentration of 50%. Depending on the population of the constituent 
peptides, > 1000 MS/MS spectra were automatically collected, and subsequently 
matched for the most probable proteins or peptides by the software algorithm Mascot. 
In all cases, the best results are achieved where two or more peptides were mapped to 
the same protein. A singly-matched peptide at high confidence is nevertheless 
indicative. The proteins identified via this method were summarized in Table 10.1.  
 
In de novo sequencing, sequences with the best de novo score (Table 10.2) was 
submitted for further bioinformatics analysis (BLAST searching) at NCBI BLAST 
website (blastp suite at www.ncbi.nlm.nih.gov/BLAST) using settings suggested for 
short peptide sequences. When the identity of the top hit for de novo peptides was 
determined, all were matched to known venom proteins listed under the Serpentes or 
Viperidae taxon in the database. Proteins matched to the first three hits for each de novo 
sequence appeared to be mostly of the same protein family. This indicates that the 
homology matching of short sequences is likely producing true venom protein matches, 
above that expected by chance. The identity of protein derived from de novo peptide 
sequencing was further verified based on its putative functional category derived using a 
simple function-scoring system for each probable protein matched to the top hits (Table 
10.2), as modified from Bringans et al. (2008) . 
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By using the shotgun approach including enrichment with de novo sequencing method, 
a total of 52 individual proteins were identified from H. hypnale venom. Out of these, 
39 were determined by ≥ 2 homology-matched peptides, 4 were determined with single 
homology-matched peptide, and 9 were identified from de novo-derived sequences 
based on putative functions. Major proteins found in the venom are of secretory types (> 
70% by protein identities), which are mainly enzymes with toxinological activities. 
Three major enzymes commonly present in viperid venoms were recognized: 
metalloproteases (10), serine proteases (4) and L-amino acid oxidases (4).  
 
The numbers of various types of proteins identified as components of H. hypnale venom 
by the Shotgun approach (including de novo sequencing) were illustrated in Figure 10.2.
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Figure 10.1 Elution profile of tryptic peptides of Hypnale hypnale venom from reverse-phase HPLC monitored at 214 nm.
2
1
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Table 10.1 Proteins identified from shotgun-LC-MS/MS of trypsin-digested venom proteins. 
 
No. Accession Protein  Species 
Molecular 
mass  (Da) 
Theoreti-
cal pI Peptide sequences matched 
Coverage 
(%) 
 
1 P0DI84 L-amino-acid oxidase Vipera  54,989 7.71 YPVKPSEEGK 12.4 
   
ammodytes  
  
IQFEPPLPPK 
 
   
ammodytes 
  
FWEDDGIHGGK 
 
   
 
  
HDDIFAYEKR 
 
   
 
  
IQFEPPLPPKK 
 
   
 
  
DCADIVFNDLSLIHQLPK 
 
   
 
    2 P81382 L-amino-acid oxidase  Agkistrodon  58,506 6.05 FWEDDGIHGGK 10.7 
   
rhodostoma 
  
HDDIFAYEKR 
 
   
 
  
LNEFSQENDNAWYFIK 
 
   
 
  
DCADIVFNDLSLIHQLPK 
 
   
 
    3 B5AR80 L-amino-acid oxidase  Bothropoides 
pauloensis 
57,086 6.31 TNCSYMLNK 8.0 
     
IKFEPPLPPK 
 
   
 
  
FWEDDGIHGGK 
 
   
 
  
HDDIFAYEKR 
 
   
 
    4 A6MFL0 L-amino-acid oxidase  Demansia 
vestigiata 
59,159 7.16 AHGWIDSTIK 
 
     
AHGWIDSTIK 
 
   
 
  
DVNRASQKPSR 
 
   
 
  
FWEDDGIHGGK 
         
5 P26324  Serine protease ancrod  Agkistrodon 
rhodostoma 
27,105 8.61 VLCAGDLR 17.1 
     
VMGWGSINR 
         
 
2
1
8
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Table 10.1, continued 
   
 
  
RMNLVFGMHR 
 
   
 
  
VIGGDECNINEHR 
 
   
 
    6 P85109 Thrombin-like enzyme kangshuanmei Agkistrodon 
halys 
brevicaudus 
26,967 8.27 FFMYIR 11.9 
     
WDKDIMLIR 
 WDKDIMLIR  
   
 
  
WDKDIMLIR 
 
   
 
  
VIGGDECNINEHR 
 
   
 
    7 P47797 Serine protease ancrod-2  Agkistrodon 
rhodostoma 
29,724 8.64 ILCAGDLQGR 7.4 
     
WGEDIMLIR 
 
   
 
  
WGEDIMLIR 
 
   
 
    8 Q7SZE2 Bradykinin-releasing enzyme KR-E-1  Gloydius  25,887 4.82 DIMLIKLDSR 9.8 
   ussuriensis   DIMLIKLDSR  
   
 
  
DIMLIKLDSR 
 
   
 
  
VIGGDECNINEHR 
 
   
 
    9 P0C6E3 Zinc metalloproteinase-disintegrin 
bilitoxin-1  
Agkistrodon 
bilineatus 
33,304 5.28 FKGAGTECR 6.5 
    
CTGQSADCPR  
   
 
   
 
10 P30403  Zinc metalloprotease-disintegrin 
(rhodostoxin-rhodostomin) 
Agkistrodon  55,075 5.6 HSNDLEVIR 4 
  rhodostoma   CTGQSADCPR  
        
11 Q9IAY4 Zinc metalloproteinase H4  Agkistrodon  40,767 5.64 VNDYEVVYPR 2.8 
   acutus     
        
 
 
 
2
1
9
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Table 10.1, continued 
 
12 Q2LD49 Zinc metalloproteinase-disintegrin 
TSV-DM  
Viridovipera 
stejnegeri 
70,513 6.4 IACEPENVK 1.4 
     
 
   
 
   
 
13 C6G1U7 Neurotrophin-3 Hypsiglena 
chlorophaea 
19,539 8.63 DGVPTTVRK 10.5 
     
TLIQATIWK  
   
 
  
TLIQADIWK  
   
 
  
TLIQADIWK  
   
 
  
TLIQAMIWK  
   
 
  
TLIQAFIWK  
   
 
  
TLIQAFIWK  
   
 
  
TLIQACIWK  
   
 
  
TLIQACIWK  
   
 
  
TLIQACIWK  
   
 
  
TLIQARIWK  
   
 
   
 
14 D6P6B6 Neurotrophin 3   Typhlops sp. 24,389 9.74 FAEGKSHR 17.4 
   
 
  
DWIQTTVK  
   
 
  
TLIQADIWK  
   
 
  
TLIQADIWK  
   
 
  
WVTDKSSAVDCR  
   
 
   
 
15 D6P679 Neurotrophin 3   Typhlops 
anchaurus 
24,513 9.72 AEPDAAAHK 16.4 
     
FAEGKSHR  
   
 
  
DDVQTTGKR  
   
 
  
TLIQADIWK  
   
 
  
TLIQADIWK  
      22
0
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Table 10.1, continued  
 
16 D3J183 Neurotrophin 3 Mitophis  18,639 8.78 FAEGKSHR 15.8 
   pyrites   TLIQADIWK  
   
 
  
TLIQADIWK  
   
 
  
QQRQFSSPR  
   
 
   
 
17 Q9PSM4 Galactose-specific lectin Lachesis  16,626 5.05 NQPDHYEGK 14.1 
   
stenophrys 
  
DFSWEWTDR  
   
 
  
DFSWEWTDR  
   
 
  
DFSWEWTDR  
   
 
  
KDFSWEWTDR  
   
 
  
KDFSWEWTDR  
   
 
   
 
18 Q6X5S0 C-type lectin 7 Echis pyramidum  17,493 6.51 ADVVWIGLR 6.1 
   
leakeyi 
   
 
19 P81114  
 
14,679 4.62 PWREQFECLVSR 22 Alboaggregin-A subunit 4 Cryptelytrops 
   
albolabris 
  
DCPSDWSSYEGHCYR  
   
 
  
DCPSDWSSYEGHCYR  
   
 
   
 
20 D2YW39 Rhodocetin subunit gamma  Agkistrodon  15,957 5.69 TWDEAER 13.4 
   
rhodostoma 
  
RPELYVWIGLR  
   
 
   
 
21 Q9DEA2 Agkicetin-C subunit alpha  Agkistrodon  18,109 8.83 TWEDAER 11 
   
acutus 
  
IKPYVWIGLR  
   
 
   
 
 
 
 
    
 
2
2
1
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Table 10.1, continued 
 
22 B6EWW5 Aminopeptidase N  Agkistrodon halys 
brevicaudus 
112,390 5.4 ALSNMPIK 3.2 
     
DNEDVGFGSATR  
   
 
  
MLSEFLTEAVFR  
   
 
   
 
23 A5HUI5 Aminopeptidase A Agkistrodon halys 
brevicaudus 
110,497 5.54 RYTLNDR 3.3 
     
VNYEPQVWR  
   
 
  
AVVAVSYIGQMVEDDK  
   
 
   
 
24 F8S101 Phospholipase B Crotalus 
adamanteus 
64,284 8.66 QDEWTR 8.5 
     
DDPFWR  
   
 
  
DDPFWR  
   
 
  
VTDMESMK  
   
 
  
NGYWPSYNIPFDK  
   
 
  
EIYNMSGYGEYVQR  
   
 
   
 
25 A8QL55 Complement-depleting factor  Ophiophagus 
hannah 
185,524 6.12 VLMAASTGK 4.1 
     
SDLWPMKDK  
   
 
  
GALMLKICMR  
   
 
  
LSEGVDRYISR  
   
 
  
IPILDGDGEATLKR  
   
 
  
DTCMGMLVVKGASSR  
      
26 A0RZG1 Complement protein C3-1  Austrelaps  185,821 6.17 VLMAASTGR 2.9 
   superbus   
AAQFQDQNLR 
ASVRGELASDGVR 
LEGDPGARVGLVAVDK 
 
   
 
  
 
   
 
  
 
        
 
  
2
2
2
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Table 10.1, continued 
 
27 D9J014 NADH dehydrogenase subunit 4  Acrochordus 
granulatus 
25,250 9.04 GMQVLPTTK  
     
GMQVLPTTK  
   
 
  
GMQVLPTTK  
   
 
  
GMQVLPTTK  
   
 
  
GMQVLPTTK  
   
 
  
AMQVLPTTK  
   
 
  
GMQVLPTTK  
   
 
  
GMQVLPTTK  
   
 
  
RMQVLPTTK  
   
 
  
CMQVLPTTK  
   
 
  
WMQVLPTTK  
   
 
  
WMQVLPTTK`  
   
 
   
 
28 Q8HI16 NADH dehydrogenase subunit 4   Contia tenuis 25,482 8.99 LAGYGICR 7.4 
   
 
  
LAGYGIWR  
   
 
  
LAGYGIWR  
   
 
  
LAGYGICRMMQTLPTMK  
   
 
   
 
29 Q8WFF7 NADH-ubiquinone oxidoreductase 
chain 2  
Crotalus atrox 37,315 10.2 NPLWLTVR 5 
  
 
  
IITLAKMMK  
   
 
  
IITLAEMMK  
   
 
    30 Q64G16 G protein-binding protein  
Oxyuranus 
scutellatus 
scutellatus 
23,484 9.85 IMVVPSAK 11.7 
     
YGDSLYR 
 
     
MCTIIKR 
 
   
 
  
MCTIIKR  
KIMVVPSAK 
 
  
   
 
2
2
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Table 10.1, continued 
31 A9QXJ8 Mitochondrial uncoupling protein B  Rhabdophis 
tigrinus 
33,870 9.81 EEGVRGLWK 9.4 
     
GLWKGTLPNVSR 
 
   
 
  
MLQDEGPLAFYK 
 
   
 
    32 F2WUN8 ATP synthase subunit a  Crotalus sp. 24,979 9 MFLLSMTSQLTPK 12.4 
   
 
  
LLGNRMTTAITGLLK 
 
   
 
    33 F8UIL6 A kinase anchor protein 9  Trachyboa  53,899 5.04` VKLDLEENK 7.6 
  boulengeri   TELLEKQMK  
   
 
  
DAVLDRMAESQEAELER 
 
   
 
    34 P0CV92 Glutaminyl-peptide cyclotransferase  Crotalus atrox 7,894 6.44 LIFFDGEEAFVR 16.9 
   
 
    35 B4YHB7 Recombination activating protein 1  Vermicella 
intermedia 
41,137 9.03 KGMLNSQLSK 3.1 
  
 
  KGMLNSQLSK  
  
 
  
KGMLNSQLSK 
 
   
 
  
VMLNSQLSKK 
 
   
 
  
TMLNSQLSKK 
 
   
 
  
 
 36 Q5FY47 Calbindin D28K  Pantherophis 
guttatus 
30,275 4.72 FQGIKMCGK 14.9 
     
KNIMALSDGGK 
 
   
 
  
LELTEMARLLPVQENFLLK 
 
   
 
    37 D0VY30 Eukaryotic translation elongation factor 
2  
Leiolepis reevesii 
rubritaeniata 
36,276 8.61 KVEDMMK 10.2 
    
DKEGKPLLK 
 
 
 
  
EGKPLLKAVMR 
IFSGVVSTGLKCR 
IFSGVVSTGLKCR 
 
 
 
 
 
   
 
2
2
4
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Table 10.1, continued 
 
38 D2IL03 Dynein axonemal heavy chain 3   
Leptodeira 
annulata 
rhombifera 
28,442 7.7 VAEVVAPK 7.3 
     
LISGLGGEK 
 
     
VAAVVAPKR 
 
   
 
  
VASVVAPKR 
 
   
 
  
VASVVAPKR 
 
   
 
    39 D2IL04 Dynein axonemal heavy chain 3   Leptodeira bakeri 28,476 7.7 KFMGDLK 6.5 
   
 
  
LISGLGGEK 
 
   
 
    40 F8V4K2 Prolactin receptor   Lampropeltis 
pyromelana 
7,827 8.15 HLSETLK 26.5 
     
CLSETLK 
 
   
 
  
DPEEVCR 
 
   
 
  
DPEEVTRNTDR 
 
   
 
    41 B8QC49 Aryl hydrocarbon receptor  Liotyphlops 
albirostri 
17,269 4.17 SNKIVLER 5.4 
     
SNKINLER 
 
   
 
  
SNKIHLER 
 
   
 
    42 B7TXS4 RAG2  Duberria lutrix 26,298 5.09 MIVIIGGR 6 
   
 
  
MIVIIGGRSYMALR 
 
   
 
    43 D0VXZ7 SRY-box 9   Leiolepis reevesii 
rubritaeniata 
22,573 9.95 LVPMPVR 9 
     
LVPMPVR 
 
   
 
  
RPFVEEAERLR 
         
 
  
2
2
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Table 10.2 De novo peptide sequences and their protein functional categories.  
 
No. of 
sequence 
Precursor ion mass 
(Da) 
De novo Sequence De novo 
score (%) 
Protein functional category 
1 1344.57 FQSVGVVQDHTK 100 Snake venom metalloproteases - III 
2 1597.56 TGALVVQNPAECCHR 100) R35 (cellular protein) 
3 1202.49 FDDVLDPEPR 100 Snake venom serine proteases 
4 1136.55 YNDDLEVLR 100 Snake venom metalloproteases - I 
5 1200.59 FDDVLDPEPR 100 Snake venom serine proteases 
6 1653.76 HEMGHNLGLHHDEK* 96 Snake venom metalloproteases - III 
7 1526.74 GGFNPDYEVLYPR 95 Snake venom metalloproteases - II 
8 1098.41 LVCCGDDMDK 62 Disintegrins 
9 2898.49 VFSSDHAAVNVLVADESMVKKPGAVPCK 61 Snake venom metalloproteases - I 
10 2118.08 NSEDPATVTLVLVADEFLGK 50 Snake venom metalloproteases - III 
 
*  with putative conserved domains of ZnMc Superfamily
2
2
6
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Figure 10.2 Number of various proteins identified by shotgun-LC-MS/MS 
approach coupled with de novo peptide sequencing. 70% of the proteins represent the 
putative toxins in the venom responsible for most biological effects including 
envenoming pathology. The figure illustrates the complexity expected for the venom, 
without indicating the abundance or composition percentage of each protein. 
Number of protein assigned to each protein family/category 
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10.3.2 Sequential use of reverse-phase HPLC, SDS-PAGE and peptide sequencing  
 
10.3.2.1 Reverse-phase HPLC separation of venom proteins and SDS-PAGE 
Reverse-phase HPLC resolved the venom into 12 major peaks as monitored at 215 nm 
absorbance. Proteins were present in 10 peaks as determined by Bradford method and 
SDS-PAGE under reducing condition (Figure 10.3).   
 
10.3.2.2 Peptide sequencing for protein identification 
There were approximately 20-24 distinct proteins identified through the N-terminal 
and/or internal sequences. The proteins nevertheless are limited to only several families 
expected from snake venoms. Among these are the common ones like the zinc-
dependent metalloproteases, serine proteases/thrombin-like enzymes, phospholipases 
A2, L-amino acid oxidases, C-type lectins.; and the less commonly  reported nerve 
growth factors. Besides, aminopeptidases and low-molecular mass proteins with 
sequences similar to those of three-finger toxins were also identified,  but these two 
protein groups were present in relatively low abundance (< 2%).  
 
The assignment of the various proteins identified was tabulated in Table 10.3. Figure 
10.4 illustrates the composition of the major protein families identified based on their 
percentage of occurrence in the venom.  
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Figure 10.3 Reverse-phase HPLC separation of Hypnale hypnale venom and 
further separation by 15% SDS-PAGE under reducing condition. Chromatogram in 
the lower panel shows the venom fractionation by reverse-phase HPLC (absorbance: 
215 nm) that yielded 12 major peaks of which 10 were peptidic with significant amount 
of proteins (fractions 2 and 3: non-peptidic). The proteins were further separated by 
reducing SDS-PAGE as shown in the upper panel. Peaks (fractions) were numbered 1-
12 (8a and 11a were collected from the ascending slope; 8b and 11b from the 
descending slope). On the SDS-PAGE profile, each visible protein band was 
alphabetically labelled. Protein molecular markers (M) were in kDa molecular masses. 
M M M 
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Table 10.3 Assignment of the reverse-phase HPLC and SDS-PAGE fractions of Hypanel hypnale venom to major protein families by N-
terminal Edman sequencing and/or peptide mass fingerprinting (MALDI-TOF/TOF mass spectrometry) of selected peptide ions from in-gel 
digested protein bands separated by SDS-PAGE as shown in Figure 10.3. 
Fraction Band N-terminal sequence MALDI-TOF/TOF sequence Protein family Molecular 
mass (kDa) 
1 a EKEE No matches unknown 15 
2 & 3 - - - (non-peptidic) - 
4 b -- No matches unknown 15 
5 c HLLQFESMIK -- Phospholipase A2 15 
6 d HLMQFELMIMHET
GK 
--  Phospholipase A2 15 
7 e HLLQFESLMIM FAELLLTKFSYR* Phospholipase A2 15 
8a f IIGGDP -- Serine protease (thrombin-like enzyme) 48 
 g -- LQGETYFIEPMK  
NNDEPPQK* 
Zinc-dependent metalloproteases PII  
(homology with rhodostoxin) 
31 
 h NLWDLWKMVM -- Phospholipase A2 14 
8b i VIGGDECNIN VMGWGSINR 
EKYFFR  
Thrombin-like enzyme ancrod (serine protease) 37 
 j -- -- (Deduced as zinc-dependent metalloprotease PII) 31 
 k NLWDLWKMVM SDPNPDTTK* 
MVSAMTNR* 
Phospholipase A2  14 
 l -- DGENLCVKR 
IFLTCTTKFWEDDGIHGGK* 
Low molecular weight protein (matched to 3-finger 
toxin) 
8 
9 m -- RQFQSPR 
TEAGLELTTSQVTK 
Venom nerve growth factor/neurotrophin 21 
10 n -- RSWTAVR 
IENHEGVR* 
Zinc-dependent metalloproteases (likely PII) 24 
 o -- FEPQGEGSAW C-type lectin 14 
      
 
 
   2
3
0
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Table 10.3, continued. 
11a p ADD- 
 
K.SAGQLYEESLGK.V 
K.FNPPLLPK.K 
L-amino acid oxidase  60 
 
 q -- SVGIVR 
R.SVGIVR.D 
R.VALIGTEIWSTGNLSK.V 
Zinc-dependent metalloproteases 40 
 r TLELLGD R.SFGEWR.E 
K.VPDSEAHAVYK.Y 
K.GEHDPMERPASAK.G 
K.GEHDPMERPATAK.G 
Zinc-dependent metalloproteases (likely PII) 25 
 s -- K.RPELYVWIGLR.D C-type lectin (rhodocetin) 14 
 t -- GCAATCPKMK 
IFLTCTTKFWEDDGIHGGK 
Low molecular weight protein (matched to 3-finger 
toxin) 
9 
11b u -- AMEVYDRVADVVAPK 
SAVYCSAIR 
Aminopeptidase  95 
 v -- K.HDDIFAYEKR.F 
K.KFWEDDGIHGGK.S 
R.IYFAGEYTAQAHGWIDSTIK.S 
L-amino acid oxidase 60 
 w --  K.KESLQDALFR.R 
R.VTLVGLEFWSNR.D 
K.FIKLVIVVVHSMVTK.Y 
Zinc-dependent metalloproteases (likely PII) 25 
 x -- K.DFSWEWTDR.S 
K.KDFSWEWTDR.S 
C-type lectin 14 
12 Y SLLLQA* KWSDQNCR 
NELQRNGQPCLK 
Zinc-dependent metalloproteases (likely PII) 25 
 z -- K.NAFLCQCKF 
K.DFSWEWTDR.S 
K.KDFSWEWTDR.S  
C-type lectin 14 
-- peptide sequences not determined due to terminus blockeade and/or limitation of protein amount 
** peptides with <100% sequence coverage
2
3
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Figure 10.4 Overall protein compositions (relative abundance in %) of Hypnale 
hypnale venom according to major protein families. Venom separation was achieved 
by reverse-phase HPLC separation of the venom followed by SDS-PAGE of the 
fractions; and protein categories were identified through peptide mass fingerprinting 
and/or N-terminal sequences. 
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10.4 Discussion 
 
10.4.1 Shotgun-LC-MS/MS approach in Hypnale hypnale venomic study 
 
In this approach, direct protein digestion with trypsin was carried out, prior to 
separation of the resultant tryptic peptides by liquid chromatography. This method was 
thought to be able to minimize the loss of proteins and peptides as compared to 
multiple-step protein separation prior to digestion. Shotgun-LC-MS/MS method 
reported by Li et al. (2004) indeed identified ~80 proteins from Naja atra venom and 28 
proteins from Agkistrodon halys venom. Fry et al (2003c) identified 2 to 26 proteins 
from various undigested snake venoms by using an LC-MS/MS approach. From a 
spider venom, dos Santos et al. (2009) recovered 36 proteins with a similar shotgun 
approach. This approach provides information on the types of proteins from a mixture 
of protein (venom). However, the shotgun-LC-MS/MS method does not determine the 
relative abundance of the different protein components, hence limiting the correlation of 
major toxin components with the pathophysiology of envenoming.  
 
In addition, it is known that results generated by automatic database searching were not 
absolute, especially when considering the fact of unavailability of species-specific 
genomic sequences. In situations where no significant hits were obtained, it is possible 
that the amount of certain peptides was insufficient, or there is lack of homologous 
sequences in the database (Bringans et al., 2008). De novo sequencing hence provides 
an alternative approach, whereby internal sequences of peptides were generated based 
on the ‘best fit’ to the MS/MS data after considering the complexity of the spectra and 
numerous possible a, b, c, x, y, z ion combinations. Conventional BLAST searching 
assigns an E-value (Expect value for a ‘chance occurrence’) to any possible sequence 
mapping (between the query peptide and database), and generally a lower E-value 
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predict a better homology match. However, the true meaning and usefulness of E-value 
is controversial when a short de novo sequence is matched against a large database 
where with a lack of species-specific genomic information. In this de novo sequencing-
BLAST approach, the stringency of search parameter was therefore lowered by 
adopting a higher E-value threshold that allows reporting of low scoring matches. 
 
As indicated, most of the proteins identified could be categorized into a few major types 
with conserved molecular structures respectively. The finding supported the view that 
venom proteins belong to only several major protein families as a consequence of the 
recruitment of a restricted set of proteins into the venom proteome before the 
diversification of the advanced snakes at the base of the radiation of Colubroidea (Vidal, 
2002; Fry and Wüster, 2004; Calvete et al., 2009).  By comparison with other snake 
venom proteomes, the occurrence of multiple isoforms with function variations within 
each major protein family evidences the emergence of paralogous groups of genes (for 
gene duplications that led to molecular novelties) before the divergence of the various 
snakes (Calvete et al., 2009). The predominance of certain protein families nevertheless 
can still be anticipated in some phylogenetically related snake venoms.  
 
Majority of proteins identified from H. hypnale venom using the shotgun-LC-MS/MS 
and de novo sequencing approach belong to the enzyme families of metalloproteases, 
serine proteases and L-amino acid oxidases. Like many viperid venoms, H. hypnale 
venom contains diverse isoforms of snake venom metalloproteases (SVMPs). All 10 
metalloproteases identified belong to the zinc-dependent snake venom metalloprotease 
family, with a breakdown by subtypes as SVMP-I (3), SVMP-II (3) and SVMP-III (4). 
Generally, SVMP-I is proteolytic (tissue-damaging) without significant hemorrhagic 
effect, while SVMP-II (with disintegrin domain) and SVMP-III (with disintergrin and 
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cysteine-rich domain), cause extensive hemorrhages over the bitten site in addition to 
systemic bleeding tendency, hence the toxin name of ‘hemorrhagin’ in some literatures. 
The hemorrhagic action is mainly due to proteolytic damages on connective tissues, 
basal membranes and vasculature, as well as anti-platelet activities of the SVMPs (Fox 
and Serrano, 2008). Several snake venom serine proteases (SVSPs) too were identified 
in the venom. Not surprisingly, serine protease peptides of H. hypnale venom were 
homologously mapped to thrombin-like enzymes (ancrod-1 and ancrod-2) from the 
Malayan pit viper, Calloselasma rhodostoma, a close sister taxon of the former 
(Parkinson et al., 1997). Similar venom antigenic properties between the venoms of H. 
hypnale and C. rhodostoma have been indicated and supported by cross-neutralization 
as well as cross-reactivity studies discussed in Chapters 5, 6 and 8. It is noted that 4 
SVSPs identified were functionally related to thrombin-like/procoagulant activity, 
mediated through fibrinogenolytic action that frequently complicates 
hypofibrinogenemia, leading to venom-induced consumptive coagulopathy. In addition 
to these 4 thrombin-like SVSPs, one protein shows homology with a bradykinin-
releasing SVSP, indicating this possible biological function of the venom which has not 
been characterized previously. Several isoforms of L-amino acid oxidase were also 
identified. This class of enzyme possesses diverse biological properties which include 
cytotoxic and potentially hemorrhagic activities (Tan and Fung, 2010) that contribute to 
the envenoming pathophysiology. 
 
Disintegrins and lectins (galactose-specific, C-type lectins) are less abundant 
components commonly present in hemorrhagic venoms especially from the Viperidae 
snakes. Their pharmacological actions are mainly directed on platelet activities, either 
of potentiating or inhibitory effect. Alboaggregatin (Peng et al., 1991) and rhodocetin 
(Wang et al., 1999a), two C-type lectins isolated from Asiatic pit viper venoms 
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(Cryptelyptrops albolabris and C. rhodostoma, respectively), were among those with 
homologies mapped to H. hypnale venom peptides. The effect of a platelet aggregation-
inhibiting toxin is self-explanatory, but for a platelet aggregation-inducer, the ultimate 
systemic outcome is usually still related to a hemorrhagic syndrome as aggregation of 
functional platelets leads to thrombocytopenia. This is a feature frequently reported in 
pit viper envenomings, including that for C. rhodostoma and H. hypnale bites (Reid et 
al., 1963; de Silva et al., 1994; Joseph et al., 2007).  
 
The shotgun-LC-MS/MS approach also identified aminopeptidases, very high molecular 
mass enzymes with presumably peptidolytic/proteolytic function that aids in 
extracellular matrix digestion of prey and, potentially contributes to tissue-damaging 
effect in envenoming cases. It too identified complement system-related proteins, which 
are possibly involved in inflammatory responses and immunological reactions. The 
approach however, failed to detect the presence of phospholipase A2 which is 
commonly present in snake venoms, although the system identified the presence of one 
phospholipase B. A possible explanation for this is ion suppressions by other peptides 
of similar masses (Fry et al., 2003(c)); further optimization of the instrumentation and 
repetition of the study were possible but unfortunately would incur very high cost. 
Instead, we proceeded to explore the proteome using another multi-dimensional 
approach (see Section 10.4.2 discussion on the combined use of HPLC, SDS-PAGE, 
peptide sequencing & MS), which successfully determine the composition of 
phospholipases A2. In fact, the enzyme activity has been readily identified via functional 
(biochemical) study as reported in Chapter 4, suggesting that multiple approaches and 
triangulation of data are essential in studying the venom composition and functions. 
Other proteins and enzymes not identified at this stage include phosphodiesterase, 
phosphomonoesterase, hyaluronidase, nucleotidase, and protease inhibitors etc., which 
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are expected to be low in abundances and have limited species-specific information on 
the database. Nevertheless, many of these proteins, like PLA2 enzyme, have been 
screened for their activities on various enzymatic assays as described in Chapter 4. The 
absence of some of these proteins in proteomics reports reflects the limitation of venom 
proteomic studies that rely heavily on the quality of mass spectrometry results and the 
completeness of a snake gene/protein database while in reality not all sequence 
information are readily available.  
 
Nerve growth factor (NGF), a member of the neurotrophin family was identified in 
venom H. hypnale venom through the current shotgun-LC-MS/MS analysis. The 
presence of NGFs in snake venom seems somewhat incongruous, as these are 
stimulatory proteins for nerve growth that obviously contradict the killing and digestive 
functions of a venom (Cohen and Levi-Montalcini, 1954). It however remains possible 
that snake venom NGFs at predatory doses may exhibit neurotoxic effects on selected 
preys. Their presence in many snake venoms has been reported, and neurotrophic 
activities have been characterized mainly on neuron cell cultures (Lavin et al., 2010). 
This is indeed another group of snake venom constituents, after the widely-studied 
anticoagulant, anticancer and antimicrobial toxins, shown to have therapeutic potential 
related to neurodegenerative or brain disorders, e.g. Alzheimer’s disease (Blesch and 
Tuszynski, 2004; Koh et al., 2006).  
 
Using the shotgun-LC-MS/MS method, a number of proteins mapped to tryptic peptides 
of H. hypnale venom were found to be of cellular types, with functions mainly involved 
in energy production, protein synthesis and ciliary movement. Functions of the majority 
of these proteins are relevant to the physiology of snake venom gland, a specialized 
organ comprised of secretory cells, myoepithelial cells and mitochondria-rich cells, with 
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numerous of these being ciliated (Weinstein et al., 2010).  The glandular cells are highly 
active in synthesis of venom proteins (enzymes and toxins) which are stored in the 
glandular lumens and delivered (expelled) via ducts and fangs into recipient tissues 
during envenomation. The presence of these cellular proteins in the venom might be due 
to an incidental release of these proteins from the cells, possibly through ruptured or 
dislodged cells induced by the milking process. Nevertheless, the amount of these 
proteins was believed to be small; the fact that the protein hits were significant from the 
automatic database search could be due to a more established databanks of cellular 
physiological proteins where higher degrees of homology is expected to be conserved 
across various taxonomic lineages, in contrast to venom proteins that have undergone 
rapid sequence amino acid divergence under accelerated evolution (Deshimaru et al., 
1996; Ohno et al., 1998; Ogawa et al., 2005). 
 
The wide variety of major enzymes e.g. metalloproteases, serine proteases/thrombin-
like enzymes and L-amino acid oxidases present in H. hypnale venom correlates well 
with H. hypnale envenoming syndrome and the venom toxinological profiles. 
Procoagulant enzymes, SVMP-II, SVMP-III, lectins as well as disintegrins, were often 
conveniently categorized as “hematoxic components” of venom to highlight (or warn 
against) their pathological effects on platelet activities and blood clotting mechanisms, 
particularly in clinical setting. Systemic envenoming by H. hypnale is generally 
characterized by hemostatic disturbances and infrequently, acute kidney injury, a life-
threatening complication likely secondary to consumptive coagulopathy. In addition, the 
presence of cytotoxic and cytolytic enzymes including SVMPs and LAAOs correlates 
with the severe local tissue inflammation and necrosis (Viperine syndrome of local 
envenomation), features consistent in the majority of H. hypnale envenoming cases 
(Joseph et al., 2007; Ariaratnam et al., 2008).  
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10.4.2 Sequential use of reverse-phase HPLC, SDS-PAGE and peptide sequencing 
for protein identification and abundance estimation 
 
In contrast to the shotgun-LC-MS/MS approach, sequential venom separation by 
reverse-phase chromatography and SDS-PAGE prior to mass spectrometry analysis has 
allowed the estimation of the relative abundances (percentage of the total venom 
proteins) of different protein families present in H. hypnale venom. Knowledge of the 
constituents and their compositions in snake venom is potentially useful for a better 
understanding of the envenoming pathophysiology, treatment (antivenom) design, and 
novel drug discovery. 
 
MALDI-TOF/TOF mass spectrometry was used for peptide mass fingerprinting with 
automatic database search. This approach unfortunately was not able to assign all the 
tryptic peptides (in-gel digests of each electrophoretic band) to known protein families 
due to their low significance of protein score. The following proteins were affected: 
band g (peak 8a), bands k and l (peak 8b), band m (peak 9), band n (peak 10), band t 
(peak 11a) and band y (peak 12). Despite the low significance, there were generally at 
least 3-5 peptides which sequences were determined with protein hit ranked number 1. 
These represented sequences present within a sample, however unfortunately did not 
match existing proteins in the database. This is expected from the rapid amino acid 
sequence divergence of venom proteins, even within a same protein family, and reflects 
molecular adaptation of venom proteins under accelerated evolution (Deshimaru et al., 
1996; Ohno et al., 1998; Ogawa et al., 2005). Hence, it is rational to revise manually 
these MALDI-TOF/TOF peptide ion sequences by submitting them to BLAST 
similarity searches. The manual approach (with BLAST analysis) has been adopted in 
similar situations where MALDI-TOF peptide mass fingerprinting could not identify 
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any protein in the existing database of snake venom proteins (Angulo et al., 2008; 
Calvete et al., 2007a). Based on the approach, following BLAST similarity searches, the 
most probable proteins for peptides with low significance scores in the current study 
were determined based on the peptide sequence coverage and molecular mass. 
 
In this study, zinc-dependent metalloproteases appear to be the most abundant 
constituent (30%) in H. hypnale venom. Snake venom metalloproteases (SVMPs) are 
known for diverse actions resulting in local and systemic envenomations. Clinical 
features such as inflammation (swelling and pain), wound hemorrhage, blistering, and 
irreversible tissue destruction i.e. necrosis are not uncommon. The patholophysiological 
actions have been well characterized: disruption of capillary vessel integrity, matrix 
degradation, dermal-epidermal junction separating, secretion of proinflammatory 
mediators; all lead to tissue ischemia, disrupted tissue repair, and a varied degree of 
tissue damages (e.g. dermonecrosis, myonecrosis) (Gutiérrez et al., 2010). Indeed, the 
local effects can be synergistically ‘enhanced’ by the presence of cytolytic toxins e.g. L-
amino acid oxidases and phospholipases, which in H. hypnale venom represent the 
other two most abundant components (≥ 20% of total composition, respectively). High 
abundance of these moderate to high molecular weight proteins (SVMPs, PLA2s and 
LAAOs) which are able to exert their actions primarily on local tissues (surrounding a 
bite site) correlates with the severe tissue damages reported (de Silva et al., 1994; 
Ariaratnam et al 2008). The intensive interaction of most venom components with the 
local tissue accompanied by consequent tissue destructions may also explain for the low 
systemic absorption of the venom injected intramuscularly in rabbits (Section 9.4.1).  
 
When absorbed systemically, the SVMPs (specifically the SVMP-II and SVMP-III 
subtypes) can induce systemic effect associated with hemorrhagic syndrome: mediated 
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by their proteolytic actions that result in microvasculature damages, activation of Factor 
X and prothrombin, inhibition of platelet functions and von Willebrand factor 
(Markland, 1998a; Gutiérrez et al., 2010). The potent tissue-damaging property of 
SVMPs also suggests its possible involvement in end-organ damage, e.g. acute kidney 
injury. The renal complication could be resulted from SVMPs-induced capillary 
damages that lead to impaired renal hemodynamics, in addition to coagulopathy 
induced by other hematoxic toxins e.g. thrombin-like enzyme. This forms a hypothesis 
for potential research work in the future to elucidate the complex nephrotoxic activity of 
the venom. 
 
By analyzing the SDS-PAGE profile and N-terminal sequences, two major forms of 
snake venom serine proteases (SVSPs) were identified in the venom,  which constitute 
~7% of the total venom weight. The abundance was comparable to that of ancrod, a 
major thrombin-like enzyme in Calloselasma rhodostoma venom (7%) (Esnouf and 
Tunnah, 1967), although ancrod is known for a much potent procoagulant activity 
(Section 4.3.4). SVSPs are important coagulant enzymes that induce defibrinogenation 
leading to consumptive coagulopathy. SVSPs, hematoxic SVMPs, along with C-type 
lectins and disintegrins that disrupt normal platelet function (as discussed in Section 
10.4.1), are likely responsible for the major systemic envenoming syndrome in H. 
hypnale bites, i.e. blood incoagulability (de Silva et al., 1994; Premawardena et al., 
1996, 1998; Joseph et al., 2007; Ariaratnam et al., 2008). The major components of 
SVSPs and SVMPs from H. hypnale venom are however believed to share common 
antigenic epitopes with those from C. rhodoselasma venom, based on the cross-
neutralization and immunological studies reported in Chapters 5, 6 and 8.  
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L-amino acid oxidases usually constitute only 1 to 4% of most snake venoms (Tan, 
1998), while venoms from mambas and sea snakes contain either no or only trace 
amount of LAAOs. In colubrid venoms, LAAO activity is typically absent (Mackessy, 
2002). This class of enzyme however exists in a much higher abundance (20%) in H. 
hypnale venom, comparable to that observed in the case of C. rhodostoma (up to 30% 
by weight of the dried venom) (Tan, 1998).  The enzyme’s primary function in most 
snake venoms is believed to be of antimicrobial purpose, however, the huge amount of 
LAAOs in H. hypnale and C. rhodostoma venoms seem to suggest a more diverse 
pharmacological and toxinological property of the LAAOs besides antimicrobial 
activities. Indeed, hemorrhagic, platelet-disrupting, anticoagulant, and apoptotic 
activities have been reported in several snake LAAOs (Tan and Fung, 2010). Further 
characterization of LAAOs from H. hypnale venom, a rich source of the enzyme, is 
therefore useful for drug discovery for various therapeutic applications. 
 
In this study with the use of reverse-phase HPLC and SDS-PAGE, phospholipase A2 
was clearly shown to constitute a large proportion of the venom content (22%). Several 
(~4) isoforms exist, and the N-terminal sequences were consistent to a previous report 
(Wang et al., 1999b), where 2 subtypes of PLA2 were recognized based on their 
residues 6: Glu 6 (E6-PLA2), and Trp 6 (W6-PLA2). Wang et al. (1999b) reported that 
E6-PLA2s inhibited platelet aggregation induced by ADP and agonists, whereas W6-
PLA2s possessed a potential heparin-binding property and edema-inducing effect. The 
authors also reported the occurrence of the two PLA2s subtypes in C. rhodostoma 
venom with their distinct activities as described for the PLA2s of H. hypnale venom, 
and suggested that the findings supported the phylogenetic relatedness of the two 
Asiatic pit vipers. The W6-PLA2s indeed shared characteristics of K49-PLA2 subtypes 
isolated from many crotalid venoms (presence of L5, W6, Q11, N28, P31, mutations at 
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G32/G33) including those of New World species with highly conserved primary 
structures. Although being relatively less active enzymatically, these enzymes are 
known for membrane-damaging and myotoxic properties (Selistre de Araujo et al., 
1996; Ward et al., 1998; Arni et al., 1999; Angulo et al., 2002; Lomonte et al., 2003). 
Generalized myotoxicity has never been reported clinically in H. hypnale 
envenomations, however, the cytolytic activity of snake venom PLA2s causing 
myonecrosis has been widely reported (Gopalakrishnakone et al., 1997; Lomonte et al., 
2003). Therefore, in H. hypnale envenomations, the E6-PLA2 and W6-PLA2 may 
respectively contribute to haemorrhage (platelet dysfunction) and local myonecrosis, in 
addition to pathological effects induced by other components in the venom. 
 
On reverse-phase HPLC, the C-type lectins (~15 kDa) were eluted at a later course than 
the PLA2s which was unfortunately missed out by the shotgun-LC-MS/MS method 
possibly due to ion suppression. The eluted lectins included one that is homologous 
with rhodocetin derived from C. rhodostoma venom. The effects of snake venom C-
type lectins were mainly on platelet activity impairment as discussed in Section 10.4.1, 
contributing to hemorrhagic syndrome on the whole. Nerve growth factors and 
aminopeptidases were also identified, consistent with the shotgun-LC-MS/MS findings 
but in rather low abundances. Nevertheless, the presence of low molecular mass 
proteins (~8-9 kDa) shown on the SDS-PAGE profiles for peaks 8 and 11 was 
intriguing. The identities would have been deduced to be most likely disintegrins, 
however, MS/MS tryptic peptides of the digests revealed sequences partially matched to 
3-finger toxins instead. The occurrence of 3-finger toxins (genes and/or proteins) was 
recently reported in several viperid venoms of Atropoides nummifer (Angulo et al., 
2008), Daboia russelii (Shelke et al., 2002), Lachesis muta (Junqueira-de-Azevedo et 
al., 2006), and Sistrurus catenatus edwardsii (Doley et al., 2008), indicating that the 
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toxin family may be more widely distributed than previously thought confined to only 
the elapids and some colubrids (Fry et al., 2003b; Pawlak et al., 2006), hence 
supporting the view that venom toxins likely evolved from proteins with normal 
physiological functions recruited into the venom proteome before the diversification of 
the advanced snakes at the base of the Colubroidea radiation (Vidal, 2002; Fry et al., 
2006; Calvete et al., 2007a). The presence of the low molecular mass proteins with 
possible 3-finger toxins-like structures in H. hypnale venom, however, requires further 
investigations. 
 
The two approaches used in the proteomic study for H. hypnale venom appear to 
complement one another in the identification of important protein contents. A major 
limitation was on the inability of the currently employed technology to detect some 
proteins of low abundance which were anticipated, e.g. venom endothelial growth 
factors, cysteine-rich secretory proteins, vasoactive peptides, kunitz-type inhibitors, 
enzymes such as hyarulonidases, phosphodiesterases and nucleases, possibly due to an 
incomplete specific venom protein database. Further investigations are therefore 
required to study in-depth proteome and subproteome of the venom, with combined 
tools for a more sophisticated multidimensional fractionations (e.g. gel filtration 
chromatography, followed by 2D-electrophoresis and subsequent LC-MS/MS). The 
results nevertheless provide valuable insights into the composition of toxins correlated 
with the envenoming syndrome, and highlight the following concerns: 
 
(1) The toxin compositions were comparable to those of many Asiatic vipers and pit 
vipers. Particularly noteworthy are some homologous peptide sequences 
conserved among venoms of H. hypnale and C. rhodostoma; 
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(2) Substantial amounts of SVMPs, SVSPs, C-type lectins and E6-PLA2s are related 
to hematoxic complications; 
(3) SVMPs, W6-PLA2s and LAAOs are likely responsible for cytotoxicity, 
hemorrhage and necrosis leading to local tissue destruction;  
(4) Antivenom designed/proposed should aim to neutralize the prominent toxins 
including their subtypes, for instance, both the E6- and W6-PLA2s must be 
targeted.  
(5) Unusually large amount of LAAOs suggests potentially diverse pharmacological 
properties which may worth further characterizations. 
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CHAPTER 11 
 
Isolation and Characterization of Hypnobin, a Thrombin-like Enzyme  
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11.1 Introduction 
 
Repeated gene duplication over evolutionary time gave rise to a structurally conserved 
protein family within which a diverse set of pharmacologies present. It is by such 
mechanism that the multigene family of snake venom serine proteases (SVSPs) is 
accounted for (Deshimaru et al., 1999). Numerous SVSP subsets exist, and one of these 
is functionally related to thrombin and conventionally called thrombin-like enzymes 
(TLEs). Substantial amount of TLEs are commonly found in venoms of viperid and 
crotalid snakes including Calloselasma rhodostoma and Hypnale hypnale. Despite the 
high degree of inter-species TLE mutual sequence identity (> 60%), there are 
phylogenetical and geo-trophic factors that lead to variations in their functional 
“thrombin-like” properties (Kini, 2005; Mackessy, 2010b). Biomedical studies of 
individual TLE is therefore important for defining the structure-function relationship of 
its coagulant action, therefore advancing the knowledge on envenoming pathology, 
treatment improvement, and potential drug discovery. 
 
As shown in Chapter 5, the procoagulant activity of H. hypnale venom, in addition to 
lethality, was effectively neutralized by antivenoms (monovalent and polyvalent) raised 
against Calloselasma rhodostoma venom. This indicated the presence of similar 
antigenic properties between venom TLEs of the two sister taxa. While the TLE isolated 
from C. rhodostoma venom has been studied for almost half a century (Esnouf and 
Tunnah, 1967), little is yet known about that of H. hypnale venom. In this chapter, some 
preliminary findings on the biochemical and molecular aspects of the major TLE 
isolated from this venom were reported.  
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11.2 METHODS 
 
11.2.1 Isolation of TLE from Hypnale hypnale venom 
 
Two milligram of H. hypnale venom was dissolved in 0.1% TFA and injected into a 
LiChrospher
®
 RP100 C18 reverse phase column (250 x 4 mm, 5 um particle size) pre-
equilibrated with 0.1% TFA. Elution was carried out at 1 ml/min flow rate with a linear 
gradient of 0.1% TFA in 100% acetonitrile over 60 min. The solvent delivery and 
gradient formation was achieved using the Shimadzu LC-20AD HPLC system. Eluted 
fractions were collected manually according to 215 nm absorbance, and dried in a 
Speed-Vac system. The fractions were reconstituted in 200 µL PBS (pH 7.2) and 
screened for procoagulant activity using bovine fibrinogen (2 g/L) as described in 
Chapter 4 (Section 4.2.5.2).  
 
The fraction which showed fibrinogen-clotting activity was further separated on a 
Superdex
TM
 200 HR 10/30 gel filtration column (10 × 300 mm, 13 µm particle size; GE 
Healthcare, Sweeden). Elution buffer was PBS (pH 7.2) at a flow rate of 0.75 ml/min. 
Protein was monitored by absorbance measurement at 280 nm and collected cautiously 
at small volume (0.3-0.5 ml in each tube). The column was calibrated using the 
following protein standards obtained from Bio-Rad (BIO-RAD Gel filtration Standard): 
thyroglobulin (670 kDa), γ-globulin (158 kDa), ovalbumin (44 kDa) and myoglobin (17 
kDa). Fractionated products were screened for procoagulant activity using bovine 
fibrinogen (2 g/L), and the purity of protein was monitored by a 12% SDS-PAGE under 
reducing condition with beta-mercaptoethanol.  
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11.2.2 Deglycosylation of thrombin-like enzyme 
 
The purified thrombin-like enzyme (1 mg/mL in PBS, pH 7.2) was incubated with N-
glycosidase F (2 units/mg protein; Sigma) at 37 °C for 24 h and the deglycosylated 
protein was subjected to 12% SDS-PAGE under reducing condition. 
 
11.2.3 Peptide sequencing and protein identification 
 
The Coomasie Blue-stained gel band of purified thrombin-like enzyme was excised and 
subsequently processed at Proteomic International, Perth, Australia for in-gel trypsin 
digestion and MALDI-TOF/TOF analysis with peptide mass fingerprinting according to 
Bringans et al. (2008) (Section 10.3.2). The purified protein was also blotted onto a 
PVDF membrane by using Invitrogen iBlot
TM
 System (Program P2, 8-10 minutes) and 
subjected to N-terminal sequencing by Edman degradation (Procise Sequencer, Applied 
Biosystem, available at Mission Biotech, Taipei, Taiwan ROC). The N-terminal 
sequence was compared to those of several snake venom thrombin-like enzymes. The 
internal and N-terminal sequences determined were also subjected to a multiple 
sequence alignment using progressive pair-wise alignments with hierarchical clustering 
(Corpet, 1988) to identify homologous regions in the peptides. Alignment was done 
using Mutalin
®
 on-line software available from 
http://multalin.toulouse.inra.fr/multalin/multalin.html. 
 
11.2.4 Arginine esterase activity and kinetic study 
 
Arginine esterase was assayed using α-benzoyl arginine ethyl ester (BAEE) as substrate 
(Collins and Jones, 1972). The assay mixture contained 0.95 ml of 0.1-2.0 mM substrate 
in 0.05 M Tris-HCl buffer, pH 7.8, and 50 µL of the thrombin-like enzyme (1 μg). The 
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reaction was followed by measuring the rate of increase in absorbance at 255 nm. The 
difference in the extinction coefficient at 255 nm is 815 cm
-1
M
-1
. 
 
11.2.5 Arginine amidase activity and kinetic study 
 
Arginine amidase was determined according to Svendsen and Stocker (1977). Four 
tripeptide-substrates were used to investigate the TLE specificity. Each substrate was 
dissolved in 1:1 acetonitrile/water mixture. The arginine amidase activity was then 
determined by mixing 0.85 ml of 0.05 M Tris buffer (pH 8.0) with 100 µL of substrate 
(which final concentration was kept at 0.1-1.0 mM) and 50 µL of the thrombin-like 
enzyme (1 μg). The reaction was followed by measuring the absorbance at 410 nm, with 
extinction coefficient of 9400 cm
-1
M
-1
. 
 
11.2.6 Fibrinogen clotting (procoagulant) activity on various fibrinogens 
 
Procoagulant activity on various fibrinogens was determined by the method described 
by Bogarín et al. (2000). The thrombin-like enzyme (50 μg in 0.1 mL PBS) was added 
to 0.2 mL of fibrinogen solution (2 g/L) of various mammals at 37 °C. The coagulation 
time (time taken for fibrin strands to form) was recorded. A shorter coagulation time 
suggests a higher procoagulant activity. 
 
To study the time course of the enzyme procoagulant activity, the thrombin-like enzyme 
(50 µg in 0.1 ml) was added to 0.2 ml of fibrinogen solution (2 g/l) preincubated at 37 
°C. The absorbance of the mixture at 450 nm was read up to 50 minutes to monitor the 
formation and degradation of fibrin clots. The method was modified from Pirkle et al. 
(1986). 
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11.2.7 Fibrinogenolytic activity 
 
Thrombin-like enzyme (10 μg) was added to a series of 1% bovine fibrinogen at the 
ratio of enzyme:substrate = 1:100 (w/w), followed by incubation at 37 °C. At indicated 
times (1 min, 1 h, 3 h, 6 h, 12 h and 24 h), the reaction was terminated by heating in a 
boiling water bath for 5 min, which also deproteinized the mixture. Clots that formed 
were removed by centrifugation at 10,000 g for 10 min. The supernatants containing 
fibrinopeptides were analyzed by reversed-phase HPLC. The solution (100 µL) was 
loaded onto a LiChrospher
®
 RP100 C18 reverse phase column (250 x 4 mm, 5 um 
particle size; Merck) on the Shimadzu LC-20AD HPLC system, and the fibrinopeptides 
A and B released from the bovine fibrinogen were characterized essentially as described 
by Shimokawa and Takahashi (1995). The eluents consisted of solvent A (0.025 M 
ammonium acetate, pH 6.0) and solvent B (50% acetonitrile in 0.05 M ammonium 
acetate, pH 6.0), with a linear gradient containing 0-100 % solvent B delivered over 60 
min. The peptide peaks were monitored by measuring the absorbance at 214 nm. 
 
A mixture of 1% bovine fibrinogen with 0.25 units of bovine thrombin was used as the 
positive control to exhibit the release of fibrinogen A and fibrinogen B. The negative 
control consisted of similar amounts of fibrinogen and denatured thrombin (by boiling 
prior to mixing for reaction). In another set of independent experiments, 20 μg of H. 
hypnale whole venom was used to react with the bovine fibrinogen to study the 
fibrinopeptide release at 24 h incubation.  
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11.3 RESULTS 
 
11.3.1 Isolation and purification of thrombin-like enzyme (TLE) 
  
Fibrinogen-clotting activity was detected in a heterogeneous fraction eluted between 40-
45% ACN on reverse-phase HPLC. Further separation by gel filtration column yielded a 
fraction of procoagulant enzyme with molecular weight of approx. 35-40 kDa. On SDS-
PAGE, the molecular weight was determined to be 37 kDa, while that of its 
deglycosylated form was 30 kDa, indicating that the enzyme was ~23% glycosylated in 
native condition (Figure 11.1). 
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Figure 11.1 Purification of thrombin-like enzyme from Hypnale hypnale venom. 
Upper panel: Fractionation of H. hypnale venom by reverse-phase HPLC monitored at 
absorbance 215 nm; lower panel: Separation of the procoagulant fraction by gel 
filtration HPLC monitored at absorbance 280 nm. Shaded bars at the base of a peak 
indicate the presence of fibrinogen-clotting activity. Insets showed the SDS-PAGE 
(under reducing condition) for the fractions of interest collected from the respective 
HPLC. M: molecular marker; P: procoagulant fraction; TLE: thrombin-like enzyme; 
TLE-d: deglycosylated thrombin-like enzyme. 
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11.3.2 Peptide sequencing and protein identification 
 
Peptide mass finger printing of the 37 kDa thrombin-like enzyme identified it as a snake 
venom serine protease with high homologous internal sequences matched to thrombin-
like enzymes ancrod (P26324) of Calloselasma rhodostoma (score: 51) and 
kangshuanmei (P85109) of Gloydius brevicaudus (score: 32) [Individual ions scores > 
24 indicate identity or extensive homology (p < 0.05)]. The TLE isolated from H. 
hypnale venom was designated in the current work as hypnobin.  The N-terminal 
sequence of hypnobin was also determined and compared with those of several 
procoagulant serine proteases in Table 11.1. In addition, hypnobin N-terminal and 
internal sequences were aligned with the sequences of some snake venom serine 
proteases in Figure 11.2 to show the regions of high homology consensus. 
 
Table 11.1 N-terminal amino acid sequences of hypnobin and other serine 
proteases. 
Enzymes N-terminal sequences 
 1                            10 
References 
Hypnobin V I G G D E C N I N This work 
Ancrod V I G G D E C N I N Burkhart et al. (1992) 
Kangshuanmei V I G G D E C N I N Sakai et al. (2006) 
Acutobin V I G G V E C D I N Wang et al. (2001) 
Purpurase VVG G D E C N I N Tan (2010) 
Flavoxobin V I G G D E C D I N Shieh et al. (1988) 
Crotalase V I G G D E C N I N Pirkle et al. (1981) 
Gabonase VV G G A E C K I D Pirkle et al. (1986) 
Kallikrein             V V G G Y N C EMN Swift et al. (1982) 
Trypsin              I  V G G Y T C GAN Titani et al. (1975) 
Thrombin  I V E G Q D A E VG Magnusson et al. (1975) 
** Letters in red contribute to the homology of N-terminal sequences.  
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Figure 11.2 Alignment of the peptide sequence read by hypnobin with serine proteases sequences from several Viperidae snakes. 
 
2
5
5
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(Figure 11.2, continued.) 
H1: terminal sequence, H2-4: internal sequences of hypnobin; P85109 kangshuanmei (Gloydius brevicaudus );  ADI47569 Serine protease (Echis 
coloratus); CAA01524 Ancrod-like protein (Calloselasma rhodostoma); AAM96674  Serine alpha-fibrinogenase precursor (Macrovipera lebetina); 
ADP88559 Serine alpha-fibrinogenase-like protein (Daboia russellii siamensis); ABS12074 Thrombin-like serine protease 1 (Cryptelytrops 
albolabris); Q91507 Mucrofibrase-1precursor (Protobothrops mucrosquamatus); AAN52348 stejnefibrase 1 (Viridovipera stejnegeri); Q072L7 
Thrombin-like enzyme acutobin (Deinagkistrodon acutus); P05620 Thrombin-like enzyme flavoxobin (Trimeresurus flavoviridis); P26324 Thrombin-
like enzyme ancrod (Calloselasma rhodostoma). Consensus regions are shown in red and these include the conserved cysteine 22 for disulfide bonding 
and aspartic acid 102 which forms the catalytic triad of serine proteases. Numbering was based on chymotrypsin. Alignment was done using Mutalin
®
 
on-line software available from http://multalin.toulouse.inra.fr/multalin/multalin.html.  
  
2
5
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11.3.3 Arginine esterase and amidase activities with kinetic studies 
 
 
The Km and kcat values of hypnobin with BAEE as the substrate were 0.13 mM and 6.39 
s
-1
, respectively, giving rise to a kcat/Km of 49.15 mM
-1
s
-1
. The kinetic parameters of 
hypnobin on the tripeptide nitroanilide chromogenic substrates are shown in Table 11.2.  
 
 
Table 11.2 Kinetic parameters of hypnobin with tripeptide nitroanilide substrates. 
 
Substrate Km (mM) kcat (s
-1
) kcat/Km (mM
-1
s
-1
) 
N-benzoyl-L-proline-L-phenylalanine-L-
arginine p-nitroanilide (BPPAN) 
0.44 4.73 10.79 
N-p-tosyl-glycine-L-proline-L-lysine p-
nitroanilide (TGPLN) 
0.69 5.59 8.10 
N-benzoyl-L-phenylalanine-L-valyl-L-
arginine p-nitroanilide (BPVAN) 
0.21 1.46 6.78 
N-benzyol-L-valine-L-glycine-L-arginine 
p-nitroanilide (BVGAN) 
6.20 0.90 0.14 
 
Km:  Michaelis constant. It is the substrate concentration at which the reaction rate is at 
half-maximum, and is an inverse measure of the substrate's affinity for the enzyme. 
kcat: Catalytic constant, or turnover number. It represents the number of reactions 
catalysed per unit time by each active site. 
kcat/Km: This value reflects the enzyme efficiency. It indicates the number of ‘turn overs’ 
(reaction steps) at each active site per unit time by the enzyme. 
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11.3.4 Fibrinogen clotting (procoagulant) activity 
 
Hypnobin exhibited rather distinct species-specific clotting activity on fibrinogens from 
various mammals (Table 11.3). The clotting time by hypnobin was in the decreasing 
order (i.e. increasing rate): rabbit << horse, goat < cow < human.  
 
Table 11.3 The clotting time of hypnobin and bovine thrombin on various 
mammalian fibrinogens. 
 
Mammalian origin of the 
fibrinogen 
Hypnobin clotting time* 
(s) 
Bovine thrombin clotting 
time (s) 
Cow 177.7 ± 1.2 179.0 ± 0.6 
Goat 195.3 ± 2.9 174.7 ± 1.8 
Horse 245.3 ± 2.9 208.3 ± 2.7 
Rabbit Turbidity** > 300 Turbidity > 250 
Human 167.7 ± 1.5 172.7 ± 1.5 
The fibrinogen clotting time was determined at 37
 
°C by mixing 200 μg fibrinogen (2 
mg/mL in PBS) and I μg hypnobin and 0.25 unit of bovine thrombin (amount of 
thrombin that causes similar clotting time on bovine fibrinogen with 1 μg hypnobin.  
* Clotting time is defined as the time (s) for apparent fibrin strands to appear in the 
mixture of venom and fibrinogen.  
** Turbidity refers to cloudiness appearing in the mixture of venom and fibrinogen, 
which may be interpreted as the formation of fibrin clots. Results are expressed as the 
mean ± SEM from three experiments. 
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In the time course study of hypnobin procoagulant activity (Figure 11.3), clotting was 
noted to be the least effective for rabbit fibrinogen and followed by horse fibrinogen: it 
was characterized by a slow increase in the clotting rate (defined by the slope/gradient 
of each curve calculated from the steepest upward portion of the graph), and a low 
amount of product as indicated by the maximal absorbance values. Clotting was fastest 
for the fibrinogen of human closely followed by that of cow, and then goat, all with 
similar product yields.   
 
 
 
Figure 11.3 Time course of clotting activities of hypnobin on fibrinogens of several 
mammalian sources. The slope (gradient) for each curve is calculated from the steepest 
upward portion of the graph representing the maximal clotting rate expressed as 
absorbance/minute. Absorbance at 450 nm reflects the change in mixture clarity, which 
is responsible for the formation of fibrin strands as well as their dissolution/degradation.  
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11.3.5 Fibrinogenolytic activity 
The reverse-phase chromatograms of the incubation mixtures of hypnobin and bovine 
fibrinogen were shown in Figure 11.4b-g, depicting the time-dependent fibrinopeptides-
releasing by the TLE. Classically, as shown in Fig. 11.4a, bovine thrombin released 
both fibrionopeptides A and B, with the former released faster than the latter in the 
beginning of the reaction, but soon achieved an equal quantity (indicated by area under 
the peaks) by 10 min incubation. The peaks with retention times of 30.5 min and 33.5 
min corresponded with the release of fibrinopeptides A and B, respectively. Hypnobin 
released fibrinopeptide A from the fibrinogen slower, with the fibrinopeptide A only 
detected from the incubation after 1 h reaction. The fibrinopoptide A level increased 
slowly since then over the next 23 h, and achieved its maximum at the end of the study 
period (24 h). A relatively much smaller amount of fibrinopeptide B was present at 6 h 
and persisted throughout the experiment (≤ 10% of fibrinopeptide A at 24 h). Under the 
same experimental condition, H. hypnale whole venom appeared to liberate both 
fibrinopeptides A and B from the bovine fibrinogen from the 24 h incubation (Figure 
11.4h). However, the observation was accompanied by a slightly early shift in the 
retention time of fibrinopeptide B noted in repeated experiments.  
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Figure 11.4 Reverse-phase HPLC profiles of fibrinopeptides release from 
incubation of bovine fibrinogen with (a) thrombin; (b)-(g) hypnobin; and (h) 
Hypnale hypnale venom. The incubation time of fibrinogen with thrombin and H. 
hypnale venom was 10 min and 24 h respectively, while that for hypnobin were 1, 2, 4, 
6, 12 and 24 h (b-g, correspondingly). Major peaks observed reflected the cleavages of 
fibrinopeptide A and fibrinopeptide B by thrombin and thrombin-like enzyme, which 
are important mechanisms in the formation of fibrin clot. 
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11.4 Discussion 
 
11.4.1 Purification and peptide sequencing of hypnobin 
 
Defining thrombin-like enzymes from the myriad snake venom serine proteases can be 
challenging especially so when the term ‘thrombin-like’ is already rather a misnomer 
(Mackessy, 2010b). The current study undertook the approaches that cover salient 
physical, biochemical and molecular aspects for characterizing hypnobin with relevance 
to its ‘thrombin-like’ properties as conventionally suggested. Hypnobin appeared 
readily purified with a two-step chromatography approach, similar to previous reports 
for pure TLE isolation, e.g. purpurase from Cryptelytrops purpureomaculatus that 
involved a combination of Resource
®
 Q anion exchanger and Superose
TM
 filtration 
column (Tan, 2010). Most of the TLE isolations appear somewhat technically 
demanding, likely because of the complex glycosylation nature of the enzyme. With its 
primary role for conferring stability to the enzymes, glycosylation has also given rise to 
multiple TLE isoforms, complicating the HPLC fractionation process. In this study, 
glycosylation of hypnobin was shown to be moderate and the molecular masses of both 
glycosylated and deglycosylated forms were within the expected range of most snake 
venom TLEs, excluding the likelihood of dimerization and extensive glycosylation 
where molecular weights could be as high as 50-70 kDa (Koh et al., 2001; Paes Leme et 
al., 2008).  Nevertheless, the presence of other TLE isoforms within the venom remains 
possible and further exploratory isolation work should be performed. 
  
The combined use of chromatography, gel electrophoresis and mass spectrometry has 
been advocated by several authors in proteomic studies of snake venoms (Li et al., 2004; 
Calvete et al., 2007b; Gutiérrez et al, 2009), with the main objective to separate and 
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identify the proteins in venom on molecular basis. Some of the proteomic strategies 
were used in the study of hypnobin, where the purified protein from successive HPLC 
fractionation (showing single electrophoretic band) was tryptically digested into 
peptides and subjected to MALDI-TOF/TOF analysis and database search. Despite the 
lack of transcriptomic information of H. hypnale venom gland, the peptide sequences of 
the snake venom serine proteases (and thrombin-like enzymes) appeared to be highly 
homologous across taxa, therefore enabling the peptide matching possible for the 
identification of hypnobin. Noteworthy are the conserved cysteine 22 for disulfide 
bonding, and aspartic acid 102 which forms the catalytic triad of serine proteases. It 
reflects the role of balancing selection and gene duplication that have resulted in a 
robust conservation of serine protease structures across taxonomic levels (Calvete et al., 
2007b). In addition, the N-terminal amino acids of hypnobin was sequenced (a 
conventional method for protein identification), and the findings too revealed high 
degree of homology among the various crotalid venom TLEs from both New World and 
Old World species.   
 
11.4.2 Arginine esterase and amidase activities with kinetic studies 
 
Hypnobin, similar to many TLE of viperid venoms, exhibits esterolytic activity towards 
N-α-benzoyl-l-arginine ethyl ester, hence indicating its specific binding to the arginine 
residues in its substrate. Preferential hydrolysis was noted for thrombin specific 
substrates Bz-Phe-Val-Arg-pNA and Bz-Pro-Phe-Arg-pNA as indicated by the higher 
kcat/Km values. Interestingly, hypnobin also hydrolyzed p-Tos-Gly-Pro-Lys-pNA (a 
plasmin substrate) with activity comparable to that of the thrombin substrates. On the 
other hand, Bz-Val-Gly-Arn-pNA, a substrate for factor Xa, showed very minimal 
reaction with hypnobin, indicating its lack of activity on the activation of prothrombin.  
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11.4.3 Fibrinogen clotting activities 
 
Snake venom TLEs were known to exhibit distinct specificity towards fibrinogens from 
different animals (Wik et al., 1972; Tan, 2010). The observation was reported too in 
Chapter 4 where crude H. hypnale venom was used in the clotting reaction, and in the 
current experiment using the isolated TLE. These findings reflected the differences of 
fibrinogen structures from different animals as well as the specificity of snake venom 
TLE towards them.  When monitored spectrophotometrically, the time course of fibrin 
clot assembly or dissolution induced by hypnobin could be described as: Generally, a 
higher clotting rate was accompanied by a shorter lag phase between the addition of 
enzyme and the first appearance of any turbidity, and the clot assembly appeared to 
persist with no dissolution within the measured time. The result seemed to suggest that 
hypnobin has a high affinity towards human fibrinogen with a rapid onset of 
procoagulant activity and prominent clot formation.  This observation when 
extrapolated to clinical situation, it may reflect the intense turnover activity of the 
clotting enzyme that leads to rapid defibrinogenation and subsequent consumptive 
coagulopathy.  The clotting time course profile of TLEs on various fibrinogens, 
however, should be distinguished from that of the whole venom where differences in 
clotting rates and early clot dissolution were noted (Section 4.3.7), presumably due to 
the presence of other enzymes in the venom that contributed to the observed effect. In 
this study, the finding that hypnobin reacted least towards rabbit fibrinogen is 
unequivocally consistent with the findings from reptilase, purpurase and albolabrase 
(Wik et al, 1972; Tan, 2010; Tan et al., 2012), as reported by  Blomback et al. (1966), 
rabbit fibrinogen has a different amino acid composition from those of other animals. 
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11.4.4 Fibrinogenolytic activity 
 
A limiting definition for a venom TLE includes the enzyme specific catalytic activity 
towards the Aα and/or Bβ chains of fibrinogen, and its clotting mechanism mediated 
through the release of fibrinopeptides A (FpA) and/or B (FpB) (Mackessy, 2010b). 
Unlike thrombin, some venom TLEs release FpA predominantly, e.g. arvin (ancrod), 
flavoxobin and purpurase (Holleman and Coen, 1970; Shieh et al., 1988; Tan, 2010) to 
trigger the clotting process. However, clotting with many venom TLEs is often 
accompanied by a later release of FpB, for examples, gabonase and cerastobin (Pirkle et 
al., 1986; Farid et al., 1989); whereas okinaxobin I almost exclusively releases FpB 
(Iwasaki et al., 1990). Hence TLEs are broadly grouped based on their cleavage 
specificity for releasing the fibrinopeptides, although such specificity for the Aα and/or 
Bβ chains is not absolute since there is substantial degradation of the alternate chain 
with increasing time (Markland, 1998b). The current study indicates that hypnobin 
preferentially releases FpA to initiate fibrinogen clotting. Upon extended enzyme 
reaction, digestion of fibrinogen Bβ chain was detected and it was assumed to be of 
limited activity, evidenced by the slow release of FpB with small amount, saturated at ≤ 
10% of the FpA maximum. This suggests that hypnobin belongs to the Class AB of 
thrombin-like snake venom serine proteases, along with the following TLEs from the 
venoms of Asiatic crotalids: acuthrombins from Agkistrodon (Deinagkistrodon) acutus 
(Huang et al., 1999), kangshuanmei from Agkistrodon (Gloydius) halys brevicaudus 
stejneger (Zhang et al., 2001), okinaxobin II from Trimeresurus (Ovophis) okinavensis 
(Nose et al., 1994), a TLE from Agkistrodon (Gloydius) saxatilis (Koh et al., 2001) and 
albolabrase from Cryptelytrops albolabris (Tan et al., 2012), but not arvin (ancrod) 
from its close sister taxon, Calloselasma rhodostoma, which releases only FpA from 
fibrinogen (Holleman and Coen, 1970). The role of phylogeny and/or geo-trophic 
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adaptation is beyond the scope of this study for explaining such variations. Nonetheless, 
the finding indicates that hypnobin and ancrod likely possess different structural and 
functional determinants in terms of fibrinopeptide specificity; however, such difference 
does not seem to have any remarkable influence affecting the cross-neutralization of H. 
hypnale venom by the C. rhodostoma antivenom (Chapter 5). A possible explanation is 
that the common antigenic epitopes shared by the two TLE molecules extend beyond 
their catalytic domains for the cleavage of fibrinogen chain.  
 
The identities of small peaks eluted between the FpA and FpB at extended reaction time 
are not known, although they may be related to other fibrinopeptide variants e.g. 
disarginine FpB that presents in small amounts (Koehn and Canfield, 1981). When 
incubated with fibrinogen, H. hypnale whole venom liberated both FpA and, to a lesser 
extent, FpB, an observation consistent with that of hypnobin. The release of FpA and 
FpB also suggests the possible coexistence of other β chain-selective TLE or β-
fibrinogenase in the venom. The shift in the elution time of FpB (~1 min earlier) was 
probably due to some subtle modifications in the FpB peptide caused by coexistent 
active components in the venom.  
 
It is known that incomplete release of FpA and FpB (as exhibited by the  
fibrinogenolytic mechanism of virtually all snake venom TLEs including hypnobin, 
which releases predominantly FpA followed by FpB slowly in lesser amount) forms 
fibrin clot that is friable and unstable. The intravascular coagulation affects the 
equilibrium of in vivo fibrinolytic system and triggers off plasmin activity (Collen, 
1980). “Tenuous thrombi” or “weak clots” induced by the described mechanism are 
usually more susceptible to lytic degradation by endogenous plasmin (Turpie et al., 
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1971), while potential fibrinolytic enzymes found in the venom may serve to augment 
the effect. Repeated formation and continuous dissolution of the tenuous thrombi will 
give rise to increased fibrin degradation products during the initial defibrinogenation 
phase, which may gradually normalize after fibrinogen depletion. In addition, certain 
fibrino(geno)lytic enzymes in some venom may potentiate the defibrinogenation effect 
by direct degradation of fibrin polymer (Siigur et al., 1998) or by the generation of 
fibrinogenolytic products that are no longer convertible to normal fibrin clots by 
thrombin (Matsui et al., 1998). This eventually results in hemostatic dysfunction 
associated with consumptive coagulopathy commonly reported in viperid snakebites, 
including H. hypnale envenomation (Premawardena et al., 1996, 1998; Ariaratnam et 
al., 2008). Further experimental characterization of the TLE is therefore essential not 
only for elucidating the functional mechanism of the protease in relation to its 
envenoming effect, but also for discovery of therapeutic candidates especially those 
related to the treatment of thromboembolic disorders. 
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12.1 Present investigations: toxinological profiling of Hypnale hypnale venom 
 
Important findings from the current investigations can be summarized in the following 
concluding remarks: 
 
1. Hypnale hypnale venom exhibits a variety of enzymatic activities, noteworthy of 
the procoagulant enzymes, proteolytic enzymes, L-amino acid oxidases and 
phospholipases A2. These are enzymes of moderate to high molecular masses 
present in most viperid venoms, and are significant in the pathophysiology of 
envenomations. Thrombin-like enzymes are related to the procoagulant activity 
which induces defibrinogenation and consumptive coagulopathy. Proteolytic 
enzymes contribute to systemic and local hemorrhagic syndrome. Some 
proteolytic enzymes and cytotoxic components such as L-amino acid oxidases and 
phospholipases A2, induce massive cell deaths at the bite site and leading to tissue 
necrosis. 
 
2. The median lethal dose (LD50) of the venom varies on different routes of 
administration, in the increasing order of intravenous < intraperitoneal < 
intramuscular.  The procoagulant nature of the venom possibly induces acute 
thromboembolic event and death when a substantial amount was administered 
intravenously. Intraperitoneal administration subjects the venom to first pass 
effect where venom proteins are likely degraded by hepatic metabolism. On 
intramuscular route, intense interaction of the venom proteins with local tissues 
leads to massive destruction of local tissues (including vasculature) and hence 
impairing the venom absorption. A higher intramuscular dose is therefore needed 
to cause systemic complications (principally hematoxic effects) and death. 
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3. The lethal, procoagulant, hemorrhagic and necrotic effects of H. hypnale venom 
were effectively cross-neutralized by the monovalent Malayan pit viper antivenom 
and Hemato polyvalent antivenom, with the polyvalent one being more superior. 
This is likely due to the presence of common antigenic properties between the 
venoms of H. hypnale and Calloselasma rhodostoma (Malayan pit viper) which 
share close phylogenetic relationship. The findings imply that Hemato polyvalent 
antivenom (which also cross-neutralized the lethal effect of Sri Lankan Daboia 
russelii venom) may be a beneficial therapeutic antivenom in the endemic areas 
where there is still no effective antivenom available clinically. Nevertheless, more 
extensive studies on various factors modulating the antivenom effectiveness may 
be required using suitable animal models, and the antivenom neutralization 
efficacy in humans needs to be assessed by clinical trials. 
 
4. Acute kidney injury (AKI) was induced in mice experimentally envenomed with 
H. hypnale venom at 1 and 1.5 LD50, characterized by raised blood urea and 
creatinine. Prolonged blood clotting time and hemorrhagic spots in lung implied 
bleeding tendency. Pallor noted in renal cortices was suggestive of renal ischemia 
secondary to consumptive coagulopathy. Intravenous infusion of Hemato 
polyvalent antivenom following the experimental envenomation effectively 
prevented death and AKI in all mice, hence supporting its potential therapeutic 
use in envenomation by H. hypnale. 
 
5. Repeated immunization with H. hypnale venom in rabbits induced satisfactory 
antibody production. The antibody (prepared with capric acid precipitation 
method) was shown with comparable potency of venom neutralization (against 
lethal, procoagulant, hemorrhagic and necrotic activities) with the monovalent 
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Malayan pit viper antivenom, but less than that of Hemato polyvalent antivenom. 
The findings indicate the feasibility of producing an effective homologous 
antivenom against H. hypnale bite, as conceptually, a specific antivenom has a 
fuller neutralizing spectrum on various toxins in the homologous venom.  
Nevertheless, considering the extremely high costs associated with antivenom 
production, the socioeconomical status of the country, and the possibility of 
ambiguous diagnosis of the biting snake, it is proposed that the manufacturing of  
H. hypnale antivenom in the future be incorporated into the existing production of 
Indian polyvalent antivenoms (the current treatment of choice for envenoming by 
the Big Four in South Asia without addressing bites from H. hypnale) 
 
6. Both the monovalent Malayan pit viper antivenom and Hemato polyvalent 
antivenom showed very high ELISA cross-reactivity (~90%) with H. hypnale 
venom, supporting the cross-neutralization activities reported. Using affinity-
purified IgG raised against H. hypale venom, the indirect ELISA showed that the 
IgG cross-reacted extensively with several Asiatic crotalid venoms, particularly 
that of C. rhodostoma (73.6%), indicating the presence of venom antigens 
common to both snakes. The levels of immunological cross-reactivity were vastly 
reduced with double-sandwich ELISA, and the assay was further shown to 
distinguish and quantify venoms of H. hypnale, Daboia russelii and Echis 
carinatus sinhaleyus (three common local viperid), separately, in human sera 
spiked with the venoms. The assay hence can be a useful investigating tool for 
diagnosing biting species and studying the time course profile of venom 
concentrations in blood, especially during clinical studies.  
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7. Pharmacokinetic study in rabbits showed that H. hypnale venom has a long 
elimination half-life that is consistent with its prolonged systemic effects reported, 
and hence justifying the need for frequent and extended clinical monitoring on the 
coagulation profile and renal functions. The venom has an unusually low 
bioavailability (by intramuscular route), reflecting low systemic absorption from 
the injection site, possibly due to the venom’s intense binding to the local tissues, 
while triggering destruction of the tissues and vasculatures that leads to 
compromised venom absorption. This may account for the huge difference of 
LD50 between the intravenous and intramuscular routes. In experimentally 
envenomed rabbits, Hemato polyvalent antivenom altered the pharmacokinetics of 
H. hypnale venom with a remarkable initial blood venom level reduction followed 
by a subsequent rebound (venom redistribution phenomenon) following the law of 
mass diffusion. The redistributed venom was then completely neutralized with an 
additional dose of HPA. These findings were consistent with the pharmacological 
basis of an effective antivenom where immunocomplexes are formed to render the 
toxins inactive, while venom redistribution is essential to enhance venom toxins 
removal from tissues and hence a faster venom clearance from the body. The 
findings corroboratively support the previous cross-neutralization of Hemato 
polyvalent antivenom, and provide preliminary information for an optimization on 
the dosing and monitoring of the antivenom treatment. 
 
8. Shotgun-LC-MS/MS approach identified a total of 52 proteins from H. hypnale 
venom of which 70% are secretory types and toxinologically related. The proteins 
however are restricted to only several major protein families, reflecting the 
recruitment of several physiological proteins and subsequent molecular adaptation 
under accelerated evolution that occurred in the venom glands over an 
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evolutionary time course. Several isoforms of toxic enzymes, e.g. snake venom 
metalloproteases, serine proteases, L-amino acid oxidases, are identified and 
likely possess diverse pharmacological properties as a result of molecular 
adaptation and neofunctionalization of the proteins. With the use of reverse-phase 
HPLC in studying the venom proteome, it was shown that the venom comprises of 
zinc-dependent metalloproteases, phospholipases A2, L-amino acid oxidases, 
serine proteases and C-type lectins in high abundances. These major components 
in the venom correlate with the toxinological effects particularly on hematoxicity 
(hemorrhage, coagulopathy) and, local inflammation and tissue destruction 
(necrosis). The understanding of the venom composition is important in 
ascertaining the principal toxins, and for an optimization of antivenom 
formulation, for instance, to include both E6- and W6- subtypes of phospholipases 
A2 in the spectrum of the antivenom neutralization.  
 
9. A thrombin-like enzyme, hypnase, with molecular mass of 37 kDa 
(deglycosylated form: 30 kDa), was isolated from the venom with successive 
HPLC and shown to be homologous to several crotalid thrombin-like enzymes by 
comparing their internal and N-terminal sequences. It exhibits both arginine ester 
hydrolase and amidase activities, and has distinct specificity towards fibrinogens 
of different mammalian sources. In initiation of fibrinogen clotting, hypnase 
preferentially cleaves the Aα chain of fibrinogen, therefore releasing 
fibrinopeptide A. Upon extended reaction time, a small amount of fibrinopeptide 
B is released, suggesting that hypnase belongs to the AB class of snake venom 
thrombin-like enzymes. The findings provide insights into the structures and 
functional mechanisms of the thrombin-like enzyme, and elucidate some aspects 
of the venom’s hematoxic pathophysiology. In addition, the understanding of the 
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mechanism of this enzyme is important for potential drug discovery in the future, 
for example, as a drug lead of anticoagulant for thromboembolic disorders.  
 
12.2 Future directions: further works suggested for Hypnale hypnale venom 
 
There are several potential future research works related to H. hypnale venom. These 
suggested works are listed below: 
 
1. Clinical trial of Hemato polyvalent antivenom in H. hypnale envenomations. 
2. Clinical study of the sensitivity and specificity of the double-sandwich ELISA in 
detecting H. hypnale venom in blood samples from patients envenomed by the 
snake. 
3. Study of the mechanisms of the venom nephrotoxic action, using isolated 
perfused rat kidney preparation, and an in vivo anesthetized rat model. 
4. Purifications and characterizations of medically important components from the 
venom, e.g. zinc-dependent metalloproteases, phosphoslipases A2, L-amino acid 
oxidases, C-type lectins etc. 
5. Venom gland transcriptomic study for a solid and specific genetic database 
corresponding to the proteins synthesized in the gland. 
6. Further study on the proteome and subproteome of H. hypnale venom using 
various state-of-the-art techniques. 
7. Antivenomic study – based on the proteomic data, antivenom therapy can be 
analytically assessed in vitro by studying the extent of immunocomplexation 
with the principal toxins in the venom.  
8. Comparative and neutralization studies of venoms from other Hypnale species 
(H. nepa and H. zara). 
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a b s t r a c t
Hypnale hypnale (hump-nosed pit viper) is a medically important venomous snake in Sri Lanka and
Southwestern India. Bite of this snake may result in hemostatic dysfunction, acute kidney injury and
death. Clinical studies indicated that the locally available polyvalent antivenoms produced in India are
not effective against hump-nosed pit viper envenoming. Hence, there is an urgent need to search for
effective antivenom. In this paper, we examined the ability of Calloselasma rhodostoma (Malayan pit
viper) monovalent antivenom and the Hemato polyvalent antivenom (both produced by Thai Red Cross
Society, TRCS) to neutralize the lethality and toxic effects of H. hypnale venom, as C. rhodostoma is con-
sidered a sister taxon of H. hypnale. In vitro neutralization studies showed that the Hemato polyvalent
antivenom effectively neutralized the lethality of H. hypnale venom (1.52mgvenom/mL antivenom) as
well as the hemorrhagic, procoagulant and necrotic activities of the venom. The monovalent C. rhodos-
toma antivenom could also neutralize the lethality and toxic activities of the venom, but the potencywas
lower. The Hemato polyvalent antivenom also effectively protectedmice from the lethal and local effects
of H. hypnale venom in an in vivo rodent model of envenoming. Furthermore, the polyvalent antivenom
could also effectively neutralize the venom of Daboia russelii (2.50mgvenom/mL antivenom), another
common cause of snake bites in Sri Lanka and South India. These ﬁndings suggested that the Hemato
polyvalent antivenom may be beneﬁcial in the antivenom treatment of H. hypnale envenoming.
© 2010 Elsevier B.V. All rights reserved.
1. Introduction
Hypnale hypnale (hump-nosed pit viper) is widely distributed in
Sri Lanka and southwestern coast of India (Ariaratnam et al., 2008).
It is the major cause of venomous snake bites in Sri Lanka (de Silva
et al., 1994). In India, the medical importance of H. hypnale bite has
been overlooked for many years perhaps because of misidentiﬁca-
tionofbiting speciesmainlyasEchis carinatus. Recently, Josephetal.
(2007) reported the ﬁrst authenticated cases of life-threatening
envenoming by H. hypnale in southwestern India. de Silva et al.
(1994) and Ariaratnam et al. (2008) also reported that bites by this
snake can cause debilitating local and fatal systemic envenoming.
Victims of H. hypnale bite may develop hemostatic dysfunctions
including coagulopathy, thrombocytopenia or spontaneous sys-
temic hemorrhage, as well as acute kidney injury, with an overall
∗ Corresponding author. Tel.: +60 3 79674912; fax: +60 3 79674957.
E-mail address: tanngethong@yahoo.com.sg (N.H. Tan).
fatality rate of 1.7% inhospitalizedpatients (Ariaratnamet al., 2008;
Joseph et al., 2007; Premawardena et al., 1996, 1998).
Previous clinical and laboratory studies of H. hypnale venom
demonstrated that the venom exhibits procoagulant and ﬁbri-
nolytic activities (de Silva et al., 1994; Premawardena et al., 1998)
and contains phopholipases A2 similar to those in the Malayan pit
viper (Calloselasma rhodostoma) venom (Wang et al., 1999). Tan
et al. (2010) also reported the presence of hyaluronidase, l-amino
acid oxidase, thrombin-like enzymes, arginine esterase and pro-
teases in the venom. To date, however, there is still no speciﬁc
antivenomagainst the venom for envenoming treatment. The poly-
valent antivenoms available in Sri Lanka and southwestern India,
including Bharat polyvalent antivenoms and Haffkine polyvalent
antivenoms, for examples, were found to be not effective in the
treatment of H. hypnale bite (Ariaratnam et al., 2008; Joseph et
al., 2007). There is therefore an urgent need to search for effective
antivenom against the venom.
The Malayan pit viper (C. rhodostoma) is the sister taxon of H.
hypnale (Parkinson et al., 1997; Vidal and Lecointre, 1998). Previ-
0001-706X/$ – see front matter © 2010 Elsevier B.V. All rights reserved.
doi:10.1016/j.actatropica.2010.11.001
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ously, both snakes were classiﬁed as members of the Agkistrodon
genus. As such, the venom of C. rhodostoma may possess toxic
components similar to those in the H. hypnale venom. In view
of the close phylogenetic relationship between H. hypnale and C.
rhodostoma, the Thai Red Cross Malayan Pit Viper antivenom had
been tested for neutralizing H. hypnale venom using rodent assay
(Ariaratnam et al., 2008). However, there was no effective pro-
tection found. In this paper, we report our studies on the in vitro
cross-neutralizations of H. hypnale venom by newly manufactured
monovalent Malayan pit viper antivenom, and in vitro as well as
in vivo (rodent model) cross-neutralizations of the venom by the
newly developed Hemato polyvalent antivenom. Both antivenoms
were produced by Thai Red Cross Society (TRCS) in Thailand. The
Hemato polyvalent antivenom was produced by immunization of
horses with a mixture of the following venoms, all of Thai origins:
C. rhodostoma, Cryptelytrops albolabris (Green pit viper) and Daboia
siamensis (Russell’s viper).
2. Materials and methods
2.1. Venoms and antivenoms
H. hypnale venomwas a pooled sample obtained from themilk-
ing of >10 adult snakes captured in Sri Lanka (Gamapha, Kelaniya,
Avissawela, Colombo regions). The snakes were kept at the snake
farm at University of Colombo, Sri Lanka and were identiﬁed by
Anslemde Silva, an expert herpetologist.Daboia russelii venomwas
from the same source and the snakes were captured in Sri Lanka
(Anuradhapura, Ratnapura, Galle and Colombo regions). C. rhodos-
toma (Malayan pit viper, from Malaysia) venom and E. carinatus
sochureki (Pakistan) venom used in this study were obtained from
Latoxan (France).MonovalentMalayanpit viper antivenom(MPVA)
(Batch no. CR00909, exp. date 2/11/2014) and Hemato polyva-
lent antivenom (HPA) (Batch no. HP00108, exp. date 6/11/2013)
were supplied by Queen Saobhva Memorial Institute, Thai Red
Cross Society (TRCS). The antivenoms were freeze-dried F(ab′)2
(90%) immunoglobulin fragments, obtained fromhyperimmunized
horses, reﬁned by caprylic acid precipitation and pepsin digestion.
The Bharat Polyvalent ASVS (anti-snake venom serum) (Batch no.
A5309049, exp. date 03/2013) is a gift from Bharat Serums and
Vaccines, Mumbai, India. This antivenom is a reﬁned and con-
centrated preparation of F(ab′)2 obtained by fractionating antisera
from hyperimmunized horses, and is capable of neutralizing cobra,
common krait, Russell’s viper and saw-scaled viper venoms. The
antivenoms were reconstituted with sterile water according to
instructions and stored at 4 ◦C.
2.2. Reagents and animals
All reagents and chemicals were purchased from Sigma Chemi-
cal Company (USA) and were of analytical grade. Albino mice (ICR
strain) were supplied by the Laboratory Animal Center, Faculty of
Medicine, University of Malaya. The animals were handled accord-
ing to the guidelines given by CIOMS on animal experimentation
(Howard-Jones, 1995). Human citrated sera were a pooled sample
from ﬁve healthy adult volunteers with consents.
2.3. Determination of lethality, hemorrhagic, procoagulant and
necrotic activities
The LD50 values of the venom were determined by intravenous
(via caudal veins) as well as intramuscular injection into mice
(16–25g, n=4) and the survival ratio was recorded after 48h. The
LD50 (and the 95% conﬁdence intervals, C.I.) values were calculated
with the probit analysis method of Finney (1952), using Biostat
Analysis software. MLD (minimum lethal dose) of the venom was
the dose that killed all the animals tested.
Hemorrhagic activity was determined using mice, a method
modiﬁed from Theakston and Reid (1983) where rats were used.
The minimum hemorrhage dose (MHD) was determined by inject-
ing 40L of varying amount of venom (dissolved in normal saline)
intradermally into the shaved dorsal skin of lightly sedated mice
(with diethyl ether). After 90min, the animals (n=3 per dose) were
killedbyoverdoseof diethyl ether and thedorsal skinwas removed.
The mean diameter of the hemorrhagic lesion on the inner surface
of the skin was measured immediately upon skin removal. Dose
response curve between the mean diameter of the hemorrhagic
lesion and the venom dose was plotted. The MHD was the dose
that caused a hemorrhagic lesion diameter of 10mm.
Procoagulant activity was determined by the method adapted
from Bogarin et al. (2000). Various amounts of venom, dissolved in
0.1mLofnormal saline,wereaddedseparately into0.2mLofbovine
ﬁbrinogen solution (2 g/L) or 0.2mL of human citrated plasma at
37 ◦C. Coagulation times were recorded. The minimum coagulant
dose (MCD) is deﬁned as the minimal amount of venom (g/mL)
that clots a standard solution of bovine ﬁbrinogen or human cit-
rated plasma in 60 s.
Necrotic activity was determined by injection of the venom at
varying amount intradermally into the shaved dorsal skin of lightly
sedated mice (with diethyl ether), and the animals were kept with
free access to water and feed ad libitum. After 72h, the animals
(n=3) were killed by overdose of diethyl ether and the dorsal skin
was removed. The mean diameter of the necrotic lesion was then
measured immediately upon skin removal. The minimum necrotic
dose (MND) is deﬁned as the amount of venom that induces a
necrotic lesion with a diameter of 5mm.
2.4. In vitro neutralization of the venom lethality, hemorrhagic,
procoagulant and necrotic activities by antivenoms
These were carried out as modiﬁed from Ramos-Cerrillo et al.
(2008).
Neutralization of lethality: 5 LD50 of H. hypnale venom was
mixed thoroughly with various dilutions of the antivenom in
phosphate-buffered saline, to give a total volume of 300L. The
mixture was incubated at 37 ◦C for 30min with gentle shak-
ing. The mixture was subsequently centrifuged at 10,000× g and
then injected intravenously into the caudal vein of mice, and the
number of animals survived 48h post-injection was recorded.
Neutralization potency of the antivenom is measured by ED50
(L antivenom/5 LD50 venom), which is deﬁned as the amount of
antivenom (L) at which the survival ratio of the animals is 50%.
The estimated amount of venom neutralized per mL of antivenom
was then calculated based on the ED50 value, the LD50 value and
weight of animals used.
Neutralization of the hemorrhagic activity: 2 MHDs of H. hyp-
nale venom was mixed thoroughly with various dilutions of the
antivenom in phosphate-buffered saline, to give a total volume of
40L. The mixture was incubated at 37 ◦C for 30min with gentle
shaking. The mixtures were subsequently injected intradermally
into the dorsal areas of lightly sedated mice (with diethyl ether).
After 90min, the animals were killed by overdose of diethyl ether.
The dorsal skin was removed immediately and the mean diameter
of the hemorrhagic spot was measured. Neutralization potency of
the antivenom ismeasured by ED50 which is deﬁned as the volume
of antivenom (L) which reduced the activity of the challenge dose
(2 MHDs) of the venom by 50%. For comparison purpose, it is also
expressed in terms of the ratio of L antivenom/mgvenom.
Neutralization of procoagulant activity: 2 MCDs of H. hyp-
nale venom were mixed thoroughly with various dilutions of the
antivenom in phosphate-buffered saline, to give a total volume of
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100L. The mixture was incubated at 37 ◦C for 30min with gen-
tle shaking. To these, 200L of bovine ﬁbrinogen (2 g/L) or human
citrated plasma, preincubated at 37 ◦C, was added and the coagula-
tion timeswere recorded. Neutralization potency of the antivenom
is measured by effective dose (ED), which is deﬁned as the volume
of the antivenom (L) at which coagulation time was increased
three times when compared to coagulation time of the ﬁbrinogen
solution or citrated human plasma incubated with venom alone.
For comparison purpose, it is also expressed in terms of the ratio of
L antivenom/mgvenom.
Neutralization of necrotic activity: 2.5 MNDs of the venom
(100g) was mixed well with various dilutions of the antivenoms
in phosphate-buffered saline to give a total volume of 50–80L.
The mixtures were incubated at 37 ◦C for 30min under gentle agi-
tation. Themixtureswere subsequently injected intradermally into
the dorsal areas of lightly sedated mice (with diethyl ether), and
the animals were kept with free access to feed and water ad libi-
tum. After 72h, the animals were killed by an overdose of diethyl
ether and following which, the skins were removed immediately
to examine the mean diameter of the dermal necrotic lesion. Neu-
tralization potency of the antivenom is measured by ED50 which
is deﬁned as the volume of antivenom (L) which reduced the
necrotic activity of the challenge dose (2.5 MNDs) of the venom
by 50%. For comparison purpose, it is also expressed in terms of the
ratio of L antivenom/mgvenom.
2.5. In vivo neutralization of the lethality of H. hypnale venom by
Hemato polyvalent antivenom using a rodent model
This was carried out by intramuscular injection of the mini-
mum lethal dose (20g/g) of H. hypnale venom into mice (n=4)
followed by intravenous injection of 200L of the Hemato polyva-
lent antivenom, 5min after the venom inoculation. The number
of animals survived 48h post-injection was recorded. The local
effects of the venom were also examined. Control group consisted
ofmice (n=4) challengedwith intramuscularminimum lethal dose
of thevenom, followedby intravenous injectionof200Lofnormal
saline.
2.6. Statistical analysis
Results forprocoagulant, hemorrhagicandnecrotic activities are
presented as mean± S.E.M., while the variability of lethality assays
was expressed as 95% conﬁdence intervals (C.I.). The signiﬁcance
of the differences of themeans was determined by Student’s t-test.
ED50 (median effective dose) and the 95% conﬁdence intervals (C.I.)
were calculated using the probit analysis method of Finney (1952).
Statistical analyseswere carried out using the Biostat Analysis soft-
ware.
3. Results and discussion
3.1. Toxinological activities of H. hypnale venom
The intravenous LD50 and intramuscular LD50 of H. hypnale
venom were determined to be 0.90g/g mouse (95% conﬁdence
interval of 0.42–1.84g/g mouse) and 13.7g/g (8.44–19.50g/g
mouse), respectively. The i.v. LD50 reported herein is slightly lower
than an earlier one reported by Ariaratnam et al. (2008), who
reported an intravenous LD50 of 65.4g per mouse, or approxi-
mately equivalent to 3g/g. The difference could be due to either
geographic or individual variation. The i.v. LD50 of the venom is
comparable to that of C. rhodostoma venom examined in this study
(LD50 of 1.48g/g, 95% C.I. 0.78–2.06g/g mouse).
The venom exhibited strong procoagulant, hemorrhagic and
necrotic activities. This is consistent with the clinical observations
in proven H. hypnale bite (Ariaratnam et al., 2008). The minimum
coagulation dose (MCD) is 56.2g/mL for bovine ﬁbrinogen, and
55.1g/mL for human citrated plasma. Theminimumhemorrhagic
dose (MHD) and minimum necrotic dose (MND) are 10.5g and
39.3g, respectively. These values are comparable to those of the
C. rhodostoma venom, with MCDs of 27.3g/mL for bovine ﬁbrino-
gen or 24.9g/mL for human citrated plasma; MHD of 24.0g and
MND of 28.7g, respectively.
3.2. In vitro neutralization of H. hypnale and C. rhodostoma
venoms
We examined the abilities of three commercial antivenoms to
neutralize the toxic activities ofH. hypnale venom in vitro. The neu-
tralization was evaluated in assays involving incubation of venom
and antivenom for 30min prior to testing.
Bharat polyvalent antivenom (ASVS), the antivenom produced
by immunizing horseswith venoms from the ‘Big 4’ (Naja naja,Bun-
garus caeruleus, D. russelii and E. carinatus) failed to protect against
H. hypnale venom: all mice (n=4) injected with 5 LD50 (i.v.) of the
venomdied despite receiving 200L/mouse of the antivenom. This
is consistentwith the clinical observations reported by Joseph et al.
(2007) that administration of the Bharat polyvalent antivenom did
notbring anybeneﬁts topatients envenomatedbyH. hypnale. Other
authors also reported that the Haffkine polyvalent antivenom (also
producedagainst the ‘Big 4’)was totally ineffective in the treatment
of victims bitten by H. hypnale (Ariaratnam et al., 2008; Sellahewa
et al., 1995).
The capability of the monovalent Malayan pit viper (MPV)
antivenom to neutralize H. hypnale venom was then examined, as
Malayan pit viper (C. rhodostoma) is considered a sister taxon to
H. hypnale by mitochondrial DNA analysis (Parkinson et al., 1997).
Ariaratnam et al. (2008) reported that (expired) monovalent MPV
antivenom failed to neutralize 5 i.v. LD50 of H. hypnale venom
in vitro, even with 200L of the antivenom. A preliminary study,
however, showed that when lesser amount of H. hypnale venom
was used (2 LD50, intraperitoneal injection), the newly manufac-
tured monovalent MPV antivenom could neutralize the lethality
of the venom in mice, though only moderately (Tan et al., 2010).
The present study showed that the newly manufactured monova-
lent MPV antivenom indeed could effectively protect mice injected
with5 i.v. LD50 ofH.hypnalevenom,and theED50 wasdetermined to
be 70.71L/5 i.v. LD50, or equivalent of 0.89mg venom neutralized
per mL of antivenom. The discrepancies with the previous report
by Ariaratnam et al. (2008) could be due to batch differences in
the antivenom, as the batch of monovalent MPV antivenom used
in this study was manufactured using a new process (caprylic acid
precipitation) and appears to be more potent (Khomvilai, 2008).
The monovalent MPV antivenom was also effective in the neu-
tralization of the procoagulant effect on both bovine ﬁbrinogen
and human citrated plasma, with EDs of 432.1L/mgvenom and
384.4L/mgvenom, respectively. It also neutralized the hemor-
rhagic and necrotic activities of H. hypnale venom, with ED50s
of 472.3L/mg venom and 612.6L/mg venom, respectively. As
expected, the monovalent MPV antivenomwas much more potent
in the neutralization of the lethality and toxicities (p<0.05) of
C. rhodostoma venom, in particular the necrotic and hemorrhagic
activities. The ED50 against C. rhodostoma venom lethal effect was
41.53L/5 i.v. LD50, or equivalent of 3.23mgvenomneutralizedper
mLof antivenom. Theneutralization ED/ED50s are 209.2L/mg and
152.7L/mg for procoagulant activities against bovine ﬁbrinogen
and human citrated plasma, respectively; 151.7L/mg for hemor-
rhagic activity and 38.1L/mg for necrotic activity of the venom
(see Tables 1 and 2). Nevertheless, these results suggest that at
least some of the venom toxins from the two snakes, H. hypnale
and C. rhodostoma, are antigenically similar. It is known that the
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Table 1
Neutralization of lethality ofHypnale hypnale, Calloselasma rhodostoma and other venoms by themonovalentMalayan pit viper antivenomandHemato polyvalent antivenom.
Antivenom Venom LD50 (i.v.) (g/g) ED50 (L antivenom/5 i.v. LD50) mg venom neutralized per
mL antivenom
Monovalent
Malayan Pit
Viper antivenom
C. rhodostoma 1.48g/g (0.78–2.06) 41.53L (20.4–88.4) 3.23
H. hypnale 0.90g/g (0.42–1.84) 70.71L (33.7–148.4) 0.89
Hemato polyvalent
antivenom
C. rhodostoma 1.48g/g (0.78–2.06) 22.47L (14.8–34.1) 7.14
H. hypnale 0.90g/g (0.42–1.84) 41.53L (20.4–88.4) 1.52
D. russelii 0.24g/g (0.19–0.62) 7.52L (3.53–15.3) 2.50
E. carinatus sochureki 2.08g/g (1.02–4.42) >200L Not effective
Values in range for LD50 and ED50 indicated 95% conﬁdence intervals. For neutralization experiments, mice (n=4) were challenged with 5 i.v. LD50 of the various venoms.
procoagulantenzymes (thrombin-likeenzymes) andhemorrhagins
from different venomous snakes can have very different antigenic
properties. For example, thrombin-like enzyme from Cryptelytrops
purpureomaculatus exhibited very little ELISA cross reactions with
the thrombin-like enzymes from C. rhodostoma venom (Tan, 2010).
Also, Fung (2002) reported that the major hemorrhagin of C. pur-
pureomaculatus venom did not cross-react with C. rhodostoma
venom at all when examined by double sandwich ELISA. The ability
of the monovalent MPV antivenom to neutralize the lethality, pro-
coagulant, hemorrhagic and necrotic activities ofH. hypnale venom
therefore supports the conclusion by Parkinson et al. (1997) that
C. rhodostoma is a sister taxon to H. hypnale. This is an interest-
ing example of similarities in the immunological properties of the
venom proteins support phylogenetic relationship derived from
mitochondrial DNA analysis. The close phylogenetic relationship
betweenH. hypnale, found in India subcontinent and C. rhodostoma,
found in Southeast Asia, is a fascinating example of the existence of
the ‘Malayan’ element in the fauna of Peninsular India. This phe-
nomenon has been known since a long time, and the cause of
these similarities have been explained by the Satpura Hypothe-
sis (Hora, 1949), according to which fauna migration followed the
Satpura trends of mountain through Peninsular India during the
Pleistocene. The validity of Satpura Hypothesis, however, has been
disputed recently (Karanth, 2003).
Recently, a new polyvalent antivenom against hematotoxic
snake venoms in Thailand has become available. This polyvalent
antivenom, termed Hemato polyvalent antivenom, was produced
from plasma of horses hyperimmunized by venoms from the three
common viper and pit vipers in Thailand: Green pit viper (C.
albolabris), Russell’s viper (D. siamensis) and Malayan pit viper
(C. rhodostoma). The Hemato polyvalent antivenom was found to
be much more effective than the monovalent MPV antivenom in
neutralizing the lethality, procoagulant, hemorrhagic and necrotic
activities of C. rhodostoma venom: the ED50 for neutralization
of the lethality was determined to be 22.47L/5 i.v. LD50, or
7.14mg venom neutralized per mL of antivenom. The EDs for the
neutralization of procoagulant activities against bovine ﬁbrino-
gen and human citrated plasma are 133.9L/mg and 104.0L/mg
venom, correspondingly; whereas the ED50s for the neutralization
of hemorrhagic and necrotic activities are 122.8L/mgvenom and
29.7L/mgvenom, respectively (Tables 1 and 2). It is therefore not
surprising toﬁnd that theHematopolyvalentantivenomisalsovery
effective in theneutralizationof the lethality, procoagulant, hemor-
rhagic and necrotic activities of H. hypnale venom (Tables 1 and 2).
Against 5 LD50 (i.v.), the ED50 of the polyvalent antivenom was
determined to be 41.53L, which is equivalent to neutraliza-
tion of 1.52mg of H. hypnale venom per mL of the reconstituted
Hemato polyvalent antivenom. In comparison, 1mL of mono-
valent MPV antivenom neutralized only 0.89mg of the venom.
Comparison of the ED/ED50s of neutralization of procoagulant,
hemorrhagic and necrotic activities of the venom also showed that
the Hemato polyvalent antivenom is far more effective (p<0.05)
than the monovalent MPV in neutralizing the toxic activities of
the H. hypnale venom. In fact, the ED50s of the neutralization of
the procoagulant, hemorrhagic and necrotic activities ofH. hypnale
venom by the Hemato polyvalent antivenom is comparable to the
ED/ED50s against C. rhodostoma venom (Tables 1 and 2), though the
antivenom ismore effective against C. rhdostoma thanH. hypnale in
terms of neutralization of lethality (7.14mgvenom/mLantivenom,
versus 1.52mgvenom/mLantivenom, p<0.05).
The greater efﬁcacy of the Hemato polyvalent antivenom than
the monovalent MPV antivenom in the neutralization of H. hyp-
nale venom suggested that the other two venoms (of D. siamensis
and C. albolabris) used in the immunization scheme of prepara-
Table 2
Neutralization of the procoagulant, hemorrhagic and necrotic activities of H. hypnale and C. rhodostoma venoms by the monovalent MPV antivenom and Hemato polyvalent
antivenom.
Toxic activity Minimum dose Neutralization by MPV antivenom (ED or ED50) Neutralization by HP antivenom (ED or ED50)
Procoagulant MCD
H. hypnale 56.2±1.3g/mLa ED=4.8±0.1La (432.1±10.9L/mgvenom) ED=1.3±0.0La (114.2±2.7L/mgvenom)
55.1±1.4g/mLb ED=4.2±0.1Lb (384.4±11.2L/mgvenom) ED=1.3±0.0Lb (121.3±0.7L/mgvenom)
C. rhodostoma 27.3±0.3g/mLa ED=1.1±0.0La (209.2±0.2L/mgvenom) ED=0.7±0.0La (133.9±0.3L/mgvenom)
24.9±0.4g/mLb ED=0.8±0.0Lb (152.7±3.7L/mgvenom) ED=0.5±0.0Lb (104.0±1.2L/mgvenom)
Hemorrhagic MHD
H. hypnale 10.5±0.6g ED50 =9.9±0.3L (472.3±13.9L/mgvenom) ED50 =1.4±0.1L (67.4±5.1L/mgvenom)
C. rhodostoma 24.0±0.9g ED50 =7.3±1.4L (151.7±29.3L/mgvenom) ED50 =5.9±0.2L (122.8±3.9L/mgvenom)
Necrotic MND
H. hypnale 39.3±1.6g ED50 =61.2±1.7L (612.6±17.5L/mgvenom) ED50 =5.3±0.1L (53.8±0.59L/mgvenom)
C. rhodostoma 28.7±2.6g ED50 =2.7±0.1 (38.1±1.9L/mgvenom) ED50 =2.1±0.0L (29.7±0.4L/mgvenom)
Neutralization of hemorrhagic and procoagulant activities were determined by challenge with 2 MHDs and incubation with 2 MCDs, respectively, of the venom. For neutral-
ization of necrotic activity, mice were challenged 2.5 MNDs of venom intradermally. Values are expressed as mean± S.E.M. (n=3 for procoagulant, hemorrhagic and necrotic
activities).
a Procoagulant activity tested on bovine ﬁbrinogen.
b Procoagulant activity tested on human citrated plasma.
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tion of the polyvalent antivenom may contain venom toxins that
are immunologically similar to some H. hypnale venom toxins.
Our preclinical studies therefore suggest that both the monova-
lent MPV and the Hemato polyvalent antivenom may be useful in
the antivenom treatment of systemic H. hypnale envenoming. The
polyvalent antivenom might be the preferred one because of its
greater efﬁcacy, though the drawback is its higher cost (USD 60 per
vial compared to USD 20 per vial for the monovalent antivenom).
In view of the relatively low yield (average of 13mg permilking) of
venom fromH. hypnalebecause of its relatively small size (Tan et al.,
2010), and the strong neutralization capacity of the Hemato poly-
valent antivenom, 1–2 vial (10–20mL reconstituted antivenom)
of the polyvalent antivenom would probably be sufﬁcient in the
treatment of most systemic H. hypnale envenomation. Neverthe-
less, while the results of the preclinical studies are promising, these
studies must be followed by a randomized controlled clinical trial
in the relevant regions, which is the ﬁnal criterion for assessing the
clinical efﬁcacy and safety of the antivenom.
3.3. In vitro neutralization of the lethalities of D. russelii and E.
carinatus sochureki venom by the Hemato polyvalent antivenom
The ability of the Hemato polyvalent antivenom to neutralize
the other two common vipers (D. russelii and E. carinatus sochureki)
in Sri Lanka and India subcontinent was also investigated, as these
two vipers are also common causes of snake bites in the region,
and it is not always possible to identify the biting species in
these snake bites. Our results showed that the Hemato polyva-
lent antivenom could neutralize the Sri Lankan D. russelii venom
effectively, with an ED50 of 7.52L/5 LD50 (i.v.), or equivalent to
2.50mgvenom/mLantivenom. This is not surprising as theHemato
polyvalent antivenom was raised against a mixture of 3 venoms,
including the Thai D. siamensis venom, which presumably contains
some common antigens with the Sri Lanka D. russelii venom. The
polyvalent antivenom,however,wasnot effective in theneutraliza-
tion of E. carinatus sochureki venom: all 4 mice that were injected
with 5 LD50 (i.v.) died despite receiving a maximum of 200L of
the antivenom. This result is not surprising as the toxinology of
E. carinatus sochureki venom is very different from the three ven-
oms used in the production of the Hemato polyvalent antivenom.
Nevertheless, the ability of the Hemato polyvalent antivenom to
neutralize D. russelii venom increases the potential beneﬁt of the
use of Hemato polyvalent antivenom in management of viper/pit
viper bites in Sri Lanka and Southern India, as D. russelii is the sec-
ond commonest cause of snake bite in the region, next toH. hypnale
(Ariaratnam et al., 2009). Since clinically it is not always possi-
ble to distinguish between envenomation by H. hypnale, D. russelii
and E. carinatus, double-sandwich ELISA should be developed to
assist in biting species identiﬁcation in future clinical trials of the
antivenoms.
3.4. In vivo neutralization of H. hypnale venom using a rodent
model of envenoming
To further evaluate the potential of the application of the
Hemato polyvalent antivenom in the treatment of H. hypnale bites,
we also carried out an in vivo neutralization experiment, using a
rodent model. In this experiment, four mice received intravenous
injectionof 200L ofHematopolyvalent antivenom5min after i.m.
injection of minimum lethal dose (400g per mouse) of H. hyp-
nale venom. All four mice survived, and observations of the treated
animals indicated that in addition to neutralization of the venom
lethality of the venom in vivo, the antivenom also prevented or
largely reduced the occurrence of venom-induced local tissue dam-
age (myonecrosis and bleeding) of the venom. This observation is
consistent with the result of in vitro neutralization of the necrotic
and hemorrhagic effects of H. hypnale venom by the polyvalent
antivenom (Table 2).
Ariaratnam et al. (2008) reported in the series of humped-nose
pit viper bites, 117 (39%) were systematically envenomed, all with
hemostatic abnormalities and30with acute renal failure.Weat this
moment have not been able to assess the ability of the antiven-
oms to neutralize the nephrotoxicity due to the lack of sufﬁcient
amount of H. hypnale venom to develop a reliable in vivo nephro-
toxicity assay. Nevertheless, coupled with our in vitro ﬁndings, the
current in vivo results demonstrate further the potential beneﬁts of
the polyvalent antivenom in the treatment of H. hypnale bite.
4. Conclusions
Our results showed that both the monovalent MPV antivenom
and the Hemato polyvalent antivenoms are effective in the neu-
tralizations of the lethality and major toxic activities induced
by H. hypnale venom when using in vitro and in vivo rodent
assay protocols, in spite of the fact that the H. hypnale venom is
not included in the immunizing mixture used in the production
of the antivenom. Hence, this indicates that there are substan-
tial immunological cross-reactivities between toxic components
present in H. hypnale venom and the viperid venoms used in the
production of the Hemato polyvalent antivenom. Extensive cross-
neutralization between several Bothrops venoms and antivenoms
has been described (Rojas et al., 2005; Bogarin et al., 2000). Our
results therefore support the hypothesis that some antivenoms can
be effective against heterologous venoms in other countries and
may be helpful in situations where locally produced antivenoms
are not available, as demonstrated by Otero et al. (1996).
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Enzymatic and toxinological activities of Hypnale hypnale (hump-nosed 
pit viper) venom and its fractionation by ion exchange high performance 
liquid chromatography
Tan CH (1, 2), Sim SM (1, 2), Gnanathasan CA (3), Fung SY (2, 4), Ponnudurai G (3), Pailoor J (5), Tan 
NH (4)
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Kuala Lumpur, Malaysia.
Abstract: Hypnale hypnale (hump-nosed pit viper) has been recently identified as one of the medically 
important venomous snakes in Sri Lanka and on the southwestern coast of India. The characterization 
of its venom is essential for understanding the pathophysiology of envenomation and for optimizing 
its management. In the present study, the biological properties of Hypnale hypnale venom and venom 
fractions obtained using Resource Q ion exchange chromatography were determined. The venom 
exhibited toxic activities typical of pit viper venom, comparable to that of its sister taxon, the Malayan pit 
viper (Calloselasma rhodostoma). Particularly noteworthy were its high activities of thrombin-like enzyme, 
proteases, phospholipase A2, L-amino acid oxidase and hyaluronidase. The thrombin-like enzyme was 
mainly acidic and distributed over several chromatography fractions, indicating its existence in multiple 
isoforms. The hemorrhagic and necrotic activities of the venom were likely associated with the proteolytic 
enzyme found mainly in the basic fraction. Phospholipase A2 and phosphomonoesterase exist in both acidic 
and basic isoforms, while L-amino acid oxidase and hyaluronidase are highly acidic. The venom clotting 
activity on fibrinogens showed distinct species specificity in the following increasing order for clotting time: 
bovine < rabbit < goat < human < horse < < dog, and was comparable to that of C. rhodostoma venom. Its 
clot formation on human fibrinogen is gradual and prolonged, a phenomenon suggestive of consumptive 
coagulopathy as a complication observed clinically. At an intramuscular sublethal dose, the venom did not 
cause acute kidney injury in a rodent model, contrary to the positive control group treated with Daboia 
russelii venom. Nephrotoxicity may result from higher venom doses in the context of coagulopathy, as a 
complication provoked by venom hematoxicity.
Key words: Hypnale hypnale, venom, enzymes, toxins, fibrinogen, nephrotoxicity.
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INTRODUCTION
Snakes from the Viperidae family, including 
both vipers (viperines) and pit vipers (crotalids), 
are known to produce venoms that are principally 
hematoxic (1, 2). These venoms generally contain 
well over one hundred protein constituents, of 
which toxins belong to only a few major protein 
families that include such enzymes as serine 
proteases, Zn2+-metalloproteases, L-amino 
acid oxidase and group II PLA2; as well as non-
enzymatic proteins (constituting a smaller 
portion) including disintegrins, C-type lectins, 
myotoxins, cysteine-rich secretory protein 
(CRISP) toxins etc. (3, 4). This context reflects 
the emergence of toxins from a restricted set 
of physiological protein families recruited 
into the venom proteome at the base of the 
Colubroidea radiation, ideal for their primary 
role in predation and defense (5, 6). Nevertheless, 
envenomation of humans causes serious public 
health problems, for which it has been duly 
categorized as a “disease” according to the WHO 
International Classification of Disease (ICD-10), 
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and appropriately categorized as a Neglected 
Tropical Disease (7). This problem also affects 
most tropical and subtropical countries, many 
of which are still underdeveloped, hence its apt 
description as a disease of poverty (8). Despite 
this, the envenomation issue remains systemically 
neglected in many parts of the world (9). 
In South Asia, annual mortality due to 
snakebites has been estimated to be 1,000 in 
Sri Lanka and 20,000 in India (10). Hypnale 
hypnale (hump-nosed pit viper) has been recently 
recognized as a medically important venomous 
snake in Sri Lanka and on the southwestern coast 
of India (11, 12). It is now listed as a category I 
snake of medical importance by the World Health 
Organization, owing to its wide distribution and 
high prevalence of bites which cause significant 
morbidity and mortality in the region (13). This 
snake is mainly nocturnal and both arboreal and 
terrestrial. It inhabits both wet and dry deciduous 
zones; can be found in settings ranging from 
secondary forests, hilly areas, various plantations 
to low land gardens and even latrines within home 
compounds. Being well camouflaged and tiny in 
size (body length rarely exceeds 0.5 m), it is easily 
missed and trodden upon even in the daytime, 
resulting in its defensive bite (11). In Sri Lanka, 
it is not uncommon to come across H. hypnale 
envenoming even in the capital city of Colombo, 
although more cases occur in the suburban and 
rural areas. 
Although the local effects of its bites were well 
observed and documented, it remains controversial 
after more than a century as to whether H. 
hypnale bites could be fatal (14-18). Recent 
clinical studies indicated that envenomation 
by this snake resulted in local edema, necrosis, 
regional lymphadenopathy, as well as systemic 
effects characterized by hemostatic dysfunction 
(coagulopathy, fibrinolysis, thrombocytopenia, 
spontaneous systemic hemorrhage) and acute 
renal failure, with an overall fatality rate of 1.7% in 
authenticated cases (11, 12, 19-22). To date, apart 
from the Calloselasma rhodostoma antivenoms 
(produced by the Thai Red Cross Society) which 
were shown to confer paraspecific neutralization 
in rodent models, there is no specific antivenom 
that is clinically effective against the H. hypnale 
venom (11, 12, 23). 
In order to address the envenoming issue 
holistically, the venom’s toxinological profile 
should be studied to elucidate its pathogenesis. In 
this paper, we report the biological properties of 
the venom and its ion exchange chromatography-
fractionated components, using in vitro and/or 
in vivo methods. Its clotting activity on several 
mammalian fibrinogens was also investigated. A 
rodent model was also used to study the in vivo 
nephrotoxic effects of this venom. 
MATERIALS
Venoms
Hypnale hypnale venom was a pooled sample 
obtained from the milking of adult snakes captured 
in Sri Lanka (Gamapha, Kelaniya, Avissawela, 
Colombo regions). The snakes were kept at the 
snake farm in the University of Colombo, Sri 
Lanka and were identified by Anslem de Silva, 
an expert herpetologist. Venoms of Calloselasma 
rhodostoma, Cryptelytrops purpureomaculatus 
and Daboia russelii (Myanmar) were purchased 
from Latoxan (Valence, France).
Reagents and Animals
All reagents and chemicals were purchased 
from Sigma Chemical Company (USA) and were 
of analytical grade. Albino mice (ICR strain) 
and Sprague Dawley rats were supplied by the 
Laboratory Animal Center, Faculty of Medicine, 
University of Malaya. The use of animals was 
approved by the institute and these animals were 
handled according to the guidelines of the Council 
for International Organizations of Medical Sciences 
(CIOMS) on animal experimentation (24). 
METHODS
Fractionation of H. hypnale venom by 
Resource® Q Ion-Exchange Chromatography 
Five milligrams of the venom dissolved in 200 
µL of starting buffer (20 mM Tris-HCl, pH 8.5) 
was filtered through a 0.2 µm pore size syringe 
filter. The filtrate was then injected into Resource® 
Q ion-exchange column  (GE Healthcare, USA) 
(6.4 mm x 30 mm, 1 mL gel volume, 15 µm particle 
size, 200-10,000 Å) pre-equilibrated with starting 
buffer, and subsequently eluted by a linear, 0.0 to 
0.5 M sodium chloride gradient (0-30% from 5 
to 30 minutes, followed by 30-100% from 30 to 
55 minutes), at the flow rate of 1 mLmin–1. The 
solvent delivery and gradient formation over 60 
minutes was achieved by using the Shimadzu LC-
20AD® high performance liquid chromatography 
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(HPLC) system (Japan). Protein peaks were 
monitored by measuring the absorbance at 280 
nm. The protein content of the fractions was 
determined by the Bradford method (25).
Determination of Enzymatic Activities
This portion of the study was done on 
the venoms of H. hypnale and Calloselasma 
rhodostoma for comparison, as well as on the 
HPLC-isolated protein fractions of H. hypnale 
venom. Two independent experiments were 
carried out on each test for each sample, and the 
average results were reported.
Protease assay
Protease activity was measured by 
modification of the method described by Kunitz 
(26). One milliliter of 1% casein in 0.25 M sodium 
phosphate buffer, pH 7.75, and 50 μL of sample 
solution were incubated for 30 minutes at 37°C. 
The reaction was terminated by adding 1 mL of 
5% trichloroacetic acid. After centrifugation at 
10,000 x g for ten minutes, the absorbance of the 
supernatant was measured at 280 nm. One unit of 
protease activity was defined as an increase of one 
absorbance unit per hour at 280 nm. 
Phospholipase A2 assay
Phospholipase A2 activity was determined 
by the acidimetric method (27). The egg yolk 
substrate suspension was prepared by mixing one 
part chicken egg yolk, one part 18 mM calcium 
(II) chloride, and one part 8.1 mM sodium 
deoxycholate. The pH of the substrate suspension 
was adjusted to 8.0 with 1 M sodium hydroxide. 
The suspension was stirred to ensure good mixing. 
One hundred microliters of venom solution was 
added to 15 mL of the substrate suspension and 
the rate of decrease in pH was recorded using a 
pH meter. A decrease of 1 pH unit of the egg yolk 
suspension corresponded to 133 μmol of fatty 
acids released.
Arginine ester hydrolase assay
Arginine ester hydrolase was assayed using 
α-benzoyl arginine ethyl ester as substrate (28). 
The assay mixture contained 0.95 mL of 0.8 mM 
substrate in 0.05 M Tris-HCl buffer, pH 7.8, 
and 50 μL of sample solution. The reaction was 
monitored by measuring the rate of increase 
in absorbance at 255 nm. The difference in the 
extinction coefficient at 255 nm is 815 cm–1M–1.
Phosphodiesterase assay
Phosphodiesterase activity was determined 
by a method modified from Lo et al. (29). One 
hundred microliters of sample was added to 
an assay mixture containing 0.5 mL of 2.5 mM 
calcium bis-p-nitrophenylphosphate, 0.3 mL of 
0.01 M magnesium sulfate and 0.5 mL of 0.17 
M veronal buffer, pH 9.0. The hydrolysis of the 
substrate was monitored by measuring the rate of 
increase of absorbance at 400 nm. The extinction 
coefficient is 8100 cm–1M–1.
Alkaline phosphomonoesterase assay
Alkaline phosphomonoesterase activity was 
determined by a method modified from Lo et 
al. (29). One hundred microliters of sample was 
added to an assay mixture containing 0.5 mL of 
0.5 M glycine buffer (pH 8.5), 0.5 mL of 10 mM 
p-nitrophenylphosphate and 0.3 mL of 0.01 M 
magnesium sulfate. The mixture was incubated at 
37°C for 30 minutes. At the end of the incubation 
period, 2 mL of 0.2 M sodium hydroxide was 
added and allowed to stand for 20 minutes at 
room temperature. The absorbance at 400 nm 
was then measured. The extinction coefficient is 
18500 cm–1M–1.
5’-Nucleotidase assay
5’-Nucleotidase activity was determined 
using 5’-AMP as substrate (30). One hundred 
microliters of sample was added to an assay 
mixture containing 0.5 mL of 0.02 M 5’-AMP 
(preadjusted to pH 8.5), 0.5 mL of 0.2 M glycine 
buffer, pH 8.5, and 0.1 mL of 0.1 M magnesium 
sulfate. The mixture was incubated for ten minutes 
at 37°C, and the reaction was terminated by the 
addition of 1.5 mL of 10% trichloroacetic acid. 
The ascorbic acid method was used to determine 
the inorganic phosphate content (31). To the 
above mixture, 1 mL of ascorbic acid reagent – 
containing equal parts of 3 M sulfuric acid, 2.5% 
ammonium molybdate, 10% ascorbic acid and 
water – was added. The mixture was left at room 
temperature for 30 minutes, and the absorbance 
at 820 nm was then measured. A standard curve 
was constructed using known concentrations of 
inorganic phosphate.
Hyaluronidase assay
Hyaluronidase activity was determined 
turbidimetrically (32). The assay mixture 
contained 0.45 mL of 0.2 M acetate buffer, pH 5.0, 
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containing 0.15 M sodium chloride and 0.2 mg 
of human umbilical cord hyaluronic acid and 50 
μL of sample solution. The mixture was incubated 
for 1 h at 37°C. The reaction was terminated by 
the addition of 1 mL of 2.5% cetyltrimethyl-
ammonium bromide in 2% sodium hydroxide 
solution. After 30 minutes, the absorbance at 
400 nm was measured. Enzymatic activity was 
expressed as NFU/mg (National Formulary 
Units). Appropriate dilutions of sample were 
performed to ensure that the difference in 
absorbance between the blank and sample was 
less than 0.4. Hyaluronidase (EC 3.2.1.35), 
originating from bovine testes, was purchased 
from Sigma Chemical Co. (USA) and used as a 
standard; its activity is 270 NFU per mg. Several 
dilutions of hyaluronidase representing a series of 
NFUs were tested on solution containing 0.2 mg 
of hyaluronic acid. The absorbance values were 
plotted against the NFUs for calibration. 
L-amino acid oxidase
L-amino acid oxidase activity was determined 
as described by Tan et al. (33). Fifty microliters of 
horseradish peroxidase (100 purpurogalin unit/
mg) was added to 0.9 mL of 0.2 M triethanolamine 
buffer, pH 7.6, containing 0.1% L-leucine and 
0.0075% o-dianidisine and incubated for three 
minutes at room temperature. Sample solution 
(50 μL) was then added and the increase in 
absorbance at 436 nm was measured. The molar 
absorption coefficient is 8.31 x 103 cm–1M–1.
Determination of Lethality, Hemorrhagic, 
Procoagulant and Necrotic Activities
Median lethal dose (LD50)
The LD50 values of H. hypnale venom were 
determined by intraperitoneal injection of the 
venom into mice (18-22 g, n = 4 per dose) whose 
survival ratio was recorded after 48 hours. The 
intraperitoneal LD50 (and the 95% confidence 
intervals, CI) of the venom was calculated using 
the Probit analysis method of Finney (34). The 
intramuscular LD50 value of H. hypnale was 
based on a previous determination from the 
same laboratory as reported by Tan et al. (23), 
while that for D. russelii was determined via 
intramuscular injection of the venom into hind 
legs of mice (n = 4 per dose), and analyzed as 
previously mentioned.
Hemorrhagic activity 
Hemorrhagic activity was determined 
according to Theakston and Reid (35) with 
modifications. The venom dissolved in phosphate-
buffered saline (50 μg in 50 μL) or the venom 
fraction (50 μL) was injected intradermally into 
the shaved dorsal skin of lightly anesthetized mice. 
After 90 minutes, the animals were euthanized 
with an overdose of diethyl ether. The dorsal skin 
was removed carefully, and the mean diameter of 
the hemorrhagic lesion on the inner surface of 
the skin was measured. 
Procoagulant activity
Procoagulant activity was determined by the 
method described by Bogarin et al. (36). The 
venom (50 µg in 0.1 mL) or venom fraction (0.1 
mL) was added to 0.2 mL of bovine fibrinogen 
solution (2 g/L) at 37°C. The coagulation time 
(time required for fibrin strands to form) was 
recorded. A shorter coagulation time suggests 
higher procoagulant activity.
Necrotic activity
Necrotic activity was determined by a modified 
version of the method of Theakston and Reid (35). 
The venom, (50 μg in 50 μL) or venom fraction 
(50 µL) was injected intradermally into the 
shaved dorsal skin of lightly anesthetized mice. 
After 72 hours, the animals were euthanized with 
an overdose of diethyl ether, the dorsal skin was 
removed, and the mean diameter of the necrotic 
lesion was measured. 
Fibrinogen clotting activity 
The fibrinogen clotting activity (procoagulant 
effect) of H. hypnale venom was tested further 
on fibrinogens from several mammalian sources. 
Venoms from two other Asiatic pit vipers, C. 
rhodostoma and C. purpureomaculatus, well 
known for their procoagulant effects, were 
studied simultaneously for comparison (37, 38).
The venom (50 µg in 0.1 mL) was added to 0.2 
mL of fibrinogen solution from various animal 
sources (2 g/L) at 37°C. The coagulation time (time 
elapsed for fibrin strands to form) was recorded. To 
study the time course of venomous procoagulant 
activities, each venom (50 µg in 0.1 mL) was added to 
0.2 mL of fibrinogen solution (2 g/L) preincubated 
at 37°C. The absorbance of the mixture at 450 nm 
was read for ten minutes to monitor the formation 
and degradation of fibrin clots.
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Nephrotoxicity study
Sprague dawley rats were divided into three 
groups of three animals each: normal saline 
(NS) group, H. hypnale venom (HV) group 
and Daboia russelii venom (DV) group. The NS 
group and DV groups represented, respectively, 
the negative and positive controls. Rats from 
each group received intramuscular injections of 
treatment as follows: 200 µL of normal saline, or 
200 µL of venom solution corresponding to one 
third of the venom’s intramuscular LD50. The rats 
were kept for 24 hours in metabolic cages with 
access to feed and water ad libitum. Urine was 
collected throughout 24 hours, while blood was 
collected via cardiac puncture under anesthesia at 
the end of experiment. The urine and blood were 
sent for biochemical analysis, to an outsourced 
service at a pathology analytical laboratory. Major 
organs harvested from rats upon death following 
cardiac punctures were sent for histopathological 
studies. Specimens were fixed in 10% formalin, 
followed by paraffin wax-embedding, sectioning 
of tissue, dewaxing, rehydration, and staining 
with hematoxylin and eosin. The sections were 
cover-slipped and images were captured using a 
Nikon Research Trinocular Teaching Microscope 
Eclipse 80i® (Japan) equipped with a camera. 
Statistical analysis
The variability of lethality assays was 
expressed within 95% confidence intervals (CI). 
The significance of the differences of the means 
was determined by two-tailed unpaired Student’s 
t-test or one-way ANOVA. Statistical analyses 
were carried out using the statistical software 
SPSS. 
RESULTS AND DISCUSSION
Milking of Snake Venom
In an investigation of venom yield, the milking 
of six adult H. hypnale snakes yielded 10.0 mg, 
8.7 mg, 11.4 mg, 20.0 mg, 12.2 mg and 15.6 mg, 
respectively, of dried venom. The average amount 
of venom obtained per milking is therefore 13 
mg (± 4.2 mg). Hence the maximum amount of 
venom injected per bite is expected to be less than 
20 mg, much lower than the roughly 50 mg per 
yield reported in its sister taxon, C. rhodostoma 
(37). This is predictable as the body size of H. 
hypnale is small and rarely grows beyond 0.5 m.
Lethality of the Venom
H. hypnale venom has an intraperitoneal 
median lethal dose (LD50) of 6.0 µg/g (95% CI 
4.2-8.1 µg/g) of mouse body weight, which is 
intermediate between the intravenous LD50 (0.9 
µg/g) and the intramuscular LD50 (13.7 µg/g) 
reported by our research group in an earlier 
study (23). This suggests that the potency 
of toxins causing lethality differs depending 
on the administration route. A much lower 
intravenous LD50 indicates that the venom is 
likely to be principally hematoxic in action, 
while the intraperitoneal LD50 is higher than 
the intravenous value possibly due to delayed 
an/or incomplete absorption (as in first pass 
phenomenon) of the toxins before reaching the 
systemic circulation (39, 40). The fact that the 
intraperitoneal LD50 value is lower than that of 
the intramuscular route is likely due to higher 
bioavailability given that more venom is quickly 
absorbed intraperitoneally (larger surface area 
and richer blood supplies) without having to bind 
and interact with muscle and connective tissues. 
The median intramuscular lethal dose of D. 
russelii venom tested in mice was 0.70 µg/g (95% 
CI, 0.45-0.9 µg/g) of body weight, which was 
determined for use in the nephrotoxicity study.
Biological Properties of H. hypnale and C. 
rhodostoma Venoms
The H. hypnale venom used in this study showed 
higher activities of proteases, phospholipase A2, 
L-amino acid oxidase and hyaluronidase than 
those found in a previous report (41) (Table 1). 
This may be due to ontogenic differences as the 
venom used in this study was a recently pooled 
sample. The procoagulant activity, however, did 
not differ markedly between the two reports. 
H. hypnale venom exhibited enzymatic 
properties similar to C. rhodostoma venom 
(Table 1), which are quite typical of pit viper 
venoms, notably the presence of arginine 
ester hydrolase and potent protease activities. 
Particularly noteworthy is the substantially 
higher phospholipase A2 activity in H. hypnale 
venom; in comparison, C. rhodostoma venom 
usually exhibits rather / very low phospholipase 
A2 activity. Phospholipases A2 are known to 
exhibit multiple pharmacological activities, 
including lipid membrane damage, myotoxicity 
and myonecrosis (42, 43). High amounts of 
phospholipase A2, proteases and L-amino acid 
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oxidase, known for their cytotoxic and tissue-
damaging properties, are likely responsible for the 
local envenoming features, e.g. edema, necrosis 
and hemorrhagic blistering commonly seen after 
H. hypnale bites (11, 12, 43-45). In addition, 
hyaluronidase that presents substantially in the 
venom can synergistically potentiate the venom 
propagation and its local effects, contributing to 
severe local tissue destruction (46).
H. hypnale venom also showed potent 
procoagulant or thrombin-like enzyme activities 
(lower than that of C. rhodostoma), as well as 
hemorrhagic and necrotic properties (higher 
than or similar to that of C. rhodostoma). These 
activities are hallmark of the pathophysiology 
induced by pit viper venoms. The general 
similarities in the biological activities of H. hypnale 
venom and C. rhodostoma venom are expected as 
they are closely related phylogenetically, hence 
the possibility of sharing similar venom antigens 
(47, 48). 
Fractionation of H. hypnale venom 
by Resource® Q Anion Exchange 
Chromatography 
Ion exchange chromatography separates 
proteins based on their ionic charges, and has been 
useful in snake venom fractionations as it does 
not affect the biological activity of eluted proteins, 
hence allowing their characterizations (33, 38). 
With Resouce® Q column, an anion exchanger, H. 
hypnale venom was fractionated yielding twelve 
major fractions (Figure 1). Protein estimation by 
the Bradford method (25) showed that fraction 
12 has very little protein content. Fractions 1 
and 2 are unbound fractions and contain basic 
proteins, while the remaining fractions generally 
contain proteins of an increasingly acidic nature. 
Biochemical Properties of the Protein 
Fractions of H. hypnale venom 
Table 2 shows the biological properties of 
the 12 fractions obtained from Resource® Q 
chromatography of H. hypnale venom. Fraction 
1, containing the basic proteins, was certainly 
heterogeneous, as it possessed multiple enzyme 
activities including proteases, phospholipase 
A2, alkaline phosphomonoesterase, 
phosphodiesterase and 5’-nucleotidase activities. 
It was also the only fraction that exhibited 
hemorrhagic and necrotic activities, and both 
of these toxic effects were likely associated with 
the proteolytic activity, as reported in viperid 
metalloproteinases (1). Both fractions 1 and 3 
exhibited phospholipase A2 activity, suggesting 
that the venom contains at least two forms of 
phospholipase A2. This finding is in accord with 
a previous report (49) where only two out of four 
PLA2 isoforms isolated from H. hypnale venom, 
using combined gel filtration and reversed-phase 
chromatography, exhibited enzymatic activities. 
We suggest that these two reported enzymes 
belong to a basic form (fraction 1) and an acidic 
form (fraction 3), respectively. 
Hydrolytic enzymes – such as 
phosphodiesterase (a nuclease), 5’-nucleotidase 
Table 1. Enzymatic, hemorrhagic and necrotic activities of H. hypnale and C. rhodostoma venoms
Activity
Species
PRO PLA2 LAO AEH PME PDE 5’-Nuc HYA TLE HEM NEC
H. hypnale# 15.8 191.5 191.7 10.05 4.8 4.1 1.8 115.5 20 23 7.5
C. rhodostoma# 18.5 79.8 165.4 8.96 4.6 18.5 1.9 76.6 10 16 8.0
H. hypnale@ 7.8 126 110 15.2 12 6 2.7 85 22 1.6* ND
PRO: protease, unit/mg; PLA2: phosphopholipase A2, µmol/min/mg; LAO: L-amino acid oxidase, nmol/min/mg; AEH: arginine ester 
hydrolase, µmol/min/mg; PME: alkaline phosphomonoesterase, nmol/min/mg; PDE: phosphodiesterase, nmol/min/mg; 5’-Nuc: 
5’-nucleotidase, µmol/min/mg; HYA: hyaluronidase, NFU/mg; TLE: thrombin-like enzyme (procoagulant enzyme), s/50 µg venom; 
Hem: hemorrhagin, mm/50 µg venom; NEC: necrosis, mm/50 µg venom; ND: not determined. Values were the average results from 
two independent experiments. 
# Present study; @ reference to Tan and Ponnudurai (41); * the unit was expressed as the product of two perpendicular diameters of 
the lesion, which is different from the unit defined in the present study. 
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and alkaline phosphomonoesterase – are 
high molecular weight proteins known to be 
widely distributed across many snake taxa, but 
their toxic effects have been less extensively 
characterized partly due to the fact that these 
enzymes share similar substrates and biochemical 
properties (50). In general, our results showed 
that all three enzymes were found in H. hypnale 
venom in appreciable amounts, particularly 
phosphodiesterase, which is usually abundant 
in crotalid venoms. Phosphodiesterase had been 
associated with a drop in mean arterial pressure 
and locomotor depression, presumably due to 
reduced cAMP levels (51). This feature, however, 
has not been reported in systemic envenomation 
by H. hypnale, implying that its function might 
be more digestive than purely toxinological. 
The chromatography result also showed that 
5’-nucleotidase and phosphomonoesterase from 
H. hypnale venom exist in both basic and acidic 
isoforms. It is intriguing to note the existence 
of acidic phosphomonoesterase in this venom, 
as this enzyme, contrary to the basic/alkaline 
phosphomonoesterase, has so far only been 
purified from sea snake venoms and rarely been 
reported in other snake venoms (52). 
Thrombin-like activity was found to be 
widespread from fraction 2 to fraction 8, 
indicating that the enzyme likely existed in 
multiple isoforms. The two fractions (fraction 
5, 6) with the strongest thrombin-like activity 
were also the two fractions that hydrolyzed 
arginine esters, suggesting that the thrombin-
like enzymes exhibited arginine ester hydrolase 
activity, a property similar to that of ICR-50 
arvin, a coagulant enzyme derived from C. 
rhodostoma venom (28). The enzyme esterolytic 
activity towards N-α-benzoyl-l-arginine ethyl 
ester indicated its specific binding to the arginine 
residues in its substrate. The venom also contained 
one or more forms of L-amino acid oxidase which 
appeared more acidic than many other enzymes, 
and its activity was noted to be lost by freezing. 
Such freeze-labile activity had been reported and 
the mechanism is presumably due to a limited 
conformational change of the enzyme structure 
(53, 54). Fraction 12, which contained few 
proteins, was found to be devoid of enzymatic 
activities. As demonstrated, venom fractionation 
helps elucidate the different components in 
venoms allowing their toxic characterizations for 
pathophysiological correlations. Nonetheless, it 
also opens the door to manipulating specific toxins 
in search of potential therapeutic compounds, as 
already observed in drug discoveries of ancrod, 
captopril etc. (55). 
Figure 1. Fractionation of Hypnale hypnale venom with Resource® Q anion exchange chromatography. The 
venom (5 mg) was injected into the column equilibrated with 20 mM Tris-HCl, pH 8.5, and eluted by a linear, 
0.0 to 0.5 M NaCl gradient (0-30% from 5 to 30 minutes, followed by 30-100% from 30 to 55 minutes. Flow 
rate was 1 mL/min. (-----): NaCl concentration gradient (%)
Tan CH, et al. Toxinology of H. hypnale venom and its HPLC fractions
J Venom Anim Toxins incl Trop Dis  |  2011  |  volume 17  |  issue 4 480
Fibrinogen Clotting Activity 
The clotting activity of H. hypnale venom 
showed distinct species differences (Table 3). 
The clotting time of mammalian fibrinogens by 
H. hypnale venom was in the increasing order as 
follows: bovine < rabbit < goat < human < horse 
< < dog. The clotting activity of C. rhodostoma 
venom exhibited a similar pattern (most and least 
active towards the bovine and dog, respectively) 
indicating that the thrombin-like activity of the 
venoms of these two phylogenetically related 
crotalids exhibited similar specificity towards 
fibrinogens. On the other hand, the specificity 
of the clotting activity of C. purpureomaculatus 
venom (bovine < goat < human < horse < < 
rabbit, dog) was rather different, and generally 
showed a lower clotting potency for bovine, goat 
and human fibrinogens (p < 0.05). 
The clotting activities of the three venoms 
were also monitored spectrophotometrically 
whereby the turbidity of the reaction mixture was 
continuously monitored for absorbance at 450 
nm. The investigation of the time course of clot 
assembly had also been described by Pirkle et al. 
(56). Generally, the appearance of fibrin or clots 
would result in turbidity, while degradation of the 
clots would reduce this property. Figure 2 (A to 
D) shows that both H. hypnale and C. rhodostoma 
venoms caused rapid clotting with fibrinogens 
from bovine, goat, horse and rabbit specimens. 
Dissolution of clots was rapid in the case of goat 
(Figure 2 – B) and horse fibrinogens (Figure 2 
– C) (turbidity reduced from 30 seconds). Both 
venoms were active in the clotting of human 
fibrinogen (Figure 2 – E), showing a slow but 
prolonged clotting effect. C. purpureomaculatus 
venom generally demonstrated moderate to 
low clotting activities, except for the case of dog 
fibrinogen (Figure 2– F) where it appeared more 
active than the venoms of H. hypnale and C. 
rhodostoma. 
We suggest that a rapid clotting profile implies 
the possibility that the venom may precipitate 
acute thrombotic syndrome that can be instantly 
Table 2. Enzymatic, hemorrhagic and necrotic   activities  of major  protein fractions  of H. hypnale 
venom obtained from Resource Q ion-exchange chromatography
Test
Fraction
AMT PRO PLA2 LAO AEH PME PDE 5’-Nuc HYA TLE HEM NEC
1 240 8.3 79.8 – – 0.5 9.8 0.18 – – 9 6
2 59 – – – – – – – – 470 – –
3 77 – 159.6 – – – – – – 212 – –
4 32 – – – – – – 0.15 – 115 – –
5 47 – – – 9.8 – – 0.30 – 84 – –
6 58 – – – 2.5 – – 0.66 – 77 – –
7 28 – – – – – – – – 146 – –
8 18 – – – – 1.7 – – – 610 – –
9 12 – – 13.8 – 0.9 – – 6.9 – – –
10 41 – – 11.3 – 0.1 – – 46.9 – – –
11 10 – – – – – – – 6.6 – – –
12 4 – – – – – – – – – – –
AMT: Total protein amount recovered in each respective fraction, µg; PRO: protease, unit/mL; PLA2: phosphopholipase 
A2, µmol/min/mL; LAO: L-amino acid oxidase, nmol/min/mL; AEH: arginine ester hydrolase, µmol/min/mL; PME: alkaline 
phosphomonoesterase, nmol/min/mL; PDE: phosphodiesterase, nmol/min/mL; 5’-Nuc: 5’-nucleotidase, µmol/min/
mL; HYA: hyaluronidase, NFU/mL; TLE: thrombin-like enzyme (procoagulant enzyme), s/100 µL; HEM: hemorrhagic 
activity, mm/50 µL; NEC: necrotic activity, mm/50 µL, –: absent activity. Values were the average results from two 
independent experiments.
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fatal, as observed in an experiment where a 
rabbit was injected with H. hypnale venom 
intravenously (unpublished data). In cases where 
clot formation is less rapid, or is accompanied by 
a concurrent degradation, the most likely cause of 
death would be a consumptive coagulopathy that 
gradually affects hemostasis, causing prolonged 
bleeding and a “slower” death. This is consistent 
with main clinical features reported in cases of 
envenomation by C. rhodostoma (57, 58) and H. 
hypnale (11, 12). Deranged hemostasis leading to 
systemic bleeding has been the main feature in 
systemic envenomation by these crotalids. This 
severe, potentially fatal complication might only 
manifest itself temporarily following the bite as 
the pre-existing coagulant factors get depleted or 
rendered inactive by the venom more rapidly than 
their production, hence tilting the hemostatic 
balance towards a tendency to bleed. A recent 
example was that of an extensive retroperitoneal 
hemorrhage only detected five weeks after a bite 
by H. hypnale in an adult patient (59).
Nephrotoxicity Study
Ariaratnam et al. (11) reported a series of 302 
hump-nosed pit viper bites in which 117 (39%) 
were systematically envenomed, all with hemostatic 
abnormalities, while 30 presented with acute renal 
failure. The kidney, as a highly vascularized excretory 
organ, is certainly vulnerable to acute injury by 
venom toxicity. The injury mechanisms can be 
either by direct effect of the toxins or secondary 
to hemostatic defect, intravascular hemolysis, 
shock, immune response or rhabdomyolysis. 
Hematoxic and myotoxic venoms from viperids or 
crotalids are a rich source of enzymes that include 
phospholipases, endopeptidases, L-amino acid 
oxidases and metalloproteases which can directly 
cause cellular damage and kidney injury (60, 61). In 
the present study, D. russellii venom from Myanmar 
was administered to the positive control group (DV 
group) to produce acute kidney injury as the venom 
was known to be highly nephrotoxic (62-65).
Rats from both HV and DV groups treated 
with a sublethal dose (1/3 LD50) of venoms of 
H. hypnale and D. russelii respectively, exhibited 
envenomation signs e.g. local hemorrhage, 
malaise, drowsiness and limping in the first 
few hours. All animals survived the 24-hour 
observation period. Gross inspection of urines 
showed marked hematuria among the DV group, 
with no inter-group difference in the urine 
volumes. Biochemical and microscopic urinalysis 
revealed significant proteinuria and hematuria in 
the DV group compared to the HV and NS groups 
(p < 0.05) (Table 4). The urea and creatinine 
levels, used as indicators for acute renal failure, 
were observably higher in the DV group although 
this elevation was insignificant in relation to the 
other two groups (Table 4), a finding probably 
attributable to the fact that the observation 
period was not sufficiently long. Nevertheless, 
the significant proteinuria and hematuria are 
sufficient indication that the injected D. russelii 
venom did cause acute nephrotoxicity in the 
animals. The absence of these features in rats 
Table 3. Procoagulant effects of venoms from three pit vipers on mammalian fibrinogens
Venom H. hypnale C. rhodostoma C. purpureomaculatus
Source of 
fibrinogen
Clotting time* (s) 
(mean ± SEM)
Clotting time (s) 
(mean ± SEM)
Clotting time (s) 
(mean ± SEM)
Rabbit 18.3 ± 0.9 30.7 ± 1.2 Turbidity > 120 s
Horse 42.2 ± 1.0 40.1 ± 0.6 Turbidity > 60 s
Dog Turbidity** > 180 s Turbidity > 180 s Turbidity > 80 s
Goat 30.3 ± 0.9 33.0 ± 0.6 71.0 ± 0.6
Bovine 14.3 ± 0.3 11.3 ± 0.9 56.7 ± 0.7
Human 32.7 ± 0.7 28.4 ± 0.8 75.0 ± 0.6
* Clotting time is defined as the time (s) for apparent fibrin strands to appear in the mixture of venom and fibrinogen.** Turbidity 
refers to cloudiness appearing in the mixture of venom and fibrinogen, which may be interpreted as the formation of fibrin clots. 
Results are expressed as the mean ± SEM from three experiments.
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injected with a similar sublethal dose of H. 
hypnale venom suggested that the given dose of 
the venom does not cause direct nephrotoxicity. 
This is further demonstrated by light microscopic 
examination of histological cuts from the kidney 
(data not shown) and other vital organs (heart, 
lung, liver, spleen and diaphragm) of rats injected 
with the sublethal dose of H. hypnale venom, where 
all tissues appeared histologically intact. Thus, a 
tentative explanation of nephropathy observed 
in some of the victims (11, 66) is that the kidney 
damage is likely the result of complications from 
Figure 2. Time course of thrombin-like enzyme activity of three different crotalid venoms on fibrinogens 
from several mammals (A: cow; B: goat; C: horse; D: rabbit; E: human; F: dog). The slope (gradient) for 
each curve is calculated from the steepest upward portion of the graph representing the maximal 
clotting rate expressed as absorbance/minute. Absorbance reflects the change in mixture clarity, which is 
responsible for the formation of fibrin strands as well as their dissolution/degradation. “Clot” used in this 
discussion represents the formation of fibrins.  The crotalid species are: ─ H. hypnale; --- C. rhodostoma; ∙∙∙∙ C. 
purpureomaculatus. 
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the venom’s hematoxic effects mediated through 
its procoagulant and possibly fibrinolytic actions. 
This suggestion is in line with the view that the 
nephropathy was associated with disseminated 
intravascular coagulopathy (61).
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a  b  s  t  r  a  c  t
Envenomation  by hump-nosed  pit  viper  (Hypnale  hypnale,  Hh)  in  Sri  Lanka  has  caused  signiﬁcant  mor-
bidity  and  mortality,  attributed  to 35%  of  total  venomous  snakebites.  In  Southwestern  India  (Kerala),  H.
hypnale  was  increasingly  identiﬁed  as  a dangerous  and  common  source  of  envenomation,  second  to  the
Russell’s  viper  but ahead  of the  cobra  bites.  Unfortunately,  there  is  still  no  speciﬁc  antivenom  to  date.
This study  aims  to  investigate  the  immunological  properties  of  the  venom  and  to  assess  the  feasibility  of
speciﬁc  Hh  antivenom  production  as  well  as the  development  of  a diagnostic  assay.  Hh  venom  elicited
satisfactory  titers  of  anti-Hh  IgG  in  rabbits  after  3rd  immunization.  The  anti-Hh  IgG, isolated  with  caprylic
acid precipitation  method,  was  effective  in  neutralizing  the  venom  lethality  (potency  = 48  LD50 per ml
IgG)  as  well  as  its  procoagulant,  hemorrhagic  and  necrotic  effects,  indicating  the possibility  to  produce  the
speciﬁc  antivenom  using  the common  immunization  regime.  Cross-reactivity  studies  using  indirect  ELISA
showed that  anti-Hh  IgG  cross-reacted  extensively  with  several  Asiatic  crotalid  venoms,  particularly  that
of Calloselasma  rhodostoma  (73.6%),  presumably  due  to the  presence  of  venom  antigens  common  to  both
snakes. Levels  of  immunological  cross-reactivity  were  vastly  reduced  with  double-sandwich  ELISA. Fur-
ther  work  demonstrated  that  the  assay  was  able  to distinguish  and  quantify  venoms  of  H. hypnale,  Daboia
russelii  and  Echis  carinatus  sinhaleyus  (three  common  local  viperid)  used  to spike human  sera  at  various
concentrations.  The  assay  hence  may  be  a useful  investigating  tool  for  diagnosing  biting  species  and
studying  the  time  course  proﬁle  of  venom  concentrations  in  blood.
© 2012 Elsevier B.V. All rights reserved.
1. Introduction
The Merrem’s hump-nosed pit viper, Hypnale hypnale is a med-
ically important venomous snake in Sri Lanka and southwestern
coast of India (de Silva et al., 1994; Warrell, 1995; Joseph et al.,
2007; Ariaratnam et al., 2008). The hump-nosed pit viper bite has
been recorded as the major cause of venomous snake bites in Sri
Lanka (35% of total venomous bites, Ariaratnam et al., 2008), and
being second to the Russell’s viper but ahead of the cobra bite
as a major cause of envenoming in central Kerala, India (Joseph
et al., 2007). Envenomed victims often develop debilitating local-
ized features, e.g. pain, edema, hemorrhagic blistering and necrosis;
while in worse scenarios, potentially fatal systemic envenom-
ing ensues with predominant features of hemostatic dysfunction
that includes intravascular coagulopathy and spontaneous sys-
temic bleeding. An infrequent but fatal complication, acute kidney
injury, had been reported as well (Joseph et al., 2007; Ariaratnam
∗ Corresponding author. Tel.: +60 3 79674951; fax: +60 3 79674791.
E-mail addresses: tanchoohock@gmail.com,  tanch@um.edu.my (C.H. Tan).
et al., 2008), and as described by Sitprija (2008),  such complica-
tion is likely secondary to consumptive coagulopathy, mediated
through the venom procoagulant and ﬁbrinolytic actions. Despite
its high prevalence and severe sequelae, there is still no speciﬁc
antivenom to date for the treatment of H. hypnale envenomation
(Ariaratnam et al., 2008). Nevertheless, Tan et al. (2011a) showed
that two commercial antivenoms (monovalent and polyvalent)
raised against Malayan pit viper (Calloselasma rhodostoma) venom
effectively neutralized the venom lethality as well as its procoagu-
lant, hemorrhagic and necrotic toxicities in mice. Such paraspeciﬁc
venom neutralization was possible due to the presence of similar
antigenic properties between the venoms of H. hypnale and C. rho-
dostoma, between which close phylogenetic relationships had been
established (Parkinson et al., 1997; Vidal and Lecointre, 1998).
Snake envenomation, known for its neglected status, faces
various global pertinent challenges including that for antivenom
production and supply (Gutiérrez et al., 2006; WHO, 2009). In snake
envenomation, serotherapy, i.e. administration of antivenom is the
only deﬁnite therapeutic treatment (Chippaux and Goyffon, 1998).
In our previous study, the Malayan pit viper antivenom has been
suggested for therapeutic use in endemic areas where antidotes
0001-706X/$ – see front matter ©  2012 Elsevier B.V. All rights reserved.
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are urgently needed to abate the envenoming crisis in view of its
capability of cross-neutralizing H. hypnale venom. However, the
antivenom has yet to be assessed for its clinical efﬁcacy in human
patients. We  also presume that in paraspeciﬁc protection, though
effective, not all toxins of the H. hypnale venom will be neutralized
at optimum by a heterologous antivenom. Conceptually, produc-
tion of speciﬁc antivenom using the homologous H. hypnale venom
is therefore essential and warranted; and long-term efforts should
be undertaken for this industry. To apply such therapeutic princi-
ple, two pertinent issues need to be addressed: (a) the antigenicity
of the venom and the potency of antibodies produced and (b) the
identiﬁcation of biting species. H. hypnale has been misidentiﬁed
especially as Echis carinatus (saw-scaled viper), or occasionally as
Daboia russelii (Russell’s viper)—two common biting snakes in those
areas, hence complicating the clinical management (Joseph et al.,
2007; Ariaratnam et al., 2009). Development of a diagnostic tool for
accurate identiﬁcation of biting species and in particular one that is
able to distinguish H. hypnale bite from E. carninatus and D. russelli
bites is therefore essential for meaningful clinical management.
In this work, the immune response elicited by H. hypnale venom
was investigated in rabbits, and the monospeciﬁc antisera as well
as the immunoglobulins (IgG) elicited by the venom antigens were
assessed for venom-neutralizing potencies. The antibody cross-
reactivities with several other venoms, as well as cross-reactivities
of Malayan pit viper antivenoms with H. hypnale venom were also
investigated on ELISA. The feasibility of ELISA developed as a tool
for biting species identiﬁcation and venom quantitation was  also
examined using human sera spiked with the venom.
2. Materials and methods
2.1. Venoms and antivenoms
H. hypnale venom was  a pooled sample obtained from the
milking of >10 adult snakes captured in Sri Lanka (Gamapha,
Kelaniya, Avissawela, Colombo regions). The snakes were kept at
the serpentarium at the University of Colombo, Sri Lanka and
were identiﬁed by Anslem de Silva, an expert herpetologist. D.
russelii and Echis carinatus sinhaleyus venoms were obtained from
the same source and the snakes were captured in Sri Lanka
(Anuradhapura, Ratnapura, Galle, Colombo regions for D. rus-
selii; and Mannar for E. carinatus sinhaleyus). All other venoms
were purchased from Latoxan (France), with exceptions of Agk-
istrodon piscivorus leukostoma, Crotalus atrox from Sigma (USA);
Crotalus viridis from Miami  Serpentarium (USA); Popeia popeiorum,
Viridovipera stejnegeri, Bothrops asper from Ventoxin (USA); Den-
droaspis angusticeps, Pseudonaja textilis,  Oxyuranus microlepidotus
from Venom Supplies (South Australia); Enhydrina schistosa from
Penang Snake Venom Institute (Malaysia). Monovalent Malayan pit
viper antivenom (MPVA) (Batch no. CR00909, exp. date 2/11/2014)
and Hemato polyvalent antivenom (HPA) (Batch no. HP00108, exp.
date 6/11/2013) were supplied by Queen Saobhva Memorial Insti-
tute, Thai Red Cross Society (TRCS).
2.2. Animals and reagents
New Zealand white rabbits and albino mice (ICR strains) were
supplied by the Laboratory Animal Centre, Faculty of Medicine,
University of Malaya. The animals were handled according to the
guidelines given by CIOMS on animal experimentation (Howard-
Jones, 1995). Human sera were a pooled sample from six healthy
volunteer donors, where consent had been obtained. Ninety-six-
well ﬂat bottom microtiter plates (Nunc, Denmark), goat anti-rabbit
IgG-horseradish peroxidase (HRP) conjugate (Bio-Rad Laborato-
ries, USA), PBS–Tween 20 (Sigma, USA), ortho-phenylenediamine
(OPD) (Sigma, USA), caprylic acid (Sigma, USA), HiTrapTM Pro-
tein A-Sepharose 5-ml column (GE Healthcare, Sweden), and
VivaspinTM centrifugal concentrators (Sartorius Stedim Biotech,
Germany) were purchased from the respective manufacturers. All
other chemicals and reagents utilized were of analytical grade
(Sigma, USA).
2.3. Immunization
Rabbits (n = 3) of 2 kg each were initially immunized intramus-
cularly over the back with H. hypnale venom (50 g in 0.5 ml  PBS,
pH 7.4) emulsiﬁed in 0.5 ml  complete Freund’s adjuvant, followed
by three other intramuscular doses of 100 g in 0.5 ml  PBS emulsi-
ﬁed in 0.5 ml  incomplete Freund’s adjuvant at fortnightly intervals.
The antibody titer levels were monitored by indirect ELISA, every
two weeks following each injection.
Using the same immunization protocols, D. russelii and E. cari-
natus sinhaleyus venoms were used to raise antibodies from rabbits
(n = 2 and n = 1, respectively) for double-sandwich ELISA.
2.4. Puriﬁcation of immunoglobulins G (IgG)
Antisera showing highest antibody titer (as monitored by ELISA)
were collected from rabbits by cardiac puncture under anesthesia.
The puriﬁcation of anti-H. hypnale IgG was  then carried out using
two approaches: (A) by afﬁnity chromatography using Protein A
column and (B) by protein precipitation using caprylic acid. In (A),
the sera were desalted by Sephadex G-25 gel ﬁltration column to
yield the serum protein fractions which were subsequently pooled
and freeze-dried. The IgG puriﬁcation was carried out as described
by Hudson and Hay (1980) with slight modiﬁcations. One hun-
dred milligrams freeze-dried serum proteins was dissolved in 1 ml
20 mM sodium phosphate (pH 8.0), and applied to the HiTrapTM
Protein A-Sepharose gel afﬁnity column connected to Micro Tube
Pump MP-3 (Tokyo Rikakidai Co.). Washing of unbound compo-
nents began with 20 mM sodium phosphate, followed by elution
with 0.1 M citric acid (pH 3.0 in 1 M Tris–HCl pH 9.0), at ﬂow rate
of 5 ml/min. The eluted IgG were then pooled, desalted and the
lyophilized powder was stored at −20 ◦C. The purity of isolated IgG
was validated on SDS-polyacrylamide gel electrophoresis accord-
ing to Laemmli (1970) (data not shown). The isolated IgG were kept
at −20 ◦C for use in double-sandwich ELISA and for horseradish per-
oxidase conjugation. In (B), the procedure was carried out according
to Rojas et al. (1994).  In brief, caprylic acid was mixed with 10 ml
anti-Hh sera to a ﬁnal concentration of 5% at pH 6. Following
vigorous stirring for 1 h at room temperature, the mixture was  cen-
trifuged at 10,000 × g × 10 min, and the supernatant was  collected,
diaﬁltered, then lyophilized. The product was kept at −20 ◦C for
later use in venom neutralization studies.
Isolation of anti-D. russelii and anti-E. carinatus sinhaleyus
IgG was performed using the Protein A afﬁnity chromatography
method, as described above.
2.5. Conjugation of IgG with horseradish peroxidase
The assay was performed according to Tijssen (1985).  Four mil-
ligrams horseradish peroxidase (HRP) was  dissolved in 1.0 ml  of
distilled water and 0.2 ml  of freshly prepared 0.1 M sodium peri-
odate was  added and stirred. The resulting HRP-aldehyde was
dialyzed against 1 mM sodium acetate buffer (pH 4.4) at 4 ◦C for
several changes of buffer to reduce auto-conjugation. The pH was
then raised to approximately 9.0–9.5 by adding 20 l of 0.2 M
sodium carbonate buffer (pH 9.5). Eight milligrams of IgG, dissolved
in 1 ml  of 0.01 M sodium carbonate buffer (pH 9.5), was added
immediately. The mixture was stirred for 2 h at room tempera-
ture, followed by adding 100 l freshly made sodium borohydride
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solution (4 mg/ml  in distilled water) to reduce the Schiff’s base.
After 2 h incubation at 4 ◦C, the IgG–HRP conjugate was ﬁltered for
buffer exchange with PBS (pH 7.2) at 4 ◦C, aliquoted and stored at
−20 ◦C.
2.6. Indirect ELISA for determination of antibodies
Microtiter wells were each coated with 100 l venom of H. hyp-
nale, D. russelii or E. carinatus sinhaleyus,  respectively (100 ng/ml
in carbonate–bicarbonate buffer, pH 9.6) overnight at 4 ◦C. After
washing with 100 l PBS–Tween 20 for four times, each well was
incubated with 100 l serum samples diluted 1:400 in PBS–Tween
20, pH 7.4, for 1 h at room temperature. Following another cycle
of washing, goat anti-rabbit IgG–HRP in PBS–Tween 20 (1:3000
dilution made up to 100 l) was added and left for 1 h at room
temperature. The HRP activity was commenced after washing by
incubation with substrate o-phenylenediamine (OPD, 0.4 mg/ml
and 0.006% H2O2 in 0.1 M citrate-phosphate, pH 5) for 30 min  at
room temperature in dark. The reaction was terminated by the
addition of 50 l of 12.5% H2SO4 and absorbance was  read at
492 nm with a microplate reader (SUNRISE-TECAN Type Touch
Screen F039300). All experiments were performed in triplicates.
2.7. Double-sandwich ELISA for detection of venom antigen
Microtiter wells were each coated with 100 l afﬁnity-
puriﬁed rabbit anti-venom IgG (4 g/ml for anti-H. hypnale;
5 g/ml for anti-D. russelii and anti-E. carinatus sinhaleyus,  respec-
tively, as determined by chequerboard titration) dissolved in
carbonate–bicarbonate buffer, pH 9.6, by incubating overnight at
4 ◦C. After washing with 100 l PBS–Tween 20 for four times, each
well was incubated for 2 h at room temperature with 100 l venom
solution (100 ng/ml) dissolved in PBS–Tween 20, or in human sera
diluted with PBS–Tween 20 (1:10 dilution made up to 100 l).
Following another cycle of washing, rabbit anti-venom IgG–HRP
conjugate, freshly diluted to 100 l (1:200 for anti-H. hypnale;
1:600 for anti-E. carinatus sinhaleyus;  1:800 for anti-D. russelii,
determined by chequerboard titration) was dispensed into each
well and left for another 2 h at room temperature. The HRP activ-
ity was initiated after washing by incubation with 100 l substrate
OPD (0.4 mg/ml  and 0.006% H2O2 in 0.1 M citrate-phosphate, pH 5)
for 30 min  at room temperature in dark. The reaction was termi-
nated by the addition of 50 l of 12.5% H2SO4 and the absorbance
was read at 492 nm with a microplate reader (SUNRISE-TECAN Type
Touch Screen F039300). All experiments were performed in tripli-
cates.
2.8. Cross-reactivity of anti-H. hypnale (anti-Hh) sera and
anti-Hh IgG with various venoms
Venoms of various species (100 l of 100 ng/ml solution) were
coated on microtiter walls by overnight incubation. Antisera
(1:400) from the ﬁnal (4th) immunization and puriﬁed IgG (1:500),
diluted in PBS–Tween 20 (for both, made up to 100 l), were
each incubated with the precoated venoms then for 1 h and the
cross-reactivities were determined using indirect ELISA. For dou-
ble sandwich ELISA, anti-Hh IgG (100 l of 4 g/ml solution) was
coated on microtiter wells by overnight incubation. 100 l venoms
of various species (100 ng/ml solutions) were used as samples to
incubate with the precoated IgG for 2 h, and the cross-reactivities
were then determined. ELISA cross-reactivities were expressed in
mean percentage ± SEM of the absorbance with reference to reac-
tion between anti-Hh sera or IgG with H. hypnale venom.
2.9. ELISA cross-reactivity of H. hypnale venom with C.
rhodostoma monovalent and polyvalent antivenoms
For indirect ELISA, 100 l H. hypnale venom (100 ng/ml) was
used to coat the microtiter wells, of which after washing were incu-
bated with 100 l antivenoms (MPVA or HPA, with 1:5000 dilution
in PBS–Tween 20 made up to 100 l). Goat anti-equine IgG–HRP
conjugate (1:8000 dilution in PBS–Tween 20 made up to 100 l)
was used as secondary antibody to which the HRP activity on OPD
was then measured. A hundred microliter C. rhodostoma venom
(100 ng/ml) coated on each microtiter well was  used as the positive
control, where homologous venom neutralization has been estab-
lished in murine model (Tan et al., 2011a); while 100 l Naja naja
venom (100 ng/ml) coated on each microtiter well served as the
negative control, where no in vitro cross-neutralization has been
observed (data not shown).
The study was  repeated with double-sandwich ELISA, where
both coating and primary antibodies were replaced by antiven-
oms  (MPVA or HPA) in 100 l coating buffer or PBS–Tween 20
(1:5000 dilution made up to 100 l) accordingly. Goat anti-equine
IgG–HRP conjugates (1:8000 dilution in PBS–Tween 20 made up
to 100 l) served as secondary antibodies to which HRP activity
on OPD was  measured then. The samples consisted of 100 l ven-
oms  (100 ng/ml) of H. hypnale, C. rhodostoma (positive control) and
N. naja (negative control). The cross-reactivities were expressed in
mean percentage ± SEM of the absorbance with reference to the
controls.
2.10. Detection and quantitation of venom in human sera
H. hypnale, E. carinatus sinhaleyus and D. russelii venoms were
respectively dissolved in a 1:10 mixture of human serum and
PBS–Tween 20, subsequently diluted with the mixture to a series
of known concentrations (0–100 ng/ml). These then served as the
samples for the double-sandwich ELISA described in Section 2.7,
under each optimal working condition as predetermined. The
absorbance values were then plotted against the venom concen-
trations. Limit of detection (LoD) and limit of quantitation (LoQ)
for venom detected in human sera were calculated with the LoD
deﬁned as three times (3×)  the standard deviation of the blank,
and the LoQ deﬁned as ten times (10×) the standard deviation of
the blank, with the blank being serum without venom antigens.
2.11. Determination of lethality, hemorrhagic, procoagulant and
necrotic activities
The values of intravenous median lethal dose (LD50) of Hh
venom in mice, minimum hemorrhagic dose (MHD, the dose that
caused a hemorrhagic lesion diameter of 10 mm),  minimum coag-
ulant dose (MCD, the minimal dose that clots a standard solution of
bovine ﬁbrinogen in 60 s), and the minimum necrotic dose (MND,
the minimal dose that induces a necrotic lesion with a diameter of
5 mm)  were based on previous determinations from the same lab-
oratory reported by Tan et al. (2011a). These values were used for
the in vitro neutralization studies (Section 2.12).
2.12. In vitro neutralization of the venom lethality, hemorrhagic,
procoagulant and necrotic activities by anti-Hh sera and IgG
These were carried out as modiﬁed from Ramos-Cerrillo et al.
(2008) and Tan et al. (2011a). Challenge doses for lethality, pro-
coagulant, hemorrhagic and necrotic effects were respectively 2.5
LD50 (for antisera), 5 LD50 (for IgG), 2 MCD, 2 MHD  and 2.5 MND.
In brief, the venom was mixed thoroughly with various dilutions
of antisera or IgG solution (made up to 50 l for intradermal injec-
tions; and 200 l for intravenous injections). The IgG dilution was
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Fig. 1. Immune response elicited in three rabbits monitored by indirect ELISA fol-
lowing a fortnightly immunization schedule. Arrows show the days of immunization
with contents of injection: Hhv: H. hypnale venom; CFA: complete Freund’s adju-
vant; IFA: incomplete Freund’s adjuvant. Values were mean absorbance ± SEM.
made according to MPVA/HPA instruction manual where 1 vial of
∼1 g antivenom is to be reconstituted in 10 ml  solution. The mix-
tures of venom and antisera or IgG were then incubated at 37 ◦C
for 30 min  with gentle shaking, following which tests for the corre-
sponding toxic activities were carried out. The effective doses (ED
or ED50) were calculated as described by Tan et al. (2011a). In addi-
tion, potency of the antivenom, P, deﬁned as the amount of venom
(expressed in number of median lethal doses) that is completely
neutralized per unit volume of antivenom, was calculated accord-
ing to the European Directorate for the Quality of Medicines (1997)
and Araujo et al. (2008).
2.13. Statistical analysis
The results for procoagulant, hemorrhagic and necrotic activi-
ties as well as cross-reactivities are presented as mean ± SEM, while
the variability of lethality assays is expressed as 95% conﬁdence
intervals (C.I.). The signiﬁcance of the differences of the means was
determined by Student’s t-test or ANOVA test. The ED50 (median
effective dose) and the 95% conﬁdence intervals (C.I.) were calcu-
lated using the probit analysis method of Finney (1952).  Statistical
analyses were carried out using the Biostat Analysis software.
3. Results and discussion
3.1. Immunization and antisera production
The antigenicity of H. hypnale venom was expressed with a
steady rise of titer level following the primary immunization
(Fig. 1), indicating that the venom was sufﬁciently antigenic to gen-
erate a good immune response in the animals. Viperid venoms are
known to be qualitatively and quantitatively different from many
elapid venoms, with the predominant presence of high molecular
weight components especially hydrolytic enzymes, e.g. serine pro-
teases and metalloproteases (Mackessy, 2010; Serrano et al., 2005).
H. hypnale venom has been shown to exhibit various enzymatic
activities, notably the thrombin-like enzyme, proteolytic enzyme,
hyaluronidase, l-amino acid oxidase and phospholipase A2 (Tan
et al., 2011b). These toxic protein components are medium to
large molecules (molecular weights of 14–28 kDa and above) which
generally elicit greater antibody production, as immunogenicity is
known to increase with the size of the antigen (Harlow and Lane,
1988). The use of adjuvant in the immunization scheme also served
to augment the antigen complexity, hence enhancing the immune
response and antibody production (Herbert, 1978). In Fig. 1, the
antibody titer level rose steadily toward the third immunization,
following which it plateaued on subsequent booster. The ﬁnal level
upon completion of the immunization was  noted to be slightly
lower than the previous one but the difference was  statistically
insigniﬁcant (p > 0.05). Plateauing of the antibody titer level implied
that the immune response was mature and the antibodies produced
were essentially immunoglobulins G from the secondary response.
The results suggested that in the production of antivenom against H.
hypnale venom, a short duration (3 immunizations in total) may be
adequate using the protocol, hence reducing the amount of venom
required for antivenom production. This is an important consider-
ation as the supply of H. hypnale venom is always limited due to the
tiny body size of the snake (Joseph et al., 2007; Tan et al., 2011b).
The antisera production for D. russelii and E. carinatus sinhaleyus
venoms generally followed the similar pattern for H. hypnale
venom, where the antibody titers rose toward the third immuniza-
tion, following which a plateau was observed (data not shown).
3.2. Neutralization of the lethal and toxin effects of H. hypnale
venom with anti-Hh sera and IgG
The antisera produced by immunization with H. hypnale venom
in rabbits are effective in neutralizing the lethality of the venom
with an ED50 of 97.6 l (95% C.I. = 46.6–187.2 l) when tested
against 2.5 LD50 in mice. Preliminary tests with 5 LD50, unfortu-
nately, killed most mice despite the animals receiving maximal
dose of 200 l antisera, a phenomenon likely explained by the fact
that venom–antivenom dose–response does not necessarily follow
linearity at higher doses, which was  also observed by Bogarin et al.
(2000). The IgG isolated using caprylic acid precipitation, a common
and effective way  of yielding IgG in large-scale antivenom man-
ufacturing (Rojas et al., 1994; Raweerith and Ratanabanangkoon,
2003; Khomvilai, 2008), were nonetheless effective in neutralizing
the lethal effect of 5 LD50 with an ED50 of 83.1 l (40.9–176.8 l).
Caprylic acid precipitation method was used in this study as to
mimic  the production of MPVA and HPA by the Thai Red Cross
Society from hyperimmune equine sera. In order to standard-
ize the comparison of neutralization efﬁcacy on lethality and to
avoid ambiguity using ED50 alone, the parameter ‘potency’, P, was
adopted as it is independent of the number of LD50 used in chal-
lenge (Morais et al., 2010). Table 1 shows that the potency of the
anti-Hh IgG (48 LD50 per ml)  was apparently higher than that of
anti-Hh sera (by 3-fold), and only slightly lower than the MPVA
potency (57 LD50 per ml), but much less than that of HPA (96 LD50
per ml).
Table 1
Neutralization of the lethal effect of Hypnale hypnale venom by the monovalent
Malayan pit viper antivenom, Hemato polyvalent antivenom, anti-Hypnale hypnale
sera and anti-Hypnale hypnale IgG.
Antivenom ED50 (l antivenom/challenge
dose)
Potency, P (LD50
per ml)
Monovalent
Malayan pit viper
antivenom (MPVA)
70.71 la (33.7–148.4) 57
Hemato polyvalent
antivenom (HPA)
41.53 la(20.4–88.4) 96
Anti-Hypnale
hypnale sera
97.59 lb (46.6–187.2) 15
Anti-Hypnale
hypnale IgG
83.10 la (40.9–176.8) 48
a Venom challenge dose = 5 LD50.
b Venom challenge dose = 2.5 LD50.
The i.v. LD50 of H. hypnale venom (0.9 g/g), ED50 of MPVA and HPA were based on
Tan et al. (2011a).
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Table 2
Neutralization of the procoagulant, hemorrhagic and necrotic activities of Hypnale hypnale venom by the monovalent Malayan pit viper antivenom, Hemato polyvalent
antivenom, anti-Hypnale hypnale sera and anti-Hypnale hypnale IgG.
Toxic activity Minimum dose ED or ED50
(MPVA) (l/mg)
ED or ED50
(HPA) (l/mg)
ED or ED50
(anti-Hh sera)
(l/mg)
ED or ED50
(anti-Hh IgG)
(l/mg)
Procoagulant 56.2 ± 1.3 g/ml 432.1 ± 10.9 114.2 ± 2.7 644.1 ± 8.1 556.36 ± 12
Hemorrhagic 10.5 ± 0.2 g 472.3 ± 13.9 67.4 ± 5.1 781.00 ± 11.4 618.50 ± 12
Necrotic  39.3 ± 1.6 g 612.6 ± 17.5 53.8 ± 0.5 646.0 ± 20.5 615.59 ± 11
The minimal doses of procoagulant, hemorrhagic and necrotic activities, as well as the effective doses of MPVA and HPA were based on Tan et al. (2011a). Values were
expressed as mean ± SEM. MPVA: Malayan pit viper antivenom; HPA: Hemato polyvalent antivenom; anti-Hh: anti-Hypnale hypnale.
The anti-Hh sera and IgG were also effective against the proco-
agulant, hemorrhagic and necrotic activities of the venom (Table 2),
with the anti-Hh IgG being signiﬁcantly more potent than the
antisera (p < 0.05). However, the effective doses of anti-Hh IgG
were signiﬁcantly higher (less potency) compared to those of HPA
(p < 0.05), a ﬁnding in line with the result from lethality neutraliza-
tion test. The IgG was also less potent than MPVA in neutralizing the
procoagulant and hemorrhagic effects, but not the necrotic effect,
where both were equally effective. In this study, nephrotoxicity
(a severe complication of H. hypnlae envenoming although occurs
infrequently) was not assessed due to the inconsistent occurrence
of acute kidney injury (unpublished observation in a rodent model),
while limited venom supply was insufﬁcient to carry out further
exploration. A sublethal dose (1/3 intramuscular LD50) of the venom
did not induce direct kidney damage from our experience (Tan et al.,
2011b), and such renal pathology may  only be manifested in the
context of severe consumptive coagulopathy in H. hypnale enveno-
mation (Sitprija, 2008). As nephrotoxicity is the complication that
causes most death, the ability of the antibody to confer protection
against lethality could be tentatively explained by its neutraliz-
ing action on coagulopathy, hence preempting the development
of acute kidney injury.
Generally, in neutralization of all prominent toxic activities
including lethal effect, the anti-Hh IgG was effective but appeared
less potent when compared to the Hemato polyvalent antivenom
(HPA), suggesting that HPA at a given volume contained higher
fractions of IgG domains which could recognize and bind to the
H. hypnale venom toxin antigens. This is either due to the addi-
tional treatment during HPA manufacturing, i.e. pepsin digestion
of the antibodies from hyperimmunized horses yielding concen-
trated (90%) F(ab′)2 fragments (Khomvilai, 2008), or the antigenic
properties of components from D. siamensis and C. albolabris ven-
oms  used together with C. rhodostoma venom as immunogens in
the production of HPA. This is supported by the observation that
anti-H. hypnale IgG cross-reacted substantially with C. albolabris
venom in both indirect and double-sandwich ELISA (see below
and Table 3). The efﬁcacy of anti-Hh IgG in neutralizing the pro-
coagulant and hemorrhagic activities was also slightly lower than
that of MPVA, which also had undergone pepsin digestion of its
antibody. At this stage we were unable to test the various param-
eters to optimize caprylic acid precipitation and pepsin digestion
as the amount of antisera/IgG collected were limited due to the
use of small animals (rabbits) for antibody production. However,
the results implied that the anti-Hh sera neutralizing capacity for
venom toxicity could be improved by caprylic acid precipitation to
yield the IgG. Pepsin digestion, initially used to remove allergenic
Fc of heterologous antibody (Pope, 1939), should also be considered
in future anti-Hh antivenom production for enhancing the thera-
peutic potency. The potential application of anti-Hh IgG can also
be further explored in future for the venoms of Hypnale zara and
Hypnale nepa (or H. walli, a junior synonym): two other species of
Hypnale genus recognized currently (Maduwage et al., 2009). The
venoms of all three species were shown to exhibit similar reversed-
phase chromatographic pattern and toxic properties (Maduwage
et al., 2011). The envenoming by these two  species is however far
more infrequent than that by H. hypnale, which is responsible for
most of the reported severe clinical problems (C.A. Gnanathasan,
personal communication, 26 June 2011).
While the Malayan pit viper polyvalent antivenom (HPA) has
been proposed for use in H. hypnale envenoming due to its medi-
cal urgency (C.A. Gnanathasan, personal communication, 26 June
2011), the production and reﬁnement of an H. hypnale-speciﬁc
antivenom is nonetheless the therapeutic of choice in the long term.
In view of the suboptimal socioeconomic and healthcare system in
the developing country, instead of producing a new monovalent
antivenom, we suggest that H. hypnale venom be incorporated into
the immunizing regimen for existing polyvalent antivenoms used
in the country. This however requires further efforts in ﬁne-tuning
the optimization for antivenom efﬁcacy, especially on a large-scale
production; hence it represents a research area beyond academic
exercise that awaits global partnership with supports to overcome
the various challenges ahead (Gutiérrez et al., 2006).
3.3. ELISA cross-reactivities of anti-Hh sera and IgG with various
venoms
Cross-reactivities of the anti-Hh antisera with various venoms
on indirect ELISA were extensive: most prominent with Asiatic
Crotalinae venoms, moderate with Viperinae venoms, and least
with Elapidae and Hydrophiidae venoms (Table 3). ELISA non-
speciﬁc binding by antisera was effectively reduced by replacing
the binding antisera with afﬁnity-puriﬁed anti-Hh IgG. Afﬁn-
ity chromatography is known to give a highly puriﬁed product
(Kukongviriyapan et al., 1982; Carroll et al., 1992), hence minimiz-
ing false positive ELISA signals attributable to various components
in the crude sera. The highest cross-reactivity of the IgG was
observed with C. rhodostoma venom (73.6%), followed by the ven-
oms  of several Old World crotalids, with exceptionally low value for
Tropidolaemus wagleri venom—this was not surprising as the venom
is known to be quite atypical among the crotalids’ whereby it does
not exhibit hemorrhagic activity, is feebly procoagulant, contains
unique phospholipases A2, and is rich in low molecular weight pro-
teins (Tan and Tan, 1989; Wang et al., 1999). Based on the extent of
the cross-reactivities, H. hypnale venom and C. rhodostoma venom
appear to be the most similar antigenically, and this is likely due
to their very close phylogenetic relatedness despite distant geo-
graphical distribution (Parkinson et al., 1997). Observations where
immunological properties of venom proteins supported snake tax-
onomy and systematics derived from mitochondrial DNA analysis
had been reported in the case of Trimeresurus Complex (Tan,
2010). In this study, the cross-reactivities generally reduced with
the increased distance of the snakes phylogenetic relationships,
and were practically nil for venoms of Elapidae snakes. Gener-
ally, the cross-reactivities between the anti-Hh IgG with Crotalinae
venoms appeared much stronger than that with the Viperinae
and Elapidae venoms, suggesting that there are antigenically
similar toxin structures conserved among the Crotalinae snakes
venoms.
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Table 3
ELISA cross-reactivities of the anti-Hypnale hypnale sera and anti-Hypnale hypnale IgG with various venoms, using indirect or double-sandwich ELISA.
Venom Test
Indirect ELISA with antisera Indirect ELISA with IgG Double-sandwich ELISA with IgG
Cross reactivity (%) ±SEM (%) Cross reactivity (%) ±SEM (%) Cross reactivity (%) ±SEM (%)
Basal crotalids
Hypnale hypnale 100.0 0.0 100.0 0.0 100.0 0.0
Calloselasma rhodostoma 90.0 1.0 73.6 0.1 11.8 1.1
Old  World, Asiatic crotalids
Protobothrops ﬂavoviridis 91.4 1.7 42.1 1.4 10.4 0.8
Protobothrops tokarensis 87.1 0.2 50.9 4.3 6.5 1.0
Viridovipera stejnegeri 82.6 0.9 61.4 0.1 9.9 2.0
Popeia  popeiorum 82.6 0.4 27.5 1.6 6.4 1.7
Cryptelytrops. purpureomaculatus 58.0 1.4 35.0 0.5 7.6 3.8
Cryptelytrops albolabris 76.5 0.6 40.2 1.2 2.1 2.1
Tropidolaemus wagleri 71.0 3.8 0.5 0.5 0.4 0.1
New  World, invasion from Asia, Beringian dispersal crotalids
Agkistrodon piscivorus leukostoma 90.1 0.3 13.0 0.8 5.4 1.3
Crotalus viridis 83.9 2.0 38.4 0.8 7.4 1.5
Crotalus atrox 60.7 1.5 24.2 0.8 6.6 2.9
Bothrops asper 79.8 1.4 14.8 2.3 3.1 1.2
Viperinae (Africa to Asia dispersal vipers)
Echis carinatus sinhaleyus 63.8 2.3 1.2 0.3 1.1 0.2
Viperinae (Eurasian dispersal)
Daboia russelli (Sri Lanka) 80.4 2.7 2.5 0.4 2.0 0.4
Daboia siamensis 52.8 2.9 2.4 0.2 0.5 0.1
Elapids
Elapidae (Asian dispersal)
Bungarus ﬂaviceps 21.4 0.2 0.0 0.0 0.0 0.0
Bungarus candidus 47.1 0.5 0.0 0.0 0.0 0.0
Ophiophagus hannah 13.4 2.4 0.0 0.0 0.0 0.0
Naja  naja (Sri Lanka) 13.3 2.4 0.0 0.0 0.0 0.0
Naja  sputarix (Java) 14.9 1.1 0.0 0.0 0.0 0.0
Elapidae (African dispersal)
Naja nigricollis (African dispersal) 17.3 0.5 0.0 0.0 0.0 0.0
Dendroaspis angusticeps 8.5 0.7 0.0 0.0 0.0 0.0
Elapidae (Papuo-Australian)
Pseudonaja textilis 7.9 0.7 0.0 0.0 0.0 0.0
Elapidae, Subfamily Hydrophiinae (Papuo-Australasian dispersal)
Oxyuranus microlepidotus 7.7 0.9 0.0 0.0 0.0 0.0
Family Hydrophiidae
Enhydrina schistosa 16.6 0.3 0.0 0.0 0.0 0.0
Values were expressed as mean absorbance ± SEM. Grouping of majority of the species were done according to Wüster et al. (2008).
Double-sandwich ELISA has been known for its high speciﬁcity
(Tan et al., 1993) in detection of venom antigens. It requires an
antigen to be stably bound twice by a speciﬁc type of IgG: ﬁrst
by coating IgG, followed by HRP-labeled IgG, hence it is more
stringent than direct and indirect ELISA. In this work, we demon-
strated that high level of cross-reactivities of indirect ELISA was
reduced markedly (>60%) using the double-sandwich ELISA, hence
improving the assay speciﬁcity for H. hypnale venom (Table 3).
In the case of anti-Hh IgG cross-reacting with the C. rhodostoma
venom, the different magnitudes of cross-reactivities between indi-
rect ELISA (73.6%) and double-sandwich ELISA (11.8%) suggest that
the IgG, although having afﬁnity for C. rhodostoma venom anti-
gens, might have an overall lesser avidity toward them. The IgG
cross-reactivities on double-sandwich ELISA were also low with
the venoms of E. carinatus sinhaleyus and D. russelii (two medically
important vipers in Sri Lanka), hence prompting us to further inves-
tigate the potential application of double-sandwich ELISA for biting
species diagnosis in H. hypnale envenomation (see below). Proper
identiﬁcation of biting snake species in Sri Lanka and Southwest-
ern India is essential as it would ensure the appropriate therapy
is instituted and avoid the use of unnecessary serotherapy that
risks hypersensitivity adverse effects, especially since the biting
species had been frequently misidentiﬁed in this region (Joseph
et al., 2007).
3.4. ELISA cross-reactivities of Malayan pit viper (C. rhodostoma)
monovalent antivenom (MPVA) and Hemato polyvalent
antivenom (HPA) with H. hypnale venom
Previous studies had shown that MPVA and, to a greater extent,
the HPA, conferred paraspeciﬁc neutralization of H. hypnale venom
(Tan et al., 2011a). Indirect ELISA showed that both antivenoms
cross-reacted strongly with H. hypnale venom (>90%) and partially
with N. naja venom (<50%). Using double-sandwich ELISA that
has a higher degree of speciﬁcity, the cross-reactivities of MPVA
and HPA with H. hypnale venom was shown as 90.2% and 91.5%,
respectively, while that of N. naja venom was  nil (Table 4). The
ﬁndings supported the paraspeciﬁc neutralization reported ear-
lier. The results, however, differed from the low cross-reactivity
(11.8%) between anti-Hh IgG and C. rhodostoma venom examined
on double-sandwich ELISA under the same condition. This is prob-
ably due to both higher afﬁnity and avidity of anti-C. rhodostoma
antibodies toward the H. hypnale venom, as compared to that of
anti-Hh IgG toward the C. rhodostoma venom. We  hypothesize that
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Table 4
ELISA cross-reactivities between monovalent MPV  antivenom and Hemato polyvalent antivenom with venoms of Calloselasma rhodostoma, Hypnale hypnale and Naja naja,
using  indirect and double-sandwich ELISA.
Venoms Indirect ELISA Double-sandwich ELISA
Cross reactivity
(%) (MPVA)
±SEM (%) Cross reactivity
(%) (HPA)
±SEM (%) Cross reactivity
(%) (MPVA)
±SEM (%) Cross reactivity
(%) (HPA)
±SEM (%)
Calloselasma rhodostoma 100.0 0.0 100.0 0.0 100.0 0.0 100.0 0.0
Hypnale hypnale 91.7 1.2 93.6 1.9 90.2 1.7 91.5 1.1
Naja  naja 40.3 0.7 45.9 0.4 0.0 0.0 0.0 0.0
MPVA: Malayan pit viper antivenom; HPA: Hemato polyvalent antivenom. Both antivenoms were previously noted effective in cross-neutralization of Hypnale hypnale venom,
but  totally ineffective against Naja naja venom. C. rhodostoma is the homologous species from which the antivenoms were produced; H. hypnale is phylogenetically closest
to  it, while N. naja is phylogenetically most distant among the three.
the anti-C. rhodostoma antibodies exhibit greater number of mul-
tivalencies (paratopes) that were able to recognize epitopes of H.
hypnale venom, in contrast to anti-Hh IgG which multivalent sites
are likely endowed with fewer binding sites for the antigenic epi-
topes of C. rhodostoma venom.
3.5. Detection and quantitation of venom in human sera
Using double-sandwich ELISA, the titration of H. hypnale venom
concentrations in human sera yields a parabolic curve with a regres-
sion factor of 0.9955, within the concentration range of 0–75 ng/ml
(Fig. 2a). The assay was sensitive with the limit of detection (LoD) of
2.78 ng/ml and the limit of quantitation (LoQ) of 10.88 ng/ml venom
with 1:10 dilution in human serum. As H. hypnale is small in size
(≤50 cm), the average dry mass of venom yield per milking is small
too (average 13 mg)  (Tan et al., 2011b). Given a situation where
13 mg  of venom was injected into a 60-kg Asian man  with plasma
volume of 2.5 L (through bite on muscle and subcutaneous tissue),
and the systemic absorption was estimated to be 5% (unpublished
data on bioavailability), the theoretical serum concentration of
venom would be close to 260 ng/ml, of which 1:10 dilution would
be equivalent to 26 ng/ml and is detectable and quantiﬁable by the
assay.
Besides, the double-sandwich ELISA demonstrated practically
no cross-reactivities with the venoms of E. carinatus and D. russelii,
two endemic biting snakes in the same regions which often cause
misidentiﬁcation for H. hypnale. We  broadened the venom iden-
tiﬁcation studies by including two separate assays for D. russelii
and E. carinatus sinhaleyus venoms, using double-sandwich ELISA
(Fig. 2b and c). Both the assays were sensitive toward their respec-
tive homologous venoms, with the LoD and LoQ being respectively
1.64 ng/ml and 5.75 ng/ml for E. carinatus sinhaleyus;  while for D.
russelii, 2.43 ng/ml and 9.83 ng/ml. Generally, each assay was able
to distinguish the homologous venom from the other two based
on a signiﬁcant difference in the absorbance values at each con-
centration (p < 0.05). This suggests that the double-sandwich ELISA
developed from afﬁnity-puriﬁed anti-venom IgG has the potential
to be developed into a speciﬁc diagnostic kit for viperid enveno-
mation in the region, and this is important in clinical studies where
the biting species needs to be accurately diagnosed, and the blood
venom levels to be monitored. It also has the potential to improve
routine clinical diagnosis and to ensure that appropriate serother-
apy is instituted. Although in practice, many dubious snakebite
cases were empirically treated with polyvalent antivenoms, this
approach can be dangerous and is not appropriate in H. hypnale
envenomation as the polyvalent antivenom available in Sri Lanka is
Fig. 2. Titration curve for the concentrations of venoms from three common biting snakes in Sri Lanka dissolved in human serum, with 1:10 dilution in PBS–Tween 20, on
double-sandwich ELISA using IgG for Hypnale hypnale venom (a), Echis carinatus sinhaleyus (b) and Daboia russelii (c). Values were mean absorbance ± SEM.
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only effective against D. russelii and E. carinatus, but not H. hypnale.
In addition, the documentation of accurate biting species iden-
tity is vital for epidemiology study, an important aspect for global
health sustainability; and this also provides accurate information
for future research at both clinical and laboratory settings.
In highlighting the beneﬁts of a potential ‘Sri Lankan hematoxic
viperids’ diagnostic kit, cost is always an obstacle that should be
addressed. Among the various proposed and experimental venom-
screening tools, we believe that ELISA is the most economical,
least technically demanding and most stable way  as compared
to radioisotopic assay, polymerase chain reaction or immunoblot-
ting. A portable pocket-sized plate can be designed to have three
parallel panels, each consisting two control wells (negative and
positive) and two to three sample wells for venom detection based
on chromogenicity. ELISA is a rather generic facility that should be
available in major medical centers in the developing countries for
common serology use, and in places where such facility has been
equipped, costing would mainly concern consumables like buffers,
IgG, enzyme and substrate, which are generally required in very
small, diluted amounts. Hence, it is hoped that with international
collaborative supports, such diagnostic application can be made
possible at low-resource setting.
4. Conclusion
Immunological properties of H. hypnale venom were proﬁled
according to potential clinical applications, where the speciﬁc
IgG produced showed venom-neutralizing potency, indicating the
possibility of large-scale antivenom manufacturing. Caprylic acid
precipitation and pepsin digestion are steps to be considered in
the production for enhancing the antivenom efﬁcacy. Results of
cross-reactivity studies were in line with the phylogenic relation-
ship between C. rhodostoma and H. hypnale, and supported the
paraspeciﬁc cross-neutralization in our previous work. The double-
sandwich ELISA is speciﬁc to distinguish among venoms of H.
hypnale, D. russelii and E. carinatus sinhaleyus,  hence the potential
as a diagnostic and investigating tool in envenoming cases by these
Sri Lankan hematoxic viperid snakes that are at time misidentiﬁed.
This is particularly relevant to a recent progress where the paraspe-
ciﬁc Hemato polyvalent antivenom has been proposed for use in H.
hypnale envenoming, as the assay may  serve as an investigating
tool to ascertain the species diagnosis and to study the time course
proﬁle of blood venom concentrations during clinical trial.
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a b s t r a c t
Mice experimentally envenomed with Hypnale hypnale venom (1 and 1.5 LD50)
developed acute kidney injury (AKI) principally characterized by raised blood urea and
creatinine. Prolonged blood clotting time and hemorrhage in lungs implied bleeding
tendency. Pallor noted in most renal cortices was suggestive of renal ischemia secondary to
consumptive coagulopathy. Intravenous infusion of Hemato polyvalent antivenom
following experimental envenoming effectively prevented death and AKI in all mice,
supporting its potential therapeutic use in envenoming cases.
 2012 Elsevier Ltd. All rights reserved.
Bites by hump-nosed pit vipers (Hypnale hypnale) have
been identiﬁed as a leading and potentially fatal cause of
snake envenomation in Sri Lanka as well as southwestern
region of India (Kerala) (Ariaratnam et al., 2008; Joseph
et al., 2007). The majority (90%) of envenomed patients
suffered from local tissue damages, e.g., hemorrhagic blis-
tering and extensive tissue necrosis, while approximately
40% of them developed concurrent systemic syndrome
characterized by hemostatic derangement. Acute kidney
injury (AKI), a severe systemic complication associatedwith
the bite, was responsible for most deaths with an overall
fatality rate of 1.8%, even though it occurred infrequently
(10% of total bite cases, n ¼ 302) (de Silva et al., 1994;
Ariaratnam et al., 2008). Themechanismof kidney injury by
H. hypnale venom was postulated to be a complication of
consumptive coagulopathy secondary to the venom’s
procoagulant and ﬁbrinolytic actions (Kanjanabuch and
Sitprija, 2008), and the venom at a sublethal dose (1/3
intramuscular LD50) did not appear to induce direct kidney
damage in a rat model (Tan et al., 2011b). Nevertheless, in
view of the venom’s prominent proteolytic and cytotoxic
activities (Tan et al., 2011b; Maduwage et al., 2011), a direct
tissue-damaging effect on the kidney or indirect immuno-
logical responses induced by the venom at higher doses
cannot be completely ruled out.
Although antivenom is the deﬁnite treatment for
snakebite envenoming (Chippaux and Goyffon,1998), there
are currently no effective antivenoms clinically available to
treat H. hypnale envenoming. A paraspeciﬁc antivenom
(Hemato polyvalent antivenom, HPA, raised against venoms
of Thai Calloselasma rhodostoma, Cryptelytrops albolabris
and Daboia siamensis), previously shown effective to
neutralize the venom’s hematoxic, necrotic and lethal
effects in mice (Tan et al., 2011a), is nonetheless a potential
therapeutic treatment for the endemic medical urgency.
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Clinically, although most cases of AKI complicating H. hyp-
nale bite were reversible with acute care (demanding dial-
ysis), some surviving patients eventually progressed to
chronic kidney disease with ensuing death within a year,
simply because of the lack of affordable renal replacement
therapy in a developing country that is socioeconomically
constrained (Ariaratnam et al., 2008). Therefore, the anti-
venomtherapyproposed for the treatmentofH. hypnalebite
needs to address the issue of venom nephrotoxicity in
addition to its neutralization of other major toxic effects,
and above all, lethality. In this study, the HPAwas tested for
its ability to prevent the development of AKI and death
using an in vivo nephrotoxic animal model.
Albino mice of ICR-strain used in the current study were
supplied by the Laboratory Animal Center, University of
Malaya. The animals were handled according to the
guidelines given by CIOMS on animal experimentation, and
the experimental protocol was approved by the Animal Use
and Care Committee of the institution [ethics clearance
number: PM/03/03/2010/FSY(R)]. The mice were divided
into one control group and two challenge groups (Group A
and Group B). Mice in the control group (n ¼ 4) each
received 200 mL normal saline, while mice in Group A
(n ¼ 9) each received H. hypnale venom at 1 intraperito-
neal LD50, and those in Group B (n ¼ 4) each received the
same venom at 1.5 intraperitoneal LD50. The venom (a
pooled sample obtained from the milking of >10 snakes
captured in Gamapha, Kelaniya, Avissawela and Colombo
regions of Sri Lanka) was dissolved in normal saline and the
volume of injection was adjusted to 200 mL. Both venom
and vehicle (normal saline) were injected intraperitoneally.
The dose used in this study was estimated from the intra-
peritoneal LD50 value of H. hypnale venom in rodents (6 mg/
g) obtained in an earlier study (Tan et al., 2011b) from the
same laboratory. Following injections, the mice were
housed individually in standard metabolic cages with
access to food and water ad libitum. Hourly observations on
the mice’s behaviors and toxic signs were charted over
48 h. Mice that showed features suggestive of impending
death (e.g., labored breathing with pauses, feeble heart-
beat, loss of righting reﬂex, inability to walk, and lack of
response to manipulation) were more closely monitored
until spontaneous death. Upon death, blood was collected
immediately from the heart, and the major organs were
then harvested for gross and microscopic examinations. At
48 h, all surviving mice were sedated with a mixture of
xylazine and ketamine (0.1 and 1.0 mg, respectively, per
20 g mouse; chemicals supplied by Troy Laboratories,
Australia), and blood was collected via cardiac puncture.
Subsequently, the mice were euthanized by cervical dislo-
cation, and the major organs were harvested. Blood
collected in plain tubes were observed for clotting time
before processing for urea and creatinine analysis. The
urine samples collected throughout the study period were
analyzed for speciﬁc gravity, hematuria and proteinuria
using urine test strips (Roche Diagnostics, Germany). The
harvested organs were ﬁxed in 10% formalin in phosphate-
buffered saline, followed by parafﬁn wax-embedding,
sectioning of tissue, dewaxing, rehydration, and staining
with hematoxylin and eosin. Kidney tissues were speciﬁ-
cally sectioned at 1.5 mm thin layer.
The experimental envenoming with 1 and 1.5 LD50
was repeated in Group C (n ¼ 9) and Group D (n ¼ 4),
respectively. Intervention was carried out 5 min following
the venom challenge, where each mouse from both groups
received an injection of 200 mL of Hemato polyvalent
antivenom (reconstituted as 1 vial of HPA: 10 mL normal
saline; antivenom was supplied by Queen Saovabha
Memorial Institute, Bangkok) via tail vein. Animal housing,
monitoring of signs, collection of blood and urine, pro-
cessing of tissues/organs of the mice and further analyses
were performed essentially as described in the nephrotoxic
model above. The signiﬁcance of the differences in the
means of the results was determined by one-way ANOVA
and Tukey’s post hoc test.
H. hypnale venom at median lethal dose (LD50) (Group A)
caused serum biochemical derangement suggestive of acute
renal failure, most prominently uremia (and observably
increased blood creatinine level) that affected all challenged
mice (Fig. 1a). Elevated blood urea level (directly propor-
tionate to blood urea nitrogen) generally indicates
a moderate-to-severe degree of renal failure. The degree of
hematuria and proteinuria correlatedwith the deterioration
of renal function and signs of toxicity observed in mice that
were dead by 24 h (Table 1). In mice challenged with 1.5
LD50 (Group B), severe azotemia (with blood creatinine
increasedhigher thanurea)wasobserved inallmice (Fig.1b),
indicating that the renal functionwas further compromised.
While signiﬁcant proteinuria and prolonged clotting time
were observed, there was however no hematuria detected,
probably because glomerular involvementwasnot extensive
in view of the short period of time to death. On autopsy,
patches of pallor noted on the renal cortices were suggestive
of renal ischemia, although histopatholgy study did not
reveal obvious abnormal ﬁndings under light microscopy
within the study period (48 h maximum). This suggests that
electronic microscopic examinations may be necessary for
investigating subcellular ultrastructural changes in the
mouse model. Additional features implying possible
bleeding disorder included prolonged clotting times (Table
1) and hemorrhagic spots in the lungs. Urine speciﬁc
gravity was noted to be marginally higher in the challenge
groupwith 1.5 LD50 (p¼ 0.04; Table 1), a peripheralﬁnding
suggestive of pre-renal azotemia as in reduced renal perfu-
sion secondary to altered hemodynamics.
The result indicated that death in mice experimentally
envenomed with H. hypnale venom was associated with
AKI, consistent with clinical reports (Joseph et al., 2007;
Ariaratnam et al., 2008). This likely cause of death was
effectively prevented by the Hemato polyvalent antivenom
(HPA) in the current in vivo rodent model, evidenced by
normalization of blood and urine biochemistry of the
envenomed animals (Fig. 1a: signiﬁcant amelioration of
hematuria (p  0.001), proteinuria (p  0.001) and uremia
(p  0.05); Fig. 1b: signiﬁcant amelioration of proteinuria
(p  0.05), uremia (p  0.001) and azotemia (p  0.001)).
Moreover, in the intervened groups, urine speciﬁc gravity
was improved signiﬁcantly (p  0.05), along with normal
anatomy of the kidneys and lungs as well as 100% survival.
The HPA neutralizing efﬁcacies on H. hypnale venom has
been established previously by Tan et al. (2011a): against
lethality, median effective dose at 1.52 mg venom/mL;
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against procoagulant, hemorrhagic and necrotic effects,
effective/median effective doses at 114.2, 67.4, and 53.8 mL/
mg venom, respectively. The mechanism of nephrotoxicity
neutralization likely involved the HPA cross neutralizing
the procoagulant and hemorrhagic effects of H. hypnale
venom, hence preempting AKI, a complication associated
with consumptive coagulopathy (Sitprija, 2008). The cross
neutralization observed was also recently supported by
immunological cross reactivity study (Tan et al., 2012),
which reﬂected similarity of antigenic properties between
the venoms of H. hypnale and C. rhodostoma. However,
venom-induced deﬁbrinogenation complicating AKI is not
a known feature in C. rhodostoma envenoming (Ho et al.,
1986), hence implying subtle differences in the biochem-
ical aspects of the procoagulant enzymes from these
two crotalid venoms, possibly at the ﬁbrinogenolytic
Table 1
Effects of Hypnale hypnale venom on urine and blood parameters of mice challenged with 1 LD50 (Group A) and 1.5 LD50 (Group B).
Group Test
Time to
death (h)
Urine Blood
Speciﬁc gravity Hematuria (þ) Proteinuria (þ) Clotting time (s) Urea (mmol/L) Creatinine (mmol/L)
Control (n ¼ 4) Not observed 1.023  0.002 0.0  0.0 1.0  0.0 12.5  2.9 7.8  0.6 19.3  3.1
A (n ¼ 9) 18.4  2.1 1.026  0.001 1.8  0.6a 1.9  0.3 28.9  6.5b 19.0  4.5 28.6  7.6
B (n ¼ 4) 7.4  1.3 1.029  0.001a 0.0  0.0a 1.8  0.3 45.0  2.9b 14.4  1.0 76.3  3.3c
Venom was dissolved in normal saline and volume was adjusted to 200 mL for intraperitoneal injection. Data were expressed as means  SEM. Fatality in
Group A ¼ 56%; Group B ¼ 100%.
Means (for Groups A and B) indicated with letters showed signiﬁcant difference from the corresponding means of control for the test, as determined by one-
way ANOVA and Tukey’s post hoc test: a p  0.05; b p  0.01; c p  0.001.
Fig. 1. Urine and blood biochemical parameters of mice: (a) Group A was challenged with 1 i.p. LD50 (n ¼ 9, 55% death); (b) Group B was challenged with 1.5
i.p. LD50 (n ¼ 4, 100% death). Group C and Group D were the intervened groups which received i.v. 200 mL of antivenom (HPA) 5 min after envenomation for each
mouse. Control was treated with normal saline instead of venom and antivenom. Data were expressed as means  SEM. Signiﬁcant differences of mean between
the challenged group and the intervened and/or control groups were indicated as * (p  0.05) or ** (p  0.001) over the bars, determined by one-way ANOVA and
Tukey’s post hoc test. No signiﬁcant difference of means was noted between the intervened group and the control.
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mechanism. Essentially, the current ﬁndings based on
in vivo animal experiments complement that of the cross
neutralization study reported previously on the venom
hematoxic and lethal effects, hence supporting the ability
of HPA to confer paraspeciﬁc protection, and justifying the
suggestion for its clinical trial in the future.
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